Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
Patienten is an umlsterm, Tumorprophylaxe is an umlsterm, Hypertriglyzeridaemie is an umlsterm, Hautveraenderungen is an umlsterm, Restkeratosen is an umlsterm, Langzeitergebnisse is an umlsterm
DerHautarzt.80490586.ger.abstr_task1
Sentence: Wir berichten ueber einen Patienten mit kongenitaler Poikilodermie Typ Dowling , bei dem seit dem 52. Lebensjahr wiederholt M. Bowen und initiale Spinaliome in den Arealen der verruziformen Hyperkeratosen aufgetreten und exzidiert worden sind . Da eine laengerfristige Tumorprophylaxe mit Retinoiden wegen einer Hypertriglyzeridaemie Typ IV ( nach Frederickson ) nicht durchfuehrbar war , entschlossen wir uns zu einem Behandlungsversuch mittels Dermabrasio . In einem Nachbeobachtungszeitraum von 12 Monaten zeigten sich mehrere komplett abgeheilte Hautveraenderungen , daneben in einigen Arealen noch kleinere verbliebene Restkeratosen . Langzeitergebnisse stehen noch aus . Anhand des vorgestellten Falles wird das heterogene Krankheitsbild der kongenitalen Poikilodermie Typ Dowling diskutiert und auf das hohe Entartungsrisiko hingewiesen . Instructions: please typing these entity words according to sentence: Patienten, Tumorprophylaxe, Hypertriglyzeridaemie, Hautveraenderungen, Restkeratosen, Langzeitergebnisse Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Wir berichten ueber einen Patienten mit kongenitaler Poikilodermie Typ Dowling , bei dem seit dem 52. Lebensjahr wiederholt M. Bowen und initiale Spinaliome in den Arealen der verruziformen Hyperkeratosen aufgetreten und exzidiert worden sind . Da eine laengerfristige Tumorprophylaxe mit Retinoiden wegen einer Hypertriglyzeridaemie Typ IV ( nach Frederickson ) nicht durchfuehrbar war , entschlossen wir uns zu einem Behandlungsversuch mittels Dermabrasio . In einem Nachbeobachtungszeitraum von 12 Monaten zeigten sich mehrere komplett abgeheilte Hautveraenderungen , daneben in einigen Arealen noch kleinere verbliebene Restkeratosen . Langzeitergebnisse stehen noch aus . Anhand des vorgestellten Falles wird das heterogene Krankheitsbild der kongenitalen Poikilodermie Typ Dowling diskutiert und auf das hohe Entartungsrisiko hingewiesen .
[ "Wir", "berichten", "ueber", "einen", "Patienten", "mit", "kongenitaler", "Poikilodermie", "Typ", "Dowling", ",", "bei", "dem", "seit", "dem", "52", ".", "Lebensjahr", "wiederholt", "M.", "Bowen", "und", "initiale", "Spinaliome", "in", "den", "Arealen", "der", "verruziformen", "Hyperkeratosen", "aufgetreten", "und", "exzidiert", "worden", "sind", ".", "Da", "eine", "laengerfristige", "Tumorprophylaxe", "mit", "Retinoiden", "wegen", "einer", "Hypertriglyzeridaemie", "Typ", "IV", "(", "nach", "Frederickson", ")", "nicht", "durchfuehrbar", "war", ",", "entschlossen", "wir", "uns", "zu", "einem", "Behandlungsversuch", "mittels", "Dermabrasio", ".", "In", "einem", "Nachbeobachtungszeitraum", "von", "12", "Monaten", "zeigten", "sich", "mehrere", "komplett", "abgeheilte", "Hautveraenderungen", ",", "daneben", "in", "einigen", "Arealen", "noch", "kleinere", "verbliebene", "Restkeratosen", ".", "Langzeitergebnisse", "stehen", "noch", "aus", ".", "Anhand", "des", "vorgestellten", "Falles", "wird", "das", "heterogene", "Krankheitsbild", "der", "kongenitalen", "Poikilodermie", "Typ", "Dowling", "diskutiert", "und", "auf", "das", "hohe", "Entartungsrisiko", "hingewiesen", "." ]
[ "umlsterm" ]
Patienten, Tumorprophylaxe, Hypertriglyzeridaemie, Hautveraenderungen, Restkeratosen, Langzeitergebnisse
DerHautarzt.80490586.ger.abstr_task2
Sentence: Wir berichten ueber einen Patienten mit kongenitaler Poikilodermie Typ Dowling , bei dem seit dem 52. Lebensjahr wiederholt M. Bowen und initiale Spinaliome in den Arealen der verruziformen Hyperkeratosen aufgetreten und exzidiert worden sind . Da eine laengerfristige Tumorprophylaxe mit Retinoiden wegen einer Hypertriglyzeridaemie Typ IV ( nach Frederickson ) nicht durchfuehrbar war , entschlossen wir uns zu einem Behandlungsversuch mittels Dermabrasio . In einem Nachbeobachtungszeitraum von 12 Monaten zeigten sich mehrere komplett abgeheilte Hautveraenderungen , daneben in einigen Arealen noch kleinere verbliebene Restkeratosen . Langzeitergebnisse stehen noch aus . Anhand des vorgestellten Falles wird das heterogene Krankheitsbild der kongenitalen Poikilodermie Typ Dowling diskutiert und auf das hohe Entartungsrisiko hingewiesen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Wir berichten ueber einen Patienten mit kongenitaler Poikilodermie Typ Dowling , bei dem seit dem 52. Lebensjahr wiederholt M. Bowen und initiale Spinaliome in den Arealen der verruziformen Hyperkeratosen aufgetreten und exzidiert worden sind . Da eine laengerfristige Tumorprophylaxe mit Retinoiden wegen einer Hypertriglyzeridaemie Typ IV ( nach Frederickson ) nicht durchfuehrbar war , entschlossen wir uns zu einem Behandlungsversuch mittels Dermabrasio . In einem Nachbeobachtungszeitraum von 12 Monaten zeigten sich mehrere komplett abgeheilte Hautveraenderungen , daneben in einigen Arealen noch kleinere verbliebene Restkeratosen . Langzeitergebnisse stehen noch aus . Anhand des vorgestellten Falles wird das heterogene Krankheitsbild der kongenitalen Poikilodermie Typ Dowling diskutiert und auf das hohe Entartungsrisiko hingewiesen .
[ "Wir", "berichten", "ueber", "einen", "Patienten", "mit", "kongenitaler", "Poikilodermie", "Typ", "Dowling", ",", "bei", "dem", "seit", "dem", "52", ".", "Lebensjahr", "wiederholt", "M.", "Bowen", "und", "initiale", "Spinaliome", "in", "den", "Arealen", "der", "verruziformen", "Hyperkeratosen", "aufgetreten", "und", "exzidiert", "worden", "sind", ".", "Da", "eine", "laengerfristige", "Tumorprophylaxe", "mit", "Retinoiden", "wegen", "einer", "Hypertriglyzeridaemie", "Typ", "IV", "(", "nach", "Frederickson", ")", "nicht", "durchfuehrbar", "war", ",", "entschlossen", "wir", "uns", "zu", "einem", "Behandlungsversuch", "mittels", "Dermabrasio", ".", "In", "einem", "Nachbeobachtungszeitraum", "von", "12", "Monaten", "zeigten", "sich", "mehrere", "komplett", "abgeheilte", "Hautveraenderungen", ",", "daneben", "in", "einigen", "Arealen", "noch", "kleinere", "verbliebene", "Restkeratosen", ".", "Langzeitergebnisse", "stehen", "noch", "aus", ".", "Anhand", "des", "vorgestellten", "Falles", "wird", "das", "heterogene", "Krankheitsbild", "der", "kongenitalen", "Poikilodermie", "Typ", "Dowling", "diskutiert", "und", "auf", "das", "hohe", "Entartungsrisiko", "hingewiesen", "." ]
[ "umlsterm" ]
diethylstilbestrol is a TRIVIAL, NIH - FSH - S13 is a TRIVIALVAR, cholera toxin is a TRIVIAL, [ 1 beta-3H]testosterone is a IUPAC, cholera toxin is a TRIVIAL, 3H2O is a SUM, 3H2O is a SUM, ( Bu)2cAMP is a IUPAC, 3-isobutyl - l - methylxanthine is a IUPAC, cholera toxin is a TRIVIAL, ( Bu)2cAMP is a IUPAC, ( Bu)2cAMP is a IUPAC
example-9_task0
Sentence: Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro. The abilities of LHRH and a potent LHRH agonist ([D-Ser-(But),6, des-Gly-NH210]LHRH ethylamide) inhibit FSH responses by rat granulosa cells and Sertoli cells in vitro have been compared. Granulosa cells isolated from 22- or 25-day-old diethylstilbestrol-primed rats and cultured under defined conditions for 48 h with NIH-FSH-S13 ( ng/ml) or cholera toxin (0.1 microgram/ml) showed increased aromatase activity, as determined by the release of 3H2O from [1 beta-3H]testosterone. LHRH ( (-7) M) or th agonist ( (-8) M) added simultaneously with FSH or cholera toxin inhibited the effects on the release of 3H2O without influencing the protein content of the cell cultures. A smaller stimulation of 3H2O production occurred with (Bu)2cAMP (1.0 mM) plus 3-isobutyl-l-methylxanthine (0.1 mM), and this was partially suppressed in the presence of LHRH or the agonist. Parallel studies with Sertoli cells from 15- or -day-old rats demonstrated that culture under appropriate conditions with FSH, cholera toxin, or (Bu)2cAMP (0.5 mM) for 24 h caused an increase in cellular aromatase activity and enhanced secretion into the medium of plasminogen activator. However, no inhibition by LHRH ( (-7) or (-9) M) or the agonist ( (-6) or (-8) M) occurred when the peptides were added either simultaneously or 24 h before the stimulatory agent. Similarly, Sertoli cells from 11-day-old rats treated daily with LHRH agonist for 5 days in culture, showed no inhibition of aromatase activity after a 4-h stimulation with FSH or (Bu)2cAMP. FSH dose-response curves (0-300 ng/ml) for aromatase activity were shown to be similar after 5 days of culture with or without (-8) M LHRH agonist, indicating that the LHRH did not cause a shift in the sensitivity to FSH. The lack of inhibition was seen in Sertoli cell cultures maintained at 37 or 32 C. The enzyme digestion method used to isolated Sertoli cells was not responsible for the lack of effects of LHRH, since cell cultures prepared without the aid of proteolytic enzymes showed similar FSH stimulation of aromatase activity in the presence or absence of (-8) M agonist. Further, there was no evidence of degradation of the LHRH agonist when incubated with Sertoli cell cultures. From these studies, we conclude that 1) granulosa cells and Sertoli cells from immature rats differ in their responses to LHRH, and 2) the immature Sertoli cell is an unlikely target for a direct inhibiting influence of LHRH on spermatogenesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: , IUPAC, TRIVIAL, SUM, TRIVIALVAR
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "B-SUM", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SUM", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro. The abilities of LHRH and a potent LHRH agonist ([D-Ser-(But),6, des-Gly-NH210]LHRH ethylamide) inhibit FSH responses by rat granulosa cells and Sertoli cells in vitro have been compared. Granulosa cells isolated from 22- or 25-day-old diethylstilbestrol-primed rats and cultured under defined conditions for 48 h with NIH-FSH-S13 ( ng/ml) or cholera toxin (0.1 microgram/ml) showed increased aromatase activity, as determined by the release of 3H2O from [1 beta-3H]testosterone. LHRH ( (-7) M) or th agonist ( (-8) M) added simultaneously with FSH or cholera toxin inhibited the effects on the release of 3H2O without influencing the protein content of the cell cultures. A smaller stimulation of 3H2O production occurred with (Bu)2cAMP (1.0 mM) plus 3-isobutyl-l-methylxanthine (0.1 mM), and this was partially suppressed in the presence of LHRH or the agonist. Parallel studies with Sertoli cells from 15- or -day-old rats demonstrated that culture under appropriate conditions with FSH, cholera toxin, or (Bu)2cAMP (0.5 mM) for 24 h caused an increase in cellular aromatase activity and enhanced secretion into the medium of plasminogen activator. However, no inhibition by LHRH ( (-7) or (-9) M) or the agonist ( (-6) or (-8) M) occurred when the peptides were added either simultaneously or 24 h before the stimulatory agent. Similarly, Sertoli cells from 11-day-old rats treated daily with LHRH agonist for 5 days in culture, showed no inhibition of aromatase activity after a 4-h stimulation with FSH or (Bu)2cAMP. FSH dose-response curves (0-300 ng/ml) for aromatase activity were shown to be similar after 5 days of culture with or without (-8) M LHRH agonist, indicating that the LHRH did not cause a shift in the sensitivity to FSH. The lack of inhibition was seen in Sertoli cell cultures maintained at 37 or 32 C. The enzyme digestion method used to isolated Sertoli cells was not responsible for the lack of effects of LHRH, since cell cultures prepared without the aid of proteolytic enzymes showed similar FSH stimulation of aromatase activity in the presence or absence of (-8) M agonist. Further, there was no evidence of degradation of the LHRH agonist when incubated with Sertoli cell cultures. From these studies, we conclude that 1) granulosa cells and Sertoli cells from immature rats differ in their responses to LHRH, and 2) the immature Sertoli cell is an unlikely target for a direct inhibiting influence of LHRH on spermatogenesis.
[ " ", "Differential", "effects", "of", "luteinizing", "hormone", "-", "releasing", "hormone", "on", "follicle", "-", "stimulating", "hormone", "-", "dependent", "responses", "in", "rat", "granulosa", "cells", "and", "Sertoli", "cells", "in", "vitro", ".", " ", "The", "abilities", "of", "LHRH", "and", "a", "potent", "LHRH", "agonist", "(", "[", "D", "-", "Ser-(But),6", ",", "des", "-", "Gly", "-", "NH210]LHRH", "ethylamide", ")", "inhibit", "FSH", "responses", "by", "rat", "granulosa", "cells", "and", "Sertoli", "cells", "in", "vitro", "have", "been", "compared", ".", "Granulosa", "cells", "isolated", "from", "22-", "or", "25-day", "-", "old", "diethylstilbestrol", "-", "primed", "rats", "and", "cultured", "under", "defined", "conditions", "for", "48", "h", "with", "NIH", "-", "FSH", "-", "S13", "(", " ", "ng", "/", "ml", ")", "or", "cholera", "toxin", "(", "0.1", "microgram", "/", "ml", ")", "showed", "increased", "aromatase", "activity", ",", "as", "determined", "by", "the", "release", "of", "3H2O", "from", "[", "1", "beta-3H]testosterone", ".", "LHRH", "(", " ", "(", "-7", ")", "M", ")", "or", "th", "agonist", "(", " ", "(-8", ")", "M", ")", "added", "simultaneously", "with", "FSH", "or", "cholera", "toxin", "inhibited", "the", "effects", "on", "the", "release", "of", "3H2O", "without", "influencing", "the", "protein", "content", "of", "the", "cell", "cultures", ".", "A", "smaller", "stimulation", "of", "3H2O", "production", "occurred", "with", "(", "Bu)2cAMP", "(", "1.0", "mM", ")", "plus", "3-isobutyl", "-", "l", "-", "methylxanthine", "(", "0.1", "mM", ")", ",", "and", "this", "was", "partially", "suppressed", "in", "the", "presence", "of", "LHRH", "or", "the", "agonist", ".", "Parallel", "studies", "with", "Sertoli", "cells", "from", "15-", "or", " ", "-day", "-", "old", "rats", "demonstrated", "that", "culture", "under", "appropriate", "conditions", "with", "FSH", ",", "cholera", "toxin", ",", "or", "(", "Bu)2cAMP", "(", "0.5", "mM", ")", "for", "24", "h", "caused", "an", "increase", "in", "cellular", "aromatase", "activity", "and", "enhanced", "secretion", "into", "the", "medium", "of", "plasminogen", "activator", ".", "However", ",", "no", "inhibition", "by", "LHRH", "(", " ", "(", "-7", ")", "or", " ", "(", "-9", ")", "M", ")", "or", "the", "agonist", "(", " ", "(", "-6", ")", "or", " ", "(-8", ")", "M", ")", "occurred", "when", "the", "peptides", "were", "added", "either", "simultaneously", "or", "24", "h", "before", "the", "stimulatory", "agent", ".", "Similarly", ",", "Sertoli", "cells", "from", "11-day", "-", "old", "rats", "treated", "daily", "with", "LHRH", "agonist", "for", "5", "days", "in", "culture", ",", "showed", "no", "inhibition", "of", "aromatase", "activity", "after", "a", "4-h", "stimulation", "with", "FSH", "or", "(", "Bu)2cAMP", ".", "FSH", "dose", "-", "response", "curves", "(", "0", "-", "300", "ng", "/", "ml", ")", "for", "aromatase", "activity", "were", "shown", "to", "be", "similar", "after", "5", "days", "of", "culture", "with", "or", "without", " ", "(-8", ")", "M", "LHRH", "agonist", ",", "indicating", "that", "the", "LHRH", "did", "not", "cause", "a", "shift", "in", "the", "sensitivity", "to", "FSH", ".", "The", "lack", "of", "inhibition", "was", "seen", "in", "Sertoli", "cell", "cultures", "maintained", "at", "37", "or", "32", "C.", "The", "enzyme", "digestion", "method", "used", "to", "isolated", "Sertoli", "cells", "was", "not", "responsible", "for", "the", "lack", "of", "effects", "of", "LHRH", ",", "since", "cell", "cultures", "prepared", "without", "the", "aid", "of", "proteolytic", "enzymes", "showed", "similar", "FSH", "stimulation", "of", "aromatase", "activity", "in", "the", "presence", "or", "absence", "of", " ", "(-8", ")", "M", "agonist", ".", "Further", ",", "there", "was", "no", "evidence", "of", "degradation", "of", "the", "LHRH", "agonist", "when", "incubated", "with", "Sertoli", "cell", "cultures", ".", "From", "these", "studies", ",", "we", "conclude", "that", "1", ")", "granulosa", "cells", "and", "Sertoli", "cells", "from", "immature", "rats", "differ", "in", "their", "responses", "to", "LHRH", ",", "and", "2", ")", "the", "immature", "Sertoli", "cell", "is", "an", "unlikely", "target", "for", "a", "direct", "inhibiting", "influence", "of", "LHRH", "on", "spermatogenesis", "." ]
[ "", "IUPAC", "TRIVIAL", "TRIVIALVAR", "SUM" ]
diethylstilbestrol is a TRIVIAL, NIH - FSH - S13 is a TRIVIALVAR, cholera toxin is a TRIVIAL, [ 1 beta-3H]testosterone is a IUPAC, cholera toxin is a TRIVIAL, 3H2O is a SUM, 3H2O is a SUM, ( Bu)2cAMP is a IUPAC, 3-isobutyl - l - methylxanthine is a IUPAC, cholera toxin is a TRIVIAL, ( Bu)2cAMP is a IUPAC, ( Bu)2cAMP is a IUPAC
example-9_task1
Sentence: Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro. The abilities of LHRH and a potent LHRH agonist ([D-Ser-(But),6, des-Gly-NH210]LHRH ethylamide) inhibit FSH responses by rat granulosa cells and Sertoli cells in vitro have been compared. Granulosa cells isolated from 22- or 25-day-old diethylstilbestrol-primed rats and cultured under defined conditions for 48 h with NIH-FSH-S13 ( ng/ml) or cholera toxin (0.1 microgram/ml) showed increased aromatase activity, as determined by the release of 3H2O from [1 beta-3H]testosterone. LHRH ( (-7) M) or th agonist ( (-8) M) added simultaneously with FSH or cholera toxin inhibited the effects on the release of 3H2O without influencing the protein content of the cell cultures. A smaller stimulation of 3H2O production occurred with (Bu)2cAMP (1.0 mM) plus 3-isobutyl-l-methylxanthine (0.1 mM), and this was partially suppressed in the presence of LHRH or the agonist. Parallel studies with Sertoli cells from 15- or -day-old rats demonstrated that culture under appropriate conditions with FSH, cholera toxin, or (Bu)2cAMP (0.5 mM) for 24 h caused an increase in cellular aromatase activity and enhanced secretion into the medium of plasminogen activator. However, no inhibition by LHRH ( (-7) or (-9) M) or the agonist ( (-6) or (-8) M) occurred when the peptides were added either simultaneously or 24 h before the stimulatory agent. Similarly, Sertoli cells from 11-day-old rats treated daily with LHRH agonist for 5 days in culture, showed no inhibition of aromatase activity after a 4-h stimulation with FSH or (Bu)2cAMP. FSH dose-response curves (0-300 ng/ml) for aromatase activity were shown to be similar after 5 days of culture with or without (-8) M LHRH agonist, indicating that the LHRH did not cause a shift in the sensitivity to FSH. The lack of inhibition was seen in Sertoli cell cultures maintained at 37 or 32 C. The enzyme digestion method used to isolated Sertoli cells was not responsible for the lack of effects of LHRH, since cell cultures prepared without the aid of proteolytic enzymes showed similar FSH stimulation of aromatase activity in the presence or absence of (-8) M agonist. Further, there was no evidence of degradation of the LHRH agonist when incubated with Sertoli cell cultures. From these studies, we conclude that 1) granulosa cells and Sertoli cells from immature rats differ in their responses to LHRH, and 2) the immature Sertoli cell is an unlikely target for a direct inhibiting influence of LHRH on spermatogenesis. Instructions: please typing these entity words according to sentence: [ D - Ser-(But),6 , des - Gly - NH210]LHRH ethylamide, diethylstilbestrol, NIH - FSH - S13, cholera toxin, [ 1 beta-3H]testosterone, cholera toxin, 3H2O, 3H2O, ( Bu)2cAMP, 3-isobutyl - l - methylxanthine, cholera toxin, ( Bu)2cAMP, ( Bu)2cAMP Options: , IUPAC, TRIVIAL, SUM, TRIVIALVAR
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "B-SUM", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SUM", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro. The abilities of LHRH and a potent LHRH agonist ([D-Ser-(But),6, des-Gly-NH210]LHRH ethylamide) inhibit FSH responses by rat granulosa cells and Sertoli cells in vitro have been compared. Granulosa cells isolated from 22- or 25-day-old diethylstilbestrol-primed rats and cultured under defined conditions for 48 h with NIH-FSH-S13 ( ng/ml) or cholera toxin (0.1 microgram/ml) showed increased aromatase activity, as determined by the release of 3H2O from [1 beta-3H]testosterone. LHRH ( (-7) M) or th agonist ( (-8) M) added simultaneously with FSH or cholera toxin inhibited the effects on the release of 3H2O without influencing the protein content of the cell cultures. A smaller stimulation of 3H2O production occurred with (Bu)2cAMP (1.0 mM) plus 3-isobutyl-l-methylxanthine (0.1 mM), and this was partially suppressed in the presence of LHRH or the agonist. Parallel studies with Sertoli cells from 15- or -day-old rats demonstrated that culture under appropriate conditions with FSH, cholera toxin, or (Bu)2cAMP (0.5 mM) for 24 h caused an increase in cellular aromatase activity and enhanced secretion into the medium of plasminogen activator. However, no inhibition by LHRH ( (-7) or (-9) M) or the agonist ( (-6) or (-8) M) occurred when the peptides were added either simultaneously or 24 h before the stimulatory agent. Similarly, Sertoli cells from 11-day-old rats treated daily with LHRH agonist for 5 days in culture, showed no inhibition of aromatase activity after a 4-h stimulation with FSH or (Bu)2cAMP. FSH dose-response curves (0-300 ng/ml) for aromatase activity were shown to be similar after 5 days of culture with or without (-8) M LHRH agonist, indicating that the LHRH did not cause a shift in the sensitivity to FSH. The lack of inhibition was seen in Sertoli cell cultures maintained at 37 or 32 C. The enzyme digestion method used to isolated Sertoli cells was not responsible for the lack of effects of LHRH, since cell cultures prepared without the aid of proteolytic enzymes showed similar FSH stimulation of aromatase activity in the presence or absence of (-8) M agonist. Further, there was no evidence of degradation of the LHRH agonist when incubated with Sertoli cell cultures. From these studies, we conclude that 1) granulosa cells and Sertoli cells from immature rats differ in their responses to LHRH, and 2) the immature Sertoli cell is an unlikely target for a direct inhibiting influence of LHRH on spermatogenesis.
[ " ", "Differential", "effects", "of", "luteinizing", "hormone", "-", "releasing", "hormone", "on", "follicle", "-", "stimulating", "hormone", "-", "dependent", "responses", "in", "rat", "granulosa", "cells", "and", "Sertoli", "cells", "in", "vitro", ".", " ", "The", "abilities", "of", "LHRH", "and", "a", "potent", "LHRH", "agonist", "(", "[", "D", "-", "Ser-(But),6", ",", "des", "-", "Gly", "-", "NH210]LHRH", "ethylamide", ")", "inhibit", "FSH", "responses", "by", "rat", "granulosa", "cells", "and", "Sertoli", "cells", "in", "vitro", "have", "been", "compared", ".", "Granulosa", "cells", "isolated", "from", "22-", "or", "25-day", "-", "old", "diethylstilbestrol", "-", "primed", "rats", "and", "cultured", "under", "defined", "conditions", "for", "48", "h", "with", "NIH", "-", "FSH", "-", "S13", "(", " ", "ng", "/", "ml", ")", "or", "cholera", "toxin", "(", "0.1", "microgram", "/", "ml", ")", "showed", "increased", "aromatase", "activity", ",", "as", "determined", "by", "the", "release", "of", "3H2O", "from", "[", "1", "beta-3H]testosterone", ".", "LHRH", "(", " ", "(", "-7", ")", "M", ")", "or", "th", "agonist", "(", " ", "(-8", ")", "M", ")", "added", "simultaneously", "with", "FSH", "or", "cholera", "toxin", "inhibited", "the", "effects", "on", "the", "release", "of", "3H2O", "without", "influencing", "the", "protein", "content", "of", "the", "cell", "cultures", ".", "A", "smaller", "stimulation", "of", "3H2O", "production", "occurred", "with", "(", "Bu)2cAMP", "(", "1.0", "mM", ")", "plus", "3-isobutyl", "-", "l", "-", "methylxanthine", "(", "0.1", "mM", ")", ",", "and", "this", "was", "partially", "suppressed", "in", "the", "presence", "of", "LHRH", "or", "the", "agonist", ".", "Parallel", "studies", "with", "Sertoli", "cells", "from", "15-", "or", " ", "-day", "-", "old", "rats", "demonstrated", "that", "culture", "under", "appropriate", "conditions", "with", "FSH", ",", "cholera", "toxin", ",", "or", "(", "Bu)2cAMP", "(", "0.5", "mM", ")", "for", "24", "h", "caused", "an", "increase", "in", "cellular", "aromatase", "activity", "and", "enhanced", "secretion", "into", "the", "medium", "of", "plasminogen", "activator", ".", "However", ",", "no", "inhibition", "by", "LHRH", "(", " ", "(", "-7", ")", "or", " ", "(", "-9", ")", "M", ")", "or", "the", "agonist", "(", " ", "(", "-6", ")", "or", " ", "(-8", ")", "M", ")", "occurred", "when", "the", "peptides", "were", "added", "either", "simultaneously", "or", "24", "h", "before", "the", "stimulatory", "agent", ".", "Similarly", ",", "Sertoli", "cells", "from", "11-day", "-", "old", "rats", "treated", "daily", "with", "LHRH", "agonist", "for", "5", "days", "in", "culture", ",", "showed", "no", "inhibition", "of", "aromatase", "activity", "after", "a", "4-h", "stimulation", "with", "FSH", "or", "(", "Bu)2cAMP", ".", "FSH", "dose", "-", "response", "curves", "(", "0", "-", "300", "ng", "/", "ml", ")", "for", "aromatase", "activity", "were", "shown", "to", "be", "similar", "after", "5", "days", "of", "culture", "with", "or", "without", " ", "(-8", ")", "M", "LHRH", "agonist", ",", "indicating", "that", "the", "LHRH", "did", "not", "cause", "a", "shift", "in", "the", "sensitivity", "to", "FSH", ".", "The", "lack", "of", "inhibition", "was", "seen", "in", "Sertoli", "cell", "cultures", "maintained", "at", "37", "or", "32", "C.", "The", "enzyme", "digestion", "method", "used", "to", "isolated", "Sertoli", "cells", "was", "not", "responsible", "for", "the", "lack", "of", "effects", "of", "LHRH", ",", "since", "cell", "cultures", "prepared", "without", "the", "aid", "of", "proteolytic", "enzymes", "showed", "similar", "FSH", "stimulation", "of", "aromatase", "activity", "in", "the", "presence", "or", "absence", "of", " ", "(-8", ")", "M", "agonist", ".", "Further", ",", "there", "was", "no", "evidence", "of", "degradation", "of", "the", "LHRH", "agonist", "when", "incubated", "with", "Sertoli", "cell", "cultures", ".", "From", "these", "studies", ",", "we", "conclude", "that", "1", ")", "granulosa", "cells", "and", "Sertoli", "cells", "from", "immature", "rats", "differ", "in", "their", "responses", "to", "LHRH", ",", "and", "2", ")", "the", "immature", "Sertoli", "cell", "is", "an", "unlikely", "target", "for", "a", "direct", "inhibiting", "influence", "of", "LHRH", "on", "spermatogenesis", "." ]
[ "", "IUPAC", "TRIVIAL", "TRIVIALVAR", "SUM" ]
[ D - Ser-(But),6 , des - Gly - NH210]LHRH ethylamide, diethylstilbestrol, NIH - FSH - S13, cholera toxin, [ 1 beta-3H]testosterone, cholera toxin, 3H2O, 3H2O, ( Bu)2cAMP, 3-isobutyl - l - methylxanthine, cholera toxin, ( Bu)2cAMP, ( Bu)2cAMP
example-9_task2
Sentence: Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro. The abilities of LHRH and a potent LHRH agonist ([D-Ser-(But),6, des-Gly-NH210]LHRH ethylamide) inhibit FSH responses by rat granulosa cells and Sertoli cells in vitro have been compared. Granulosa cells isolated from 22- or 25-day-old diethylstilbestrol-primed rats and cultured under defined conditions for 48 h with NIH-FSH-S13 ( ng/ml) or cholera toxin (0.1 microgram/ml) showed increased aromatase activity, as determined by the release of 3H2O from [1 beta-3H]testosterone. LHRH ( (-7) M) or th agonist ( (-8) M) added simultaneously with FSH or cholera toxin inhibited the effects on the release of 3H2O without influencing the protein content of the cell cultures. A smaller stimulation of 3H2O production occurred with (Bu)2cAMP (1.0 mM) plus 3-isobutyl-l-methylxanthine (0.1 mM), and this was partially suppressed in the presence of LHRH or the agonist. Parallel studies with Sertoli cells from 15- or -day-old rats demonstrated that culture under appropriate conditions with FSH, cholera toxin, or (Bu)2cAMP (0.5 mM) for 24 h caused an increase in cellular aromatase activity and enhanced secretion into the medium of plasminogen activator. However, no inhibition by LHRH ( (-7) or (-9) M) or the agonist ( (-6) or (-8) M) occurred when the peptides were added either simultaneously or 24 h before the stimulatory agent. Similarly, Sertoli cells from 11-day-old rats treated daily with LHRH agonist for 5 days in culture, showed no inhibition of aromatase activity after a 4-h stimulation with FSH or (Bu)2cAMP. FSH dose-response curves (0-300 ng/ml) for aromatase activity were shown to be similar after 5 days of culture with or without (-8) M LHRH agonist, indicating that the LHRH did not cause a shift in the sensitivity to FSH. The lack of inhibition was seen in Sertoli cell cultures maintained at 37 or 32 C. The enzyme digestion method used to isolated Sertoli cells was not responsible for the lack of effects of LHRH, since cell cultures prepared without the aid of proteolytic enzymes showed similar FSH stimulation of aromatase activity in the presence or absence of (-8) M agonist. Further, there was no evidence of degradation of the LHRH agonist when incubated with Sertoli cell cultures. From these studies, we conclude that 1) granulosa cells and Sertoli cells from immature rats differ in their responses to LHRH, and 2) the immature Sertoli cell is an unlikely target for a direct inhibiting influence of LHRH on spermatogenesis. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "I-TRIVIALVAR", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "B-SUM", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SUM", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro. The abilities of LHRH and a potent LHRH agonist ([D-Ser-(But),6, des-Gly-NH210]LHRH ethylamide) inhibit FSH responses by rat granulosa cells and Sertoli cells in vitro have been compared. Granulosa cells isolated from 22- or 25-day-old diethylstilbestrol-primed rats and cultured under defined conditions for 48 h with NIH-FSH-S13 ( ng/ml) or cholera toxin (0.1 microgram/ml) showed increased aromatase activity, as determined by the release of 3H2O from [1 beta-3H]testosterone. LHRH ( (-7) M) or th agonist ( (-8) M) added simultaneously with FSH or cholera toxin inhibited the effects on the release of 3H2O without influencing the protein content of the cell cultures. A smaller stimulation of 3H2O production occurred with (Bu)2cAMP (1.0 mM) plus 3-isobutyl-l-methylxanthine (0.1 mM), and this was partially suppressed in the presence of LHRH or the agonist. Parallel studies with Sertoli cells from 15- or -day-old rats demonstrated that culture under appropriate conditions with FSH, cholera toxin, or (Bu)2cAMP (0.5 mM) for 24 h caused an increase in cellular aromatase activity and enhanced secretion into the medium of plasminogen activator. However, no inhibition by LHRH ( (-7) or (-9) M) or the agonist ( (-6) or (-8) M) occurred when the peptides were added either simultaneously or 24 h before the stimulatory agent. Similarly, Sertoli cells from 11-day-old rats treated daily with LHRH agonist for 5 days in culture, showed no inhibition of aromatase activity after a 4-h stimulation with FSH or (Bu)2cAMP. FSH dose-response curves (0-300 ng/ml) for aromatase activity were shown to be similar after 5 days of culture with or without (-8) M LHRH agonist, indicating that the LHRH did not cause a shift in the sensitivity to FSH. The lack of inhibition was seen in Sertoli cell cultures maintained at 37 or 32 C. The enzyme digestion method used to isolated Sertoli cells was not responsible for the lack of effects of LHRH, since cell cultures prepared without the aid of proteolytic enzymes showed similar FSH stimulation of aromatase activity in the presence or absence of (-8) M agonist. Further, there was no evidence of degradation of the LHRH agonist when incubated with Sertoli cell cultures. From these studies, we conclude that 1) granulosa cells and Sertoli cells from immature rats differ in their responses to LHRH, and 2) the immature Sertoli cell is an unlikely target for a direct inhibiting influence of LHRH on spermatogenesis.
[ " ", "Differential", "effects", "of", "luteinizing", "hormone", "-", "releasing", "hormone", "on", "follicle", "-", "stimulating", "hormone", "-", "dependent", "responses", "in", "rat", "granulosa", "cells", "and", "Sertoli", "cells", "in", "vitro", ".", " ", "The", "abilities", "of", "LHRH", "and", "a", "potent", "LHRH", "agonist", "(", "[", "D", "-", "Ser-(But),6", ",", "des", "-", "Gly", "-", "NH210]LHRH", "ethylamide", ")", "inhibit", "FSH", "responses", "by", "rat", "granulosa", "cells", "and", "Sertoli", "cells", "in", "vitro", "have", "been", "compared", ".", "Granulosa", "cells", "isolated", "from", "22-", "or", "25-day", "-", "old", "diethylstilbestrol", "-", "primed", "rats", "and", "cultured", "under", "defined", "conditions", "for", "48", "h", "with", "NIH", "-", "FSH", "-", "S13", "(", " ", "ng", "/", "ml", ")", "or", "cholera", "toxin", "(", "0.1", "microgram", "/", "ml", ")", "showed", "increased", "aromatase", "activity", ",", "as", "determined", "by", "the", "release", "of", "3H2O", "from", "[", "1", "beta-3H]testosterone", ".", "LHRH", "(", " ", "(", "-7", ")", "M", ")", "or", "th", "agonist", "(", " ", "(-8", ")", "M", ")", "added", "simultaneously", "with", "FSH", "or", "cholera", "toxin", "inhibited", "the", "effects", "on", "the", "release", "of", "3H2O", "without", "influencing", "the", "protein", "content", "of", "the", "cell", "cultures", ".", "A", "smaller", "stimulation", "of", "3H2O", "production", "occurred", "with", "(", "Bu)2cAMP", "(", "1.0", "mM", ")", "plus", "3-isobutyl", "-", "l", "-", "methylxanthine", "(", "0.1", "mM", ")", ",", "and", "this", "was", "partially", "suppressed", "in", "the", "presence", "of", "LHRH", "or", "the", "agonist", ".", "Parallel", "studies", "with", "Sertoli", "cells", "from", "15-", "or", " ", "-day", "-", "old", "rats", "demonstrated", "that", "culture", "under", "appropriate", "conditions", "with", "FSH", ",", "cholera", "toxin", ",", "or", "(", "Bu)2cAMP", "(", "0.5", "mM", ")", "for", "24", "h", "caused", "an", "increase", "in", "cellular", "aromatase", "activity", "and", "enhanced", "secretion", "into", "the", "medium", "of", "plasminogen", "activator", ".", "However", ",", "no", "inhibition", "by", "LHRH", "(", " ", "(", "-7", ")", "or", " ", "(", "-9", ")", "M", ")", "or", "the", "agonist", "(", " ", "(", "-6", ")", "or", " ", "(-8", ")", "M", ")", "occurred", "when", "the", "peptides", "were", "added", "either", "simultaneously", "or", "24", "h", "before", "the", "stimulatory", "agent", ".", "Similarly", ",", "Sertoli", "cells", "from", "11-day", "-", "old", "rats", "treated", "daily", "with", "LHRH", "agonist", "for", "5", "days", "in", "culture", ",", "showed", "no", "inhibition", "of", "aromatase", "activity", "after", "a", "4-h", "stimulation", "with", "FSH", "or", "(", "Bu)2cAMP", ".", "FSH", "dose", "-", "response", "curves", "(", "0", "-", "300", "ng", "/", "ml", ")", "for", "aromatase", "activity", "were", "shown", "to", "be", "similar", "after", "5", "days", "of", "culture", "with", "or", "without", " ", "(-8", ")", "M", "LHRH", "agonist", ",", "indicating", "that", "the", "LHRH", "did", "not", "cause", "a", "shift", "in", "the", "sensitivity", "to", "FSH", ".", "The", "lack", "of", "inhibition", "was", "seen", "in", "Sertoli", "cell", "cultures", "maintained", "at", "37", "or", "32", "C.", "The", "enzyme", "digestion", "method", "used", "to", "isolated", "Sertoli", "cells", "was", "not", "responsible", "for", "the", "lack", "of", "effects", "of", "LHRH", ",", "since", "cell", "cultures", "prepared", "without", "the", "aid", "of", "proteolytic", "enzymes", "showed", "similar", "FSH", "stimulation", "of", "aromatase", "activity", "in", "the", "presence", "or", "absence", "of", " ", "(-8", ")", "M", "agonist", ".", "Further", ",", "there", "was", "no", "evidence", "of", "degradation", "of", "the", "LHRH", "agonist", "when", "incubated", "with", "Sertoli", "cell", "cultures", ".", "From", "these", "studies", ",", "we", "conclude", "that", "1", ")", "granulosa", "cells", "and", "Sertoli", "cells", "from", "immature", "rats", "differ", "in", "their", "responses", "to", "LHRH", ",", "and", "2", ")", "the", "immature", "Sertoli", "cell", "is", "an", "unlikely", "target", "for", "a", "direct", "inhibiting", "influence", "of", "LHRH", "on", "spermatogenesis", "." ]
[ "", "IUPAC", "TRIVIAL", "TRIVIALVAR", "SUM" ]
Inducible nitric oxide is an inorganic, autoregulatory feedback inhibitor is an inorganic, vascular inflammation is an other_name
75055_task0
Sentence: Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: inorganic, other_name
[ "B-inorganic", "I-inorganic", "I-inorganic", "O", "O", "B-inorganic", "I-inorganic", "I-inorganic", "O", "B-other_name", "I-other_name", "O" ]
Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation.
[ "Inducible", "nitric", "oxide", ":", "an", "autoregulatory", "feedback", "inhibitor", "of", "vascular", "inflammation", "." ]
[ "other_name", "cell_line", "inorganic", "amino_acid_monomer", "DNA_family_or_group", "protein_molecule", "cell_component", "protein_complex", "cell_type", "protein_subunit", "DNA_domain_or_region", "lipid", "protein_family_or_group" ]
Inducible nitric oxide is an inorganic, autoregulatory feedback inhibitor is an inorganic, vascular inflammation is an other_name
75055_task1
Sentence: Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. Instructions: please typing these entity words according to sentence: Inducible nitric oxide, autoregulatory feedback inhibitor, vascular inflammation Options: inorganic, other_name
[ "B-inorganic", "I-inorganic", "I-inorganic", "O", "O", "B-inorganic", "I-inorganic", "I-inorganic", "O", "B-other_name", "I-other_name", "O" ]
Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation.
[ "Inducible", "nitric", "oxide", ":", "an", "autoregulatory", "feedback", "inhibitor", "of", "vascular", "inflammation", "." ]
[ "other_name", "cell_line", "inorganic", "amino_acid_monomer", "DNA_family_or_group", "protein_molecule", "cell_component", "protein_complex", "cell_type", "protein_subunit", "DNA_domain_or_region", "lipid", "protein_family_or_group" ]
Inducible nitric oxide, autoregulatory feedback inhibitor, vascular inflammation
75055_task2
Sentence: Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. Instructions: please extract entity words from the input sentence
[ "B-inorganic", "I-inorganic", "I-inorganic", "O", "O", "B-inorganic", "I-inorganic", "I-inorganic", "O", "B-other_name", "I-other_name", "O" ]
Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation.
[ "Inducible", "nitric", "oxide", ":", "an", "autoregulatory", "feedback", "inhibitor", "of", "vascular", "inflammation", "." ]
[ "other_name", "cell_line", "inorganic", "amino_acid_monomer", "DNA_family_or_group", "protein_molecule", "cell_component", "protein_complex", "cell_type", "protein_subunit", "DNA_domain_or_region", "lipid", "protein_family_or_group" ]
actin is a Gene/protein/RNA, fimbrin is a Gene/protein/RNA
384_task0
Sentence: Immunohistochemical identification and localization of actin and fimbrin in vestibular hair cells in the normal guinea pig and in a strain of the waltzing guinea pig. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA
[ "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Immunohistochemical identification and localization of actin and fimbrin in vestibular hair cells in the normal guinea pig and in a strain of the waltzing guinea pig.
[ "Immunohistochemical", "identification", "and", "localization", "of", "actin", "and", "fimbrin", "in", "vestibular", "hair", "cells", "in", "the", "normal", "guinea", "pig", "and", "in", "a", "strain", "of", "the", "waltzing", "guinea", "pig", "." ]
[ "Gene/protein/RNA" ]
actin is a Gene/protein/RNA, fimbrin is a Gene/protein/RNA
384_task1
Sentence: Immunohistochemical identification and localization of actin and fimbrin in vestibular hair cells in the normal guinea pig and in a strain of the waltzing guinea pig. Instructions: please typing these entity words according to sentence: actin, fimbrin Options: Gene/protein/RNA
[ "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Immunohistochemical identification and localization of actin and fimbrin in vestibular hair cells in the normal guinea pig and in a strain of the waltzing guinea pig.
[ "Immunohistochemical", "identification", "and", "localization", "of", "actin", "and", "fimbrin", "in", "vestibular", "hair", "cells", "in", "the", "normal", "guinea", "pig", "and", "in", "a", "strain", "of", "the", "waltzing", "guinea", "pig", "." ]
[ "Gene/protein/RNA" ]
actin, fimbrin
384_task2
Sentence: Immunohistochemical identification and localization of actin and fimbrin in vestibular hair cells in the normal guinea pig and in a strain of the waltzing guinea pig. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Immunohistochemical identification and localization of actin and fimbrin in vestibular hair cells in the normal guinea pig and in a strain of the waltzing guinea pig.
[ "Immunohistochemical", "identification", "and", "localization", "of", "actin", "and", "fimbrin", "in", "vestibular", "hair", "cells", "in", "the", "normal", "guinea", "pig", "and", "in", "a", "strain", "of", "the", "waltzing", "guinea", "pig", "." ]
[ "Gene/protein/RNA" ]
Objectives is an umlsterm, Germany is an umlsterm, children is an umlsterm, age is an umlsterm, origin is an umlsterm, age group is an umlsterm, prevalence is an umlsterm, asthma is an umlsterm, diseases is an umlsterm, children is an umlsterm, Germany is an umlsterm
MonatsschriftKinderheilkunde.91470328.eng.abstr_task0
Sentence: Objectives : In Germany 4.2% ( in Munich 8.6% ) of all children under 15 years of age are of Turkish origin , representing the largest ethnic minority in this age group . However , very little is known about the prevalence , severity and management of asthma and other atopic diseases in Turkish children living in Germany . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Objectives : In Germany 4.2% ( in Munich 8.6% ) of all children under 15 years of age are of Turkish origin , representing the largest ethnic minority in this age group . However , very little is known about the prevalence , severity and management of asthma and other atopic diseases in Turkish children living in Germany .
[ "Objectives", ":", "In", "Germany", "4.2", "%", "(", "in", "Munich", "8.6", "%", ")", "of", "all", "children", "under", "15", "years", "of", "age", "are", "of", "Turkish", "origin", ",", "representing", "the", "largest", "ethnic", "minority", "in", "this", "age", "group", ".", "However", ",", "very", "little", "is", "known", "about", "the", "prevalence", ",", "severity", "and", "management", "of", "asthma", "and", "other", "atopic", "diseases", "in", "Turkish", "children", "living", "in", "Germany", "." ]
[ "umlsterm" ]
Objectives is an umlsterm, Germany is an umlsterm, children is an umlsterm, age is an umlsterm, origin is an umlsterm, age group is an umlsterm, prevalence is an umlsterm, asthma is an umlsterm, diseases is an umlsterm, children is an umlsterm, Germany is an umlsterm
MonatsschriftKinderheilkunde.91470328.eng.abstr_task1
Sentence: Objectives : In Germany 4.2% ( in Munich 8.6% ) of all children under 15 years of age are of Turkish origin , representing the largest ethnic minority in this age group . However , very little is known about the prevalence , severity and management of asthma and other atopic diseases in Turkish children living in Germany . Instructions: please typing these entity words according to sentence: Objectives, Germany, children, age, origin, age group, prevalence, asthma, diseases, children, Germany Options: umlsterm
[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Objectives : In Germany 4.2% ( in Munich 8.6% ) of all children under 15 years of age are of Turkish origin , representing the largest ethnic minority in this age group . However , very little is known about the prevalence , severity and management of asthma and other atopic diseases in Turkish children living in Germany .
[ "Objectives", ":", "In", "Germany", "4.2", "%", "(", "in", "Munich", "8.6", "%", ")", "of", "all", "children", "under", "15", "years", "of", "age", "are", "of", "Turkish", "origin", ",", "representing", "the", "largest", "ethnic", "minority", "in", "this", "age", "group", ".", "However", ",", "very", "little", "is", "known", "about", "the", "prevalence", ",", "severity", "and", "management", "of", "asthma", "and", "other", "atopic", "diseases", "in", "Turkish", "children", "living", "in", "Germany", "." ]
[ "umlsterm" ]
Objectives, Germany, children, age, origin, age group, prevalence, asthma, diseases, children, Germany
MonatsschriftKinderheilkunde.91470328.eng.abstr_task2
Sentence: Objectives : In Germany 4.2% ( in Munich 8.6% ) of all children under 15 years of age are of Turkish origin , representing the largest ethnic minority in this age group . However , very little is known about the prevalence , severity and management of asthma and other atopic diseases in Turkish children living in Germany . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Objectives : In Germany 4.2% ( in Munich 8.6% ) of all children under 15 years of age are of Turkish origin , representing the largest ethnic minority in this age group . However , very little is known about the prevalence , severity and management of asthma and other atopic diseases in Turkish children living in Germany .
[ "Objectives", ":", "In", "Germany", "4.2", "%", "(", "in", "Munich", "8.6", "%", ")", "of", "all", "children", "under", "15", "years", "of", "age", "are", "of", "Turkish", "origin", ",", "representing", "the", "largest", "ethnic", "minority", "in", "this", "age", "group", ".", "However", ",", "very", "little", "is", "known", "about", "the", "prevalence", ",", "severity", "and", "management", "of", "asthma", "and", "other", "atopic", "diseases", "in", "Turkish", "children", "living", "in", "Germany", "." ]
[ "umlsterm" ]
RU 486 is a Intervention_Pharmacological, pregnant is a Participant_Condition, non - pregnant is a Participant_Condition, women is a Participant_Sex, RU 42633-monodemethyl , RU 42848-didemethyl is a Intervention_Pharmacological, RU 42698-hydroxymetabolite is a Intervention_Pharmacological, nine is a Participant_Sample-size, 36 is a Participant_Sample-size, Blood samples is a Outcome_Physical, Peak concentrations of RU 486 is a Outcome_Physical, Plasma concentrations is a Outcome_Physical, Plasma concentrations of RU 42633 is a Outcome_Physical, plasma concentrations of the metabolites is a Outcome_Physical, RU 486 to RU 42633 is a Outcome_Physical
85599_task0
Sentence: Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women . RU 486 and three of its metabolites ( RU 42633-monodemethyl , RU 42848-didemethyl , and RU 42698-hydroxymetabolite ) were determined by HPLC in plasma from nine non-pregnant and 36 pregnant women . Each non-pregnant subject took an oral dose of RU 486 ( 25 , 100 , 400 and 600 mg consecutively ) once per menstrual cycle . Six of the nine women also received a dose of 200 mg . The 36 pregnant women were randomized into four groups which were given a single dose of 25 , 100 , 400 or 600 mg RU 486 . Blood samples were taken up to 120 h after dosing . Peak concentrations of RU 486 occurred on most occasions within 2 h. Plasma concentrations at 1 h and at 24 h increased in proportion to log dose . There was a wide variability ( up to ten-fold ) in the pharmacokinetic parameters within each dose group . Plasma concentrations of RU 42633 were similar to those of RU 486 but concentrations of RU 42848 and RU 42698 were much lower . As with RU 486 , the plasma concentrations of the metabolites were maintained at high levels for up to 48-72 h after dosing . The findings were consistent with a rapid metabolism of RU 486 to RU 42633 ; removal of the second methyl group leading to RU 42698 occurred much more slowly and to a much less extent than removal of the first . There appeared to be no significant differences between the non-pregnant and pregnant women in either the plasma concentrations or pharmacokinetic parameters of RU 486 and its metabolites . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Sex, Participant_Condition, Outcome_Physical, Participant_Sample-size
[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women . RU 486 and three of its metabolites ( RU 42633-monodemethyl , RU 42848-didemethyl , and RU 42698-hydroxymetabolite ) were determined by HPLC in plasma from nine non-pregnant and 36 pregnant women . Each non-pregnant subject took an oral dose of RU 486 ( 25 , 100 , 400 and 600 mg consecutively ) once per menstrual cycle . Six of the nine women also received a dose of 200 mg . The 36 pregnant women were randomized into four groups which were given a single dose of 25 , 100 , 400 or 600 mg RU 486 . Blood samples were taken up to 120 h after dosing . Peak concentrations of RU 486 occurred on most occasions within 2 h. Plasma concentrations at 1 h and at 24 h increased in proportion to log dose . There was a wide variability ( up to ten-fold ) in the pharmacokinetic parameters within each dose group . Plasma concentrations of RU 42633 were similar to those of RU 486 but concentrations of RU 42848 and RU 42698 were much lower . As with RU 486 , the plasma concentrations of the metabolites were maintained at high levels for up to 48-72 h after dosing . The findings were consistent with a rapid metabolism of RU 486 to RU 42633 ; removal of the second methyl group leading to RU 42698 occurred much more slowly and to a much less extent than removal of the first . There appeared to be no significant differences between the non-pregnant and pregnant women in either the plasma concentrations or pharmacokinetic parameters of RU 486 and its metabolites .
[ "Pharmacokinetic", "study", "of", "RU", "486", "and", "its", "metabolites", "after", "oral", "administration", "of", "single", "doses", "to", "pregnant", "and", "non", "-", "pregnant", "women", ".", "RU", "486", "and", "three", "of", "its", "metabolites", "(", "RU", "42633-monodemethyl", ",", "RU", "42848-didemethyl", ",", "and", "RU", "42698-hydroxymetabolite", ")", "were", "determined", "by", "HPLC", "in", "plasma", "from", "nine", "non", "-", "pregnant", "and", "36", "pregnant", "women", ".", "Each", "non", "-", "pregnant", "subject", "took", "an", "oral", "dose", "of", "RU", "486", "(", "25", ",", "100", ",", "400", "and", "600", "mg", "consecutively", ")", "once", "per", "menstrual", "cycle", ".", "Six", "of", "the", "nine", "women", "also", "received", "a", "dose", "of", "200", "mg", ".", "The", "36", "pregnant", "women", "were", "randomized", "into", "four", "groups", "which", "were", "given", "a", "single", "dose", "of", "25", ",", "100", ",", "400", "or", "600", "mg", "RU", "486", ".", "Blood", "samples", "were", "taken", "up", "to", "120", "h", "after", "dosing", ".", "Peak", "concentrations", "of", "RU", "486", "occurred", "on", "most", "occasions", "within", "2", "h.", "Plasma", "concentrations", "at", "1", "h", "and", "at", "24", "h", "increased", "in", "proportion", "to", "log", "dose", ".", "There", "was", "a", "wide", "variability", "(", "up", "to", "ten", "-", "fold", ")", "in", "the", "pharmacokinetic", "parameters", "within", "each", "dose", "group", ".", "Plasma", "concentrations", "of", "RU", "42633", "were", "similar", "to", "those", "of", "RU", "486", "but", "concentrations", "of", "RU", "42848", "and", "RU", "42698", "were", "much", "lower", ".", "As", "with", "RU", "486", ",", "the", "plasma", "concentrations", "of", "the", "metabolites", "were", "maintained", "at", "high", "levels", "for", "up", "to", "48", "-", "72", "h", "after", "dosing", ".", "The", "findings", "were", "consistent", "with", "a", "rapid", "metabolism", "of", "RU", "486", "to", "RU", "42633", ";", "removal", "of", "the", "second", "methyl", "group", "leading", "to", "RU", "42698", "occurred", "much", "more", "slowly", "and", "to", "a", "much", "less", "extent", "than", "removal", "of", "the", "first", ".", "There", "appeared", "to", "be", "no", "significant", "differences", "between", "the", "non", "-", "pregnant", "and", "pregnant", "women", "in", "either", "the", "plasma", "concentrations", "or", "pharmacokinetic", "parameters", "of", "RU", "486", "and", "its", "metabolites", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Participant_Sex", "Participant_Sample-size" ]
RU 486 is a Intervention_Pharmacological, pregnant is a Participant_Condition, non - pregnant is a Participant_Condition, women is a Participant_Sex, RU 42633-monodemethyl , RU 42848-didemethyl is a Intervention_Pharmacological, RU 42698-hydroxymetabolite is a Intervention_Pharmacological, nine is a Participant_Sample-size, 36 is a Participant_Sample-size, Blood samples is a Outcome_Physical, Peak concentrations of RU 486 is a Outcome_Physical, Plasma concentrations is a Outcome_Physical, Plasma concentrations of RU 42633 is a Outcome_Physical, plasma concentrations of the metabolites is a Outcome_Physical, RU 486 to RU 42633 is a Outcome_Physical
85599_task1
Sentence: Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women . RU 486 and three of its metabolites ( RU 42633-monodemethyl , RU 42848-didemethyl , and RU 42698-hydroxymetabolite ) were determined by HPLC in plasma from nine non-pregnant and 36 pregnant women . Each non-pregnant subject took an oral dose of RU 486 ( 25 , 100 , 400 and 600 mg consecutively ) once per menstrual cycle . Six of the nine women also received a dose of 200 mg . The 36 pregnant women were randomized into four groups which were given a single dose of 25 , 100 , 400 or 600 mg RU 486 . Blood samples were taken up to 120 h after dosing . Peak concentrations of RU 486 occurred on most occasions within 2 h. Plasma concentrations at 1 h and at 24 h increased in proportion to log dose . There was a wide variability ( up to ten-fold ) in the pharmacokinetic parameters within each dose group . Plasma concentrations of RU 42633 were similar to those of RU 486 but concentrations of RU 42848 and RU 42698 were much lower . As with RU 486 , the plasma concentrations of the metabolites were maintained at high levels for up to 48-72 h after dosing . The findings were consistent with a rapid metabolism of RU 486 to RU 42633 ; removal of the second methyl group leading to RU 42698 occurred much more slowly and to a much less extent than removal of the first . There appeared to be no significant differences between the non-pregnant and pregnant women in either the plasma concentrations or pharmacokinetic parameters of RU 486 and its metabolites . Instructions: please typing these entity words according to sentence: RU 486, pregnant, non - pregnant, women, RU 42633-monodemethyl , RU 42848-didemethyl, RU 42698-hydroxymetabolite, nine, 36, Blood samples, Peak concentrations of RU 486, Plasma concentrations, Plasma concentrations of RU 42633, plasma concentrations of the metabolites, RU 486 to RU 42633 Options: Intervention_Pharmacological, Participant_Sex, Participant_Condition, Outcome_Physical, Participant_Sample-size
[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women . RU 486 and three of its metabolites ( RU 42633-monodemethyl , RU 42848-didemethyl , and RU 42698-hydroxymetabolite ) were determined by HPLC in plasma from nine non-pregnant and 36 pregnant women . Each non-pregnant subject took an oral dose of RU 486 ( 25 , 100 , 400 and 600 mg consecutively ) once per menstrual cycle . Six of the nine women also received a dose of 200 mg . The 36 pregnant women were randomized into four groups which were given a single dose of 25 , 100 , 400 or 600 mg RU 486 . Blood samples were taken up to 120 h after dosing . Peak concentrations of RU 486 occurred on most occasions within 2 h. Plasma concentrations at 1 h and at 24 h increased in proportion to log dose . There was a wide variability ( up to ten-fold ) in the pharmacokinetic parameters within each dose group . Plasma concentrations of RU 42633 were similar to those of RU 486 but concentrations of RU 42848 and RU 42698 were much lower . As with RU 486 , the plasma concentrations of the metabolites were maintained at high levels for up to 48-72 h after dosing . The findings were consistent with a rapid metabolism of RU 486 to RU 42633 ; removal of the second methyl group leading to RU 42698 occurred much more slowly and to a much less extent than removal of the first . There appeared to be no significant differences between the non-pregnant and pregnant women in either the plasma concentrations or pharmacokinetic parameters of RU 486 and its metabolites .
[ "Pharmacokinetic", "study", "of", "RU", "486", "and", "its", "metabolites", "after", "oral", "administration", "of", "single", "doses", "to", "pregnant", "and", "non", "-", "pregnant", "women", ".", "RU", "486", "and", "three", "of", "its", "metabolites", "(", "RU", "42633-monodemethyl", ",", "RU", "42848-didemethyl", ",", "and", "RU", "42698-hydroxymetabolite", ")", "were", "determined", "by", "HPLC", "in", "plasma", "from", "nine", "non", "-", "pregnant", "and", "36", "pregnant", "women", ".", "Each", "non", "-", "pregnant", "subject", "took", "an", "oral", "dose", "of", "RU", "486", "(", "25", ",", "100", ",", "400", "and", "600", "mg", "consecutively", ")", "once", "per", "menstrual", "cycle", ".", "Six", "of", "the", "nine", "women", "also", "received", "a", "dose", "of", "200", "mg", ".", "The", "36", "pregnant", "women", "were", "randomized", "into", "four", "groups", "which", "were", "given", "a", "single", "dose", "of", "25", ",", "100", ",", "400", "or", "600", "mg", "RU", "486", ".", "Blood", "samples", "were", "taken", "up", "to", "120", "h", "after", "dosing", ".", "Peak", "concentrations", "of", "RU", "486", "occurred", "on", "most", "occasions", "within", "2", "h.", "Plasma", "concentrations", "at", "1", "h", "and", "at", "24", "h", "increased", "in", "proportion", "to", "log", "dose", ".", "There", "was", "a", "wide", "variability", "(", "up", "to", "ten", "-", "fold", ")", "in", "the", "pharmacokinetic", "parameters", "within", "each", "dose", "group", ".", "Plasma", "concentrations", "of", "RU", "42633", "were", "similar", "to", "those", "of", "RU", "486", "but", "concentrations", "of", "RU", "42848", "and", "RU", "42698", "were", "much", "lower", ".", "As", "with", "RU", "486", ",", "the", "plasma", "concentrations", "of", "the", "metabolites", "were", "maintained", "at", "high", "levels", "for", "up", "to", "48", "-", "72", "h", "after", "dosing", ".", "The", "findings", "were", "consistent", "with", "a", "rapid", "metabolism", "of", "RU", "486", "to", "RU", "42633", ";", "removal", "of", "the", "second", "methyl", "group", "leading", "to", "RU", "42698", "occurred", "much", "more", "slowly", "and", "to", "a", "much", "less", "extent", "than", "removal", "of", "the", "first", ".", "There", "appeared", "to", "be", "no", "significant", "differences", "between", "the", "non", "-", "pregnant", "and", "pregnant", "women", "in", "either", "the", "plasma", "concentrations", "or", "pharmacokinetic", "parameters", "of", "RU", "486", "and", "its", "metabolites", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Participant_Sex", "Participant_Sample-size" ]
RU 486, pregnant, non - pregnant, women, RU 42633-monodemethyl , RU 42848-didemethyl, RU 42698-hydroxymetabolite, nine, 36, Blood samples, Peak concentrations of RU 486, Plasma concentrations, Plasma concentrations of RU 42633, plasma concentrations of the metabolites, RU 486 to RU 42633
85599_task2
Sentence: Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women . RU 486 and three of its metabolites ( RU 42633-monodemethyl , RU 42848-didemethyl , and RU 42698-hydroxymetabolite ) were determined by HPLC in plasma from nine non-pregnant and 36 pregnant women . Each non-pregnant subject took an oral dose of RU 486 ( 25 , 100 , 400 and 600 mg consecutively ) once per menstrual cycle . Six of the nine women also received a dose of 200 mg . The 36 pregnant women were randomized into four groups which were given a single dose of 25 , 100 , 400 or 600 mg RU 486 . Blood samples were taken up to 120 h after dosing . Peak concentrations of RU 486 occurred on most occasions within 2 h. Plasma concentrations at 1 h and at 24 h increased in proportion to log dose . There was a wide variability ( up to ten-fold ) in the pharmacokinetic parameters within each dose group . Plasma concentrations of RU 42633 were similar to those of RU 486 but concentrations of RU 42848 and RU 42698 were much lower . As with RU 486 , the plasma concentrations of the metabolites were maintained at high levels for up to 48-72 h after dosing . The findings were consistent with a rapid metabolism of RU 486 to RU 42633 ; removal of the second methyl group leading to RU 42698 occurred much more slowly and to a much less extent than removal of the first . There appeared to be no significant differences between the non-pregnant and pregnant women in either the plasma concentrations or pharmacokinetic parameters of RU 486 and its metabolites . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women . RU 486 and three of its metabolites ( RU 42633-monodemethyl , RU 42848-didemethyl , and RU 42698-hydroxymetabolite ) were determined by HPLC in plasma from nine non-pregnant and 36 pregnant women . Each non-pregnant subject took an oral dose of RU 486 ( 25 , 100 , 400 and 600 mg consecutively ) once per menstrual cycle . Six of the nine women also received a dose of 200 mg . The 36 pregnant women were randomized into four groups which were given a single dose of 25 , 100 , 400 or 600 mg RU 486 . Blood samples were taken up to 120 h after dosing . Peak concentrations of RU 486 occurred on most occasions within 2 h. Plasma concentrations at 1 h and at 24 h increased in proportion to log dose . There was a wide variability ( up to ten-fold ) in the pharmacokinetic parameters within each dose group . Plasma concentrations of RU 42633 were similar to those of RU 486 but concentrations of RU 42848 and RU 42698 were much lower . As with RU 486 , the plasma concentrations of the metabolites were maintained at high levels for up to 48-72 h after dosing . The findings were consistent with a rapid metabolism of RU 486 to RU 42633 ; removal of the second methyl group leading to RU 42698 occurred much more slowly and to a much less extent than removal of the first . There appeared to be no significant differences between the non-pregnant and pregnant women in either the plasma concentrations or pharmacokinetic parameters of RU 486 and its metabolites .
[ "Pharmacokinetic", "study", "of", "RU", "486", "and", "its", "metabolites", "after", "oral", "administration", "of", "single", "doses", "to", "pregnant", "and", "non", "-", "pregnant", "women", ".", "RU", "486", "and", "three", "of", "its", "metabolites", "(", "RU", "42633-monodemethyl", ",", "RU", "42848-didemethyl", ",", "and", "RU", "42698-hydroxymetabolite", ")", "were", "determined", "by", "HPLC", "in", "plasma", "from", "nine", "non", "-", "pregnant", "and", "36", "pregnant", "women", ".", "Each", "non", "-", "pregnant", "subject", "took", "an", "oral", "dose", "of", "RU", "486", "(", "25", ",", "100", ",", "400", "and", "600", "mg", "consecutively", ")", "once", "per", "menstrual", "cycle", ".", "Six", "of", "the", "nine", "women", "also", "received", "a", "dose", "of", "200", "mg", ".", "The", "36", "pregnant", "women", "were", "randomized", "into", "four", "groups", "which", "were", "given", "a", "single", "dose", "of", "25", ",", "100", ",", "400", "or", "600", "mg", "RU", "486", ".", "Blood", "samples", "were", "taken", "up", "to", "120", "h", "after", "dosing", ".", "Peak", "concentrations", "of", "RU", "486", "occurred", "on", "most", "occasions", "within", "2", "h.", "Plasma", "concentrations", "at", "1", "h", "and", "at", "24", "h", "increased", "in", "proportion", "to", "log", "dose", ".", "There", "was", "a", "wide", "variability", "(", "up", "to", "ten", "-", "fold", ")", "in", "the", "pharmacokinetic", "parameters", "within", "each", "dose", "group", ".", "Plasma", "concentrations", "of", "RU", "42633", "were", "similar", "to", "those", "of", "RU", "486", "but", "concentrations", "of", "RU", "42848", "and", "RU", "42698", "were", "much", "lower", ".", "As", "with", "RU", "486", ",", "the", "plasma", "concentrations", "of", "the", "metabolites", "were", "maintained", "at", "high", "levels", "for", "up", "to", "48", "-", "72", "h", "after", "dosing", ".", "The", "findings", "were", "consistent", "with", "a", "rapid", "metabolism", "of", "RU", "486", "to", "RU", "42633", ";", "removal", "of", "the", "second", "methyl", "group", "leading", "to", "RU", "42698", "occurred", "much", "more", "slowly", "and", "to", "a", "much", "less", "extent", "than", "removal", "of", "the", "first", ".", "There", "appeared", "to", "be", "no", "significant", "differences", "between", "the", "non", "-", "pregnant", "and", "pregnant", "women", "in", "either", "the", "plasma", "concentrations", "or", "pharmacokinetic", "parameters", "of", "RU", "486", "and", "its", "metabolites", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Participant_Sex", "Participant_Sample-size" ]
Age is a Person, 20 - 70 years old is a Value, Gender is a Person, male or female is a Scope, clinical or pathological diagnosis is a Qualifier, hepatocellular carcinoma is a Condition, HCC is a Condition, untreated is a Qualifier, expected survival is a Observation, > 3 months is a Value, Child - Pugh grade is a Measurement, A is a Value, KPS score is a Measurement, 50 - 100 points is a Value, BCLC stage is a Measurement, 0-B is a Value, indications of hepatectomy is a Observation, No is a Negation, other surgical contraindications is a Observation, women is a Person, reproductive period is a Observation, contraception is a Procedure, in 28 days before treatment , during the treatment process and in 28 days after treatment is a Scope, Men is a Person, contraception is a Procedure, prohibited is a Negation, sperm donation is a Procedure, during the treatment process and in 28 days after treatment is a Scope, prohibited is a Negation, donation is a Procedure, during the treatment process and in 28 days after treatment is a Scope
NCT02399033_inc_task0
Sentence: Age: 20-70 years old; Gender: male or female; clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients; The expected survival> 3 months; Child-Pugh grade in A-level; KPS score with 50-100 points; BCLC stage of 0-B; conform to the indications of hepatectomy; Viable tumor resection confirmed by two highly qualified surgical doctors; No other surgical contraindications. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment; Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment; All patients must be prohibited donation during the treatment process and in 28 days after treatment; In addition to the subjects, prohibitting other people taking this product. patients have a good understanding and could coordinate with investigators for the trial. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Observation, Procedure, Negation, Scope, Measurement
[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "B-Qualifier", "O", "O", "O", "O", "B-Observation", "I-Observation", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Person", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Negation", "O", "O", "B-Procedure", "I-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Age: 20-70 years old; Gender: male or female; clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients; The expected survival> 3 months; Child-Pugh grade in A-level; KPS score with 50-100 points; BCLC stage of 0-B; conform to the indications of hepatectomy; Viable tumor resection confirmed by two highly qualified surgical doctors; No other surgical contraindications. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment; Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment; All patients must be prohibited donation during the treatment process and in 28 days after treatment; In addition to the subjects, prohibitting other people taking this product. patients have a good understanding and could coordinate with investigators for the trial. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial.
[ "Age", ":", "20", "-", "70", "years", "old", ";", "\n", "Gender", ":", "male", "or", "female", ";", "\n", "clinical", "or", "pathological", "diagnosis", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", "in", "previously", "untreated", "patients", ";", "\n", "The", "expected", "survival", ">", "3", "months", ";", "\n", "Child", "-", "Pugh", "grade", "in", "A", "-", "level", ";", "\n", "KPS", "score", "with", "50", "-", "100", "points", ";", "\n", "BCLC", "stage", "of", "0-B", ";", "\n", "conform", "to", "the", "indications", "of", "hepatectomy", ";", "\n", "Viable", "tumor", "resection", "confirmed", "by", "two", "highly", "qualified", "surgical", "doctors", ";", "\n", "No", "other", "surgical", "contraindications", ".", "\n", "women", "in", "the", "reproductive", "period", "must", "be", "completely", "contraception", "in", "28", "days", "before", "treatment", ",", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "Men", "must", "be", "completely", "contraception", "and", "prohibited", "donation", "and", "sperm", "donation", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "All", "patients", "must", "be", "prohibited", "donation", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "In", "addition", "to", "the", "subjects", ",", "prohibitting", "other", "people", "taking", "this", "product", ".", "\n", "patients", "have", "a", "good", "understanding", "and", "could", "coordinate", "with", "investigators", "for", "the", "trial", ".", "\n", "Patients", "enrolled", "in", "the", "trial", "should", "sign", "an", "informed", "consent", "form", ",", "to", "indicate", "understanding", "the", "purpose", "and", "procedure", "of", "the", "trial", ",", "and", "patients", "volunteering", "to", "participate", "in", "the", "trial", ".", "\n" ]
[ "Scope", "Qualifier", "Observation", "Temporal", "Condition", "Measurement", "Value", "Procedure", "Negation", "Reference_point", "Person" ]
Age is a Person, 20 - 70 years old is a Value, Gender is a Person, male or female is a Scope, clinical or pathological diagnosis is a Qualifier, hepatocellular carcinoma is a Condition, HCC is a Condition, untreated is a Qualifier, expected survival is a Observation, > 3 months is a Value, Child - Pugh grade is a Measurement, A is a Value, KPS score is a Measurement, 50 - 100 points is a Value, BCLC stage is a Measurement, 0-B is a Value, indications of hepatectomy is a Observation, No is a Negation, other surgical contraindications is a Observation, women is a Person, reproductive period is a Observation, contraception is a Procedure, in 28 days before treatment , during the treatment process and in 28 days after treatment is a Scope, Men is a Person, contraception is a Procedure, prohibited is a Negation, sperm donation is a Procedure, during the treatment process and in 28 days after treatment is a Scope, prohibited is a Negation, donation is a Procedure, during the treatment process and in 28 days after treatment is a Scope
NCT02399033_inc_task1
Sentence: Age: 20-70 years old; Gender: male or female; clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients; The expected survival> 3 months; Child-Pugh grade in A-level; KPS score with 50-100 points; BCLC stage of 0-B; conform to the indications of hepatectomy; Viable tumor resection confirmed by two highly qualified surgical doctors; No other surgical contraindications. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment; Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment; All patients must be prohibited donation during the treatment process and in 28 days after treatment; In addition to the subjects, prohibitting other people taking this product. patients have a good understanding and could coordinate with investigators for the trial. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial. Instructions: please typing these entity words according to sentence: Age, 20 - 70 years old, Gender, male or female, clinical or pathological diagnosis, hepatocellular carcinoma, HCC, untreated, expected survival, > 3 months, Child - Pugh grade, A, KPS score, 50 - 100 points, BCLC stage, 0-B, indications of hepatectomy, No, other surgical contraindications, women, reproductive period, contraception, in 28 days before treatment , during the treatment process and in 28 days after treatment, Men, contraception, prohibited, sperm donation, during the treatment process and in 28 days after treatment, prohibited, donation, during the treatment process and in 28 days after treatment Options: Condition, Qualifier, Value, Person, Observation, Procedure, Negation, Scope, Measurement
[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "B-Qualifier", "O", "O", "O", "O", "B-Observation", "I-Observation", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Person", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Negation", "O", "O", "B-Procedure", "I-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Age: 20-70 years old; Gender: male or female; clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients; The expected survival> 3 months; Child-Pugh grade in A-level; KPS score with 50-100 points; BCLC stage of 0-B; conform to the indications of hepatectomy; Viable tumor resection confirmed by two highly qualified surgical doctors; No other surgical contraindications. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment; Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment; All patients must be prohibited donation during the treatment process and in 28 days after treatment; In addition to the subjects, prohibitting other people taking this product. patients have a good understanding and could coordinate with investigators for the trial. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial.
[ "Age", ":", "20", "-", "70", "years", "old", ";", "\n", "Gender", ":", "male", "or", "female", ";", "\n", "clinical", "or", "pathological", "diagnosis", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", "in", "previously", "untreated", "patients", ";", "\n", "The", "expected", "survival", ">", "3", "months", ";", "\n", "Child", "-", "Pugh", "grade", "in", "A", "-", "level", ";", "\n", "KPS", "score", "with", "50", "-", "100", "points", ";", "\n", "BCLC", "stage", "of", "0-B", ";", "\n", "conform", "to", "the", "indications", "of", "hepatectomy", ";", "\n", "Viable", "tumor", "resection", "confirmed", "by", "two", "highly", "qualified", "surgical", "doctors", ";", "\n", "No", "other", "surgical", "contraindications", ".", "\n", "women", "in", "the", "reproductive", "period", "must", "be", "completely", "contraception", "in", "28", "days", "before", "treatment", ",", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "Men", "must", "be", "completely", "contraception", "and", "prohibited", "donation", "and", "sperm", "donation", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "All", "patients", "must", "be", "prohibited", "donation", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "In", "addition", "to", "the", "subjects", ",", "prohibitting", "other", "people", "taking", "this", "product", ".", "\n", "patients", "have", "a", "good", "understanding", "and", "could", "coordinate", "with", "investigators", "for", "the", "trial", ".", "\n", "Patients", "enrolled", "in", "the", "trial", "should", "sign", "an", "informed", "consent", "form", ",", "to", "indicate", "understanding", "the", "purpose", "and", "procedure", "of", "the", "trial", ",", "and", "patients", "volunteering", "to", "participate", "in", "the", "trial", ".", "\n" ]
[ "Scope", "Qualifier", "Observation", "Temporal", "Condition", "Measurement", "Value", "Procedure", "Negation", "Reference_point", "Person" ]
Age, 20 - 70 years old, Gender, male or female, clinical or pathological diagnosis, hepatocellular carcinoma, HCC, untreated, expected survival, > 3 months, Child - Pugh grade, A, KPS score, 50 - 100 points, BCLC stage, 0-B, indications of hepatectomy, No, other surgical contraindications, women, reproductive period, contraception, in 28 days before treatment , during the treatment process and in 28 days after treatment, Men, contraception, prohibited, sperm donation, during the treatment process and in 28 days after treatment, prohibited, donation, during the treatment process and in 28 days after treatment
NCT02399033_inc_task2
Sentence: Age: 20-70 years old; Gender: male or female; clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients; The expected survival> 3 months; Child-Pugh grade in A-level; KPS score with 50-100 points; BCLC stage of 0-B; conform to the indications of hepatectomy; Viable tumor resection confirmed by two highly qualified surgical doctors; No other surgical contraindications. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment; Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment; All patients must be prohibited donation during the treatment process and in 28 days after treatment; In addition to the subjects, prohibitting other people taking this product. patients have a good understanding and could coordinate with investigators for the trial. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial. Instructions: please extract entity words from the input sentence
[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "B-Qualifier", "O", "O", "O", "O", "B-Observation", "I-Observation", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Observation", "I-Observation", "I-Observation", "O", "O", "B-Person", "O", "O", "B-Observation", "I-Observation", "O", "O", "O", "B-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Negation", "O", "O", "B-Procedure", "I-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Procedure", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Age: 20-70 years old; Gender: male or female; clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients; The expected survival> 3 months; Child-Pugh grade in A-level; KPS score with 50-100 points; BCLC stage of 0-B; conform to the indications of hepatectomy; Viable tumor resection confirmed by two highly qualified surgical doctors; No other surgical contraindications. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment; Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment; All patients must be prohibited donation during the treatment process and in 28 days after treatment; In addition to the subjects, prohibitting other people taking this product. patients have a good understanding and could coordinate with investigators for the trial. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial.
[ "Age", ":", "20", "-", "70", "years", "old", ";", "\n", "Gender", ":", "male", "or", "female", ";", "\n", "clinical", "or", "pathological", "diagnosis", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", "in", "previously", "untreated", "patients", ";", "\n", "The", "expected", "survival", ">", "3", "months", ";", "\n", "Child", "-", "Pugh", "grade", "in", "A", "-", "level", ";", "\n", "KPS", "score", "with", "50", "-", "100", "points", ";", "\n", "BCLC", "stage", "of", "0-B", ";", "\n", "conform", "to", "the", "indications", "of", "hepatectomy", ";", "\n", "Viable", "tumor", "resection", "confirmed", "by", "two", "highly", "qualified", "surgical", "doctors", ";", "\n", "No", "other", "surgical", "contraindications", ".", "\n", "women", "in", "the", "reproductive", "period", "must", "be", "completely", "contraception", "in", "28", "days", "before", "treatment", ",", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "Men", "must", "be", "completely", "contraception", "and", "prohibited", "donation", "and", "sperm", "donation", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "All", "patients", "must", "be", "prohibited", "donation", "during", "the", "treatment", "process", "and", "in", "28", "days", "after", "treatment", ";", "\n", "In", "addition", "to", "the", "subjects", ",", "prohibitting", "other", "people", "taking", "this", "product", ".", "\n", "patients", "have", "a", "good", "understanding", "and", "could", "coordinate", "with", "investigators", "for", "the", "trial", ".", "\n", "Patients", "enrolled", "in", "the", "trial", "should", "sign", "an", "informed", "consent", "form", ",", "to", "indicate", "understanding", "the", "purpose", "and", "procedure", "of", "the", "trial", ",", "and", "patients", "volunteering", "to", "participate", "in", "the", "trial", ".", "\n" ]
[ "Scope", "Qualifier", "Observation", "Temporal", "Condition", "Measurement", "Value", "Procedure", "Negation", "Reference_point", "Person" ]
tumor is a Pathological_formation, thrombospondin-1 is a Gene_or_gene_product, tumors is a Pathological_formation, Thrombospondin-1 is a Gene_or_gene_product, TSP-1 is a Gene_or_gene_product, TSP-1 is a Gene_or_gene_product, tumor is a Pathological_formation, tumor is a Pathological_formation, TSP-1 is a Gene_or_gene_product, tumor is a Pathological_formation, p53 is a Gene_or_gene_product, Myc is a Gene_or_gene_product, Ras is a Gene_or_gene_product, TSP-1 is a Gene_or_gene_product, endothelial cell is a Cell, transforming growth factor beta is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, TSP-1 is a Gene_or_gene_product, tumor is a Pathological_formation, tumor is a Pathological_formation
129_task0
Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Pathological_formation, Gene_or_gene_product, Cell
[ "O", "O", "B-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.
[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]
[ "Gene_or_gene_product", "Cell", "Pathological_formation" ]
tumor is a Pathological_formation, thrombospondin-1 is a Gene_or_gene_product, tumors is a Pathological_formation, Thrombospondin-1 is a Gene_or_gene_product, TSP-1 is a Gene_or_gene_product, TSP-1 is a Gene_or_gene_product, tumor is a Pathological_formation, tumor is a Pathological_formation, TSP-1 is a Gene_or_gene_product, tumor is a Pathological_formation, p53 is a Gene_or_gene_product, Myc is a Gene_or_gene_product, Ras is a Gene_or_gene_product, TSP-1 is a Gene_or_gene_product, endothelial cell is a Cell, transforming growth factor beta is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, TSP-1 is a Gene_or_gene_product, tumor is a Pathological_formation, tumor is a Pathological_formation
129_task1
Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please typing these entity words according to sentence: tumor, thrombospondin-1, tumors, Thrombospondin-1, TSP-1, TSP-1, tumor, tumor, TSP-1, tumor, p53, Myc, Ras, TSP-1, endothelial cell, transforming growth factor beta, TGF - beta, TSP-1, tumor, tumor Options: Pathological_formation, Gene_or_gene_product, Cell
[ "O", "O", "B-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.
[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]
[ "Gene_or_gene_product", "Cell", "Pathological_formation" ]
tumor, thrombospondin-1, tumors, Thrombospondin-1, TSP-1, TSP-1, tumor, tumor, TSP-1, tumor, p53, Myc, Ras, TSP-1, endothelial cell, transforming growth factor beta, TGF - beta, TSP-1, tumor, tumor
129_task2
Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.
[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]
[ "Gene_or_gene_product", "Cell", "Pathological_formation" ]
thromboembolism is an umlsterm, therapeutic is an umlsterm, treatment is an umlsterm, pulmonary embolism is an umlsterm, diagnosis is an umlsterm, treatment is an umlsterm, diagnostic is an umlsterm, testing is an umlsterm, algorithms is an umlsterm, diagnostic errors is an umlsterm, thromboembolism is an umlsterm, diagnostic is an umlsterm, pulmonary embolism is an umlsterm, diagnostic is an umlsterm, clinical trials is an umlsterm
IntensiveMedizin.00370321.eng.abstr_task0
Sentence: Venous thromboembolism remains a therapeutic challenge . Without adequate treatment , acute pulmonary embolism has a fatality rate of up to forty percent that can be reduced to less than ten percent when the diagnosis is made correctly and prompt treatment is instituted . Novel diagnostic testing algorithms now permit a reduction of diagnostic errors regarding the presence or absence of venous thromboembolism . This article reviews the diagnostic tools available to detect acute or chronic pulmonary embolism and describes diagnostic strategies that have been evaluated in clinical trials . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Venous thromboembolism remains a therapeutic challenge . Without adequate treatment , acute pulmonary embolism has a fatality rate of up to forty percent that can be reduced to less than ten percent when the diagnosis is made correctly and prompt treatment is instituted . Novel diagnostic testing algorithms now permit a reduction of diagnostic errors regarding the presence or absence of venous thromboembolism . This article reviews the diagnostic tools available to detect acute or chronic pulmonary embolism and describes diagnostic strategies that have been evaluated in clinical trials .
[ "Venous", "thromboembolism", "remains", "a", "therapeutic", "challenge", ".", "Without", "adequate", "treatment", ",", "acute", "pulmonary", "embolism", "has", "a", "fatality", "rate", "of", "up", "to", "forty", "percent", "that", "can", "be", "reduced", "to", "less", "than", "ten", "percent", "when", "the", "diagnosis", "is", "made", "correctly", "and", "prompt", "treatment", "is", "instituted", ".", "Novel", "diagnostic", "testing", "algorithms", "now", "permit", "a", "reduction", "of", "diagnostic", "errors", "regarding", "the", "presence", "or", "absence", "of", "venous", "thromboembolism", ".", "This", "article", "reviews", "the", "diagnostic", "tools", "available", "to", "detect", "acute", "or", "chronic", "pulmonary", "embolism", "and", "describes", "diagnostic", "strategies", "that", "have", "been", "evaluated", "in", "clinical", "trials", "." ]
[ "umlsterm" ]
thromboembolism is an umlsterm, therapeutic is an umlsterm, treatment is an umlsterm, pulmonary embolism is an umlsterm, diagnosis is an umlsterm, treatment is an umlsterm, diagnostic is an umlsterm, testing is an umlsterm, algorithms is an umlsterm, diagnostic errors is an umlsterm, thromboembolism is an umlsterm, diagnostic is an umlsterm, pulmonary embolism is an umlsterm, diagnostic is an umlsterm, clinical trials is an umlsterm
IntensiveMedizin.00370321.eng.abstr_task1
Sentence: Venous thromboembolism remains a therapeutic challenge . Without adequate treatment , acute pulmonary embolism has a fatality rate of up to forty percent that can be reduced to less than ten percent when the diagnosis is made correctly and prompt treatment is instituted . Novel diagnostic testing algorithms now permit a reduction of diagnostic errors regarding the presence or absence of venous thromboembolism . This article reviews the diagnostic tools available to detect acute or chronic pulmonary embolism and describes diagnostic strategies that have been evaluated in clinical trials . Instructions: please typing these entity words according to sentence: thromboembolism, therapeutic, treatment, pulmonary embolism, diagnosis, treatment, diagnostic, testing, algorithms, diagnostic errors, thromboembolism, diagnostic, pulmonary embolism, diagnostic, clinical trials Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Venous thromboembolism remains a therapeutic challenge . Without adequate treatment , acute pulmonary embolism has a fatality rate of up to forty percent that can be reduced to less than ten percent when the diagnosis is made correctly and prompt treatment is instituted . Novel diagnostic testing algorithms now permit a reduction of diagnostic errors regarding the presence or absence of venous thromboembolism . This article reviews the diagnostic tools available to detect acute or chronic pulmonary embolism and describes diagnostic strategies that have been evaluated in clinical trials .
[ "Venous", "thromboembolism", "remains", "a", "therapeutic", "challenge", ".", "Without", "adequate", "treatment", ",", "acute", "pulmonary", "embolism", "has", "a", "fatality", "rate", "of", "up", "to", "forty", "percent", "that", "can", "be", "reduced", "to", "less", "than", "ten", "percent", "when", "the", "diagnosis", "is", "made", "correctly", "and", "prompt", "treatment", "is", "instituted", ".", "Novel", "diagnostic", "testing", "algorithms", "now", "permit", "a", "reduction", "of", "diagnostic", "errors", "regarding", "the", "presence", "or", "absence", "of", "venous", "thromboembolism", ".", "This", "article", "reviews", "the", "diagnostic", "tools", "available", "to", "detect", "acute", "or", "chronic", "pulmonary", "embolism", "and", "describes", "diagnostic", "strategies", "that", "have", "been", "evaluated", "in", "clinical", "trials", "." ]
[ "umlsterm" ]
thromboembolism, therapeutic, treatment, pulmonary embolism, diagnosis, treatment, diagnostic, testing, algorithms, diagnostic errors, thromboembolism, diagnostic, pulmonary embolism, diagnostic, clinical trials
IntensiveMedizin.00370321.eng.abstr_task2
Sentence: Venous thromboembolism remains a therapeutic challenge . Without adequate treatment , acute pulmonary embolism has a fatality rate of up to forty percent that can be reduced to less than ten percent when the diagnosis is made correctly and prompt treatment is instituted . Novel diagnostic testing algorithms now permit a reduction of diagnostic errors regarding the presence or absence of venous thromboembolism . This article reviews the diagnostic tools available to detect acute or chronic pulmonary embolism and describes diagnostic strategies that have been evaluated in clinical trials . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Venous thromboembolism remains a therapeutic challenge . Without adequate treatment , acute pulmonary embolism has a fatality rate of up to forty percent that can be reduced to less than ten percent when the diagnosis is made correctly and prompt treatment is instituted . Novel diagnostic testing algorithms now permit a reduction of diagnostic errors regarding the presence or absence of venous thromboembolism . This article reviews the diagnostic tools available to detect acute or chronic pulmonary embolism and describes diagnostic strategies that have been evaluated in clinical trials .
[ "Venous", "thromboembolism", "remains", "a", "therapeutic", "challenge", ".", "Without", "adequate", "treatment", ",", "acute", "pulmonary", "embolism", "has", "a", "fatality", "rate", "of", "up", "to", "forty", "percent", "that", "can", "be", "reduced", "to", "less", "than", "ten", "percent", "when", "the", "diagnosis", "is", "made", "correctly", "and", "prompt", "treatment", "is", "instituted", ".", "Novel", "diagnostic", "testing", "algorithms", "now", "permit", "a", "reduction", "of", "diagnostic", "errors", "regarding", "the", "presence", "or", "absence", "of", "venous", "thromboembolism", ".", "This", "article", "reviews", "the", "diagnostic", "tools", "available", "to", "detect", "acute", "or", "chronic", "pulmonary", "embolism", "and", "describes", "diagnostic", "strategies", "that", "have", "been", "evaluated", "in", "clinical", "trials", "." ]
[ "umlsterm" ]
Previous is a Temporal, surgical or catheter ablation is a Scope, atrial fibrillation is a Condition, Previous is a Temporal, cardiac surgery is a Procedure, CABG is a Procedure, within the past 6 months ( 180 days ) is a Temporal, Valvular cardiac surgical / percutaneous procedure is a Scope, ventriculotomy , atriotomy , and valve repair or replacement and presence of a prosthetic valve is a Scope, carotid stenting is a Device, endarterectomy is a Procedure, LA thrombus is a Condition, imaging is a Procedure, LA size is a Measurement, > 50 mm is a Value, parasternal long axis view is a Qualifier, LVEF is a Measurement, < 40 % is a Value, Contraindication to anticoagulation is a Scope, heparin or warfarin is a Scope, History is a Observation, blood clotting or bleeding abnormalities is a Scope, PCI / MI is a Scope, within the past 2 months ( 60 days ) is a Scope, thromboembolic event ( including TIA ) is a Scope, within the past 12 months ( 365 days ) is a Scope, Rheumatic Heart Disease is a Condition, Uncontrolled is a Qualifier, heart failure is a Condition, NYHA function class III or IV is a Scope, Severe mitral regurgitation is a Scope, Regurgitant volume = 60 mL / beat , Regurgitant fraction = 50 % , and / or Effective regurgitant orifice area = 0.40cm2 is a Scope, cardiac transplantation or other cardiac surgery is a Scope, within the next 12 months is a Temporal, Unstable angina is a Condition, Acute illness is a Condition, active is a Qualifier, systemic infection is a Condition, sepsis is a Condition, AF is a Condition, secondary is a Qualifier, electrolyte imbalance is a Condition, thyroid disease is a Condition, reversible is a Qualifier, non - cardiac cause is a Condition, Significant pulmonary disease is a Scope, restrictive pulmonary disease , constrictive or chronic obstructive pulmonary disease is a Scope, any other is a Qualifier, disease or malfunction of the lungs or respiratory system is a Scope, chronic symptoms is a Condition, Gastroesophageal Reflux Disease is a Condition, GERD is a Condition, significant intervention is a Procedure, not is a Negation, OTC medication is a Drug, Significant is a Qualifier, congenital anomaly is a Condition, medical problem is a Condition, Women is a Person, pregnant is a Condition, pregnancy test is a Procedure, pre - menopausal is a Condition, intracardiac thrombus is a Condition, myxoma is a Condition, tumor is a Condition, interatrial baffle is a Condition, patch is a Device, other is a Qualifier, abnormality is a Condition, precludes is a Condition, vascular access , or manipulation of the catheter is a Scope, Life expectancy is a Observation, less than 12 months is a Value
NCT03624881_exc_task0
Sentence: Previous surgical or catheter ablation for atrial fibrillation Previous cardiac surgery (including CABG) within the past 6 months (180 days) Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) Any carotid stenting or endarterectomy Documented LA thrombus on imaging LA size > 50 mm (parasternal long axis view) LVEF < 40% Contraindication to anticoagulation (heparin or warfarin) History of blood clotting or bleeding abnormalities PCI/MI within the past 2 months (60 days) Documented thromboembolic event (including TIA) within the past 12 months (365 days) Rheumatic Heart Disease Uncontrolled heart failure or NYHA function class III or IV Severe mitral regurgitation (Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2) Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days) Unstable angina Acute illness or active systemic infection or sepsis AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. Presence of implanted ICD/CRT-D. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not including OTC medication) Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal) Concurrent enrollment in an investigational study evaluating another device, biologic, or drug. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes vascular access, or manipulation of the catheter. Life expectancy less than 12 months Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Measurement, Qualifier, Value, Person, Observation, Procedure, Negation, Scope, Device, Drug
[ "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Procedure", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Device", "I-Device", "O", "B-Procedure", "O", "O", "B-Condition", "I-Condition", "O", "B-Procedure", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "B-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Negation", "O", "B-Drug", "I-Drug", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "B-Device", "O", "B-Qualifier", "B-Condition", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "B-Value", "I-Value", "I-Value", "I-Value", "O" ]
Previous surgical or catheter ablation for atrial fibrillation Previous cardiac surgery (including CABG) within the past 6 months (180 days) Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) Any carotid stenting or endarterectomy Documented LA thrombus on imaging LA size > 50 mm (parasternal long axis view) LVEF < 40% Contraindication to anticoagulation (heparin or warfarin) History of blood clotting or bleeding abnormalities PCI/MI within the past 2 months (60 days) Documented thromboembolic event (including TIA) within the past 12 months (365 days) Rheumatic Heart Disease Uncontrolled heart failure or NYHA function class III or IV Severe mitral regurgitation (Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2) Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days) Unstable angina Acute illness or active systemic infection or sepsis AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. Presence of implanted ICD/CRT-D. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not including OTC medication) Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal) Concurrent enrollment in an investigational study evaluating another device, biologic, or drug. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes vascular access, or manipulation of the catheter. Life expectancy less than 12 months
[ "Previous", "surgical", "or", "catheter", "ablation", "for", "atrial", "fibrillation", "\n", "Previous", "cardiac", "surgery", "(", "including", "CABG", ")", "within", "the", "past", "6", "months", "(", "180", "days", ")", "\n", "Valvular", "cardiac", "surgical", "/", "percutaneous", "procedure", "(", "i.e", ".", ",", "ventriculotomy", ",", "atriotomy", ",", "and", "valve", "repair", "or", "replacement", "and", "presence", "of", "a", "prosthetic", "valve", ")", "\n", "Any", "carotid", "stenting", "or", "endarterectomy", "\n", "Documented", "LA", "thrombus", "on", "imaging", "\n", "LA", "size", ">", "50", "mm", "(", "parasternal", "long", "axis", "view", ")", "\n", "LVEF", "<", "40", "%", "\n", "Contraindication", "to", "anticoagulation", "(", "heparin", "or", "warfarin", ")", "\n", "History", "of", "blood", "clotting", "or", "bleeding", "abnormalities", "\n", "PCI", "/", "MI", "within", "the", "past", "2", "months", "(", "60", "days", ")", "\n", "Documented", "thromboembolic", "event", "(", "including", "TIA", ")", "within", "the", "past", "12", "months", "(", "365", "days", ")", "\n", "Rheumatic", "Heart", "Disease", "\n", "Uncontrolled", "heart", "failure", "or", "NYHA", "function", "class", "III", "or", "IV", "\n", "Severe", "mitral", "regurgitation", "(", "Regurgitant", "volume", "=", "60", "mL", "/", "beat", ",", "Regurgitant", "fraction", "=", "50", "%", ",", "and", "/", "or", "Effective", "regurgitant", "orifice", "area", "=", "0.40cm2", ")", "\n", "Awaiting", "cardiac", "transplantation", "or", "other", "cardiac", "surgery", "within", "the", "next", "12", "months", "(", "365", "days", ")", "\n", "Unstable", "angina", "\n", "Acute", "illness", "or", "active", "systemic", "infection", "or", "sepsis", "\n", "AF", "secondary", "to", "electrolyte", "imbalance", ",", "thyroid", "disease", ",", "or", "reversible", "or", "non", "-", "cardiac", "cause", ".", "\n", "Presence", "of", "implanted", "ICD", "/", "CRT", "-", "D.", "\n", "Significant", "pulmonary", "disease", ",", "(", "e.g", ".", ",", "restrictive", "pulmonary", "disease", ",", "constrictive", "or", "chronic", "obstructive", "pulmonary", "disease", ")", "or", "any", "other", "disease", "or", "malfunction", "of", "the", "lungs", "or", "respiratory", "system", "that", "produces", "chronic", "symptoms", ".", "\n", "Gastroesophageal", "Reflux", "Disease", "(", "GERD", ";", "active", "requiring", "significant", "intervention", "not", "including", "OTC", "medication", ")", "\n", "Significant", "congenital", "anomaly", "or", "medical", "problem", "that", "in", "the", "opinion", "of", "the", "investigator", "would", "preclude", "enrollment", "in", "this", "study", ".", "\n", "Women", "who", "are", "pregnant", "(", "as", "evidenced", "by", "pregnancy", "test", "if", "pre", "-", "menopausal", ")", "\n", "Concurrent", "enrollment", "in", "an", "investigational", "study", "evaluating", "another", "device", ",", "biologic", ",", "or", "drug", ".", "\n", "Presence", "of", "intracardiac", "thrombus", ",", "myxoma", ",", "tumor", ",", "interatrial", "baffle", "or", "patch", "or", "other", "abnormality", "that", "precludes", "vascular", "access", ",", "or", "manipulation", "of", "the", "catheter", ".", "\n", "Life", "expectancy", "less", "than", "12", "months", "\n" ]
[ "Scope", "Condition", "Temporal", "Measurement", "Procedure", "Qualifier", "Device", "Value", "Drug", "Observation", "Person", "Negation" ]
Previous is a Temporal, surgical or catheter ablation is a Scope, atrial fibrillation is a Condition, Previous is a Temporal, cardiac surgery is a Procedure, CABG is a Procedure, within the past 6 months ( 180 days ) is a Temporal, Valvular cardiac surgical / percutaneous procedure is a Scope, ventriculotomy , atriotomy , and valve repair or replacement and presence of a prosthetic valve is a Scope, carotid stenting is a Device, endarterectomy is a Procedure, LA thrombus is a Condition, imaging is a Procedure, LA size is a Measurement, > 50 mm is a Value, parasternal long axis view is a Qualifier, LVEF is a Measurement, < 40 % is a Value, Contraindication to anticoagulation is a Scope, heparin or warfarin is a Scope, History is a Observation, blood clotting or bleeding abnormalities is a Scope, PCI / MI is a Scope, within the past 2 months ( 60 days ) is a Scope, thromboembolic event ( including TIA ) is a Scope, within the past 12 months ( 365 days ) is a Scope, Rheumatic Heart Disease is a Condition, Uncontrolled is a Qualifier, heart failure is a Condition, NYHA function class III or IV is a Scope, Severe mitral regurgitation is a Scope, Regurgitant volume = 60 mL / beat , Regurgitant fraction = 50 % , and / or Effective regurgitant orifice area = 0.40cm2 is a Scope, cardiac transplantation or other cardiac surgery is a Scope, within the next 12 months is a Temporal, Unstable angina is a Condition, Acute illness is a Condition, active is a Qualifier, systemic infection is a Condition, sepsis is a Condition, AF is a Condition, secondary is a Qualifier, electrolyte imbalance is a Condition, thyroid disease is a Condition, reversible is a Qualifier, non - cardiac cause is a Condition, Significant pulmonary disease is a Scope, restrictive pulmonary disease , constrictive or chronic obstructive pulmonary disease is a Scope, any other is a Qualifier, disease or malfunction of the lungs or respiratory system is a Scope, chronic symptoms is a Condition, Gastroesophageal Reflux Disease is a Condition, GERD is a Condition, significant intervention is a Procedure, not is a Negation, OTC medication is a Drug, Significant is a Qualifier, congenital anomaly is a Condition, medical problem is a Condition, Women is a Person, pregnant is a Condition, pregnancy test is a Procedure, pre - menopausal is a Condition, intracardiac thrombus is a Condition, myxoma is a Condition, tumor is a Condition, interatrial baffle is a Condition, patch is a Device, other is a Qualifier, abnormality is a Condition, precludes is a Condition, vascular access , or manipulation of the catheter is a Scope, Life expectancy is a Observation, less than 12 months is a Value
NCT03624881_exc_task1
Sentence: Previous surgical or catheter ablation for atrial fibrillation Previous cardiac surgery (including CABG) within the past 6 months (180 days) Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) Any carotid stenting or endarterectomy Documented LA thrombus on imaging LA size > 50 mm (parasternal long axis view) LVEF < 40% Contraindication to anticoagulation (heparin or warfarin) History of blood clotting or bleeding abnormalities PCI/MI within the past 2 months (60 days) Documented thromboembolic event (including TIA) within the past 12 months (365 days) Rheumatic Heart Disease Uncontrolled heart failure or NYHA function class III or IV Severe mitral regurgitation (Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2) Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days) Unstable angina Acute illness or active systemic infection or sepsis AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. Presence of implanted ICD/CRT-D. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not including OTC medication) Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal) Concurrent enrollment in an investigational study evaluating another device, biologic, or drug. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes vascular access, or manipulation of the catheter. Life expectancy less than 12 months Instructions: please typing these entity words according to sentence: Previous, surgical or catheter ablation, atrial fibrillation, Previous, cardiac surgery, CABG, within the past 6 months ( 180 days ), Valvular cardiac surgical / percutaneous procedure, ventriculotomy , atriotomy , and valve repair or replacement and presence of a prosthetic valve, carotid stenting, endarterectomy, LA thrombus, imaging, LA size, > 50 mm, parasternal long axis view, LVEF, < 40 %, Contraindication to anticoagulation, heparin or warfarin, History, blood clotting or bleeding abnormalities, PCI / MI, within the past 2 months ( 60 days ), thromboembolic event ( including TIA ), within the past 12 months ( 365 days ), Rheumatic Heart Disease, Uncontrolled, heart failure, NYHA function class III or IV, Severe mitral regurgitation, Regurgitant volume = 60 mL / beat , Regurgitant fraction = 50 % , and / or Effective regurgitant orifice area = 0.40cm2, cardiac transplantation or other cardiac surgery, within the next 12 months, Unstable angina, Acute illness, active, systemic infection, sepsis, AF, secondary, electrolyte imbalance, thyroid disease, reversible, non - cardiac cause, Significant pulmonary disease, restrictive pulmonary disease , constrictive or chronic obstructive pulmonary disease, any other, disease or malfunction of the lungs or respiratory system, chronic symptoms, Gastroesophageal Reflux Disease, GERD, significant intervention, not, OTC medication, Significant, congenital anomaly, medical problem, Women, pregnant, pregnancy test, pre - menopausal, intracardiac thrombus, myxoma, tumor, interatrial baffle, patch, other, abnormality, precludes, vascular access , or manipulation of the catheter, Life expectancy, less than 12 months Options: Temporal, Condition, Measurement, Qualifier, Value, Person, Observation, Procedure, Negation, Scope, Device, Drug
[ "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Procedure", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Device", "I-Device", "O", "B-Procedure", "O", "O", "B-Condition", "I-Condition", "O", "B-Procedure", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "B-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Negation", "O", "B-Drug", "I-Drug", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "B-Device", "O", "B-Qualifier", "B-Condition", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "B-Value", "I-Value", "I-Value", "I-Value", "O" ]
Previous surgical or catheter ablation for atrial fibrillation Previous cardiac surgery (including CABG) within the past 6 months (180 days) Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) Any carotid stenting or endarterectomy Documented LA thrombus on imaging LA size > 50 mm (parasternal long axis view) LVEF < 40% Contraindication to anticoagulation (heparin or warfarin) History of blood clotting or bleeding abnormalities PCI/MI within the past 2 months (60 days) Documented thromboembolic event (including TIA) within the past 12 months (365 days) Rheumatic Heart Disease Uncontrolled heart failure or NYHA function class III or IV Severe mitral regurgitation (Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2) Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days) Unstable angina Acute illness or active systemic infection or sepsis AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. Presence of implanted ICD/CRT-D. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not including OTC medication) Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal) Concurrent enrollment in an investigational study evaluating another device, biologic, or drug. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes vascular access, or manipulation of the catheter. Life expectancy less than 12 months
[ "Previous", "surgical", "or", "catheter", "ablation", "for", "atrial", "fibrillation", "\n", "Previous", "cardiac", "surgery", "(", "including", "CABG", ")", "within", "the", "past", "6", "months", "(", "180", "days", ")", "\n", "Valvular", "cardiac", "surgical", "/", "percutaneous", "procedure", "(", "i.e", ".", ",", "ventriculotomy", ",", "atriotomy", ",", "and", "valve", "repair", "or", "replacement", "and", "presence", "of", "a", "prosthetic", "valve", ")", "\n", "Any", "carotid", "stenting", "or", "endarterectomy", "\n", "Documented", "LA", "thrombus", "on", "imaging", "\n", "LA", "size", ">", "50", "mm", "(", "parasternal", "long", "axis", "view", ")", "\n", "LVEF", "<", "40", "%", "\n", "Contraindication", "to", "anticoagulation", "(", "heparin", "or", "warfarin", ")", "\n", "History", "of", "blood", "clotting", "or", "bleeding", "abnormalities", "\n", "PCI", "/", "MI", "within", "the", "past", "2", "months", "(", "60", "days", ")", "\n", "Documented", "thromboembolic", "event", "(", "including", "TIA", ")", "within", "the", "past", "12", "months", "(", "365", "days", ")", "\n", "Rheumatic", "Heart", "Disease", "\n", "Uncontrolled", "heart", "failure", "or", "NYHA", "function", "class", "III", "or", "IV", "\n", "Severe", "mitral", "regurgitation", "(", "Regurgitant", "volume", "=", "60", "mL", "/", "beat", ",", "Regurgitant", "fraction", "=", "50", "%", ",", "and", "/", "or", "Effective", "regurgitant", "orifice", "area", "=", "0.40cm2", ")", "\n", "Awaiting", "cardiac", "transplantation", "or", "other", "cardiac", "surgery", "within", "the", "next", "12", "months", "(", "365", "days", ")", "\n", "Unstable", "angina", "\n", "Acute", "illness", "or", "active", "systemic", "infection", "or", "sepsis", "\n", "AF", "secondary", "to", "electrolyte", "imbalance", ",", "thyroid", "disease", ",", "or", "reversible", "or", "non", "-", "cardiac", "cause", ".", "\n", "Presence", "of", "implanted", "ICD", "/", "CRT", "-", "D.", "\n", "Significant", "pulmonary", "disease", ",", "(", "e.g", ".", ",", "restrictive", "pulmonary", "disease", ",", "constrictive", "or", "chronic", "obstructive", "pulmonary", "disease", ")", "or", "any", "other", "disease", "or", "malfunction", "of", "the", "lungs", "or", "respiratory", "system", "that", "produces", "chronic", "symptoms", ".", "\n", "Gastroesophageal", "Reflux", "Disease", "(", "GERD", ";", "active", "requiring", "significant", "intervention", "not", "including", "OTC", "medication", ")", "\n", "Significant", "congenital", "anomaly", "or", "medical", "problem", "that", "in", "the", "opinion", "of", "the", "investigator", "would", "preclude", "enrollment", "in", "this", "study", ".", "\n", "Women", "who", "are", "pregnant", "(", "as", "evidenced", "by", "pregnancy", "test", "if", "pre", "-", "menopausal", ")", "\n", "Concurrent", "enrollment", "in", "an", "investigational", "study", "evaluating", "another", "device", ",", "biologic", ",", "or", "drug", ".", "\n", "Presence", "of", "intracardiac", "thrombus", ",", "myxoma", ",", "tumor", ",", "interatrial", "baffle", "or", "patch", "or", "other", "abnormality", "that", "precludes", "vascular", "access", ",", "or", "manipulation", "of", "the", "catheter", ".", "\n", "Life", "expectancy", "less", "than", "12", "months", "\n" ]
[ "Scope", "Condition", "Temporal", "Measurement", "Procedure", "Qualifier", "Device", "Value", "Drug", "Observation", "Person", "Negation" ]
Previous, surgical or catheter ablation, atrial fibrillation, Previous, cardiac surgery, CABG, within the past 6 months ( 180 days ), Valvular cardiac surgical / percutaneous procedure, ventriculotomy , atriotomy , and valve repair or replacement and presence of a prosthetic valve, carotid stenting, endarterectomy, LA thrombus, imaging, LA size, > 50 mm, parasternal long axis view, LVEF, < 40 %, Contraindication to anticoagulation, heparin or warfarin, History, blood clotting or bleeding abnormalities, PCI / MI, within the past 2 months ( 60 days ), thromboembolic event ( including TIA ), within the past 12 months ( 365 days ), Rheumatic Heart Disease, Uncontrolled, heart failure, NYHA function class III or IV, Severe mitral regurgitation, Regurgitant volume = 60 mL / beat , Regurgitant fraction = 50 % , and / or Effective regurgitant orifice area = 0.40cm2, cardiac transplantation or other cardiac surgery, within the next 12 months, Unstable angina, Acute illness, active, systemic infection, sepsis, AF, secondary, electrolyte imbalance, thyroid disease, reversible, non - cardiac cause, Significant pulmonary disease, restrictive pulmonary disease , constrictive or chronic obstructive pulmonary disease, any other, disease or malfunction of the lungs or respiratory system, chronic symptoms, Gastroesophageal Reflux Disease, GERD, significant intervention, not, OTC medication, Significant, congenital anomaly, medical problem, Women, pregnant, pregnancy test, pre - menopausal, intracardiac thrombus, myxoma, tumor, interatrial baffle, patch, other, abnormality, precludes, vascular access , or manipulation of the catheter, Life expectancy, less than 12 months
NCT03624881_exc_task2
Sentence: Previous surgical or catheter ablation for atrial fibrillation Previous cardiac surgery (including CABG) within the past 6 months (180 days) Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) Any carotid stenting or endarterectomy Documented LA thrombus on imaging LA size > 50 mm (parasternal long axis view) LVEF < 40% Contraindication to anticoagulation (heparin or warfarin) History of blood clotting or bleeding abnormalities PCI/MI within the past 2 months (60 days) Documented thromboembolic event (including TIA) within the past 12 months (365 days) Rheumatic Heart Disease Uncontrolled heart failure or NYHA function class III or IV Severe mitral regurgitation (Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2) Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days) Unstable angina Acute illness or active systemic infection or sepsis AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. Presence of implanted ICD/CRT-D. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not including OTC medication) Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal) Concurrent enrollment in an investigational study evaluating another device, biologic, or drug. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes vascular access, or manipulation of the catheter. Life expectancy less than 12 months Instructions: please extract entity words from the input sentence
[ "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Procedure", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Device", "I-Device", "O", "B-Procedure", "O", "O", "B-Condition", "I-Condition", "O", "B-Procedure", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "B-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Qualifier", "I-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Negation", "O", "B-Drug", "I-Drug", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "B-Condition", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "B-Device", "O", "B-Qualifier", "B-Condition", "O", "B-Condition", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "B-Value", "I-Value", "I-Value", "I-Value", "O" ]
Previous surgical or catheter ablation for atrial fibrillation Previous cardiac surgery (including CABG) within the past 6 months (180 days) Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) Any carotid stenting or endarterectomy Documented LA thrombus on imaging LA size > 50 mm (parasternal long axis view) LVEF < 40% Contraindication to anticoagulation (heparin or warfarin) History of blood clotting or bleeding abnormalities PCI/MI within the past 2 months (60 days) Documented thromboembolic event (including TIA) within the past 12 months (365 days) Rheumatic Heart Disease Uncontrolled heart failure or NYHA function class III or IV Severe mitral regurgitation (Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2) Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days) Unstable angina Acute illness or active systemic infection or sepsis AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. Presence of implanted ICD/CRT-D. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not including OTC medication) Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal) Concurrent enrollment in an investigational study evaluating another device, biologic, or drug. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes vascular access, or manipulation of the catheter. Life expectancy less than 12 months
[ "Previous", "surgical", "or", "catheter", "ablation", "for", "atrial", "fibrillation", "\n", "Previous", "cardiac", "surgery", "(", "including", "CABG", ")", "within", "the", "past", "6", "months", "(", "180", "days", ")", "\n", "Valvular", "cardiac", "surgical", "/", "percutaneous", "procedure", "(", "i.e", ".", ",", "ventriculotomy", ",", "atriotomy", ",", "and", "valve", "repair", "or", "replacement", "and", "presence", "of", "a", "prosthetic", "valve", ")", "\n", "Any", "carotid", "stenting", "or", "endarterectomy", "\n", "Documented", "LA", "thrombus", "on", "imaging", "\n", "LA", "size", ">", "50", "mm", "(", "parasternal", "long", "axis", "view", ")", "\n", "LVEF", "<", "40", "%", "\n", "Contraindication", "to", "anticoagulation", "(", "heparin", "or", "warfarin", ")", "\n", "History", "of", "blood", "clotting", "or", "bleeding", "abnormalities", "\n", "PCI", "/", "MI", "within", "the", "past", "2", "months", "(", "60", "days", ")", "\n", "Documented", "thromboembolic", "event", "(", "including", "TIA", ")", "within", "the", "past", "12", "months", "(", "365", "days", ")", "\n", "Rheumatic", "Heart", "Disease", "\n", "Uncontrolled", "heart", "failure", "or", "NYHA", "function", "class", "III", "or", "IV", "\n", "Severe", "mitral", "regurgitation", "(", "Regurgitant", "volume", "=", "60", "mL", "/", "beat", ",", "Regurgitant", "fraction", "=", "50", "%", ",", "and", "/", "or", "Effective", "regurgitant", "orifice", "area", "=", "0.40cm2", ")", "\n", "Awaiting", "cardiac", "transplantation", "or", "other", "cardiac", "surgery", "within", "the", "next", "12", "months", "(", "365", "days", ")", "\n", "Unstable", "angina", "\n", "Acute", "illness", "or", "active", "systemic", "infection", "or", "sepsis", "\n", "AF", "secondary", "to", "electrolyte", "imbalance", ",", "thyroid", "disease", ",", "or", "reversible", "or", "non", "-", "cardiac", "cause", ".", "\n", "Presence", "of", "implanted", "ICD", "/", "CRT", "-", "D.", "\n", "Significant", "pulmonary", "disease", ",", "(", "e.g", ".", ",", "restrictive", "pulmonary", "disease", ",", "constrictive", "or", "chronic", "obstructive", "pulmonary", "disease", ")", "or", "any", "other", "disease", "or", "malfunction", "of", "the", "lungs", "or", "respiratory", "system", "that", "produces", "chronic", "symptoms", ".", "\n", "Gastroesophageal", "Reflux", "Disease", "(", "GERD", ";", "active", "requiring", "significant", "intervention", "not", "including", "OTC", "medication", ")", "\n", "Significant", "congenital", "anomaly", "or", "medical", "problem", "that", "in", "the", "opinion", "of", "the", "investigator", "would", "preclude", "enrollment", "in", "this", "study", ".", "\n", "Women", "who", "are", "pregnant", "(", "as", "evidenced", "by", "pregnancy", "test", "if", "pre", "-", "menopausal", ")", "\n", "Concurrent", "enrollment", "in", "an", "investigational", "study", "evaluating", "another", "device", ",", "biologic", ",", "or", "drug", ".", "\n", "Presence", "of", "intracardiac", "thrombus", ",", "myxoma", ",", "tumor", ",", "interatrial", "baffle", "or", "patch", "or", "other", "abnormality", "that", "precludes", "vascular", "access", ",", "or", "manipulation", "of", "the", "catheter", ".", "\n", "Life", "expectancy", "less", "than", "12", "months", "\n" ]
[ "Scope", "Condition", "Temporal", "Measurement", "Procedure", "Qualifier", "Device", "Value", "Drug", "Observation", "Person", "Negation" ]
Mann is an umlsterm, Verletzungen is an umlsterm, Samenwege is an umlsterm, Antigene is an umlsterm, Autoantikoerper is an umlsterm
Reproduktionsmedizin.00160003.ger.abstr_task0
Sentence: Sperma-Autoantikoerper ( SpAk ) beim Mann entstehen vorzugsweise durch Verletzungen der Samenwege . Die Kenntnisse ueber die zugeordneten Antigene sind noch sehr bruchstueckhaft . Autoantikoerper koennen verschiedene Spermatozoenfunktionen stoeren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Sperma-Autoantikoerper ( SpAk ) beim Mann entstehen vorzugsweise durch Verletzungen der Samenwege . Die Kenntnisse ueber die zugeordneten Antigene sind noch sehr bruchstueckhaft . Autoantikoerper koennen verschiedene Spermatozoenfunktionen stoeren .
[ "Sperma", "-", "Autoantikoerper", "(", "SpAk", ")", "beim", "Mann", "entstehen", "vorzugsweise", "durch", "Verletzungen", "der", "Samenwege", ".", "Die", "Kenntnisse", "ueber", "die", "zugeordneten", "Antigene", "sind", "noch", "sehr", "bruchstueckhaft", ".", "Autoantikoerper", "koennen", "verschiedene", "Spermatozoenfunktionen", "stoeren", "." ]
[ "umlsterm" ]
Mann is an umlsterm, Verletzungen is an umlsterm, Samenwege is an umlsterm, Antigene is an umlsterm, Autoantikoerper is an umlsterm
Reproduktionsmedizin.00160003.ger.abstr_task1
Sentence: Sperma-Autoantikoerper ( SpAk ) beim Mann entstehen vorzugsweise durch Verletzungen der Samenwege . Die Kenntnisse ueber die zugeordneten Antigene sind noch sehr bruchstueckhaft . Autoantikoerper koennen verschiedene Spermatozoenfunktionen stoeren . Instructions: please typing these entity words according to sentence: Mann, Verletzungen, Samenwege, Antigene, Autoantikoerper Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Sperma-Autoantikoerper ( SpAk ) beim Mann entstehen vorzugsweise durch Verletzungen der Samenwege . Die Kenntnisse ueber die zugeordneten Antigene sind noch sehr bruchstueckhaft . Autoantikoerper koennen verschiedene Spermatozoenfunktionen stoeren .
[ "Sperma", "-", "Autoantikoerper", "(", "SpAk", ")", "beim", "Mann", "entstehen", "vorzugsweise", "durch", "Verletzungen", "der", "Samenwege", ".", "Die", "Kenntnisse", "ueber", "die", "zugeordneten", "Antigene", "sind", "noch", "sehr", "bruchstueckhaft", ".", "Autoantikoerper", "koennen", "verschiedene", "Spermatozoenfunktionen", "stoeren", "." ]
[ "umlsterm" ]
Mann, Verletzungen, Samenwege, Antigene, Autoantikoerper
Reproduktionsmedizin.00160003.ger.abstr_task2
Sentence: Sperma-Autoantikoerper ( SpAk ) beim Mann entstehen vorzugsweise durch Verletzungen der Samenwege . Die Kenntnisse ueber die zugeordneten Antigene sind noch sehr bruchstueckhaft . Autoantikoerper koennen verschiedene Spermatozoenfunktionen stoeren . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Sperma-Autoantikoerper ( SpAk ) beim Mann entstehen vorzugsweise durch Verletzungen der Samenwege . Die Kenntnisse ueber die zugeordneten Antigene sind noch sehr bruchstueckhaft . Autoantikoerper koennen verschiedene Spermatozoenfunktionen stoeren .
[ "Sperma", "-", "Autoantikoerper", "(", "SpAk", ")", "beim", "Mann", "entstehen", "vorzugsweise", "durch", "Verletzungen", "der", "Samenwege", ".", "Die", "Kenntnisse", "ueber", "die", "zugeordneten", "Antigene", "sind", "noch", "sehr", "bruchstueckhaft", ".", "Autoantikoerper", "koennen", "verschiedene", "Spermatozoenfunktionen", "stoeren", "." ]
[ "umlsterm" ]
Sound is an umlsterm, hearing loss is an umlsterm, tinnitus is an umlsterm, sound is an umlsterm, tip is an umlsterm, paper is an umlsterm, tip is an umlsterm, outer hair cells is an umlsterm, Outer hair cells is an umlsterm, elastase is an umlsterm, BAPTA is an umlsterm, contrast is an umlsterm, belief is an umlsterm, tip is an umlsterm, the cell is an umlsterm, cations is an umlsterm, tip is an umlsterm, hair - cell is an umlsterm, sensorineural hearing loss is an umlsterm, tinnitus is an umlsterm, acoustic trauma is an umlsterm
HNO.00480383.eng.abstr_task0
Sentence: Sound overexposure is known to cause damage to cochlear structures and can induce permanent or temporary hearing loss and tinnitus . Perhaps the most sensitive of these structures to sound overexposure are the tip links . In this paper the elecrophysiological effects of pharmacological destruction of the tip links of outer hair cells was investigated . Outer hair cells treated with elastase ( 20 U/mL ) or BAPTA ( 5 mM ) no longer responded to sinusoidal stimuli . In contrast to common belief , transduction channels opened due to loss of tip links . Such opened channels can allow K+ and Ca2+ to enter the cell from the endolymphatic space and could lead to permanent depolarization . This influx of cations caused by loss of tip links , together with the subsequent hair-cell depolarization , might be a source of sensorineural hearing loss and tinnitus associated with acoustic trauma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Sound overexposure is known to cause damage to cochlear structures and can induce permanent or temporary hearing loss and tinnitus . Perhaps the most sensitive of these structures to sound overexposure are the tip links . In this paper the elecrophysiological effects of pharmacological destruction of the tip links of outer hair cells was investigated . Outer hair cells treated with elastase ( 20 U/mL ) or BAPTA ( 5 mM ) no longer responded to sinusoidal stimuli . In contrast to common belief , transduction channels opened due to loss of tip links . Such opened channels can allow K+ and Ca2+ to enter the cell from the endolymphatic space and could lead to permanent depolarization . This influx of cations caused by loss of tip links , together with the subsequent hair-cell depolarization , might be a source of sensorineural hearing loss and tinnitus associated with acoustic trauma .
[ "Sound", "overexposure", "is", "known", "to", "cause", "damage", "to", "cochlear", "structures", "and", "can", "induce", "permanent", "or", "temporary", "hearing", "loss", "and", "tinnitus", ".", "Perhaps", "the", "most", "sensitive", "of", "these", "structures", "to", "sound", "overexposure", "are", "the", "tip", "links", ".", "In", "this", "paper", "the", "elecrophysiological", "effects", "of", "pharmacological", "destruction", "of", "the", "tip", "links", "of", "outer", "hair", "cells", "was", "investigated", ".", "Outer", "hair", "cells", "treated", "with", "elastase", "(", "20", "U", "/", "mL", ")", "or", "BAPTA", "(", "5", "mM", ")", "no", "longer", "responded", "to", "sinusoidal", "stimuli", ".", "In", "contrast", "to", "common", "belief", ",", "transduction", "channels", "opened", "due", "to", "loss", "of", "tip", "links", ".", "Such", "opened", "channels", "can", "allow", "K+", "and", "Ca2", "+", "to", "enter", "the", "cell", "from", "the", "endolymphatic", "space", "and", "could", "lead", "to", "permanent", "depolarization", ".", "This", "influx", "of", "cations", "caused", "by", "loss", "of", "tip", "links", ",", "together", "with", "the", "subsequent", "hair", "-", "cell", "depolarization", ",", "might", "be", "a", "source", "of", "sensorineural", "hearing", "loss", "and", "tinnitus", "associated", "with", "acoustic", "trauma", "." ]
[ "umlsterm" ]
Sound is an umlsterm, hearing loss is an umlsterm, tinnitus is an umlsterm, sound is an umlsterm, tip is an umlsterm, paper is an umlsterm, tip is an umlsterm, outer hair cells is an umlsterm, Outer hair cells is an umlsterm, elastase is an umlsterm, BAPTA is an umlsterm, contrast is an umlsterm, belief is an umlsterm, tip is an umlsterm, the cell is an umlsterm, cations is an umlsterm, tip is an umlsterm, hair - cell is an umlsterm, sensorineural hearing loss is an umlsterm, tinnitus is an umlsterm, acoustic trauma is an umlsterm
HNO.00480383.eng.abstr_task1
Sentence: Sound overexposure is known to cause damage to cochlear structures and can induce permanent or temporary hearing loss and tinnitus . Perhaps the most sensitive of these structures to sound overexposure are the tip links . In this paper the elecrophysiological effects of pharmacological destruction of the tip links of outer hair cells was investigated . Outer hair cells treated with elastase ( 20 U/mL ) or BAPTA ( 5 mM ) no longer responded to sinusoidal stimuli . In contrast to common belief , transduction channels opened due to loss of tip links . Such opened channels can allow K+ and Ca2+ to enter the cell from the endolymphatic space and could lead to permanent depolarization . This influx of cations caused by loss of tip links , together with the subsequent hair-cell depolarization , might be a source of sensorineural hearing loss and tinnitus associated with acoustic trauma . Instructions: please typing these entity words according to sentence: Sound, hearing loss, tinnitus, sound, tip, paper, tip, outer hair cells, Outer hair cells, elastase, BAPTA, contrast, belief, tip, the cell, cations, tip, hair - cell, sensorineural hearing loss, tinnitus, acoustic trauma Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Sound overexposure is known to cause damage to cochlear structures and can induce permanent or temporary hearing loss and tinnitus . Perhaps the most sensitive of these structures to sound overexposure are the tip links . In this paper the elecrophysiological effects of pharmacological destruction of the tip links of outer hair cells was investigated . Outer hair cells treated with elastase ( 20 U/mL ) or BAPTA ( 5 mM ) no longer responded to sinusoidal stimuli . In contrast to common belief , transduction channels opened due to loss of tip links . Such opened channels can allow K+ and Ca2+ to enter the cell from the endolymphatic space and could lead to permanent depolarization . This influx of cations caused by loss of tip links , together with the subsequent hair-cell depolarization , might be a source of sensorineural hearing loss and tinnitus associated with acoustic trauma .
[ "Sound", "overexposure", "is", "known", "to", "cause", "damage", "to", "cochlear", "structures", "and", "can", "induce", "permanent", "or", "temporary", "hearing", "loss", "and", "tinnitus", ".", "Perhaps", "the", "most", "sensitive", "of", "these", "structures", "to", "sound", "overexposure", "are", "the", "tip", "links", ".", "In", "this", "paper", "the", "elecrophysiological", "effects", "of", "pharmacological", "destruction", "of", "the", "tip", "links", "of", "outer", "hair", "cells", "was", "investigated", ".", "Outer", "hair", "cells", "treated", "with", "elastase", "(", "20", "U", "/", "mL", ")", "or", "BAPTA", "(", "5", "mM", ")", "no", "longer", "responded", "to", "sinusoidal", "stimuli", ".", "In", "contrast", "to", "common", "belief", ",", "transduction", "channels", "opened", "due", "to", "loss", "of", "tip", "links", ".", "Such", "opened", "channels", "can", "allow", "K+", "and", "Ca2", "+", "to", "enter", "the", "cell", "from", "the", "endolymphatic", "space", "and", "could", "lead", "to", "permanent", "depolarization", ".", "This", "influx", "of", "cations", "caused", "by", "loss", "of", "tip", "links", ",", "together", "with", "the", "subsequent", "hair", "-", "cell", "depolarization", ",", "might", "be", "a", "source", "of", "sensorineural", "hearing", "loss", "and", "tinnitus", "associated", "with", "acoustic", "trauma", "." ]
[ "umlsterm" ]
Sound, hearing loss, tinnitus, sound, tip, paper, tip, outer hair cells, Outer hair cells, elastase, BAPTA, contrast, belief, tip, the cell, cations, tip, hair - cell, sensorineural hearing loss, tinnitus, acoustic trauma
HNO.00480383.eng.abstr_task2
Sentence: Sound overexposure is known to cause damage to cochlear structures and can induce permanent or temporary hearing loss and tinnitus . Perhaps the most sensitive of these structures to sound overexposure are the tip links . In this paper the elecrophysiological effects of pharmacological destruction of the tip links of outer hair cells was investigated . Outer hair cells treated with elastase ( 20 U/mL ) or BAPTA ( 5 mM ) no longer responded to sinusoidal stimuli . In contrast to common belief , transduction channels opened due to loss of tip links . Such opened channels can allow K+ and Ca2+ to enter the cell from the endolymphatic space and could lead to permanent depolarization . This influx of cations caused by loss of tip links , together with the subsequent hair-cell depolarization , might be a source of sensorineural hearing loss and tinnitus associated with acoustic trauma . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Sound overexposure is known to cause damage to cochlear structures and can induce permanent or temporary hearing loss and tinnitus . Perhaps the most sensitive of these structures to sound overexposure are the tip links . In this paper the elecrophysiological effects of pharmacological destruction of the tip links of outer hair cells was investigated . Outer hair cells treated with elastase ( 20 U/mL ) or BAPTA ( 5 mM ) no longer responded to sinusoidal stimuli . In contrast to common belief , transduction channels opened due to loss of tip links . Such opened channels can allow K+ and Ca2+ to enter the cell from the endolymphatic space and could lead to permanent depolarization . This influx of cations caused by loss of tip links , together with the subsequent hair-cell depolarization , might be a source of sensorineural hearing loss and tinnitus associated with acoustic trauma .
[ "Sound", "overexposure", "is", "known", "to", "cause", "damage", "to", "cochlear", "structures", "and", "can", "induce", "permanent", "or", "temporary", "hearing", "loss", "and", "tinnitus", ".", "Perhaps", "the", "most", "sensitive", "of", "these", "structures", "to", "sound", "overexposure", "are", "the", "tip", "links", ".", "In", "this", "paper", "the", "elecrophysiological", "effects", "of", "pharmacological", "destruction", "of", "the", "tip", "links", "of", "outer", "hair", "cells", "was", "investigated", ".", "Outer", "hair", "cells", "treated", "with", "elastase", "(", "20", "U", "/", "mL", ")", "or", "BAPTA", "(", "5", "mM", ")", "no", "longer", "responded", "to", "sinusoidal", "stimuli", ".", "In", "contrast", "to", "common", "belief", ",", "transduction", "channels", "opened", "due", "to", "loss", "of", "tip", "links", ".", "Such", "opened", "channels", "can", "allow", "K+", "and", "Ca2", "+", "to", "enter", "the", "cell", "from", "the", "endolymphatic", "space", "and", "could", "lead", "to", "permanent", "depolarization", ".", "This", "influx", "of", "cations", "caused", "by", "loss", "of", "tip", "links", ",", "together", "with", "the", "subsequent", "hair", "-", "cell", "depolarization", ",", "might", "be", "a", "source", "of", "sensorineural", "hearing", "loss", "and", "tinnitus", "associated", "with", "acoustic", "trauma", "." ]
[ "umlsterm" ]
bakterielle Infektion is an umlsterm, Gelenks is an umlsterm, Arthritis is an umlsterm, Diagnose is an umlsterm, Analyse is an umlsterm, Therapie is an umlsterm, Gelenkspuelung is an umlsterm, Spuelungen is an umlsterm, Bewegungstherapie is an umlsterm, Therapiebeginn is an umlsterm, Gelenkempyem is an umlsterm, Notfall is an umlsterm
DerChirurg.80690828.ger.abstr_task0
Sentence: Zusammenfassung . Die bakterielle Infektion eines Gelenks ist eine seltene , hinsichtlich der funktionellen Auswirkung aber schwerwiegende Erkrankung . Dem pathophysiologischen Ablauf tragen verschiedene Stadieneinteilungen der eitrigen Arthritis Rechnung , die - in Abhaengigkeit vom jeweiligen Entzuendungsgrad - Hinweise fuer die notwendigen therapeutischen Massnahmen geben . Entscheidend fuer die Diagnose sind neben dem klinischen Befund die Analyse des Gelenkpunktats und das arthroskopische Bild . Die chirurgische Therapie umfasst : 1. das offene oder arthroskopische Débridement mit intensiver Gelenkspuelung , 2. eine postoperative Spueldrainage oder wiederholte arthroskopische Spuelungen , 3. die fruehzeitige kontinuierliche passive und aktive Bewegungstherapie . Nur bei sofortigem Therapiebeginn , moeglichst innerhalb der ersten 3 Tage , kann eine Restitutio ad integrum erreicht werden . Das Gelenkempyem ist deshalb ein Notfall und gilt als dringliche Operationsindikation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die bakterielle Infektion eines Gelenks ist eine seltene , hinsichtlich der funktionellen Auswirkung aber schwerwiegende Erkrankung . Dem pathophysiologischen Ablauf tragen verschiedene Stadieneinteilungen der eitrigen Arthritis Rechnung , die - in Abhaengigkeit vom jeweiligen Entzuendungsgrad - Hinweise fuer die notwendigen therapeutischen Massnahmen geben . Entscheidend fuer die Diagnose sind neben dem klinischen Befund die Analyse des Gelenkpunktats und das arthroskopische Bild . Die chirurgische Therapie umfasst : 1. das offene oder arthroskopische Débridement mit intensiver Gelenkspuelung , 2. eine postoperative Spueldrainage oder wiederholte arthroskopische Spuelungen , 3. die fruehzeitige kontinuierliche passive und aktive Bewegungstherapie . Nur bei sofortigem Therapiebeginn , moeglichst innerhalb der ersten 3 Tage , kann eine Restitutio ad integrum erreicht werden . Das Gelenkempyem ist deshalb ein Notfall und gilt als dringliche Operationsindikation .
[ "Zusammenfassung", ".", "Die", "bakterielle", "Infektion", "eines", "Gelenks", "ist", "eine", "seltene", ",", "hinsichtlich", "der", "funktionellen", "Auswirkung", "aber", "schwerwiegende", "Erkrankung", ".", "Dem", "pathophysiologischen", "Ablauf", "tragen", "verschiedene", "Stadieneinteilungen", "der", "eitrigen", "Arthritis", "Rechnung", ",", "die", "-", "in", "Abhaengigkeit", "vom", "jeweiligen", "Entzuendungsgrad", "-", "Hinweise", "fuer", "die", "notwendigen", "therapeutischen", "Massnahmen", "geben", ".", "Entscheidend", "fuer", "die", "Diagnose", "sind", "neben", "dem", "klinischen", "Befund", "die", "Analyse", "des", "Gelenkpunktats", "und", "das", "arthroskopische", "Bild", ".", "Die", "chirurgische", "Therapie", "umfasst", ":", "1", ".", "das", "offene", "oder", "arthroskopische", "Débridement", "mit", "intensiver", "Gelenkspuelung", ",", "2", ".", "eine", "postoperative", "Spueldrainage", "oder", "wiederholte", "arthroskopische", "Spuelungen", ",", "3", ".", "die", "fruehzeitige", "kontinuierliche", "passive", "und", "aktive", "Bewegungstherapie", ".", "Nur", "bei", "sofortigem", "Therapiebeginn", ",", "moeglichst", "innerhalb", "der", "ersten", "3", "Tage", ",", "kann", "eine", "Restitutio", "ad", "integrum", "erreicht", "werden", ".", "Das", "Gelenkempyem", "ist", "deshalb", "ein", "Notfall", "und", "gilt", "als", "dringliche", "Operationsindikation", "." ]
[ "umlsterm" ]
bakterielle Infektion is an umlsterm, Gelenks is an umlsterm, Arthritis is an umlsterm, Diagnose is an umlsterm, Analyse is an umlsterm, Therapie is an umlsterm, Gelenkspuelung is an umlsterm, Spuelungen is an umlsterm, Bewegungstherapie is an umlsterm, Therapiebeginn is an umlsterm, Gelenkempyem is an umlsterm, Notfall is an umlsterm
DerChirurg.80690828.ger.abstr_task1
Sentence: Zusammenfassung . Die bakterielle Infektion eines Gelenks ist eine seltene , hinsichtlich der funktionellen Auswirkung aber schwerwiegende Erkrankung . Dem pathophysiologischen Ablauf tragen verschiedene Stadieneinteilungen der eitrigen Arthritis Rechnung , die - in Abhaengigkeit vom jeweiligen Entzuendungsgrad - Hinweise fuer die notwendigen therapeutischen Massnahmen geben . Entscheidend fuer die Diagnose sind neben dem klinischen Befund die Analyse des Gelenkpunktats und das arthroskopische Bild . Die chirurgische Therapie umfasst : 1. das offene oder arthroskopische Débridement mit intensiver Gelenkspuelung , 2. eine postoperative Spueldrainage oder wiederholte arthroskopische Spuelungen , 3. die fruehzeitige kontinuierliche passive und aktive Bewegungstherapie . Nur bei sofortigem Therapiebeginn , moeglichst innerhalb der ersten 3 Tage , kann eine Restitutio ad integrum erreicht werden . Das Gelenkempyem ist deshalb ein Notfall und gilt als dringliche Operationsindikation . Instructions: please typing these entity words according to sentence: bakterielle Infektion, Gelenks, Arthritis, Diagnose, Analyse, Therapie, Gelenkspuelung, Spuelungen, Bewegungstherapie, Therapiebeginn, Gelenkempyem, Notfall Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die bakterielle Infektion eines Gelenks ist eine seltene , hinsichtlich der funktionellen Auswirkung aber schwerwiegende Erkrankung . Dem pathophysiologischen Ablauf tragen verschiedene Stadieneinteilungen der eitrigen Arthritis Rechnung , die - in Abhaengigkeit vom jeweiligen Entzuendungsgrad - Hinweise fuer die notwendigen therapeutischen Massnahmen geben . Entscheidend fuer die Diagnose sind neben dem klinischen Befund die Analyse des Gelenkpunktats und das arthroskopische Bild . Die chirurgische Therapie umfasst : 1. das offene oder arthroskopische Débridement mit intensiver Gelenkspuelung , 2. eine postoperative Spueldrainage oder wiederholte arthroskopische Spuelungen , 3. die fruehzeitige kontinuierliche passive und aktive Bewegungstherapie . Nur bei sofortigem Therapiebeginn , moeglichst innerhalb der ersten 3 Tage , kann eine Restitutio ad integrum erreicht werden . Das Gelenkempyem ist deshalb ein Notfall und gilt als dringliche Operationsindikation .
[ "Zusammenfassung", ".", "Die", "bakterielle", "Infektion", "eines", "Gelenks", "ist", "eine", "seltene", ",", "hinsichtlich", "der", "funktionellen", "Auswirkung", "aber", "schwerwiegende", "Erkrankung", ".", "Dem", "pathophysiologischen", "Ablauf", "tragen", "verschiedene", "Stadieneinteilungen", "der", "eitrigen", "Arthritis", "Rechnung", ",", "die", "-", "in", "Abhaengigkeit", "vom", "jeweiligen", "Entzuendungsgrad", "-", "Hinweise", "fuer", "die", "notwendigen", "therapeutischen", "Massnahmen", "geben", ".", "Entscheidend", "fuer", "die", "Diagnose", "sind", "neben", "dem", "klinischen", "Befund", "die", "Analyse", "des", "Gelenkpunktats", "und", "das", "arthroskopische", "Bild", ".", "Die", "chirurgische", "Therapie", "umfasst", ":", "1", ".", "das", "offene", "oder", "arthroskopische", "Débridement", "mit", "intensiver", "Gelenkspuelung", ",", "2", ".", "eine", "postoperative", "Spueldrainage", "oder", "wiederholte", "arthroskopische", "Spuelungen", ",", "3", ".", "die", "fruehzeitige", "kontinuierliche", "passive", "und", "aktive", "Bewegungstherapie", ".", "Nur", "bei", "sofortigem", "Therapiebeginn", ",", "moeglichst", "innerhalb", "der", "ersten", "3", "Tage", ",", "kann", "eine", "Restitutio", "ad", "integrum", "erreicht", "werden", ".", "Das", "Gelenkempyem", "ist", "deshalb", "ein", "Notfall", "und", "gilt", "als", "dringliche", "Operationsindikation", "." ]
[ "umlsterm" ]
bakterielle Infektion, Gelenks, Arthritis, Diagnose, Analyse, Therapie, Gelenkspuelung, Spuelungen, Bewegungstherapie, Therapiebeginn, Gelenkempyem, Notfall
DerChirurg.80690828.ger.abstr_task2
Sentence: Zusammenfassung . Die bakterielle Infektion eines Gelenks ist eine seltene , hinsichtlich der funktionellen Auswirkung aber schwerwiegende Erkrankung . Dem pathophysiologischen Ablauf tragen verschiedene Stadieneinteilungen der eitrigen Arthritis Rechnung , die - in Abhaengigkeit vom jeweiligen Entzuendungsgrad - Hinweise fuer die notwendigen therapeutischen Massnahmen geben . Entscheidend fuer die Diagnose sind neben dem klinischen Befund die Analyse des Gelenkpunktats und das arthroskopische Bild . Die chirurgische Therapie umfasst : 1. das offene oder arthroskopische Débridement mit intensiver Gelenkspuelung , 2. eine postoperative Spueldrainage oder wiederholte arthroskopische Spuelungen , 3. die fruehzeitige kontinuierliche passive und aktive Bewegungstherapie . Nur bei sofortigem Therapiebeginn , moeglichst innerhalb der ersten 3 Tage , kann eine Restitutio ad integrum erreicht werden . Das Gelenkempyem ist deshalb ein Notfall und gilt als dringliche Operationsindikation . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die bakterielle Infektion eines Gelenks ist eine seltene , hinsichtlich der funktionellen Auswirkung aber schwerwiegende Erkrankung . Dem pathophysiologischen Ablauf tragen verschiedene Stadieneinteilungen der eitrigen Arthritis Rechnung , die - in Abhaengigkeit vom jeweiligen Entzuendungsgrad - Hinweise fuer die notwendigen therapeutischen Massnahmen geben . Entscheidend fuer die Diagnose sind neben dem klinischen Befund die Analyse des Gelenkpunktats und das arthroskopische Bild . Die chirurgische Therapie umfasst : 1. das offene oder arthroskopische Débridement mit intensiver Gelenkspuelung , 2. eine postoperative Spueldrainage oder wiederholte arthroskopische Spuelungen , 3. die fruehzeitige kontinuierliche passive und aktive Bewegungstherapie . Nur bei sofortigem Therapiebeginn , moeglichst innerhalb der ersten 3 Tage , kann eine Restitutio ad integrum erreicht werden . Das Gelenkempyem ist deshalb ein Notfall und gilt als dringliche Operationsindikation .
[ "Zusammenfassung", ".", "Die", "bakterielle", "Infektion", "eines", "Gelenks", "ist", "eine", "seltene", ",", "hinsichtlich", "der", "funktionellen", "Auswirkung", "aber", "schwerwiegende", "Erkrankung", ".", "Dem", "pathophysiologischen", "Ablauf", "tragen", "verschiedene", "Stadieneinteilungen", "der", "eitrigen", "Arthritis", "Rechnung", ",", "die", "-", "in", "Abhaengigkeit", "vom", "jeweiligen", "Entzuendungsgrad", "-", "Hinweise", "fuer", "die", "notwendigen", "therapeutischen", "Massnahmen", "geben", ".", "Entscheidend", "fuer", "die", "Diagnose", "sind", "neben", "dem", "klinischen", "Befund", "die", "Analyse", "des", "Gelenkpunktats", "und", "das", "arthroskopische", "Bild", ".", "Die", "chirurgische", "Therapie", "umfasst", ":", "1", ".", "das", "offene", "oder", "arthroskopische", "Débridement", "mit", "intensiver", "Gelenkspuelung", ",", "2", ".", "eine", "postoperative", "Spueldrainage", "oder", "wiederholte", "arthroskopische", "Spuelungen", ",", "3", ".", "die", "fruehzeitige", "kontinuierliche", "passive", "und", "aktive", "Bewegungstherapie", ".", "Nur", "bei", "sofortigem", "Therapiebeginn", ",", "moeglichst", "innerhalb", "der", "ersten", "3", "Tage", ",", "kann", "eine", "Restitutio", "ad", "integrum", "erreicht", "werden", ".", "Das", "Gelenkempyem", "ist", "deshalb", "ein", "Notfall", "und", "gilt", "als", "dringliche", "Operationsindikation", "." ]
[ "umlsterm" ]
Personen is an umlsterm, Verletzung is an umlsterm, Verletzungen is an umlsterm
Rechtsmedizin.80090029.ger.abstr_task0
Sentence: Es wird ueber zwei Faelle berichtet , in denen die betreffenden Personen durch fallende Geschosse verletzt wurden . Bei dem ersten Ereignis ist zuvor ein lauter Knall vernommen und auch ein Projektil gefunden worden . Im zweiten Fall wird die festgestellte Verletzung auf Grund der zeitlichen und oertlichen Koinzidenz mit der ersten Begebenheit , sowie wegen der Wundbeschaffenheit auf ein fallendes Geschoss zurueckgefuehrt . Verletzungen der beschriebenen Art sind aeusserst selten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Es wird ueber zwei Faelle berichtet , in denen die betreffenden Personen durch fallende Geschosse verletzt wurden . Bei dem ersten Ereignis ist zuvor ein lauter Knall vernommen und auch ein Projektil gefunden worden . Im zweiten Fall wird die festgestellte Verletzung auf Grund der zeitlichen und oertlichen Koinzidenz mit der ersten Begebenheit , sowie wegen der Wundbeschaffenheit auf ein fallendes Geschoss zurueckgefuehrt . Verletzungen der beschriebenen Art sind aeusserst selten .
[ "Es", "wird", "ueber", "zwei", "Faelle", "berichtet", ",", "in", "denen", "die", "betreffenden", "Personen", "durch", "fallende", "Geschosse", "verletzt", "wurden", ".", "Bei", "dem", "ersten", "Ereignis", "ist", "zuvor", "ein", "lauter", "Knall", "vernommen", "und", "auch", "ein", "Projektil", "gefunden", "worden", ".", "Im", "zweiten", "Fall", "wird", "die", "festgestellte", "Verletzung", "auf", "Grund", "der", "zeitlichen", "und", "oertlichen", "Koinzidenz", "mit", "der", "ersten", "Begebenheit", ",", "sowie", "wegen", "der", "Wundbeschaffenheit", "auf", "ein", "fallendes", "Geschoss", "zurueckgefuehrt", ".", "Verletzungen", "der", "beschriebenen", "Art", "sind", "aeusserst", "selten", "." ]
[ "umlsterm" ]
Personen is an umlsterm, Verletzung is an umlsterm, Verletzungen is an umlsterm
Rechtsmedizin.80090029.ger.abstr_task1
Sentence: Es wird ueber zwei Faelle berichtet , in denen die betreffenden Personen durch fallende Geschosse verletzt wurden . Bei dem ersten Ereignis ist zuvor ein lauter Knall vernommen und auch ein Projektil gefunden worden . Im zweiten Fall wird die festgestellte Verletzung auf Grund der zeitlichen und oertlichen Koinzidenz mit der ersten Begebenheit , sowie wegen der Wundbeschaffenheit auf ein fallendes Geschoss zurueckgefuehrt . Verletzungen der beschriebenen Art sind aeusserst selten . Instructions: please typing these entity words according to sentence: Personen, Verletzung, Verletzungen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Es wird ueber zwei Faelle berichtet , in denen die betreffenden Personen durch fallende Geschosse verletzt wurden . Bei dem ersten Ereignis ist zuvor ein lauter Knall vernommen und auch ein Projektil gefunden worden . Im zweiten Fall wird die festgestellte Verletzung auf Grund der zeitlichen und oertlichen Koinzidenz mit der ersten Begebenheit , sowie wegen der Wundbeschaffenheit auf ein fallendes Geschoss zurueckgefuehrt . Verletzungen der beschriebenen Art sind aeusserst selten .
[ "Es", "wird", "ueber", "zwei", "Faelle", "berichtet", ",", "in", "denen", "die", "betreffenden", "Personen", "durch", "fallende", "Geschosse", "verletzt", "wurden", ".", "Bei", "dem", "ersten", "Ereignis", "ist", "zuvor", "ein", "lauter", "Knall", "vernommen", "und", "auch", "ein", "Projektil", "gefunden", "worden", ".", "Im", "zweiten", "Fall", "wird", "die", "festgestellte", "Verletzung", "auf", "Grund", "der", "zeitlichen", "und", "oertlichen", "Koinzidenz", "mit", "der", "ersten", "Begebenheit", ",", "sowie", "wegen", "der", "Wundbeschaffenheit", "auf", "ein", "fallendes", "Geschoss", "zurueckgefuehrt", ".", "Verletzungen", "der", "beschriebenen", "Art", "sind", "aeusserst", "selten", "." ]
[ "umlsterm" ]
Personen, Verletzung, Verletzungen
Rechtsmedizin.80090029.ger.abstr_task2
Sentence: Es wird ueber zwei Faelle berichtet , in denen die betreffenden Personen durch fallende Geschosse verletzt wurden . Bei dem ersten Ereignis ist zuvor ein lauter Knall vernommen und auch ein Projektil gefunden worden . Im zweiten Fall wird die festgestellte Verletzung auf Grund der zeitlichen und oertlichen Koinzidenz mit der ersten Begebenheit , sowie wegen der Wundbeschaffenheit auf ein fallendes Geschoss zurueckgefuehrt . Verletzungen der beschriebenen Art sind aeusserst selten . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Es wird ueber zwei Faelle berichtet , in denen die betreffenden Personen durch fallende Geschosse verletzt wurden . Bei dem ersten Ereignis ist zuvor ein lauter Knall vernommen und auch ein Projektil gefunden worden . Im zweiten Fall wird die festgestellte Verletzung auf Grund der zeitlichen und oertlichen Koinzidenz mit der ersten Begebenheit , sowie wegen der Wundbeschaffenheit auf ein fallendes Geschoss zurueckgefuehrt . Verletzungen der beschriebenen Art sind aeusserst selten .
[ "Es", "wird", "ueber", "zwei", "Faelle", "berichtet", ",", "in", "denen", "die", "betreffenden", "Personen", "durch", "fallende", "Geschosse", "verletzt", "wurden", ".", "Bei", "dem", "ersten", "Ereignis", "ist", "zuvor", "ein", "lauter", "Knall", "vernommen", "und", "auch", "ein", "Projektil", "gefunden", "worden", ".", "Im", "zweiten", "Fall", "wird", "die", "festgestellte", "Verletzung", "auf", "Grund", "der", "zeitlichen", "und", "oertlichen", "Koinzidenz", "mit", "der", "ersten", "Begebenheit", ",", "sowie", "wegen", "der", "Wundbeschaffenheit", "auf", "ein", "fallendes", "Geschoss", "zurueckgefuehrt", ".", "Verletzungen", "der", "beschriebenen", "Art", "sind", "aeusserst", "selten", "." ]
[ "umlsterm" ]
Multifaceted support is a Intervention_Educational, multifaceted intervention is a Intervention_Educational, general practitioners ( GPs ) for patients with diabetes is a Participant_Condition, 124 practices is a Participant_Sample-size, 185 is a Participant_Sample-size, feedback reports and support from a facilitator is a Intervention_Educational, no special attention is a Intervention_Control, 1410 is a Participant_Sample-size, Type 2 diabetic patients is a Participant_Condition
10707_task0
Sentence: Multifaceted support to improve clinical decision making in diabetes care : a randomized controlled trial in general practice . AIMS To evaluate the effectiveness of a multifaceted intervention to improve the clinical decision making of general practitioners ( GPs ) for patients with diabetes . To identify practice characteristics which predict success . METHODS Cluster randomized controlled trial with 124 practices and 185 GPs in The Netherlands . The intervention group received feedback reports and support from a facilitator ; the control group received no special attention . Outcome measures were the compliance rates with evidence-based recommendations pertaining to discussion of body weight control , discussion of problems with medication , blood pressure measurement , foot examination , eye examination , initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose , and scheduling a follow-up appointment . RESULTS The GPs reported on their clinical decision making in 1410 consultations with Type 2 diabetic patients at baseline and 1449 consultations after the intervention period . The intervention resulted in statistically significant improvement for two of the seven outcome measures : foot examination ( odds ratio 1.68 ; 95 % confidence interval 1.19-2.39 ) and eye examination ( 1.52 ; 1.07-2.16 ) . Discussion of problems with medication showed a near significant trend towards increased benefit for the intervention group ( 1.52 ; 0.99-2.32 ) . Practice characteristics were not found to be related to the success of the intervention . CONCLUSIONS Feedback reports with support from facilitators appear to increase rates of foot examination and eye examination in general practice . Alternative interventions should be explored to improve the pursuit of metabolic control by GPs . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Intervention_Control, Participant_Condition, Participant_Sample-size
[ "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Multifaceted support to improve clinical decision making in diabetes care : a randomized controlled trial in general practice . AIMS To evaluate the effectiveness of a multifaceted intervention to improve the clinical decision making of general practitioners ( GPs ) for patients with diabetes . To identify practice characteristics which predict success . METHODS Cluster randomized controlled trial with 124 practices and 185 GPs in The Netherlands . The intervention group received feedback reports and support from a facilitator ; the control group received no special attention . Outcome measures were the compliance rates with evidence-based recommendations pertaining to discussion of body weight control , discussion of problems with medication , blood pressure measurement , foot examination , eye examination , initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose , and scheduling a follow-up appointment . RESULTS The GPs reported on their clinical decision making in 1410 consultations with Type 2 diabetic patients at baseline and 1449 consultations after the intervention period . The intervention resulted in statistically significant improvement for two of the seven outcome measures : foot examination ( odds ratio 1.68 ; 95 % confidence interval 1.19-2.39 ) and eye examination ( 1.52 ; 1.07-2.16 ) . Discussion of problems with medication showed a near significant trend towards increased benefit for the intervention group ( 1.52 ; 0.99-2.32 ) . Practice characteristics were not found to be related to the success of the intervention . CONCLUSIONS Feedback reports with support from facilitators appear to increase rates of foot examination and eye examination in general practice . Alternative interventions should be explored to improve the pursuit of metabolic control by GPs .
[ "Multifaceted", "support", "to", "improve", "clinical", "decision", "making", "in", "diabetes", "care", ":", "a", "randomized", "controlled", "trial", "in", "general", "practice", ".", "AIMS", "To", "evaluate", "the", "effectiveness", "of", "a", "multifaceted", "intervention", "to", "improve", "the", "clinical", "decision", "making", "of", "general", "practitioners", "(", "GPs", ")", "for", "patients", "with", "diabetes", ".", "To", "identify", "practice", "characteristics", "which", "predict", "success", ".", "METHODS", "Cluster", "randomized", "controlled", "trial", "with", "124", "practices", "and", "185", "GPs", "in", "The", "Netherlands", ".", "The", "intervention", "group", "received", "feedback", "reports", "and", "support", "from", "a", "facilitator", ";", "the", "control", "group", "received", "no", "special", "attention", ".", "Outcome", "measures", "were", "the", "compliance", "rates", "with", "evidence", "-", "based", "recommendations", "pertaining", "to", "discussion", "of", "body", "weight", "control", ",", "discussion", "of", "problems", "with", "medication", ",", "blood", "pressure", "measurement", ",", "foot", "examination", ",", "eye", "examination", ",", "initiating", "anti", "-", "diabetic", "medication", "or", "increasing", "the", "dosage", "in", "cases", "of", "uncontrolled", "blood", "glucose", ",", "and", "scheduling", "a", "follow", "-", "up", "appointment", ".", "RESULTS", "The", "GPs", "reported", "on", "their", "clinical", "decision", "making", "in", "1410", "consultations", "with", "Type", "2", "diabetic", "patients", "at", "baseline", "and", "1449", "consultations", "after", "the", "intervention", "period", ".", "The", "intervention", "resulted", "in", "statistically", "significant", "improvement", "for", "two", "of", "the", "seven", "outcome", "measures", ":", "foot", "examination", "(", "odds", "ratio", "1.68", ";", "95", "%", "confidence", "interval", "1.19", "-", "2.39", ")", "and", "eye", "examination", "(", "1.52", ";", "1.07", "-", "2.16", ")", ".", "Discussion", "of", "problems", "with", "medication", "showed", "a", "near", "significant", "trend", "towards", "increased", "benefit", "for", "the", "intervention", "group", "(", "1.52", ";", "0.99", "-", "2.32", ")", ".", "Practice", "characteristics", "were", "not", "found", "to", "be", "related", "to", "the", "success", "of", "the", "intervention", ".", "CONCLUSIONS", "Feedback", "reports", "with", "support", "from", "facilitators", "appear", "to", "increase", "rates", "of", "foot", "examination", "and", "eye", "examination", "in", "general", "practice", ".", "Alternative", "interventions", "should", "be", "explored", "to", "improve", "the", "pursuit", "of", "metabolic", "control", "by", "GPs", "." ]
[ "Participant_Condition", "Intervention_Educational", "Intervention_Control", "Participant_Sample-size" ]
Multifaceted support is a Intervention_Educational, multifaceted intervention is a Intervention_Educational, general practitioners ( GPs ) for patients with diabetes is a Participant_Condition, 124 practices is a Participant_Sample-size, 185 is a Participant_Sample-size, feedback reports and support from a facilitator is a Intervention_Educational, no special attention is a Intervention_Control, 1410 is a Participant_Sample-size, Type 2 diabetic patients is a Participant_Condition
10707_task1
Sentence: Multifaceted support to improve clinical decision making in diabetes care : a randomized controlled trial in general practice . AIMS To evaluate the effectiveness of a multifaceted intervention to improve the clinical decision making of general practitioners ( GPs ) for patients with diabetes . To identify practice characteristics which predict success . METHODS Cluster randomized controlled trial with 124 practices and 185 GPs in The Netherlands . The intervention group received feedback reports and support from a facilitator ; the control group received no special attention . Outcome measures were the compliance rates with evidence-based recommendations pertaining to discussion of body weight control , discussion of problems with medication , blood pressure measurement , foot examination , eye examination , initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose , and scheduling a follow-up appointment . RESULTS The GPs reported on their clinical decision making in 1410 consultations with Type 2 diabetic patients at baseline and 1449 consultations after the intervention period . The intervention resulted in statistically significant improvement for two of the seven outcome measures : foot examination ( odds ratio 1.68 ; 95 % confidence interval 1.19-2.39 ) and eye examination ( 1.52 ; 1.07-2.16 ) . Discussion of problems with medication showed a near significant trend towards increased benefit for the intervention group ( 1.52 ; 0.99-2.32 ) . Practice characteristics were not found to be related to the success of the intervention . CONCLUSIONS Feedback reports with support from facilitators appear to increase rates of foot examination and eye examination in general practice . Alternative interventions should be explored to improve the pursuit of metabolic control by GPs . Instructions: please typing these entity words according to sentence: Multifaceted support, multifaceted intervention, general practitioners ( GPs ) for patients with diabetes, 124 practices, 185, feedback reports and support from a facilitator, no special attention, 1410, Type 2 diabetic patients Options: Intervention_Educational, Intervention_Control, Participant_Condition, Participant_Sample-size
[ "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Multifaceted support to improve clinical decision making in diabetes care : a randomized controlled trial in general practice . AIMS To evaluate the effectiveness of a multifaceted intervention to improve the clinical decision making of general practitioners ( GPs ) for patients with diabetes . To identify practice characteristics which predict success . METHODS Cluster randomized controlled trial with 124 practices and 185 GPs in The Netherlands . The intervention group received feedback reports and support from a facilitator ; the control group received no special attention . Outcome measures were the compliance rates with evidence-based recommendations pertaining to discussion of body weight control , discussion of problems with medication , blood pressure measurement , foot examination , eye examination , initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose , and scheduling a follow-up appointment . RESULTS The GPs reported on their clinical decision making in 1410 consultations with Type 2 diabetic patients at baseline and 1449 consultations after the intervention period . The intervention resulted in statistically significant improvement for two of the seven outcome measures : foot examination ( odds ratio 1.68 ; 95 % confidence interval 1.19-2.39 ) and eye examination ( 1.52 ; 1.07-2.16 ) . Discussion of problems with medication showed a near significant trend towards increased benefit for the intervention group ( 1.52 ; 0.99-2.32 ) . Practice characteristics were not found to be related to the success of the intervention . CONCLUSIONS Feedback reports with support from facilitators appear to increase rates of foot examination and eye examination in general practice . Alternative interventions should be explored to improve the pursuit of metabolic control by GPs .
[ "Multifaceted", "support", "to", "improve", "clinical", "decision", "making", "in", "diabetes", "care", ":", "a", "randomized", "controlled", "trial", "in", "general", "practice", ".", "AIMS", "To", "evaluate", "the", "effectiveness", "of", "a", "multifaceted", "intervention", "to", "improve", "the", "clinical", "decision", "making", "of", "general", "practitioners", "(", "GPs", ")", "for", "patients", "with", "diabetes", ".", "To", "identify", "practice", "characteristics", "which", "predict", "success", ".", "METHODS", "Cluster", "randomized", "controlled", "trial", "with", "124", "practices", "and", "185", "GPs", "in", "The", "Netherlands", ".", "The", "intervention", "group", "received", "feedback", "reports", "and", "support", "from", "a", "facilitator", ";", "the", "control", "group", "received", "no", "special", "attention", ".", "Outcome", "measures", "were", "the", "compliance", "rates", "with", "evidence", "-", "based", "recommendations", "pertaining", "to", "discussion", "of", "body", "weight", "control", ",", "discussion", "of", "problems", "with", "medication", ",", "blood", "pressure", "measurement", ",", "foot", "examination", ",", "eye", "examination", ",", "initiating", "anti", "-", "diabetic", "medication", "or", "increasing", "the", "dosage", "in", "cases", "of", "uncontrolled", "blood", "glucose", ",", "and", "scheduling", "a", "follow", "-", "up", "appointment", ".", "RESULTS", "The", "GPs", "reported", "on", "their", "clinical", "decision", "making", "in", "1410", "consultations", "with", "Type", "2", "diabetic", "patients", "at", "baseline", "and", "1449", "consultations", "after", "the", "intervention", "period", ".", "The", "intervention", "resulted", "in", "statistically", "significant", "improvement", "for", "two", "of", "the", "seven", "outcome", "measures", ":", "foot", "examination", "(", "odds", "ratio", "1.68", ";", "95", "%", "confidence", "interval", "1.19", "-", "2.39", ")", "and", "eye", "examination", "(", "1.52", ";", "1.07", "-", "2.16", ")", ".", "Discussion", "of", "problems", "with", "medication", "showed", "a", "near", "significant", "trend", "towards", "increased", "benefit", "for", "the", "intervention", "group", "(", "1.52", ";", "0.99", "-", "2.32", ")", ".", "Practice", "characteristics", "were", "not", "found", "to", "be", "related", "to", "the", "success", "of", "the", "intervention", ".", "CONCLUSIONS", "Feedback", "reports", "with", "support", "from", "facilitators", "appear", "to", "increase", "rates", "of", "foot", "examination", "and", "eye", "examination", "in", "general", "practice", ".", "Alternative", "interventions", "should", "be", "explored", "to", "improve", "the", "pursuit", "of", "metabolic", "control", "by", "GPs", "." ]
[ "Participant_Condition", "Intervention_Educational", "Intervention_Control", "Participant_Sample-size" ]
Multifaceted support, multifaceted intervention, general practitioners ( GPs ) for patients with diabetes, 124 practices, 185, feedback reports and support from a facilitator, no special attention, 1410, Type 2 diabetic patients
10707_task2
Sentence: Multifaceted support to improve clinical decision making in diabetes care : a randomized controlled trial in general practice . AIMS To evaluate the effectiveness of a multifaceted intervention to improve the clinical decision making of general practitioners ( GPs ) for patients with diabetes . To identify practice characteristics which predict success . METHODS Cluster randomized controlled trial with 124 practices and 185 GPs in The Netherlands . The intervention group received feedback reports and support from a facilitator ; the control group received no special attention . Outcome measures were the compliance rates with evidence-based recommendations pertaining to discussion of body weight control , discussion of problems with medication , blood pressure measurement , foot examination , eye examination , initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose , and scheduling a follow-up appointment . RESULTS The GPs reported on their clinical decision making in 1410 consultations with Type 2 diabetic patients at baseline and 1449 consultations after the intervention period . The intervention resulted in statistically significant improvement for two of the seven outcome measures : foot examination ( odds ratio 1.68 ; 95 % confidence interval 1.19-2.39 ) and eye examination ( 1.52 ; 1.07-2.16 ) . Discussion of problems with medication showed a near significant trend towards increased benefit for the intervention group ( 1.52 ; 0.99-2.32 ) . Practice characteristics were not found to be related to the success of the intervention . CONCLUSIONS Feedback reports with support from facilitators appear to increase rates of foot examination and eye examination in general practice . Alternative interventions should be explored to improve the pursuit of metabolic control by GPs . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Multifaceted support to improve clinical decision making in diabetes care : a randomized controlled trial in general practice . AIMS To evaluate the effectiveness of a multifaceted intervention to improve the clinical decision making of general practitioners ( GPs ) for patients with diabetes . To identify practice characteristics which predict success . METHODS Cluster randomized controlled trial with 124 practices and 185 GPs in The Netherlands . The intervention group received feedback reports and support from a facilitator ; the control group received no special attention . Outcome measures were the compliance rates with evidence-based recommendations pertaining to discussion of body weight control , discussion of problems with medication , blood pressure measurement , foot examination , eye examination , initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose , and scheduling a follow-up appointment . RESULTS The GPs reported on their clinical decision making in 1410 consultations with Type 2 diabetic patients at baseline and 1449 consultations after the intervention period . The intervention resulted in statistically significant improvement for two of the seven outcome measures : foot examination ( odds ratio 1.68 ; 95 % confidence interval 1.19-2.39 ) and eye examination ( 1.52 ; 1.07-2.16 ) . Discussion of problems with medication showed a near significant trend towards increased benefit for the intervention group ( 1.52 ; 0.99-2.32 ) . Practice characteristics were not found to be related to the success of the intervention . CONCLUSIONS Feedback reports with support from facilitators appear to increase rates of foot examination and eye examination in general practice . Alternative interventions should be explored to improve the pursuit of metabolic control by GPs .
[ "Multifaceted", "support", "to", "improve", "clinical", "decision", "making", "in", "diabetes", "care", ":", "a", "randomized", "controlled", "trial", "in", "general", "practice", ".", "AIMS", "To", "evaluate", "the", "effectiveness", "of", "a", "multifaceted", "intervention", "to", "improve", "the", "clinical", "decision", "making", "of", "general", "practitioners", "(", "GPs", ")", "for", "patients", "with", "diabetes", ".", "To", "identify", "practice", "characteristics", "which", "predict", "success", ".", "METHODS", "Cluster", "randomized", "controlled", "trial", "with", "124", "practices", "and", "185", "GPs", "in", "The", "Netherlands", ".", "The", "intervention", "group", "received", "feedback", "reports", "and", "support", "from", "a", "facilitator", ";", "the", "control", "group", "received", "no", "special", "attention", ".", "Outcome", "measures", "were", "the", "compliance", "rates", "with", "evidence", "-", "based", "recommendations", "pertaining", "to", "discussion", "of", "body", "weight", "control", ",", "discussion", "of", "problems", "with", "medication", ",", "blood", "pressure", "measurement", ",", "foot", "examination", ",", "eye", "examination", ",", "initiating", "anti", "-", "diabetic", "medication", "or", "increasing", "the", "dosage", "in", "cases", "of", "uncontrolled", "blood", "glucose", ",", "and", "scheduling", "a", "follow", "-", "up", "appointment", ".", "RESULTS", "The", "GPs", "reported", "on", "their", "clinical", "decision", "making", "in", "1410", "consultations", "with", "Type", "2", "diabetic", "patients", "at", "baseline", "and", "1449", "consultations", "after", "the", "intervention", "period", ".", "The", "intervention", "resulted", "in", "statistically", "significant", "improvement", "for", "two", "of", "the", "seven", "outcome", "measures", ":", "foot", "examination", "(", "odds", "ratio", "1.68", ";", "95", "%", "confidence", "interval", "1.19", "-", "2.39", ")", "and", "eye", "examination", "(", "1.52", ";", "1.07", "-", "2.16", ")", ".", "Discussion", "of", "problems", "with", "medication", "showed", "a", "near", "significant", "trend", "towards", "increased", "benefit", "for", "the", "intervention", "group", "(", "1.52", ";", "0.99", "-", "2.32", ")", ".", "Practice", "characteristics", "were", "not", "found", "to", "be", "related", "to", "the", "success", "of", "the", "intervention", ".", "CONCLUSIONS", "Feedback", "reports", "with", "support", "from", "facilitators", "appear", "to", "increase", "rates", "of", "foot", "examination", "and", "eye", "examination", "in", "general", "practice", ".", "Alternative", "interventions", "should", "be", "explored", "to", "improve", "the", "pursuit", "of", "metabolic", "control", "by", "GPs", "." ]
[ "Participant_Condition", "Intervention_Educational", "Intervention_Control", "Participant_Sample-size" ]
Arthrose is an umlsterm, Gelenkerkrankungen is an umlsterm, Genetik is an umlsterm, Hormonstatus is an umlsterm
ZfuerRheumatologie.70560342.ger.abstr_task0
Sentence: Arthrose ist die haeufigste Form der Gelenkerkrankungen . Neben verschiedenen bekannten Faktoren wie z.B. Genetik , Alter und Hormonstatus werden chronisch-repetitive Mikro- und Makrotraumatisierungen bei der Fingerpolyarthrose ( FIPO ) als Ursache diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Arthrose ist die haeufigste Form der Gelenkerkrankungen . Neben verschiedenen bekannten Faktoren wie z.B. Genetik , Alter und Hormonstatus werden chronisch-repetitive Mikro- und Makrotraumatisierungen bei der Fingerpolyarthrose ( FIPO ) als Ursache diskutiert .
[ "Arthrose", "ist", "die", "haeufigste", "Form", "der", "Gelenkerkrankungen", ".", "Neben", "verschiedenen", "bekannten", "Faktoren", "wie", "z.", "B.", "Genetik", ",", "Alter", "und", "Hormonstatus", "werden", "chronisch", "-", "repetitive", "Mikro-", "und", "Makrotraumatisierungen", "bei", "der", "Fingerpolyarthrose", "(", "FIPO", ")", "als", "Ursache", "diskutiert", "." ]
[ "umlsterm" ]
Arthrose is an umlsterm, Gelenkerkrankungen is an umlsterm, Genetik is an umlsterm, Hormonstatus is an umlsterm
ZfuerRheumatologie.70560342.ger.abstr_task1
Sentence: Arthrose ist die haeufigste Form der Gelenkerkrankungen . Neben verschiedenen bekannten Faktoren wie z.B. Genetik , Alter und Hormonstatus werden chronisch-repetitive Mikro- und Makrotraumatisierungen bei der Fingerpolyarthrose ( FIPO ) als Ursache diskutiert . Instructions: please typing these entity words according to sentence: Arthrose, Gelenkerkrankungen, Genetik, Hormonstatus Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Arthrose ist die haeufigste Form der Gelenkerkrankungen . Neben verschiedenen bekannten Faktoren wie z.B. Genetik , Alter und Hormonstatus werden chronisch-repetitive Mikro- und Makrotraumatisierungen bei der Fingerpolyarthrose ( FIPO ) als Ursache diskutiert .
[ "Arthrose", "ist", "die", "haeufigste", "Form", "der", "Gelenkerkrankungen", ".", "Neben", "verschiedenen", "bekannten", "Faktoren", "wie", "z.", "B.", "Genetik", ",", "Alter", "und", "Hormonstatus", "werden", "chronisch", "-", "repetitive", "Mikro-", "und", "Makrotraumatisierungen", "bei", "der", "Fingerpolyarthrose", "(", "FIPO", ")", "als", "Ursache", "diskutiert", "." ]
[ "umlsterm" ]
Arthrose, Gelenkerkrankungen, Genetik, Hormonstatus
ZfuerRheumatologie.70560342.ger.abstr_task2
Sentence: Arthrose ist die haeufigste Form der Gelenkerkrankungen . Neben verschiedenen bekannten Faktoren wie z.B. Genetik , Alter und Hormonstatus werden chronisch-repetitive Mikro- und Makrotraumatisierungen bei der Fingerpolyarthrose ( FIPO ) als Ursache diskutiert . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Arthrose ist die haeufigste Form der Gelenkerkrankungen . Neben verschiedenen bekannten Faktoren wie z.B. Genetik , Alter und Hormonstatus werden chronisch-repetitive Mikro- und Makrotraumatisierungen bei der Fingerpolyarthrose ( FIPO ) als Ursache diskutiert .
[ "Arthrose", "ist", "die", "haeufigste", "Form", "der", "Gelenkerkrankungen", ".", "Neben", "verschiedenen", "bekannten", "Faktoren", "wie", "z.", "B.", "Genetik", ",", "Alter", "und", "Hormonstatus", "werden", "chronisch", "-", "repetitive", "Mikro-", "und", "Makrotraumatisierungen", "bei", "der", "Fingerpolyarthrose", "(", "FIPO", ")", "als", "Ursache", "diskutiert", "." ]
[ "umlsterm" ]
Behandlung is an umlsterm, Refluxkrankheit is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Technik is an umlsterm, Zeit is an umlsterm, Langzeitergebnissen is an umlsterm
DerChirurg.80690148.ger.abstr_task0
Sentence: Zusammenfassung . Endoskopische Antirefluxchirurgie ersetzt zunehmend die traditionellen Operationsverfahren in der Behandlung der therapierefraktaeren gastrooesophagealen Refluxkrankheit . Diese laparoskopischen Verfahren sind jedoch technisch sehr anspruchsvoll . Komplikationen koennen aber durch eine sorgfaeltige Auswahl der Patienten sowie durch die geeignete chirurgische Technik minimiert werden . In juengster Zeit wurden zahlreiche Nachuntersuchungen mit guten Langzeitergebnissen und geringen Nebenwirkungen publiziert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zusammenfassung . Endoskopische Antirefluxchirurgie ersetzt zunehmend die traditionellen Operationsverfahren in der Behandlung der therapierefraktaeren gastrooesophagealen Refluxkrankheit . Diese laparoskopischen Verfahren sind jedoch technisch sehr anspruchsvoll . Komplikationen koennen aber durch eine sorgfaeltige Auswahl der Patienten sowie durch die geeignete chirurgische Technik minimiert werden . In juengster Zeit wurden zahlreiche Nachuntersuchungen mit guten Langzeitergebnissen und geringen Nebenwirkungen publiziert .
[ "Zusammenfassung", ".", "Endoskopische", "Antirefluxchirurgie", "ersetzt", "zunehmend", "die", "traditionellen", "Operationsverfahren", "in", "der", "Behandlung", "der", "therapierefraktaeren", "gastrooesophagealen", "Refluxkrankheit", ".", "Diese", "laparoskopischen", "Verfahren", "sind", "jedoch", "technisch", "sehr", "anspruchsvoll", ".", "Komplikationen", "koennen", "aber", "durch", "eine", "sorgfaeltige", "Auswahl", "der", "Patienten", "sowie", "durch", "die", "geeignete", "chirurgische", "Technik", "minimiert", "werden", ".", "In", "juengster", "Zeit", "wurden", "zahlreiche", "Nachuntersuchungen", "mit", "guten", "Langzeitergebnissen", "und", "geringen", "Nebenwirkungen", "publiziert", "." ]
[ "umlsterm" ]
Behandlung is an umlsterm, Refluxkrankheit is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Technik is an umlsterm, Zeit is an umlsterm, Langzeitergebnissen is an umlsterm
DerChirurg.80690148.ger.abstr_task1
Sentence: Zusammenfassung . Endoskopische Antirefluxchirurgie ersetzt zunehmend die traditionellen Operationsverfahren in der Behandlung der therapierefraktaeren gastrooesophagealen Refluxkrankheit . Diese laparoskopischen Verfahren sind jedoch technisch sehr anspruchsvoll . Komplikationen koennen aber durch eine sorgfaeltige Auswahl der Patienten sowie durch die geeignete chirurgische Technik minimiert werden . In juengster Zeit wurden zahlreiche Nachuntersuchungen mit guten Langzeitergebnissen und geringen Nebenwirkungen publiziert . Instructions: please typing these entity words according to sentence: Behandlung, Refluxkrankheit, Komplikationen, Patienten, Technik, Zeit, Langzeitergebnissen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zusammenfassung . Endoskopische Antirefluxchirurgie ersetzt zunehmend die traditionellen Operationsverfahren in der Behandlung der therapierefraktaeren gastrooesophagealen Refluxkrankheit . Diese laparoskopischen Verfahren sind jedoch technisch sehr anspruchsvoll . Komplikationen koennen aber durch eine sorgfaeltige Auswahl der Patienten sowie durch die geeignete chirurgische Technik minimiert werden . In juengster Zeit wurden zahlreiche Nachuntersuchungen mit guten Langzeitergebnissen und geringen Nebenwirkungen publiziert .
[ "Zusammenfassung", ".", "Endoskopische", "Antirefluxchirurgie", "ersetzt", "zunehmend", "die", "traditionellen", "Operationsverfahren", "in", "der", "Behandlung", "der", "therapierefraktaeren", "gastrooesophagealen", "Refluxkrankheit", ".", "Diese", "laparoskopischen", "Verfahren", "sind", "jedoch", "technisch", "sehr", "anspruchsvoll", ".", "Komplikationen", "koennen", "aber", "durch", "eine", "sorgfaeltige", "Auswahl", "der", "Patienten", "sowie", "durch", "die", "geeignete", "chirurgische", "Technik", "minimiert", "werden", ".", "In", "juengster", "Zeit", "wurden", "zahlreiche", "Nachuntersuchungen", "mit", "guten", "Langzeitergebnissen", "und", "geringen", "Nebenwirkungen", "publiziert", "." ]
[ "umlsterm" ]
Behandlung, Refluxkrankheit, Komplikationen, Patienten, Technik, Zeit, Langzeitergebnissen
DerChirurg.80690148.ger.abstr_task2
Sentence: Zusammenfassung . Endoskopische Antirefluxchirurgie ersetzt zunehmend die traditionellen Operationsverfahren in der Behandlung der therapierefraktaeren gastrooesophagealen Refluxkrankheit . Diese laparoskopischen Verfahren sind jedoch technisch sehr anspruchsvoll . Komplikationen koennen aber durch eine sorgfaeltige Auswahl der Patienten sowie durch die geeignete chirurgische Technik minimiert werden . In juengster Zeit wurden zahlreiche Nachuntersuchungen mit guten Langzeitergebnissen und geringen Nebenwirkungen publiziert . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zusammenfassung . Endoskopische Antirefluxchirurgie ersetzt zunehmend die traditionellen Operationsverfahren in der Behandlung der therapierefraktaeren gastrooesophagealen Refluxkrankheit . Diese laparoskopischen Verfahren sind jedoch technisch sehr anspruchsvoll . Komplikationen koennen aber durch eine sorgfaeltige Auswahl der Patienten sowie durch die geeignete chirurgische Technik minimiert werden . In juengster Zeit wurden zahlreiche Nachuntersuchungen mit guten Langzeitergebnissen und geringen Nebenwirkungen publiziert .
[ "Zusammenfassung", ".", "Endoskopische", "Antirefluxchirurgie", "ersetzt", "zunehmend", "die", "traditionellen", "Operationsverfahren", "in", "der", "Behandlung", "der", "therapierefraktaeren", "gastrooesophagealen", "Refluxkrankheit", ".", "Diese", "laparoskopischen", "Verfahren", "sind", "jedoch", "technisch", "sehr", "anspruchsvoll", ".", "Komplikationen", "koennen", "aber", "durch", "eine", "sorgfaeltige", "Auswahl", "der", "Patienten", "sowie", "durch", "die", "geeignete", "chirurgische", "Technik", "minimiert", "werden", ".", "In", "juengster", "Zeit", "wurden", "zahlreiche", "Nachuntersuchungen", "mit", "guten", "Langzeitergebnissen", "und", "geringen", "Nebenwirkungen", "publiziert", "." ]
[ "umlsterm" ]
fractures is an umlsterm, x - rays is an umlsterm, classification is an umlsterm, risk is an umlsterm, fracture is an umlsterm, secondary is an umlsterm, fracture is an umlsterm, dislocation is an umlsterm, treatment is an umlsterm, trauma is an umlsterm, case report is an umlsterm, risk of is an umlsterm, anterior is an umlsterm, classification is an umlsterm
DerUnfallchirurg.01030791.eng.abstr_task0
Sentence: Undislocated odontoid fractures may lead on the basis of conventional x-rays only to a wrong conclusion with regard to biomechanical aspect of stability . In this aspect the classification based on Anderson and D ' Alonzo takes a high risk to missunderstood the fracture stability and can results in a secondary fracture dislocation . Therefore it is important to make the decision about operative versus nonoperative treatment on the base of the trauma mechanism . In this case report we elucidate this problem and the higher risk of anterior approach for correction . Furthermore a better classification of densfractures will be recommended . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Undislocated odontoid fractures may lead on the basis of conventional x-rays only to a wrong conclusion with regard to biomechanical aspect of stability . In this aspect the classification based on Anderson and D ' Alonzo takes a high risk to missunderstood the fracture stability and can results in a secondary fracture dislocation . Therefore it is important to make the decision about operative versus nonoperative treatment on the base of the trauma mechanism . In this case report we elucidate this problem and the higher risk of anterior approach for correction . Furthermore a better classification of densfractures will be recommended .
[ "Undislocated", "odontoid", "fractures", "may", "lead", "on", "the", "basis", "of", "conventional", "x", "-", "rays", "only", "to", "a", "wrong", "conclusion", "with", "regard", "to", "biomechanical", "aspect", "of", "stability", ".", "In", "this", "aspect", "the", "classification", "based", "on", "Anderson", "and", "D", "'", "Alonzo", "takes", "a", "high", "risk", "to", "missunderstood", "the", "fracture", "stability", "and", "can", "results", "in", "a", "secondary", "fracture", "dislocation", ".", "Therefore", "it", "is", "important", "to", "make", "the", "decision", "about", "operative", "versus", "nonoperative", "treatment", "on", "the", "base", "of", "the", "trauma", "mechanism", ".", "In", "this", "case", "report", "we", "elucidate", "this", "problem", "and", "the", "higher", "risk", "of", "anterior", "approach", "for", "correction", ".", "Furthermore", "a", "better", "classification", "of", "densfractures", "will", "be", "recommended", "." ]
[ "umlsterm" ]
fractures is an umlsterm, x - rays is an umlsterm, classification is an umlsterm, risk is an umlsterm, fracture is an umlsterm, secondary is an umlsterm, fracture is an umlsterm, dislocation is an umlsterm, treatment is an umlsterm, trauma is an umlsterm, case report is an umlsterm, risk of is an umlsterm, anterior is an umlsterm, classification is an umlsterm
DerUnfallchirurg.01030791.eng.abstr_task1
Sentence: Undislocated odontoid fractures may lead on the basis of conventional x-rays only to a wrong conclusion with regard to biomechanical aspect of stability . In this aspect the classification based on Anderson and D ' Alonzo takes a high risk to missunderstood the fracture stability and can results in a secondary fracture dislocation . Therefore it is important to make the decision about operative versus nonoperative treatment on the base of the trauma mechanism . In this case report we elucidate this problem and the higher risk of anterior approach for correction . Furthermore a better classification of densfractures will be recommended . Instructions: please typing these entity words according to sentence: fractures, x - rays, classification, risk, fracture, secondary, fracture, dislocation, treatment, trauma, case report, risk of, anterior, classification Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Undislocated odontoid fractures may lead on the basis of conventional x-rays only to a wrong conclusion with regard to biomechanical aspect of stability . In this aspect the classification based on Anderson and D ' Alonzo takes a high risk to missunderstood the fracture stability and can results in a secondary fracture dislocation . Therefore it is important to make the decision about operative versus nonoperative treatment on the base of the trauma mechanism . In this case report we elucidate this problem and the higher risk of anterior approach for correction . Furthermore a better classification of densfractures will be recommended .
[ "Undislocated", "odontoid", "fractures", "may", "lead", "on", "the", "basis", "of", "conventional", "x", "-", "rays", "only", "to", "a", "wrong", "conclusion", "with", "regard", "to", "biomechanical", "aspect", "of", "stability", ".", "In", "this", "aspect", "the", "classification", "based", "on", "Anderson", "and", "D", "'", "Alonzo", "takes", "a", "high", "risk", "to", "missunderstood", "the", "fracture", "stability", "and", "can", "results", "in", "a", "secondary", "fracture", "dislocation", ".", "Therefore", "it", "is", "important", "to", "make", "the", "decision", "about", "operative", "versus", "nonoperative", "treatment", "on", "the", "base", "of", "the", "trauma", "mechanism", ".", "In", "this", "case", "report", "we", "elucidate", "this", "problem", "and", "the", "higher", "risk", "of", "anterior", "approach", "for", "correction", ".", "Furthermore", "a", "better", "classification", "of", "densfractures", "will", "be", "recommended", "." ]
[ "umlsterm" ]
fractures, x - rays, classification, risk, fracture, secondary, fracture, dislocation, treatment, trauma, case report, risk of, anterior, classification
DerUnfallchirurg.01030791.eng.abstr_task2
Sentence: Undislocated odontoid fractures may lead on the basis of conventional x-rays only to a wrong conclusion with regard to biomechanical aspect of stability . In this aspect the classification based on Anderson and D ' Alonzo takes a high risk to missunderstood the fracture stability and can results in a secondary fracture dislocation . Therefore it is important to make the decision about operative versus nonoperative treatment on the base of the trauma mechanism . In this case report we elucidate this problem and the higher risk of anterior approach for correction . Furthermore a better classification of densfractures will be recommended . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Undislocated odontoid fractures may lead on the basis of conventional x-rays only to a wrong conclusion with regard to biomechanical aspect of stability . In this aspect the classification based on Anderson and D ' Alonzo takes a high risk to missunderstood the fracture stability and can results in a secondary fracture dislocation . Therefore it is important to make the decision about operative versus nonoperative treatment on the base of the trauma mechanism . In this case report we elucidate this problem and the higher risk of anterior approach for correction . Furthermore a better classification of densfractures will be recommended .
[ "Undislocated", "odontoid", "fractures", "may", "lead", "on", "the", "basis", "of", "conventional", "x", "-", "rays", "only", "to", "a", "wrong", "conclusion", "with", "regard", "to", "biomechanical", "aspect", "of", "stability", ".", "In", "this", "aspect", "the", "classification", "based", "on", "Anderson", "and", "D", "'", "Alonzo", "takes", "a", "high", "risk", "to", "missunderstood", "the", "fracture", "stability", "and", "can", "results", "in", "a", "secondary", "fracture", "dislocation", ".", "Therefore", "it", "is", "important", "to", "make", "the", "decision", "about", "operative", "versus", "nonoperative", "treatment", "on", "the", "base", "of", "the", "trauma", "mechanism", ".", "In", "this", "case", "report", "we", "elucidate", "this", "problem", "and", "the", "higher", "risk", "of", "anterior", "approach", "for", "correction", ".", "Furthermore", "a", "better", "classification", "of", "densfractures", "will", "be", "recommended", "." ]
[ "umlsterm" ]
klinische Forschung is an umlsterm, Patientenzahlen is an umlsterm, Klinikaerzte is an umlsterm
ZfuerRheumatologie.00590057.ger.abstr_task0
Sentence: Wesentliches Ziel des Zentrums ist die Entwicklung einer innovativen Organisationsstruktur fuer die klinische Forschung , mit deren Hilfe rasch grosse Patientenzahlen definiert und fuer spezielle Studien erfasst werden koennen , die mit hoher klinischer Qualitaet und Kompetenz durchgefuehrt werden . Zu diesem Zweck haben wir fachbezogene Kompetenznetzwerke geschaffen , in denen Klinikaerzte des Universitaetsklinikums und niedergelassene Fachaerzte bei der Durchfuehrung von klinischen Studien kooperieren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Wesentliches Ziel des Zentrums ist die Entwicklung einer innovativen Organisationsstruktur fuer die klinische Forschung , mit deren Hilfe rasch grosse Patientenzahlen definiert und fuer spezielle Studien erfasst werden koennen , die mit hoher klinischer Qualitaet und Kompetenz durchgefuehrt werden . Zu diesem Zweck haben wir fachbezogene Kompetenznetzwerke geschaffen , in denen Klinikaerzte des Universitaetsklinikums und niedergelassene Fachaerzte bei der Durchfuehrung von klinischen Studien kooperieren .
[ "Wesentliches", "Ziel", "des", "Zentrums", "ist", "die", "Entwicklung", "einer", "innovativen", "Organisationsstruktur", "fuer", "die", "klinische", "Forschung", ",", "mit", "deren", "Hilfe", "rasch", "grosse", "Patientenzahlen", "definiert", "und", "fuer", "spezielle", "Studien", "erfasst", "werden", "koennen", ",", "die", "mit", "hoher", "klinischer", "Qualitaet", "und", "Kompetenz", "durchgefuehrt", "werden", ".", "Zu", "diesem", "Zweck", "haben", "wir", "fachbezogene", "Kompetenznetzwerke", "geschaffen", ",", "in", "denen", "Klinikaerzte", "des", "Universitaetsklinikums", "und", "niedergelassene", "Fachaerzte", "bei", "der", "Durchfuehrung", "von", "klinischen", "Studien", "kooperieren", "." ]
[ "umlsterm" ]
klinische Forschung is an umlsterm, Patientenzahlen is an umlsterm, Klinikaerzte is an umlsterm
ZfuerRheumatologie.00590057.ger.abstr_task1
Sentence: Wesentliches Ziel des Zentrums ist die Entwicklung einer innovativen Organisationsstruktur fuer die klinische Forschung , mit deren Hilfe rasch grosse Patientenzahlen definiert und fuer spezielle Studien erfasst werden koennen , die mit hoher klinischer Qualitaet und Kompetenz durchgefuehrt werden . Zu diesem Zweck haben wir fachbezogene Kompetenznetzwerke geschaffen , in denen Klinikaerzte des Universitaetsklinikums und niedergelassene Fachaerzte bei der Durchfuehrung von klinischen Studien kooperieren . Instructions: please typing these entity words according to sentence: klinische Forschung, Patientenzahlen, Klinikaerzte Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Wesentliches Ziel des Zentrums ist die Entwicklung einer innovativen Organisationsstruktur fuer die klinische Forschung , mit deren Hilfe rasch grosse Patientenzahlen definiert und fuer spezielle Studien erfasst werden koennen , die mit hoher klinischer Qualitaet und Kompetenz durchgefuehrt werden . Zu diesem Zweck haben wir fachbezogene Kompetenznetzwerke geschaffen , in denen Klinikaerzte des Universitaetsklinikums und niedergelassene Fachaerzte bei der Durchfuehrung von klinischen Studien kooperieren .
[ "Wesentliches", "Ziel", "des", "Zentrums", "ist", "die", "Entwicklung", "einer", "innovativen", "Organisationsstruktur", "fuer", "die", "klinische", "Forschung", ",", "mit", "deren", "Hilfe", "rasch", "grosse", "Patientenzahlen", "definiert", "und", "fuer", "spezielle", "Studien", "erfasst", "werden", "koennen", ",", "die", "mit", "hoher", "klinischer", "Qualitaet", "und", "Kompetenz", "durchgefuehrt", "werden", ".", "Zu", "diesem", "Zweck", "haben", "wir", "fachbezogene", "Kompetenznetzwerke", "geschaffen", ",", "in", "denen", "Klinikaerzte", "des", "Universitaetsklinikums", "und", "niedergelassene", "Fachaerzte", "bei", "der", "Durchfuehrung", "von", "klinischen", "Studien", "kooperieren", "." ]
[ "umlsterm" ]
klinische Forschung, Patientenzahlen, Klinikaerzte
ZfuerRheumatologie.00590057.ger.abstr_task2
Sentence: Wesentliches Ziel des Zentrums ist die Entwicklung einer innovativen Organisationsstruktur fuer die klinische Forschung , mit deren Hilfe rasch grosse Patientenzahlen definiert und fuer spezielle Studien erfasst werden koennen , die mit hoher klinischer Qualitaet und Kompetenz durchgefuehrt werden . Zu diesem Zweck haben wir fachbezogene Kompetenznetzwerke geschaffen , in denen Klinikaerzte des Universitaetsklinikums und niedergelassene Fachaerzte bei der Durchfuehrung von klinischen Studien kooperieren . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Wesentliches Ziel des Zentrums ist die Entwicklung einer innovativen Organisationsstruktur fuer die klinische Forschung , mit deren Hilfe rasch grosse Patientenzahlen definiert und fuer spezielle Studien erfasst werden koennen , die mit hoher klinischer Qualitaet und Kompetenz durchgefuehrt werden . Zu diesem Zweck haben wir fachbezogene Kompetenznetzwerke geschaffen , in denen Klinikaerzte des Universitaetsklinikums und niedergelassene Fachaerzte bei der Durchfuehrung von klinischen Studien kooperieren .
[ "Wesentliches", "Ziel", "des", "Zentrums", "ist", "die", "Entwicklung", "einer", "innovativen", "Organisationsstruktur", "fuer", "die", "klinische", "Forschung", ",", "mit", "deren", "Hilfe", "rasch", "grosse", "Patientenzahlen", "definiert", "und", "fuer", "spezielle", "Studien", "erfasst", "werden", "koennen", ",", "die", "mit", "hoher", "klinischer", "Qualitaet", "und", "Kompetenz", "durchgefuehrt", "werden", ".", "Zu", "diesem", "Zweck", "haben", "wir", "fachbezogene", "Kompetenznetzwerke", "geschaffen", ",", "in", "denen", "Klinikaerzte", "des", "Universitaetsklinikums", "und", "niedergelassene", "Fachaerzte", "bei", "der", "Durchfuehrung", "von", "klinischen", "Studien", "kooperieren", "." ]
[ "umlsterm" ]
Sarkome is an umlsterm, Leber is an umlsterm, Leber is an umlsterm, Gallengaengen is an umlsterm, Rhabdomyosarkom is an umlsterm, Leber is an umlsterm, Mann is an umlsterm
DerPathologe.40150054.ger.abstr_task0
Sentence: Zusammenfassung . Primaere Sarkome der Leber sind selten . Rhabdomyosarkome in der Leber treten in der Regel im fruehen Kindesalter auf . Sie nehmen ihren Ausgang fast immer von den grossen Gallengaengen im Leberhilus . In dieser Kasuistik wird ueber ein pleomorphes Rhabdomyosarkom der Leber bei einem 69 Jahre alten Mann berichtet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Primaere Sarkome der Leber sind selten . Rhabdomyosarkome in der Leber treten in der Regel im fruehen Kindesalter auf . Sie nehmen ihren Ausgang fast immer von den grossen Gallengaengen im Leberhilus . In dieser Kasuistik wird ueber ein pleomorphes Rhabdomyosarkom der Leber bei einem 69 Jahre alten Mann berichtet .
[ "Zusammenfassung", ".", "Primaere", "Sarkome", "der", "Leber", "sind", "selten", ".", "Rhabdomyosarkome", "in", "der", "Leber", "treten", "in", "der", "Regel", "im", "fruehen", "Kindesalter", "auf", ".", "Sie", "nehmen", "ihren", "Ausgang", "fast", "immer", "von", "den", "grossen", "Gallengaengen", "im", "Leberhilus", ".", "In", "dieser", "Kasuistik", "wird", "ueber", "ein", "pleomorphes", "Rhabdomyosarkom", "der", "Leber", "bei", "einem", "69", "Jahre", "alten", "Mann", "berichtet", "." ]
[ "umlsterm" ]
Sarkome is an umlsterm, Leber is an umlsterm, Leber is an umlsterm, Gallengaengen is an umlsterm, Rhabdomyosarkom is an umlsterm, Leber is an umlsterm, Mann is an umlsterm
DerPathologe.40150054.ger.abstr_task1
Sentence: Zusammenfassung . Primaere Sarkome der Leber sind selten . Rhabdomyosarkome in der Leber treten in der Regel im fruehen Kindesalter auf . Sie nehmen ihren Ausgang fast immer von den grossen Gallengaengen im Leberhilus . In dieser Kasuistik wird ueber ein pleomorphes Rhabdomyosarkom der Leber bei einem 69 Jahre alten Mann berichtet . Instructions: please typing these entity words according to sentence: Sarkome, Leber, Leber, Gallengaengen, Rhabdomyosarkom, Leber, Mann Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Primaere Sarkome der Leber sind selten . Rhabdomyosarkome in der Leber treten in der Regel im fruehen Kindesalter auf . Sie nehmen ihren Ausgang fast immer von den grossen Gallengaengen im Leberhilus . In dieser Kasuistik wird ueber ein pleomorphes Rhabdomyosarkom der Leber bei einem 69 Jahre alten Mann berichtet .
[ "Zusammenfassung", ".", "Primaere", "Sarkome", "der", "Leber", "sind", "selten", ".", "Rhabdomyosarkome", "in", "der", "Leber", "treten", "in", "der", "Regel", "im", "fruehen", "Kindesalter", "auf", ".", "Sie", "nehmen", "ihren", "Ausgang", "fast", "immer", "von", "den", "grossen", "Gallengaengen", "im", "Leberhilus", ".", "In", "dieser", "Kasuistik", "wird", "ueber", "ein", "pleomorphes", "Rhabdomyosarkom", "der", "Leber", "bei", "einem", "69", "Jahre", "alten", "Mann", "berichtet", "." ]
[ "umlsterm" ]
Sarkome, Leber, Leber, Gallengaengen, Rhabdomyosarkom, Leber, Mann
DerPathologe.40150054.ger.abstr_task2
Sentence: Zusammenfassung . Primaere Sarkome der Leber sind selten . Rhabdomyosarkome in der Leber treten in der Regel im fruehen Kindesalter auf . Sie nehmen ihren Ausgang fast immer von den grossen Gallengaengen im Leberhilus . In dieser Kasuistik wird ueber ein pleomorphes Rhabdomyosarkom der Leber bei einem 69 Jahre alten Mann berichtet . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Primaere Sarkome der Leber sind selten . Rhabdomyosarkome in der Leber treten in der Regel im fruehen Kindesalter auf . Sie nehmen ihren Ausgang fast immer von den grossen Gallengaengen im Leberhilus . In dieser Kasuistik wird ueber ein pleomorphes Rhabdomyosarkom der Leber bei einem 69 Jahre alten Mann berichtet .
[ "Zusammenfassung", ".", "Primaere", "Sarkome", "der", "Leber", "sind", "selten", ".", "Rhabdomyosarkome", "in", "der", "Leber", "treten", "in", "der", "Regel", "im", "fruehen", "Kindesalter", "auf", ".", "Sie", "nehmen", "ihren", "Ausgang", "fast", "immer", "von", "den", "grossen", "Gallengaengen", "im", "Leberhilus", ".", "In", "dieser", "Kasuistik", "wird", "ueber", "ein", "pleomorphes", "Rhabdomyosarkom", "der", "Leber", "bei", "einem", "69", "Jahre", "alten", "Mann", "berichtet", "." ]
[ "umlsterm" ]
Esmolol is a Intervention_Pharmacological, cerebral blood flow velocity increase is a Outcome_Physical, anesthesia is a Intervention_Pharmacological, neurosurgical patients is a Participant_Condition, Cerebral hyperemia is a Outcome_Physical, Thirty is a Participant_Sample-size, esmolol is a Intervention_Pharmacological, placebo . is a Intervention_Control, extubation is a Intervention_Physical, Cerebral blood flow velocity ( CBFV ) is a Outcome_Physical, mean arterial blood pressure is a Outcome_Physical, heart rate is a Outcome_Physical, Cardiac output ( COe ) is a Outcome_Physical, Mean arterial blood pressure is a Outcome_Physical, CBFV increase is a Outcome_Physical, cerebral hyperemia is a Outcome_Physical
12562_task0
Sentence: Esmolol blunts the cerebral blood flow velocity increase during emergence from anesthesia in neurosurgical patients . UNLABELLED Cerebral hyperemia has been demonstrated during emergence from anesthesia in neurosurgical patients , but its mechanism is speculative . We performed this study to test the hypothesis that this could be attributed to sympathetic overactivity . Thirty neurosurgical patients were included in a prospective , randomized , double-blinded study comparing esmolol , a short-acting beta-blocker , and a placebo . Esmolol ( 0.3 mg. kg ( -1 ) . min ( -1 ) ) was infused from the end of anesthesia to 15 min after extubation . Cerebral blood flow velocity ( CBFV ) , mean arterial blood pressure , and heart rate were recorded before anesthesia , during anesthesia after surgery , at extubation , and 5-60 min after extubation . Cardiac output ( COe ) was estimated by using an esophageal Doppler from anesthesia to 60 min after extubation . CBFV , COe , and heart rate were significantly lower in the esmolol group . Mean arterial blood pressure was comparable between the groups . There was no correlation between CBFV and COe at any time point during the study . In conclusion , esmolol blunted the CBFV increase during emergence , confirming that sympathetic overactivity contributes to cerebral hyperemia during neurosurgical recovery . IMPLICATIONS Esmolol blunted the postoperative increase in cerebral blood flow velocity in neurosurgical patients . The origin of sympathetic hyperactivity and its potential deleterious consequences require further study . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size
[ "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Esmolol blunts the cerebral blood flow velocity increase during emergence from anesthesia in neurosurgical patients . UNLABELLED Cerebral hyperemia has been demonstrated during emergence from anesthesia in neurosurgical patients , but its mechanism is speculative . We performed this study to test the hypothesis that this could be attributed to sympathetic overactivity . Thirty neurosurgical patients were included in a prospective , randomized , double-blinded study comparing esmolol , a short-acting beta-blocker , and a placebo . Esmolol ( 0.3 mg. kg ( -1 ) . min ( -1 ) ) was infused from the end of anesthesia to 15 min after extubation . Cerebral blood flow velocity ( CBFV ) , mean arterial blood pressure , and heart rate were recorded before anesthesia , during anesthesia after surgery , at extubation , and 5-60 min after extubation . Cardiac output ( COe ) was estimated by using an esophageal Doppler from anesthesia to 60 min after extubation . CBFV , COe , and heart rate were significantly lower in the esmolol group . Mean arterial blood pressure was comparable between the groups . There was no correlation between CBFV and COe at any time point during the study . In conclusion , esmolol blunted the CBFV increase during emergence , confirming that sympathetic overactivity contributes to cerebral hyperemia during neurosurgical recovery . IMPLICATIONS Esmolol blunted the postoperative increase in cerebral blood flow velocity in neurosurgical patients . The origin of sympathetic hyperactivity and its potential deleterious consequences require further study .
[ "Esmolol", "blunts", "the", "cerebral", "blood", "flow", "velocity", "increase", "during", "emergence", "from", "anesthesia", "in", "neurosurgical", "patients", ".", "UNLABELLED", "Cerebral", "hyperemia", "has", "been", "demonstrated", "during", "emergence", "from", "anesthesia", "in", "neurosurgical", "patients", ",", "but", "its", "mechanism", "is", "speculative", ".", "We", "performed", "this", "study", "to", "test", "the", "hypothesis", "that", "this", "could", "be", "attributed", "to", "sympathetic", "overactivity", ".", "Thirty", "neurosurgical", "patients", "were", "included", "in", "a", "prospective", ",", "randomized", ",", "double", "-", "blinded", "study", "comparing", "esmolol", ",", "a", "short", "-", "acting", "beta", "-", "blocker", ",", "and", "a", "placebo", ".", "Esmolol", "(", "0.3", "mg", ".", "kg", "(", "-1", ")", ".", "min", "(", "-1", ")", ")", "was", "infused", "from", "the", "end", "of", "anesthesia", "to", "15", "min", "after", "extubation", ".", "Cerebral", "blood", "flow", "velocity", "(", "CBFV", ")", ",", "mean", "arterial", "blood", "pressure", ",", "and", "heart", "rate", "were", "recorded", "before", "anesthesia", ",", "during", "anesthesia", "after", "surgery", ",", "at", "extubation", ",", "and", "5", "-", "60", "min", "after", "extubation", ".", "Cardiac", "output", "(", "COe", ")", "was", "estimated", "by", "using", "an", "esophageal", "Doppler", "from", "anesthesia", "to", "60", "min", "after", "extubation", ".", "CBFV", ",", "COe", ",", "and", "heart", "rate", "were", "significantly", "lower", "in", "the", "esmolol", "group", ".", "Mean", "arterial", "blood", "pressure", "was", "comparable", "between", "the", "groups", ".", "There", "was", "no", "correlation", "between", "CBFV", "and", "COe", "at", "any", "time", "point", "during", "the", "study", ".", "In", "conclusion", ",", "esmolol", "blunted", "the", "CBFV", "increase", "during", "emergence", ",", "confirming", "that", "sympathetic", "overactivity", "contributes", "to", "cerebral", "hyperemia", "during", "neurosurgical", "recovery", ".", "IMPLICATIONS", "Esmolol", "blunted", "the", "postoperative", "increase", "in", "cerebral", "blood", "flow", "velocity", "in", "neurosurgical", "patients", ".", "The", "origin", "of", "sympathetic", "hyperactivity", "and", "its", "potential", "deleterious", "consequences", "require", "further", "study", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Sample-size" ]
Esmolol is a Intervention_Pharmacological, cerebral blood flow velocity increase is a Outcome_Physical, anesthesia is a Intervention_Pharmacological, neurosurgical patients is a Participant_Condition, Cerebral hyperemia is a Outcome_Physical, Thirty is a Participant_Sample-size, esmolol is a Intervention_Pharmacological, placebo . is a Intervention_Control, extubation is a Intervention_Physical, Cerebral blood flow velocity ( CBFV ) is a Outcome_Physical, mean arterial blood pressure is a Outcome_Physical, heart rate is a Outcome_Physical, Cardiac output ( COe ) is a Outcome_Physical, Mean arterial blood pressure is a Outcome_Physical, CBFV increase is a Outcome_Physical, cerebral hyperemia is a Outcome_Physical
12562_task1
Sentence: Esmolol blunts the cerebral blood flow velocity increase during emergence from anesthesia in neurosurgical patients . UNLABELLED Cerebral hyperemia has been demonstrated during emergence from anesthesia in neurosurgical patients , but its mechanism is speculative . We performed this study to test the hypothesis that this could be attributed to sympathetic overactivity . Thirty neurosurgical patients were included in a prospective , randomized , double-blinded study comparing esmolol , a short-acting beta-blocker , and a placebo . Esmolol ( 0.3 mg. kg ( -1 ) . min ( -1 ) ) was infused from the end of anesthesia to 15 min after extubation . Cerebral blood flow velocity ( CBFV ) , mean arterial blood pressure , and heart rate were recorded before anesthesia , during anesthesia after surgery , at extubation , and 5-60 min after extubation . Cardiac output ( COe ) was estimated by using an esophageal Doppler from anesthesia to 60 min after extubation . CBFV , COe , and heart rate were significantly lower in the esmolol group . Mean arterial blood pressure was comparable between the groups . There was no correlation between CBFV and COe at any time point during the study . In conclusion , esmolol blunted the CBFV increase during emergence , confirming that sympathetic overactivity contributes to cerebral hyperemia during neurosurgical recovery . IMPLICATIONS Esmolol blunted the postoperative increase in cerebral blood flow velocity in neurosurgical patients . The origin of sympathetic hyperactivity and its potential deleterious consequences require further study . Instructions: please typing these entity words according to sentence: Esmolol, cerebral blood flow velocity increase, anesthesia, neurosurgical patients, Cerebral hyperemia, Thirty, esmolol, placebo ., extubation, Cerebral blood flow velocity ( CBFV ), mean arterial blood pressure, heart rate, Cardiac output ( COe ), Mean arterial blood pressure, CBFV increase, cerebral hyperemia Options: Intervention_Pharmacological, Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size
[ "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Esmolol blunts the cerebral blood flow velocity increase during emergence from anesthesia in neurosurgical patients . UNLABELLED Cerebral hyperemia has been demonstrated during emergence from anesthesia in neurosurgical patients , but its mechanism is speculative . We performed this study to test the hypothesis that this could be attributed to sympathetic overactivity . Thirty neurosurgical patients were included in a prospective , randomized , double-blinded study comparing esmolol , a short-acting beta-blocker , and a placebo . Esmolol ( 0.3 mg. kg ( -1 ) . min ( -1 ) ) was infused from the end of anesthesia to 15 min after extubation . Cerebral blood flow velocity ( CBFV ) , mean arterial blood pressure , and heart rate were recorded before anesthesia , during anesthesia after surgery , at extubation , and 5-60 min after extubation . Cardiac output ( COe ) was estimated by using an esophageal Doppler from anesthesia to 60 min after extubation . CBFV , COe , and heart rate were significantly lower in the esmolol group . Mean arterial blood pressure was comparable between the groups . There was no correlation between CBFV and COe at any time point during the study . In conclusion , esmolol blunted the CBFV increase during emergence , confirming that sympathetic overactivity contributes to cerebral hyperemia during neurosurgical recovery . IMPLICATIONS Esmolol blunted the postoperative increase in cerebral blood flow velocity in neurosurgical patients . The origin of sympathetic hyperactivity and its potential deleterious consequences require further study .
[ "Esmolol", "blunts", "the", "cerebral", "blood", "flow", "velocity", "increase", "during", "emergence", "from", "anesthesia", "in", "neurosurgical", "patients", ".", "UNLABELLED", "Cerebral", "hyperemia", "has", "been", "demonstrated", "during", "emergence", "from", "anesthesia", "in", "neurosurgical", "patients", ",", "but", "its", "mechanism", "is", "speculative", ".", "We", "performed", "this", "study", "to", "test", "the", "hypothesis", "that", "this", "could", "be", "attributed", "to", "sympathetic", "overactivity", ".", "Thirty", "neurosurgical", "patients", "were", "included", "in", "a", "prospective", ",", "randomized", ",", "double", "-", "blinded", "study", "comparing", "esmolol", ",", "a", "short", "-", "acting", "beta", "-", "blocker", ",", "and", "a", "placebo", ".", "Esmolol", "(", "0.3", "mg", ".", "kg", "(", "-1", ")", ".", "min", "(", "-1", ")", ")", "was", "infused", "from", "the", "end", "of", "anesthesia", "to", "15", "min", "after", "extubation", ".", "Cerebral", "blood", "flow", "velocity", "(", "CBFV", ")", ",", "mean", "arterial", "blood", "pressure", ",", "and", "heart", "rate", "were", "recorded", "before", "anesthesia", ",", "during", "anesthesia", "after", "surgery", ",", "at", "extubation", ",", "and", "5", "-", "60", "min", "after", "extubation", ".", "Cardiac", "output", "(", "COe", ")", "was", "estimated", "by", "using", "an", "esophageal", "Doppler", "from", "anesthesia", "to", "60", "min", "after", "extubation", ".", "CBFV", ",", "COe", ",", "and", "heart", "rate", "were", "significantly", "lower", "in", "the", "esmolol", "group", ".", "Mean", "arterial", "blood", "pressure", "was", "comparable", "between", "the", "groups", ".", "There", "was", "no", "correlation", "between", "CBFV", "and", "COe", "at", "any", "time", "point", "during", "the", "study", ".", "In", "conclusion", ",", "esmolol", "blunted", "the", "CBFV", "increase", "during", "emergence", ",", "confirming", "that", "sympathetic", "overactivity", "contributes", "to", "cerebral", "hyperemia", "during", "neurosurgical", "recovery", ".", "IMPLICATIONS", "Esmolol", "blunted", "the", "postoperative", "increase", "in", "cerebral", "blood", "flow", "velocity", "in", "neurosurgical", "patients", ".", "The", "origin", "of", "sympathetic", "hyperactivity", "and", "its", "potential", "deleterious", "consequences", "require", "further", "study", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Sample-size" ]
Esmolol, cerebral blood flow velocity increase, anesthesia, neurosurgical patients, Cerebral hyperemia, Thirty, esmolol, placebo ., extubation, Cerebral blood flow velocity ( CBFV ), mean arterial blood pressure, heart rate, Cardiac output ( COe ), Mean arterial blood pressure, CBFV increase, cerebral hyperemia
12562_task2
Sentence: Esmolol blunts the cerebral blood flow velocity increase during emergence from anesthesia in neurosurgical patients . UNLABELLED Cerebral hyperemia has been demonstrated during emergence from anesthesia in neurosurgical patients , but its mechanism is speculative . We performed this study to test the hypothesis that this could be attributed to sympathetic overactivity . Thirty neurosurgical patients were included in a prospective , randomized , double-blinded study comparing esmolol , a short-acting beta-blocker , and a placebo . Esmolol ( 0.3 mg. kg ( -1 ) . min ( -1 ) ) was infused from the end of anesthesia to 15 min after extubation . Cerebral blood flow velocity ( CBFV ) , mean arterial blood pressure , and heart rate were recorded before anesthesia , during anesthesia after surgery , at extubation , and 5-60 min after extubation . Cardiac output ( COe ) was estimated by using an esophageal Doppler from anesthesia to 60 min after extubation . CBFV , COe , and heart rate were significantly lower in the esmolol group . Mean arterial blood pressure was comparable between the groups . There was no correlation between CBFV and COe at any time point during the study . In conclusion , esmolol blunted the CBFV increase during emergence , confirming that sympathetic overactivity contributes to cerebral hyperemia during neurosurgical recovery . IMPLICATIONS Esmolol blunted the postoperative increase in cerebral blood flow velocity in neurosurgical patients . The origin of sympathetic hyperactivity and its potential deleterious consequences require further study . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Esmolol blunts the cerebral blood flow velocity increase during emergence from anesthesia in neurosurgical patients . UNLABELLED Cerebral hyperemia has been demonstrated during emergence from anesthesia in neurosurgical patients , but its mechanism is speculative . We performed this study to test the hypothesis that this could be attributed to sympathetic overactivity . Thirty neurosurgical patients were included in a prospective , randomized , double-blinded study comparing esmolol , a short-acting beta-blocker , and a placebo . Esmolol ( 0.3 mg. kg ( -1 ) . min ( -1 ) ) was infused from the end of anesthesia to 15 min after extubation . Cerebral blood flow velocity ( CBFV ) , mean arterial blood pressure , and heart rate were recorded before anesthesia , during anesthesia after surgery , at extubation , and 5-60 min after extubation . Cardiac output ( COe ) was estimated by using an esophageal Doppler from anesthesia to 60 min after extubation . CBFV , COe , and heart rate were significantly lower in the esmolol group . Mean arterial blood pressure was comparable between the groups . There was no correlation between CBFV and COe at any time point during the study . In conclusion , esmolol blunted the CBFV increase during emergence , confirming that sympathetic overactivity contributes to cerebral hyperemia during neurosurgical recovery . IMPLICATIONS Esmolol blunted the postoperative increase in cerebral blood flow velocity in neurosurgical patients . The origin of sympathetic hyperactivity and its potential deleterious consequences require further study .
[ "Esmolol", "blunts", "the", "cerebral", "blood", "flow", "velocity", "increase", "during", "emergence", "from", "anesthesia", "in", "neurosurgical", "patients", ".", "UNLABELLED", "Cerebral", "hyperemia", "has", "been", "demonstrated", "during", "emergence", "from", "anesthesia", "in", "neurosurgical", "patients", ",", "but", "its", "mechanism", "is", "speculative", ".", "We", "performed", "this", "study", "to", "test", "the", "hypothesis", "that", "this", "could", "be", "attributed", "to", "sympathetic", "overactivity", ".", "Thirty", "neurosurgical", "patients", "were", "included", "in", "a", "prospective", ",", "randomized", ",", "double", "-", "blinded", "study", "comparing", "esmolol", ",", "a", "short", "-", "acting", "beta", "-", "blocker", ",", "and", "a", "placebo", ".", "Esmolol", "(", "0.3", "mg", ".", "kg", "(", "-1", ")", ".", "min", "(", "-1", ")", ")", "was", "infused", "from", "the", "end", "of", "anesthesia", "to", "15", "min", "after", "extubation", ".", "Cerebral", "blood", "flow", "velocity", "(", "CBFV", ")", ",", "mean", "arterial", "blood", "pressure", ",", "and", "heart", "rate", "were", "recorded", "before", "anesthesia", ",", "during", "anesthesia", "after", "surgery", ",", "at", "extubation", ",", "and", "5", "-", "60", "min", "after", "extubation", ".", "Cardiac", "output", "(", "COe", ")", "was", "estimated", "by", "using", "an", "esophageal", "Doppler", "from", "anesthesia", "to", "60", "min", "after", "extubation", ".", "CBFV", ",", "COe", ",", "and", "heart", "rate", "were", "significantly", "lower", "in", "the", "esmolol", "group", ".", "Mean", "arterial", "blood", "pressure", "was", "comparable", "between", "the", "groups", ".", "There", "was", "no", "correlation", "between", "CBFV", "and", "COe", "at", "any", "time", "point", "during", "the", "study", ".", "In", "conclusion", ",", "esmolol", "blunted", "the", "CBFV", "increase", "during", "emergence", ",", "confirming", "that", "sympathetic", "overactivity", "contributes", "to", "cerebral", "hyperemia", "during", "neurosurgical", "recovery", ".", "IMPLICATIONS", "Esmolol", "blunted", "the", "postoperative", "increase", "in", "cerebral", "blood", "flow", "velocity", "in", "neurosurgical", "patients", ".", "The", "origin", "of", "sympathetic", "hyperactivity", "and", "its", "potential", "deleterious", "consequences", "require", "further", "study", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Sample-size" ]
TNF is a protein_molecule, gene expression is an other_name, JNK activity is an other_name, c - Jun is a protein_molecule
33571_task0
Sentence: Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, protein_molecule
[ "O", "O", "B-protein_molecule", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O" ]
Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD.
[ "Estrogen", "decreases", "TNF", "gene", "expression", "by", "blocking", "JNK", "activity", "and", "the", "resulting", "production", "of", "c", "-", "Jun", "and", "JunD." ]
[ "protein_molecule", "protein_complex", "DNA_domain_or_region", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "cell_line", "protein_domain_or_region", "lipid", "" ]
TNF is a protein_molecule, gene expression is an other_name, JNK activity is an other_name, c - Jun is a protein_molecule
33571_task1
Sentence: Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. Instructions: please typing these entity words according to sentence: TNF, gene expression, JNK activity, c - Jun Options: other_name, protein_molecule
[ "O", "O", "B-protein_molecule", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O" ]
Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD.
[ "Estrogen", "decreases", "TNF", "gene", "expression", "by", "blocking", "JNK", "activity", "and", "the", "resulting", "production", "of", "c", "-", "Jun", "and", "JunD." ]
[ "protein_molecule", "protein_complex", "DNA_domain_or_region", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "cell_line", "protein_domain_or_region", "lipid", "" ]
TNF, gene expression, JNK activity, c - Jun
33571_task2
Sentence: Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-protein_molecule", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O" ]
Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD.
[ "Estrogen", "decreases", "TNF", "gene", "expression", "by", "blocking", "JNK", "activity", "and", "the", "resulting", "production", "of", "c", "-", "Jun", "and", "JunD." ]
[ "protein_molecule", "protein_complex", "DNA_domain_or_region", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "cell_line", "protein_domain_or_region", "lipid", "" ]
6 minute walk test ( 6MWT ) is a Intervention_Physical, time in distance walked is a Outcome_Physical, 6MWD is a Outcome_Other, SGRQ Total score and FVC is a Outcome_Other
43255_task0
Sentence: The 6 minute walk in idiopathic pulmonary fibrosis : longitudinal changes and minimum important difference . RATIONALE The response characteristics of the 6 minute walk test ( 6MWT ) in studies of idiopathic pulmonary fibrosis ( IPF ) are only poorly understood , and the change in walk distance that constitutes the minimum important difference ( MID ) over time is unknown . OBJECTIVES To examine changes over time in distance walked ( ie , 6MWD ) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF . METHODS Data from a recently completed trial that included subjects with IPF who completed the 6MWT , Saint George 's Respiratory Questionnaire ( SGRQ ) and forced vital capacity ( FVC ) at 6 and 12 months were used to examine longitudinal changes in 6MWD . Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD . The SGRQ Total score and FVC were used as clinical anchors . MAIN RESULTS Among 123 subjects alive and able to complete the 6MWT at both follow-up time points , 6MWD did not change significantly over time ( 378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months , p=0.5 ) . The point estimate for the 6MWD MID was 28 m with a range of 10.8-58.5 m. CONCLUSION In a group of patients with IPF with moderate physiological impairment , for those alive and able to complete a 6MWT , 6MWD does not change over 12 months . At the population level , the MID for 6MWD appears to be approximately 28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Other, Outcome_Physical
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The 6 minute walk in idiopathic pulmonary fibrosis : longitudinal changes and minimum important difference . RATIONALE The response characteristics of the 6 minute walk test ( 6MWT ) in studies of idiopathic pulmonary fibrosis ( IPF ) are only poorly understood , and the change in walk distance that constitutes the minimum important difference ( MID ) over time is unknown . OBJECTIVES To examine changes over time in distance walked ( ie , 6MWD ) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF . METHODS Data from a recently completed trial that included subjects with IPF who completed the 6MWT , Saint George 's Respiratory Questionnaire ( SGRQ ) and forced vital capacity ( FVC ) at 6 and 12 months were used to examine longitudinal changes in 6MWD . Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD . The SGRQ Total score and FVC were used as clinical anchors . MAIN RESULTS Among 123 subjects alive and able to complete the 6MWT at both follow-up time points , 6MWD did not change significantly over time ( 378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months , p=0.5 ) . The point estimate for the 6MWD MID was 28 m with a range of 10.8-58.5 m. CONCLUSION In a group of patients with IPF with moderate physiological impairment , for those alive and able to complete a 6MWT , 6MWD does not change over 12 months . At the population level , the MID for 6MWD appears to be approximately 28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population .
[ "The", "6", "minute", "walk", "in", "idiopathic", "pulmonary", "fibrosis", ":", "longitudinal", "changes", "and", "minimum", "important", "difference", ".", "RATIONALE", "The", "response", "characteristics", "of", "the", "6", "minute", "walk", "test", "(", "6MWT", ")", "in", "studies", "of", "idiopathic", "pulmonary", "fibrosis", "(", "IPF", ")", "are", "only", "poorly", "understood", ",", "and", "the", "change", "in", "walk", "distance", "that", "constitutes", "the", "minimum", "important", "difference", "(", "MID", ")", "over", "time", "is", "unknown", ".", "OBJECTIVES", "To", "examine", "changes", "over", "time", "in", "distance", "walked", "(", "ie", ",", "6MWD", ")", "during", "the", "6MWT", "and", "to", "estimate", "the", "change", "in", "distance", "that", "constitutes", "the", "MID", "in", "patients", "with", "IPF", ".", "METHODS", "Data", "from", "a", "recently", "completed", "trial", "that", "included", "subjects", "with", "IPF", "who", "completed", "the", "6MWT", ",", "Saint", "George", "'", "s", "Respiratory", "Questionnaire", "(", "SGRQ", ")", "and", "forced", "vital", "capacity", "(", "FVC", ")", "at", "6", "and", "12", "months", "were", "used", "to", "examine", "longitudinal", "changes", "in", "6MWD", ".", "Both", "anchor-", "and", "distribution", "-", "based", "approaches", "as", "well", "as", "linear", "regression", "analyses", "were", "used", "to", "determine", "the", "MID", "for", "6MWD", ".", "The", "SGRQ", "Total", "score", "and", "FVC", "were", "used", "as", "clinical", "anchors", ".", "MAIN", "RESULTS", "Among", "123", "subjects", "alive", "and", "able", "to", "complete", "the", "6MWT", "at", "both", "follow", "-", "up", "time", "points", ",", "6MWD", "did", "not", "change", "significantly", "over", "time", "(", "378.1", "m", "at", "baseline", "vs", "376.8", "m", "at", "6", "months", "vs", "361.3", "m", "at", "12", "months", ",", "p=0.5", ")", ".", "The", "point", "estimate", "for", "the", "6MWD", "MID", "was", "28", "m", "with", "a", "range", "of", "10.8", "-", "58.5", "m.", "CONCLUSION", "In", "a", "group", "of", "patients", "with", "IPF", "with", "moderate", "physiological", "impairment", ",", "for", "those", "alive", "and", "able", "to", "complete", "a", "6MWT", ",", "6MWD", "does", "not", "change", "over", "12", "months", ".", "At", "the", "population", "level", ",", "the", "MID", "for", "6MWD", "appears", "to", "be", "approximately", "28", "m.", "Further", "investigation", "using", "other", "anchors", "and", "derivation", "methods", "is", "required", "to", "refine", "estimates", "of", "the", "MID", "for", "6MWD", "in", "this", "patient", "population", "." ]
[ "Intervention_Physical", "Outcome_Other", "Outcome_Physical" ]
6 minute walk test ( 6MWT ) is a Intervention_Physical, time in distance walked is a Outcome_Physical, 6MWD is a Outcome_Other, SGRQ Total score and FVC is a Outcome_Other
43255_task1
Sentence: The 6 minute walk in idiopathic pulmonary fibrosis : longitudinal changes and minimum important difference . RATIONALE The response characteristics of the 6 minute walk test ( 6MWT ) in studies of idiopathic pulmonary fibrosis ( IPF ) are only poorly understood , and the change in walk distance that constitutes the minimum important difference ( MID ) over time is unknown . OBJECTIVES To examine changes over time in distance walked ( ie , 6MWD ) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF . METHODS Data from a recently completed trial that included subjects with IPF who completed the 6MWT , Saint George 's Respiratory Questionnaire ( SGRQ ) and forced vital capacity ( FVC ) at 6 and 12 months were used to examine longitudinal changes in 6MWD . Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD . The SGRQ Total score and FVC were used as clinical anchors . MAIN RESULTS Among 123 subjects alive and able to complete the 6MWT at both follow-up time points , 6MWD did not change significantly over time ( 378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months , p=0.5 ) . The point estimate for the 6MWD MID was 28 m with a range of 10.8-58.5 m. CONCLUSION In a group of patients with IPF with moderate physiological impairment , for those alive and able to complete a 6MWT , 6MWD does not change over 12 months . At the population level , the MID for 6MWD appears to be approximately 28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population . Instructions: please typing these entity words according to sentence: 6 minute walk test ( 6MWT ), time in distance walked, 6MWD, SGRQ Total score and FVC Options: Intervention_Physical, Outcome_Other, Outcome_Physical
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The 6 minute walk in idiopathic pulmonary fibrosis : longitudinal changes and minimum important difference . RATIONALE The response characteristics of the 6 minute walk test ( 6MWT ) in studies of idiopathic pulmonary fibrosis ( IPF ) are only poorly understood , and the change in walk distance that constitutes the minimum important difference ( MID ) over time is unknown . OBJECTIVES To examine changes over time in distance walked ( ie , 6MWD ) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF . METHODS Data from a recently completed trial that included subjects with IPF who completed the 6MWT , Saint George 's Respiratory Questionnaire ( SGRQ ) and forced vital capacity ( FVC ) at 6 and 12 months were used to examine longitudinal changes in 6MWD . Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD . The SGRQ Total score and FVC were used as clinical anchors . MAIN RESULTS Among 123 subjects alive and able to complete the 6MWT at both follow-up time points , 6MWD did not change significantly over time ( 378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months , p=0.5 ) . The point estimate for the 6MWD MID was 28 m with a range of 10.8-58.5 m. CONCLUSION In a group of patients with IPF with moderate physiological impairment , for those alive and able to complete a 6MWT , 6MWD does not change over 12 months . At the population level , the MID for 6MWD appears to be approximately 28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population .
[ "The", "6", "minute", "walk", "in", "idiopathic", "pulmonary", "fibrosis", ":", "longitudinal", "changes", "and", "minimum", "important", "difference", ".", "RATIONALE", "The", "response", "characteristics", "of", "the", "6", "minute", "walk", "test", "(", "6MWT", ")", "in", "studies", "of", "idiopathic", "pulmonary", "fibrosis", "(", "IPF", ")", "are", "only", "poorly", "understood", ",", "and", "the", "change", "in", "walk", "distance", "that", "constitutes", "the", "minimum", "important", "difference", "(", "MID", ")", "over", "time", "is", "unknown", ".", "OBJECTIVES", "To", "examine", "changes", "over", "time", "in", "distance", "walked", "(", "ie", ",", "6MWD", ")", "during", "the", "6MWT", "and", "to", "estimate", "the", "change", "in", "distance", "that", "constitutes", "the", "MID", "in", "patients", "with", "IPF", ".", "METHODS", "Data", "from", "a", "recently", "completed", "trial", "that", "included", "subjects", "with", "IPF", "who", "completed", "the", "6MWT", ",", "Saint", "George", "'", "s", "Respiratory", "Questionnaire", "(", "SGRQ", ")", "and", "forced", "vital", "capacity", "(", "FVC", ")", "at", "6", "and", "12", "months", "were", "used", "to", "examine", "longitudinal", "changes", "in", "6MWD", ".", "Both", "anchor-", "and", "distribution", "-", "based", "approaches", "as", "well", "as", "linear", "regression", "analyses", "were", "used", "to", "determine", "the", "MID", "for", "6MWD", ".", "The", "SGRQ", "Total", "score", "and", "FVC", "were", "used", "as", "clinical", "anchors", ".", "MAIN", "RESULTS", "Among", "123", "subjects", "alive", "and", "able", "to", "complete", "the", "6MWT", "at", "both", "follow", "-", "up", "time", "points", ",", "6MWD", "did", "not", "change", "significantly", "over", "time", "(", "378.1", "m", "at", "baseline", "vs", "376.8", "m", "at", "6", "months", "vs", "361.3", "m", "at", "12", "months", ",", "p=0.5", ")", ".", "The", "point", "estimate", "for", "the", "6MWD", "MID", "was", "28", "m", "with", "a", "range", "of", "10.8", "-", "58.5", "m.", "CONCLUSION", "In", "a", "group", "of", "patients", "with", "IPF", "with", "moderate", "physiological", "impairment", ",", "for", "those", "alive", "and", "able", "to", "complete", "a", "6MWT", ",", "6MWD", "does", "not", "change", "over", "12", "months", ".", "At", "the", "population", "level", ",", "the", "MID", "for", "6MWD", "appears", "to", "be", "approximately", "28", "m.", "Further", "investigation", "using", "other", "anchors", "and", "derivation", "methods", "is", "required", "to", "refine", "estimates", "of", "the", "MID", "for", "6MWD", "in", "this", "patient", "population", "." ]
[ "Intervention_Physical", "Outcome_Other", "Outcome_Physical" ]
6 minute walk test ( 6MWT ), time in distance walked, 6MWD, SGRQ Total score and FVC
43255_task2
Sentence: The 6 minute walk in idiopathic pulmonary fibrosis : longitudinal changes and minimum important difference . RATIONALE The response characteristics of the 6 minute walk test ( 6MWT ) in studies of idiopathic pulmonary fibrosis ( IPF ) are only poorly understood , and the change in walk distance that constitutes the minimum important difference ( MID ) over time is unknown . OBJECTIVES To examine changes over time in distance walked ( ie , 6MWD ) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF . METHODS Data from a recently completed trial that included subjects with IPF who completed the 6MWT , Saint George 's Respiratory Questionnaire ( SGRQ ) and forced vital capacity ( FVC ) at 6 and 12 months were used to examine longitudinal changes in 6MWD . Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD . The SGRQ Total score and FVC were used as clinical anchors . MAIN RESULTS Among 123 subjects alive and able to complete the 6MWT at both follow-up time points , 6MWD did not change significantly over time ( 378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months , p=0.5 ) . The point estimate for the 6MWD MID was 28 m with a range of 10.8-58.5 m. CONCLUSION In a group of patients with IPF with moderate physiological impairment , for those alive and able to complete a 6MWT , 6MWD does not change over 12 months . At the population level , the MID for 6MWD appears to be approximately 28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The 6 minute walk in idiopathic pulmonary fibrosis : longitudinal changes and minimum important difference . RATIONALE The response characteristics of the 6 minute walk test ( 6MWT ) in studies of idiopathic pulmonary fibrosis ( IPF ) are only poorly understood , and the change in walk distance that constitutes the minimum important difference ( MID ) over time is unknown . OBJECTIVES To examine changes over time in distance walked ( ie , 6MWD ) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF . METHODS Data from a recently completed trial that included subjects with IPF who completed the 6MWT , Saint George 's Respiratory Questionnaire ( SGRQ ) and forced vital capacity ( FVC ) at 6 and 12 months were used to examine longitudinal changes in 6MWD . Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD . The SGRQ Total score and FVC were used as clinical anchors . MAIN RESULTS Among 123 subjects alive and able to complete the 6MWT at both follow-up time points , 6MWD did not change significantly over time ( 378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months , p=0.5 ) . The point estimate for the 6MWD MID was 28 m with a range of 10.8-58.5 m. CONCLUSION In a group of patients with IPF with moderate physiological impairment , for those alive and able to complete a 6MWT , 6MWD does not change over 12 months . At the population level , the MID for 6MWD appears to be approximately 28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population .
[ "The", "6", "minute", "walk", "in", "idiopathic", "pulmonary", "fibrosis", ":", "longitudinal", "changes", "and", "minimum", "important", "difference", ".", "RATIONALE", "The", "response", "characteristics", "of", "the", "6", "minute", "walk", "test", "(", "6MWT", ")", "in", "studies", "of", "idiopathic", "pulmonary", "fibrosis", "(", "IPF", ")", "are", "only", "poorly", "understood", ",", "and", "the", "change", "in", "walk", "distance", "that", "constitutes", "the", "minimum", "important", "difference", "(", "MID", ")", "over", "time", "is", "unknown", ".", "OBJECTIVES", "To", "examine", "changes", "over", "time", "in", "distance", "walked", "(", "ie", ",", "6MWD", ")", "during", "the", "6MWT", "and", "to", "estimate", "the", "change", "in", "distance", "that", "constitutes", "the", "MID", "in", "patients", "with", "IPF", ".", "METHODS", "Data", "from", "a", "recently", "completed", "trial", "that", "included", "subjects", "with", "IPF", "who", "completed", "the", "6MWT", ",", "Saint", "George", "'", "s", "Respiratory", "Questionnaire", "(", "SGRQ", ")", "and", "forced", "vital", "capacity", "(", "FVC", ")", "at", "6", "and", "12", "months", "were", "used", "to", "examine", "longitudinal", "changes", "in", "6MWD", ".", "Both", "anchor-", "and", "distribution", "-", "based", "approaches", "as", "well", "as", "linear", "regression", "analyses", "were", "used", "to", "determine", "the", "MID", "for", "6MWD", ".", "The", "SGRQ", "Total", "score", "and", "FVC", "were", "used", "as", "clinical", "anchors", ".", "MAIN", "RESULTS", "Among", "123", "subjects", "alive", "and", "able", "to", "complete", "the", "6MWT", "at", "both", "follow", "-", "up", "time", "points", ",", "6MWD", "did", "not", "change", "significantly", "over", "time", "(", "378.1", "m", "at", "baseline", "vs", "376.8", "m", "at", "6", "months", "vs", "361.3", "m", "at", "12", "months", ",", "p=0.5", ")", ".", "The", "point", "estimate", "for", "the", "6MWD", "MID", "was", "28", "m", "with", "a", "range", "of", "10.8", "-", "58.5", "m.", "CONCLUSION", "In", "a", "group", "of", "patients", "with", "IPF", "with", "moderate", "physiological", "impairment", ",", "for", "those", "alive", "and", "able", "to", "complete", "a", "6MWT", ",", "6MWD", "does", "not", "change", "over", "12", "months", ".", "At", "the", "population", "level", ",", "the", "MID", "for", "6MWD", "appears", "to", "be", "approximately", "28", "m.", "Further", "investigation", "using", "other", "anchors", "and", "derivation", "methods", "is", "required", "to", "refine", "estimates", "of", "the", "MID", "for", "6MWD", "in", "this", "patient", "population", "." ]
[ "Intervention_Physical", "Outcome_Other", "Outcome_Physical" ]
cáncer is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumor neuroendocrino is a MORFOLOGIA_NEOPLASIA, TNEp is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, TNEp bien diferenciado is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA
871_task0
Sentence: Anamnesis Se trata de un hombre de 33 años, casado, con dos hijos, ingeniero de profesión. Tenía antecedentes familiares de un tío materno con un cáncer de páncreas y una tía materna con cáncer de ovario. Como antecedentes personales, sobrepeso hasta un año antes de la primera visita en Oncología, fumador esporádico, bebedor social, estaba a tratamiento con eprosartán 600 mg/día por hipertensión arterial y había sido intervenido de pie varo plano. En enero de 2006, comenzó con una dieta hipocalórica, con una pérdida ponderal de hasta 18 kg incluso habiendo abandonado la dieta. Con los meses se asoció dolor en cinturón con escala visual analógica (EVA) 5/10, diarrea e intolerancia alimenticia sin esteatorrea. En octubre 2006, consultó en relación con la pérdida ponderal y en una analítica se constató anemia, alteración de pruebas hepáticas e hipercalcemia por lo que fue derivado al servicio de Medicina Interna. Exploración física Durante la exploración, el paciente tenía un buen estado general, ECOG-1 con palidez cutánea, no se palpaban adenopatías y el abdomen estaba doloroso al tacto. En el epigastrio se palpaba una dudosa masa. Pruebas complementarias Se ampliaron estudios; entre ellos, se realizó una ecografía abdominal y una tomografía computarizada (TC) que mostraban múltiples lesiones hepáticas y una gran lesión en páncreas. Mediante resonancia magnética, se confirmó que las lesiones hepáticas eran metástasis y se detectó la presencia de una gran masa en páncreas (> 9 cm) e hipertensión portal. Se realizó una punción, guiada por scanner, de la masa de páncreas con diagnóstico patológico de malignidad y sugestivo de adenocarcinoma, aunque las células aisladas fueron insuficientes para realizar estudios de inmunohistoquímica. Diagnóstico Aunque inicialmente se realizó el diagnóstico de probable adenocarcinoma de páncreas, posteriormente, como veremos tras rebiopsiar el tumor, se confirmó que se trataba de un tumor neuroendocrino de páncreas (TNEp). Tratamiento Con la confirmación histológica de un cáncer de páncreas se decidió, tras consultarlo con el paciente y firmar este consentimiento informado por escrito, iniciar 1ª línea con gemcitabina 1.000 mg/m2/semanal x 3 cada 4 semanas en enero de 2007. A los tres meses, la TC confirmó una progresión del cáncer primario por lo que se inicia, en abril de 2007, 2ª línea con capecitabina 1.000 mg/m2/12 h x 14 días y erlotinib 150 mg/día vía oral. De nuevo, a los 3 meses, en julio de 2007, la nueva TC confirma progresión del tumor primario, por lo que se inicia una tercera línea de quimioterapia con capecitabina 1.000 mg/m2/12 h x 14 días + oxaliplatino 130 mg/m2 cada 3 semanas. El paciente completó 26 ciclos en octubre de 2009 sin progresión clínica ni radiológica, manteniendo un buen estado general sin toxicidad (no presentó neuropatía) y con respuesta clínica, ganancia ponderal y desaparición del dolor y respuesta bioquímica, normalización del calcio y de las pruebas hepáticas. Evolución En diciembre de 2009, debido a la estabilización mantenida más de dos años, poco probable en tercera línea de un cáncer de páncreas, se solicita al servicio de digestivo realizar biopsia pancreática para descartar otra histología. El acceso para la biopsia fue dificultoso por la gran masa en páncreas, la hipertensión portal y el riesgo de sangrado, por lo que finalmente se llevó a cabo una laparoscopia exploradora. Se obtuvo muestra de tejido pancreático con confirmación histológica de un TNEp bien diferenciado con Ki 67 del 1 %, Octreoscan® con gran avidez por el radiotrazador (puntuación Krenning 3), elevación de cromogranina sérica y con índoles en orina normales. En mayo de 2010, a los siete meses de haber detenido la quimioterapia la TC, confirmó enfermedad estable por lo que se pautó tratamiento con análogo de somatostatina, lanreótido autogel 120 mg cada 4 semanas subcutáneo. Tras dos años y medio de tratamiento, en noviembre de 2012, se constata una progresión radiológica a nivel hepático y pancreático. El paciente mantenía buen estado general, ECOG 0 por lo que se decide incluirle en el estudio SAL-SUN-2011-01 del Grupo Español de Tumores Neuroendocrinos (GETNE) con sunitinib que recibió a dosis estándar, 37,5 mg/día vía oral entre diciembre de 2012 y septiembre de 2014, 10 meses, suspendiéndose por progresión. Como toxicidad presentó una neutropenia y trombopenia grado I, decoloración cutánea y del vello e HTA grado I2, 3. En noviembre de 2014, recibió everolimus 10 mg/día vía oral teniendo como toxicidad hiperglucemia, anemia, neutropenia y astenia grado 12. El tratamiento se detuvo en agosto de 2016, a los nueve meses, al constatarse una nueva progresión radiológica y clínica. En ese momento el paciente presenta un ECOG-1, adelgazamiento de unos 6 kg en menos de tres meses, alteración de pruebas hepáticas y reaparición de la hipercalcemia presente al diagnóstico. Ante sospecha de aumento de la agresividad tumoral, se decide rescatar la tercera línea de quimioterapia que se suspendió sin progresión mediante capecitabina y oxaliplatino. El tratamiento se pauta con una reducción de dosis del 20 % comenzando en septiembre de 2016, teniendo que ingresar a los pocos días por deterioro general, encamamiento, empeoramiento de la función renal, hematemesis e hipercalcemia severa. Tras estabilizar al paciente, se decide seguimiento por la Unidad de Cuidados Paliativos a Domicilio falleciendo en noviembre de 2016 a los 10 años del diagnóstico. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se trata de un hombre de 33 años, casado, con dos hijos, ingeniero de profesión. Tenía antecedentes familiares de un tío materno con un cáncer de páncreas y una tía materna con cáncer de ovario. Como antecedentes personales, sobrepeso hasta un año antes de la primera visita en Oncología, fumador esporádico, bebedor social, estaba a tratamiento con eprosartán 600 mg/día por hipertensión arterial y había sido intervenido de pie varo plano. En enero de 2006, comenzó con una dieta hipocalórica, con una pérdida ponderal de hasta 18 kg incluso habiendo abandonado la dieta. Con los meses se asoció dolor en cinturón con escala visual analógica (EVA) 5/10, diarrea e intolerancia alimenticia sin esteatorrea. En octubre 2006, consultó en relación con la pérdida ponderal y en una analítica se constató anemia, alteración de pruebas hepáticas e hipercalcemia por lo que fue derivado al servicio de Medicina Interna. Exploración física Durante la exploración, el paciente tenía un buen estado general, ECOG-1 con palidez cutánea, no se palpaban adenopatías y el abdomen estaba doloroso al tacto. En el epigastrio se palpaba una dudosa masa. Pruebas complementarias Se ampliaron estudios; entre ellos, se realizó una ecografía abdominal y una tomografía computarizada (TC) que mostraban múltiples lesiones hepáticas y una gran lesión en páncreas. Mediante resonancia magnética, se confirmó que las lesiones hepáticas eran metástasis y se detectó la presencia de una gran masa en páncreas (> 9 cm) e hipertensión portal. Se realizó una punción, guiada por scanner, de la masa de páncreas con diagnóstico patológico de malignidad y sugestivo de adenocarcinoma, aunque las células aisladas fueron insuficientes para realizar estudios de inmunohistoquímica. Diagnóstico Aunque inicialmente se realizó el diagnóstico de probable adenocarcinoma de páncreas, posteriormente, como veremos tras rebiopsiar el tumor, se confirmó que se trataba de un tumor neuroendocrino de páncreas (TNEp). Tratamiento Con la confirmación histológica de un cáncer de páncreas se decidió, tras consultarlo con el paciente y firmar este consentimiento informado por escrito, iniciar 1ª línea con gemcitabina 1.000 mg/m2/semanal x 3 cada 4 semanas en enero de 2007. A los tres meses, la TC confirmó una progresión del cáncer primario por lo que se inicia, en abril de 2007, 2ª línea con capecitabina 1.000 mg/m2/12 h x 14 días y erlotinib 150 mg/día vía oral. De nuevo, a los 3 meses, en julio de 2007, la nueva TC confirma progresión del tumor primario, por lo que se inicia una tercera línea de quimioterapia con capecitabina 1.000 mg/m2/12 h x 14 días + oxaliplatino 130 mg/m2 cada 3 semanas. El paciente completó 26 ciclos en octubre de 2009 sin progresión clínica ni radiológica, manteniendo un buen estado general sin toxicidad (no presentó neuropatía) y con respuesta clínica, ganancia ponderal y desaparición del dolor y respuesta bioquímica, normalización del calcio y de las pruebas hepáticas. Evolución En diciembre de 2009, debido a la estabilización mantenida más de dos años, poco probable en tercera línea de un cáncer de páncreas, se solicita al servicio de digestivo realizar biopsia pancreática para descartar otra histología. El acceso para la biopsia fue dificultoso por la gran masa en páncreas, la hipertensión portal y el riesgo de sangrado, por lo que finalmente se llevó a cabo una laparoscopia exploradora. Se obtuvo muestra de tejido pancreático con confirmación histológica de un TNEp bien diferenciado con Ki 67 del 1 %, Octreoscan® con gran avidez por el radiotrazador (puntuación Krenning 3), elevación de cromogranina sérica y con índoles en orina normales. En mayo de 2010, a los siete meses de haber detenido la quimioterapia la TC, confirmó enfermedad estable por lo que se pautó tratamiento con análogo de somatostatina, lanreótido autogel 120 mg cada 4 semanas subcutáneo. Tras dos años y medio de tratamiento, en noviembre de 2012, se constata una progresión radiológica a nivel hepático y pancreático. El paciente mantenía buen estado general, ECOG 0 por lo que se decide incluirle en el estudio SAL-SUN-2011-01 del Grupo Español de Tumores Neuroendocrinos (GETNE) con sunitinib que recibió a dosis estándar, 37,5 mg/día vía oral entre diciembre de 2012 y septiembre de 2014, 10 meses, suspendiéndose por progresión. Como toxicidad presentó una neutropenia y trombopenia grado I, decoloración cutánea y del vello e HTA grado I2, 3. En noviembre de 2014, recibió everolimus 10 mg/día vía oral teniendo como toxicidad hiperglucemia, anemia, neutropenia y astenia grado 12. El tratamiento se detuvo en agosto de 2016, a los nueve meses, al constatarse una nueva progresión radiológica y clínica. En ese momento el paciente presenta un ECOG-1, adelgazamiento de unos 6 kg en menos de tres meses, alteración de pruebas hepáticas y reaparición de la hipercalcemia presente al diagnóstico. Ante sospecha de aumento de la agresividad tumoral, se decide rescatar la tercera línea de quimioterapia que se suspendió sin progresión mediante capecitabina y oxaliplatino. El tratamiento se pauta con una reducción de dosis del 20 % comenzando en septiembre de 2016, teniendo que ingresar a los pocos días por deterioro general, encamamiento, empeoramiento de la función renal, hematemesis e hipercalcemia severa. Tras estabilizar al paciente, se decide seguimiento por la Unidad de Cuidados Paliativos a Domicilio falleciendo en noviembre de 2016 a los 10 años del diagnóstico.
[ "Anamnesis", "\n", "Se", "trata", "de", "un", "hombre", "de", "33", "años", ",", "casado", ",", "con", "dos", "hijos", ",", "ingeniero", "de", "profesión", ".", "Tenía", "antecedentes", "familiares", "de", "un", "tío", "materno", "con", "un", "cáncer", "de", "páncreas", "y", "una", "tía", "materna", "con", "cáncer", "de", "ovario", ".", "Como", "antecedentes", "personales", ",", "sobrepeso", "hasta", "un", "año", "antes", "de", "la", "primera", "visita", "en", "Oncología", ",", "fumador", "esporádico", ",", "bebedor", "social", ",", "estaba", "a", "tratamiento", "con", "eprosartán", "600", "mg", "/", "día", "por", "hipertensión", "arterial", "y", "había", "sido", "intervenido", "de", "pie", "varo", "plano", ".", "\n", "En", "enero", "de", "2006", ",", "comenzó", "con", "una", "dieta", "hipocalórica", ",", "con", "una", "pérdida", "ponderal", "de", "hasta", "18", "kg", "incluso", "habiendo", "abandonado", "la", "dieta", ".", "Con", "los", "meses", "se", "asoció", "dolor", "en", "cinturón", "con", "escala", "visual", "analógica", "(", "EVA", ")", "5/10", ",", "diarrea", "e", "intolerancia", "alimenticia", "sin", "esteatorrea", ".", "En", "octubre", "2006", ",", "consultó", "en", "relación", "con", "la", "pérdida", "ponderal", "y", "en", "una", "analítica", "se", "constató", "anemia", ",", "alteración", "de", "pruebas", "hepáticas", "e", "hipercalcemia", "por", "lo", "que", "fue", "derivado", "al", "servicio", "de", "Medicina", "Interna", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", ",", "el", "paciente", "tenía", "un", "buen", "estado", "general", ",", "ECOG-1", "con", "palidez", "cutánea", ",", "no", "se", "palpaban", "adenopatías", "y", "el", "abdomen", "estaba", "doloroso", "al", "tacto", ".", "En", "el", "epigastrio", "se", "palpaba", "una", "dudosa", "masa", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "ampliaron", "estudios", ";", "entre", "ellos", ",", "se", "realizó", "una", "ecografía", "abdominal", "y", "una", "tomografía", "computarizada", "(", "TC", ")", "que", "mostraban", "múltiples", "lesiones", "hepáticas", "y", "una", "gran", "lesión", "en", "páncreas", ".", "Mediante", "resonancia", "magnética", ",", "se", "confirmó", "que", "las", "lesiones", "hepáticas", "eran", "metástasis", "y", "se", "detectó", "la", "presencia", "de", "una", "gran", "masa", "en", "páncreas", "(", ">", "9", "cm", ")", "e", "hipertensión", "portal", ".", "Se", "realizó", "una", "punción", ",", "guiada", "por", "scanner", ",", "de", "la", "masa", "de", "páncreas", "con", "diagnóstico", "patológico", "de", "malignidad", "y", "sugestivo", "de", "adenocarcinoma", ",", "aunque", "las", "células", "aisladas", "fueron", "insuficientes", "para", "realizar", "estudios", "de", "inmunohistoquímica", ".", "\n\n", "Diagnóstico", "\n", "Aunque", "inicialmente", "se", "realizó", "el", "diagnóstico", "de", "probable", "adenocarcinoma", "de", "páncreas", ",", "posteriormente", ",", "como", "veremos", "tras", "rebiopsiar", "el", "tumor", ",", "se", "confirmó", "que", "se", "trataba", "de", "un", "tumor", "neuroendocrino", "de", "páncreas", "(", "TNEp", ")", ".", "\n\n", "Tratamiento", "\n", "Con", "la", "confirmación", "histológica", "de", "un", "cáncer", "de", "páncreas", "se", "decidió", ",", "tras", "consultarlo", "con", "el", "paciente", "y", "firmar", "este", "consentimiento", "informado", "por", "escrito", ",", "iniciar", "1ª", "línea", "con", "gemcitabina", "1.000", "mg", "/", "m2", "/", "semanal", "x", "3", "cada", "4", "semanas", "en", "enero", "de", "2007", ".", "A", "los", "tres", "meses", ",", "la", "TC", "confirmó", "una", "progresión", "del", "cáncer", "primario", "por", "lo", "que", "se", "inicia", ",", "en", "abril", "de", "2007", ",", "2ª", "línea", "con", "capecitabina", "1.000", "mg", "/", "m2/12", "h", "x", "14", "días", "y", "erlotinib", "150", "mg", "/", "día", "vía", "oral", ".", "\n", "De", "nuevo", ",", "a", "los", "3", "meses", ",", "en", "julio", "de", "2007", ",", "la", "nueva", "TC", "confirma", "progresión", "del", "tumor", "primario", ",", "por", "lo", "que", "se", "inicia", "una", "tercera", "línea", "de", "quimioterapia", "con", "capecitabina", "1.000", "mg", "/", "m2/12", "h", "x", "14", "días", "+", "oxaliplatino", "130", "mg", "/", "m2", "cada", "3", "semanas", ".", "El", "paciente", "completó", "26", "ciclos", "en", "octubre", "de", "2009", "sin", "progresión", "clínica", "ni", "radiológica", ",", "manteniendo", "un", "buen", "estado", "general", "sin", "toxicidad", "(", "no", "presentó", "neuropatía", ")", "y", "con", "respuesta", "clínica", ",", "ganancia", "ponderal", "y", "desaparición", "del", "dolor", "y", "respuesta", "bioquímica", ",", "normalización", "del", "calcio", "y", "de", "las", "pruebas", "hepáticas", ".", "\n\n", "Evolución", "\n", "En", "diciembre", "de", "2009", ",", "debido", "a", "la", "estabilización", "mantenida", "más", "de", "dos", "años", ",", "poco", "probable", "en", "tercera", "línea", "de", "un", "cáncer", "de", "páncreas", ",", "se", "solicita", "al", "servicio", "de", "digestivo", "realizar", "biopsia", "pancreática", "para", "descartar", "otra", "histología", ".", "El", "acceso", "para", "la", "biopsia", "fue", "dificultoso", "por", "la", "gran", "masa", "en", "páncreas", ",", "la", "hipertensión", "portal", "y", "el", "riesgo", "de", "sangrado", ",", "por", "lo", "que", "finalmente", "se", "llevó", "a", "cabo", "una", "laparoscopia", "exploradora", ".", "Se", "obtuvo", "muestra", "de", "tejido", "pancreático", "con", "confirmación", "histológica", "de", "un", "TNEp", "bien", "diferenciado", "con", "Ki", "67", "del", "1", "%", ",", "Octreoscan", "®", "con", "gran", "avidez", "por", "el", "radiotrazador", "(", "puntuación", "Krenning", "3", ")", ",", "elevación", "de", "cromogranina", "sérica", "y", "con", "índoles", "en", "orina", "normales", ".", "\n", "En", "mayo", "de", "2010", ",", "a", "los", "siete", "meses", "de", "haber", "detenido", "la", "quimioterapia", "la", "TC", ",", "confirmó", "enfermedad", "estable", "por", "lo", "que", "se", "pautó", "tratamiento", "con", "análogo", "de", "somatostatina", ",", "lanreótido", "autogel", "120", "mg", "cada", "4", "semanas", "subcutáneo", ".", "\n", "Tras", "dos", "años", "y", "medio", "de", "tratamiento", ",", "en", "noviembre", "de", "2012", ",", "se", "constata", "una", "progresión", "radiológica", "a", "nivel", "hepático", "y", "pancreático", ".", "El", "paciente", "mantenía", "buen", "estado", "general", ",", "ECOG", "0", "por", "lo", "que", "se", "decide", "incluirle", "en", "el", "estudio", "SAL", "-", "SUN-2011", "-", "01", "del", "Grupo", "Español", "de", "Tumores", "Neuroendocrinos", "(", "GETNE", ")", "con", "sunitinib", "que", "recibió", "a", "dosis", "estándar", ",", "37,5", "mg", "/", "día", "vía", "oral", "entre", "diciembre", "de", "2012", "y", "septiembre", "de", "2014", ",", "10", "meses", ",", "suspendiéndose", "por", "progresión", ".", "Como", "toxicidad", "presentó", "una", "neutropenia", "y", "trombopenia", "grado", "I", ",", "decoloración", "cutánea", "y", "del", "vello", "e", "HTA", "grado", "I2", ",", "3", ".", "\n", "En", "noviembre", "de", "2014", ",", "recibió", "everolimus", "10", "mg", "/", "día", "vía", "oral", "teniendo", "como", "toxicidad", "hiperglucemia", ",", "anemia", ",", "neutropenia", "y", "astenia", "grado", "12", ".", "El", "tratamiento", "se", "detuvo", "en", "agosto", "de", "2016", ",", "a", "los", "nueve", "meses", ",", "al", "constatarse", "una", "nueva", "progresión", "radiológica", "y", "clínica", ".", "En", "ese", "momento", "el", "paciente", "presenta", "un", "ECOG-1", ",", "adelgazamiento", "de", "unos", "6", "kg", "en", "menos", "de", "tres", "meses", ",", "alteración", "de", "pruebas", "hepáticas", "y", "reaparición", "de", "la", "hipercalcemia", "presente", "al", "diagnóstico", ".", "Ante", "sospecha", "de", "aumento", "de", "la", "agresividad", "tumoral", ",", "se", "decide", "rescatar", "la", "tercera", "línea", "de", "quimioterapia", "que", "se", "suspendió", "sin", "progresión", "mediante", "capecitabina", "y", "oxaliplatino", ".", "El", "tratamiento", "se", "pauta", "con", "una", "reducción", "de", "dosis", "del", "20", "%", "comenzando", "en", "septiembre", "de", "2016", ",", "teniendo", "que", "ingresar", "a", "los", "pocos", "días", "por", "deterioro", "general", ",", "encamamiento", ",", "empeoramiento", "de", "la", "función", "renal", ",", "hematemesis", "e", "hipercalcemia", "severa", ".", "Tras", "estabilizar", "al", "paciente", ",", "se", "decide", "seguimiento", "por", "la", "Unidad", "de", "Cuidados", "Paliativos", "a", "Domicilio", "falleciendo", "en", "noviembre", "de", "2016", "a", "los", "10", "años", "del", "diagnóstico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
cáncer is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumor neuroendocrino is a MORFOLOGIA_NEOPLASIA, TNEp is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA, TNEp bien diferenciado is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA
871_task1
Sentence: Anamnesis Se trata de un hombre de 33 años, casado, con dos hijos, ingeniero de profesión. Tenía antecedentes familiares de un tío materno con un cáncer de páncreas y una tía materna con cáncer de ovario. Como antecedentes personales, sobrepeso hasta un año antes de la primera visita en Oncología, fumador esporádico, bebedor social, estaba a tratamiento con eprosartán 600 mg/día por hipertensión arterial y había sido intervenido de pie varo plano. En enero de 2006, comenzó con una dieta hipocalórica, con una pérdida ponderal de hasta 18 kg incluso habiendo abandonado la dieta. Con los meses se asoció dolor en cinturón con escala visual analógica (EVA) 5/10, diarrea e intolerancia alimenticia sin esteatorrea. En octubre 2006, consultó en relación con la pérdida ponderal y en una analítica se constató anemia, alteración de pruebas hepáticas e hipercalcemia por lo que fue derivado al servicio de Medicina Interna. Exploración física Durante la exploración, el paciente tenía un buen estado general, ECOG-1 con palidez cutánea, no se palpaban adenopatías y el abdomen estaba doloroso al tacto. En el epigastrio se palpaba una dudosa masa. Pruebas complementarias Se ampliaron estudios; entre ellos, se realizó una ecografía abdominal y una tomografía computarizada (TC) que mostraban múltiples lesiones hepáticas y una gran lesión en páncreas. Mediante resonancia magnética, se confirmó que las lesiones hepáticas eran metástasis y se detectó la presencia de una gran masa en páncreas (> 9 cm) e hipertensión portal. Se realizó una punción, guiada por scanner, de la masa de páncreas con diagnóstico patológico de malignidad y sugestivo de adenocarcinoma, aunque las células aisladas fueron insuficientes para realizar estudios de inmunohistoquímica. Diagnóstico Aunque inicialmente se realizó el diagnóstico de probable adenocarcinoma de páncreas, posteriormente, como veremos tras rebiopsiar el tumor, se confirmó que se trataba de un tumor neuroendocrino de páncreas (TNEp). Tratamiento Con la confirmación histológica de un cáncer de páncreas se decidió, tras consultarlo con el paciente y firmar este consentimiento informado por escrito, iniciar 1ª línea con gemcitabina 1.000 mg/m2/semanal x 3 cada 4 semanas en enero de 2007. A los tres meses, la TC confirmó una progresión del cáncer primario por lo que se inicia, en abril de 2007, 2ª línea con capecitabina 1.000 mg/m2/12 h x 14 días y erlotinib 150 mg/día vía oral. De nuevo, a los 3 meses, en julio de 2007, la nueva TC confirma progresión del tumor primario, por lo que se inicia una tercera línea de quimioterapia con capecitabina 1.000 mg/m2/12 h x 14 días + oxaliplatino 130 mg/m2 cada 3 semanas. El paciente completó 26 ciclos en octubre de 2009 sin progresión clínica ni radiológica, manteniendo un buen estado general sin toxicidad (no presentó neuropatía) y con respuesta clínica, ganancia ponderal y desaparición del dolor y respuesta bioquímica, normalización del calcio y de las pruebas hepáticas. Evolución En diciembre de 2009, debido a la estabilización mantenida más de dos años, poco probable en tercera línea de un cáncer de páncreas, se solicita al servicio de digestivo realizar biopsia pancreática para descartar otra histología. El acceso para la biopsia fue dificultoso por la gran masa en páncreas, la hipertensión portal y el riesgo de sangrado, por lo que finalmente se llevó a cabo una laparoscopia exploradora. Se obtuvo muestra de tejido pancreático con confirmación histológica de un TNEp bien diferenciado con Ki 67 del 1 %, Octreoscan® con gran avidez por el radiotrazador (puntuación Krenning 3), elevación de cromogranina sérica y con índoles en orina normales. En mayo de 2010, a los siete meses de haber detenido la quimioterapia la TC, confirmó enfermedad estable por lo que se pautó tratamiento con análogo de somatostatina, lanreótido autogel 120 mg cada 4 semanas subcutáneo. Tras dos años y medio de tratamiento, en noviembre de 2012, se constata una progresión radiológica a nivel hepático y pancreático. El paciente mantenía buen estado general, ECOG 0 por lo que se decide incluirle en el estudio SAL-SUN-2011-01 del Grupo Español de Tumores Neuroendocrinos (GETNE) con sunitinib que recibió a dosis estándar, 37,5 mg/día vía oral entre diciembre de 2012 y septiembre de 2014, 10 meses, suspendiéndose por progresión. Como toxicidad presentó una neutropenia y trombopenia grado I, decoloración cutánea y del vello e HTA grado I2, 3. En noviembre de 2014, recibió everolimus 10 mg/día vía oral teniendo como toxicidad hiperglucemia, anemia, neutropenia y astenia grado 12. El tratamiento se detuvo en agosto de 2016, a los nueve meses, al constatarse una nueva progresión radiológica y clínica. En ese momento el paciente presenta un ECOG-1, adelgazamiento de unos 6 kg en menos de tres meses, alteración de pruebas hepáticas y reaparición de la hipercalcemia presente al diagnóstico. Ante sospecha de aumento de la agresividad tumoral, se decide rescatar la tercera línea de quimioterapia que se suspendió sin progresión mediante capecitabina y oxaliplatino. El tratamiento se pauta con una reducción de dosis del 20 % comenzando en septiembre de 2016, teniendo que ingresar a los pocos días por deterioro general, encamamiento, empeoramiento de la función renal, hematemesis e hipercalcemia severa. Tras estabilizar al paciente, se decide seguimiento por la Unidad de Cuidados Paliativos a Domicilio falleciendo en noviembre de 2016 a los 10 años del diagnóstico. Instructions: please typing these entity words according to sentence: cáncer, cáncer, lesiones hepáticas, lesiones hepáticas, metástasis, malignidad, adenocarcinoma, adenocarcinoma, tumor, tumor neuroendocrino, TNEp, cáncer, cáncer, tumor, cáncer, TNEp bien diferenciado, tumoral Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se trata de un hombre de 33 años, casado, con dos hijos, ingeniero de profesión. Tenía antecedentes familiares de un tío materno con un cáncer de páncreas y una tía materna con cáncer de ovario. Como antecedentes personales, sobrepeso hasta un año antes de la primera visita en Oncología, fumador esporádico, bebedor social, estaba a tratamiento con eprosartán 600 mg/día por hipertensión arterial y había sido intervenido de pie varo plano. En enero de 2006, comenzó con una dieta hipocalórica, con una pérdida ponderal de hasta 18 kg incluso habiendo abandonado la dieta. Con los meses se asoció dolor en cinturón con escala visual analógica (EVA) 5/10, diarrea e intolerancia alimenticia sin esteatorrea. En octubre 2006, consultó en relación con la pérdida ponderal y en una analítica se constató anemia, alteración de pruebas hepáticas e hipercalcemia por lo que fue derivado al servicio de Medicina Interna. Exploración física Durante la exploración, el paciente tenía un buen estado general, ECOG-1 con palidez cutánea, no se palpaban adenopatías y el abdomen estaba doloroso al tacto. En el epigastrio se palpaba una dudosa masa. Pruebas complementarias Se ampliaron estudios; entre ellos, se realizó una ecografía abdominal y una tomografía computarizada (TC) que mostraban múltiples lesiones hepáticas y una gran lesión en páncreas. Mediante resonancia magnética, se confirmó que las lesiones hepáticas eran metástasis y se detectó la presencia de una gran masa en páncreas (> 9 cm) e hipertensión portal. Se realizó una punción, guiada por scanner, de la masa de páncreas con diagnóstico patológico de malignidad y sugestivo de adenocarcinoma, aunque las células aisladas fueron insuficientes para realizar estudios de inmunohistoquímica. Diagnóstico Aunque inicialmente se realizó el diagnóstico de probable adenocarcinoma de páncreas, posteriormente, como veremos tras rebiopsiar el tumor, se confirmó que se trataba de un tumor neuroendocrino de páncreas (TNEp). Tratamiento Con la confirmación histológica de un cáncer de páncreas se decidió, tras consultarlo con el paciente y firmar este consentimiento informado por escrito, iniciar 1ª línea con gemcitabina 1.000 mg/m2/semanal x 3 cada 4 semanas en enero de 2007. A los tres meses, la TC confirmó una progresión del cáncer primario por lo que se inicia, en abril de 2007, 2ª línea con capecitabina 1.000 mg/m2/12 h x 14 días y erlotinib 150 mg/día vía oral. De nuevo, a los 3 meses, en julio de 2007, la nueva TC confirma progresión del tumor primario, por lo que se inicia una tercera línea de quimioterapia con capecitabina 1.000 mg/m2/12 h x 14 días + oxaliplatino 130 mg/m2 cada 3 semanas. El paciente completó 26 ciclos en octubre de 2009 sin progresión clínica ni radiológica, manteniendo un buen estado general sin toxicidad (no presentó neuropatía) y con respuesta clínica, ganancia ponderal y desaparición del dolor y respuesta bioquímica, normalización del calcio y de las pruebas hepáticas. Evolución En diciembre de 2009, debido a la estabilización mantenida más de dos años, poco probable en tercera línea de un cáncer de páncreas, se solicita al servicio de digestivo realizar biopsia pancreática para descartar otra histología. El acceso para la biopsia fue dificultoso por la gran masa en páncreas, la hipertensión portal y el riesgo de sangrado, por lo que finalmente se llevó a cabo una laparoscopia exploradora. Se obtuvo muestra de tejido pancreático con confirmación histológica de un TNEp bien diferenciado con Ki 67 del 1 %, Octreoscan® con gran avidez por el radiotrazador (puntuación Krenning 3), elevación de cromogranina sérica y con índoles en orina normales. En mayo de 2010, a los siete meses de haber detenido la quimioterapia la TC, confirmó enfermedad estable por lo que se pautó tratamiento con análogo de somatostatina, lanreótido autogel 120 mg cada 4 semanas subcutáneo. Tras dos años y medio de tratamiento, en noviembre de 2012, se constata una progresión radiológica a nivel hepático y pancreático. El paciente mantenía buen estado general, ECOG 0 por lo que se decide incluirle en el estudio SAL-SUN-2011-01 del Grupo Español de Tumores Neuroendocrinos (GETNE) con sunitinib que recibió a dosis estándar, 37,5 mg/día vía oral entre diciembre de 2012 y septiembre de 2014, 10 meses, suspendiéndose por progresión. Como toxicidad presentó una neutropenia y trombopenia grado I, decoloración cutánea y del vello e HTA grado I2, 3. En noviembre de 2014, recibió everolimus 10 mg/día vía oral teniendo como toxicidad hiperglucemia, anemia, neutropenia y astenia grado 12. El tratamiento se detuvo en agosto de 2016, a los nueve meses, al constatarse una nueva progresión radiológica y clínica. En ese momento el paciente presenta un ECOG-1, adelgazamiento de unos 6 kg en menos de tres meses, alteración de pruebas hepáticas y reaparición de la hipercalcemia presente al diagnóstico. Ante sospecha de aumento de la agresividad tumoral, se decide rescatar la tercera línea de quimioterapia que se suspendió sin progresión mediante capecitabina y oxaliplatino. El tratamiento se pauta con una reducción de dosis del 20 % comenzando en septiembre de 2016, teniendo que ingresar a los pocos días por deterioro general, encamamiento, empeoramiento de la función renal, hematemesis e hipercalcemia severa. Tras estabilizar al paciente, se decide seguimiento por la Unidad de Cuidados Paliativos a Domicilio falleciendo en noviembre de 2016 a los 10 años del diagnóstico.
[ "Anamnesis", "\n", "Se", "trata", "de", "un", "hombre", "de", "33", "años", ",", "casado", ",", "con", "dos", "hijos", ",", "ingeniero", "de", "profesión", ".", "Tenía", "antecedentes", "familiares", "de", "un", "tío", "materno", "con", "un", "cáncer", "de", "páncreas", "y", "una", "tía", "materna", "con", "cáncer", "de", "ovario", ".", "Como", "antecedentes", "personales", ",", "sobrepeso", "hasta", "un", "año", "antes", "de", "la", "primera", "visita", "en", "Oncología", ",", "fumador", "esporádico", ",", "bebedor", "social", ",", "estaba", "a", "tratamiento", "con", "eprosartán", "600", "mg", "/", "día", "por", "hipertensión", "arterial", "y", "había", "sido", "intervenido", "de", "pie", "varo", "plano", ".", "\n", "En", "enero", "de", "2006", ",", "comenzó", "con", "una", "dieta", "hipocalórica", ",", "con", "una", "pérdida", "ponderal", "de", "hasta", "18", "kg", "incluso", "habiendo", "abandonado", "la", "dieta", ".", "Con", "los", "meses", "se", "asoció", "dolor", "en", "cinturón", "con", "escala", "visual", "analógica", "(", "EVA", ")", "5/10", ",", "diarrea", "e", "intolerancia", "alimenticia", "sin", "esteatorrea", ".", "En", "octubre", "2006", ",", "consultó", "en", "relación", "con", "la", "pérdida", "ponderal", "y", "en", "una", "analítica", "se", "constató", "anemia", ",", "alteración", "de", "pruebas", "hepáticas", "e", "hipercalcemia", "por", "lo", "que", "fue", "derivado", "al", "servicio", "de", "Medicina", "Interna", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", ",", "el", "paciente", "tenía", "un", "buen", "estado", "general", ",", "ECOG-1", "con", "palidez", "cutánea", ",", "no", "se", "palpaban", "adenopatías", "y", "el", "abdomen", "estaba", "doloroso", "al", "tacto", ".", "En", "el", "epigastrio", "se", "palpaba", "una", "dudosa", "masa", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "ampliaron", "estudios", ";", "entre", "ellos", ",", "se", "realizó", "una", "ecografía", "abdominal", "y", "una", "tomografía", "computarizada", "(", "TC", ")", "que", "mostraban", "múltiples", "lesiones", "hepáticas", "y", "una", "gran", "lesión", "en", "páncreas", ".", "Mediante", "resonancia", "magnética", ",", "se", "confirmó", "que", "las", "lesiones", "hepáticas", "eran", "metástasis", "y", "se", "detectó", "la", "presencia", "de", "una", "gran", "masa", "en", "páncreas", "(", ">", "9", "cm", ")", "e", "hipertensión", "portal", ".", "Se", "realizó", "una", "punción", ",", "guiada", "por", "scanner", ",", "de", "la", "masa", "de", "páncreas", "con", "diagnóstico", "patológico", "de", "malignidad", "y", "sugestivo", "de", "adenocarcinoma", ",", "aunque", "las", "células", "aisladas", "fueron", "insuficientes", "para", "realizar", "estudios", "de", "inmunohistoquímica", ".", "\n\n", "Diagnóstico", "\n", "Aunque", "inicialmente", "se", "realizó", "el", "diagnóstico", "de", "probable", "adenocarcinoma", "de", "páncreas", ",", "posteriormente", ",", "como", "veremos", "tras", "rebiopsiar", "el", "tumor", ",", "se", "confirmó", "que", "se", "trataba", "de", "un", "tumor", "neuroendocrino", "de", "páncreas", "(", "TNEp", ")", ".", "\n\n", "Tratamiento", "\n", "Con", "la", "confirmación", "histológica", "de", "un", "cáncer", "de", "páncreas", "se", "decidió", ",", "tras", "consultarlo", "con", "el", "paciente", "y", "firmar", "este", "consentimiento", "informado", "por", "escrito", ",", "iniciar", "1ª", "línea", "con", "gemcitabina", "1.000", "mg", "/", "m2", "/", "semanal", "x", "3", "cada", "4", "semanas", "en", "enero", "de", "2007", ".", "A", "los", "tres", "meses", ",", "la", "TC", "confirmó", "una", "progresión", "del", "cáncer", "primario", "por", "lo", "que", "se", "inicia", ",", "en", "abril", "de", "2007", ",", "2ª", "línea", "con", "capecitabina", "1.000", "mg", "/", "m2/12", "h", "x", "14", "días", "y", "erlotinib", "150", "mg", "/", "día", "vía", "oral", ".", "\n", "De", "nuevo", ",", "a", "los", "3", "meses", ",", "en", "julio", "de", "2007", ",", "la", "nueva", "TC", "confirma", "progresión", "del", "tumor", "primario", ",", "por", "lo", "que", "se", "inicia", "una", "tercera", "línea", "de", "quimioterapia", "con", "capecitabina", "1.000", "mg", "/", "m2/12", "h", "x", "14", "días", "+", "oxaliplatino", "130", "mg", "/", "m2", "cada", "3", "semanas", ".", "El", "paciente", "completó", "26", "ciclos", "en", "octubre", "de", "2009", "sin", "progresión", "clínica", "ni", "radiológica", ",", "manteniendo", "un", "buen", "estado", "general", "sin", "toxicidad", "(", "no", "presentó", "neuropatía", ")", "y", "con", "respuesta", "clínica", ",", "ganancia", "ponderal", "y", "desaparición", "del", "dolor", "y", "respuesta", "bioquímica", ",", "normalización", "del", "calcio", "y", "de", "las", "pruebas", "hepáticas", ".", "\n\n", "Evolución", "\n", "En", "diciembre", "de", "2009", ",", "debido", "a", "la", "estabilización", "mantenida", "más", "de", "dos", "años", ",", "poco", "probable", "en", "tercera", "línea", "de", "un", "cáncer", "de", "páncreas", ",", "se", "solicita", "al", "servicio", "de", "digestivo", "realizar", "biopsia", "pancreática", "para", "descartar", "otra", "histología", ".", "El", "acceso", "para", "la", "biopsia", "fue", "dificultoso", "por", "la", "gran", "masa", "en", "páncreas", ",", "la", "hipertensión", "portal", "y", "el", "riesgo", "de", "sangrado", ",", "por", "lo", "que", "finalmente", "se", "llevó", "a", "cabo", "una", "laparoscopia", "exploradora", ".", "Se", "obtuvo", "muestra", "de", "tejido", "pancreático", "con", "confirmación", "histológica", "de", "un", "TNEp", "bien", "diferenciado", "con", "Ki", "67", "del", "1", "%", ",", "Octreoscan", "®", "con", "gran", "avidez", "por", "el", "radiotrazador", "(", "puntuación", "Krenning", "3", ")", ",", "elevación", "de", "cromogranina", "sérica", "y", "con", "índoles", "en", "orina", "normales", ".", "\n", "En", "mayo", "de", "2010", ",", "a", "los", "siete", "meses", "de", "haber", "detenido", "la", "quimioterapia", "la", "TC", ",", "confirmó", "enfermedad", "estable", "por", "lo", "que", "se", "pautó", "tratamiento", "con", "análogo", "de", "somatostatina", ",", "lanreótido", "autogel", "120", "mg", "cada", "4", "semanas", "subcutáneo", ".", "\n", "Tras", "dos", "años", "y", "medio", "de", "tratamiento", ",", "en", "noviembre", "de", "2012", ",", "se", "constata", "una", "progresión", "radiológica", "a", "nivel", "hepático", "y", "pancreático", ".", "El", "paciente", "mantenía", "buen", "estado", "general", ",", "ECOG", "0", "por", "lo", "que", "se", "decide", "incluirle", "en", "el", "estudio", "SAL", "-", "SUN-2011", "-", "01", "del", "Grupo", "Español", "de", "Tumores", "Neuroendocrinos", "(", "GETNE", ")", "con", "sunitinib", "que", "recibió", "a", "dosis", "estándar", ",", "37,5", "mg", "/", "día", "vía", "oral", "entre", "diciembre", "de", "2012", "y", "septiembre", "de", "2014", ",", "10", "meses", ",", "suspendiéndose", "por", "progresión", ".", "Como", "toxicidad", "presentó", "una", "neutropenia", "y", "trombopenia", "grado", "I", ",", "decoloración", "cutánea", "y", "del", "vello", "e", "HTA", "grado", "I2", ",", "3", ".", "\n", "En", "noviembre", "de", "2014", ",", "recibió", "everolimus", "10", "mg", "/", "día", "vía", "oral", "teniendo", "como", "toxicidad", "hiperglucemia", ",", "anemia", ",", "neutropenia", "y", "astenia", "grado", "12", ".", "El", "tratamiento", "se", "detuvo", "en", "agosto", "de", "2016", ",", "a", "los", "nueve", "meses", ",", "al", "constatarse", "una", "nueva", "progresión", "radiológica", "y", "clínica", ".", "En", "ese", "momento", "el", "paciente", "presenta", "un", "ECOG-1", ",", "adelgazamiento", "de", "unos", "6", "kg", "en", "menos", "de", "tres", "meses", ",", "alteración", "de", "pruebas", "hepáticas", "y", "reaparición", "de", "la", "hipercalcemia", "presente", "al", "diagnóstico", ".", "Ante", "sospecha", "de", "aumento", "de", "la", "agresividad", "tumoral", ",", "se", "decide", "rescatar", "la", "tercera", "línea", "de", "quimioterapia", "que", "se", "suspendió", "sin", "progresión", "mediante", "capecitabina", "y", "oxaliplatino", ".", "El", "tratamiento", "se", "pauta", "con", "una", "reducción", "de", "dosis", "del", "20", "%", "comenzando", "en", "septiembre", "de", "2016", ",", "teniendo", "que", "ingresar", "a", "los", "pocos", "días", "por", "deterioro", "general", ",", "encamamiento", ",", "empeoramiento", "de", "la", "función", "renal", ",", "hematemesis", "e", "hipercalcemia", "severa", ".", "Tras", "estabilizar", "al", "paciente", ",", "se", "decide", "seguimiento", "por", "la", "Unidad", "de", "Cuidados", "Paliativos", "a", "Domicilio", "falleciendo", "en", "noviembre", "de", "2016", "a", "los", "10", "años", "del", "diagnóstico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
cáncer, cáncer, lesiones hepáticas, lesiones hepáticas, metástasis, malignidad, adenocarcinoma, adenocarcinoma, tumor, tumor neuroendocrino, TNEp, cáncer, cáncer, tumor, cáncer, TNEp bien diferenciado, tumoral
871_task2
Sentence: Anamnesis Se trata de un hombre de 33 años, casado, con dos hijos, ingeniero de profesión. Tenía antecedentes familiares de un tío materno con un cáncer de páncreas y una tía materna con cáncer de ovario. Como antecedentes personales, sobrepeso hasta un año antes de la primera visita en Oncología, fumador esporádico, bebedor social, estaba a tratamiento con eprosartán 600 mg/día por hipertensión arterial y había sido intervenido de pie varo plano. En enero de 2006, comenzó con una dieta hipocalórica, con una pérdida ponderal de hasta 18 kg incluso habiendo abandonado la dieta. Con los meses se asoció dolor en cinturón con escala visual analógica (EVA) 5/10, diarrea e intolerancia alimenticia sin esteatorrea. En octubre 2006, consultó en relación con la pérdida ponderal y en una analítica se constató anemia, alteración de pruebas hepáticas e hipercalcemia por lo que fue derivado al servicio de Medicina Interna. Exploración física Durante la exploración, el paciente tenía un buen estado general, ECOG-1 con palidez cutánea, no se palpaban adenopatías y el abdomen estaba doloroso al tacto. En el epigastrio se palpaba una dudosa masa. Pruebas complementarias Se ampliaron estudios; entre ellos, se realizó una ecografía abdominal y una tomografía computarizada (TC) que mostraban múltiples lesiones hepáticas y una gran lesión en páncreas. Mediante resonancia magnética, se confirmó que las lesiones hepáticas eran metástasis y se detectó la presencia de una gran masa en páncreas (> 9 cm) e hipertensión portal. Se realizó una punción, guiada por scanner, de la masa de páncreas con diagnóstico patológico de malignidad y sugestivo de adenocarcinoma, aunque las células aisladas fueron insuficientes para realizar estudios de inmunohistoquímica. Diagnóstico Aunque inicialmente se realizó el diagnóstico de probable adenocarcinoma de páncreas, posteriormente, como veremos tras rebiopsiar el tumor, se confirmó que se trataba de un tumor neuroendocrino de páncreas (TNEp). Tratamiento Con la confirmación histológica de un cáncer de páncreas se decidió, tras consultarlo con el paciente y firmar este consentimiento informado por escrito, iniciar 1ª línea con gemcitabina 1.000 mg/m2/semanal x 3 cada 4 semanas en enero de 2007. A los tres meses, la TC confirmó una progresión del cáncer primario por lo que se inicia, en abril de 2007, 2ª línea con capecitabina 1.000 mg/m2/12 h x 14 días y erlotinib 150 mg/día vía oral. De nuevo, a los 3 meses, en julio de 2007, la nueva TC confirma progresión del tumor primario, por lo que se inicia una tercera línea de quimioterapia con capecitabina 1.000 mg/m2/12 h x 14 días + oxaliplatino 130 mg/m2 cada 3 semanas. El paciente completó 26 ciclos en octubre de 2009 sin progresión clínica ni radiológica, manteniendo un buen estado general sin toxicidad (no presentó neuropatía) y con respuesta clínica, ganancia ponderal y desaparición del dolor y respuesta bioquímica, normalización del calcio y de las pruebas hepáticas. Evolución En diciembre de 2009, debido a la estabilización mantenida más de dos años, poco probable en tercera línea de un cáncer de páncreas, se solicita al servicio de digestivo realizar biopsia pancreática para descartar otra histología. El acceso para la biopsia fue dificultoso por la gran masa en páncreas, la hipertensión portal y el riesgo de sangrado, por lo que finalmente se llevó a cabo una laparoscopia exploradora. Se obtuvo muestra de tejido pancreático con confirmación histológica de un TNEp bien diferenciado con Ki 67 del 1 %, Octreoscan® con gran avidez por el radiotrazador (puntuación Krenning 3), elevación de cromogranina sérica y con índoles en orina normales. En mayo de 2010, a los siete meses de haber detenido la quimioterapia la TC, confirmó enfermedad estable por lo que se pautó tratamiento con análogo de somatostatina, lanreótido autogel 120 mg cada 4 semanas subcutáneo. Tras dos años y medio de tratamiento, en noviembre de 2012, se constata una progresión radiológica a nivel hepático y pancreático. El paciente mantenía buen estado general, ECOG 0 por lo que se decide incluirle en el estudio SAL-SUN-2011-01 del Grupo Español de Tumores Neuroendocrinos (GETNE) con sunitinib que recibió a dosis estándar, 37,5 mg/día vía oral entre diciembre de 2012 y septiembre de 2014, 10 meses, suspendiéndose por progresión. Como toxicidad presentó una neutropenia y trombopenia grado I, decoloración cutánea y del vello e HTA grado I2, 3. En noviembre de 2014, recibió everolimus 10 mg/día vía oral teniendo como toxicidad hiperglucemia, anemia, neutropenia y astenia grado 12. El tratamiento se detuvo en agosto de 2016, a los nueve meses, al constatarse una nueva progresión radiológica y clínica. En ese momento el paciente presenta un ECOG-1, adelgazamiento de unos 6 kg en menos de tres meses, alteración de pruebas hepáticas y reaparición de la hipercalcemia presente al diagnóstico. Ante sospecha de aumento de la agresividad tumoral, se decide rescatar la tercera línea de quimioterapia que se suspendió sin progresión mediante capecitabina y oxaliplatino. El tratamiento se pauta con una reducción de dosis del 20 % comenzando en septiembre de 2016, teniendo que ingresar a los pocos días por deterioro general, encamamiento, empeoramiento de la función renal, hematemesis e hipercalcemia severa. Tras estabilizar al paciente, se decide seguimiento por la Unidad de Cuidados Paliativos a Domicilio falleciendo en noviembre de 2016 a los 10 años del diagnóstico. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se trata de un hombre de 33 años, casado, con dos hijos, ingeniero de profesión. Tenía antecedentes familiares de un tío materno con un cáncer de páncreas y una tía materna con cáncer de ovario. Como antecedentes personales, sobrepeso hasta un año antes de la primera visita en Oncología, fumador esporádico, bebedor social, estaba a tratamiento con eprosartán 600 mg/día por hipertensión arterial y había sido intervenido de pie varo plano. En enero de 2006, comenzó con una dieta hipocalórica, con una pérdida ponderal de hasta 18 kg incluso habiendo abandonado la dieta. Con los meses se asoció dolor en cinturón con escala visual analógica (EVA) 5/10, diarrea e intolerancia alimenticia sin esteatorrea. En octubre 2006, consultó en relación con la pérdida ponderal y en una analítica se constató anemia, alteración de pruebas hepáticas e hipercalcemia por lo que fue derivado al servicio de Medicina Interna. Exploración física Durante la exploración, el paciente tenía un buen estado general, ECOG-1 con palidez cutánea, no se palpaban adenopatías y el abdomen estaba doloroso al tacto. En el epigastrio se palpaba una dudosa masa. Pruebas complementarias Se ampliaron estudios; entre ellos, se realizó una ecografía abdominal y una tomografía computarizada (TC) que mostraban múltiples lesiones hepáticas y una gran lesión en páncreas. Mediante resonancia magnética, se confirmó que las lesiones hepáticas eran metástasis y se detectó la presencia de una gran masa en páncreas (> 9 cm) e hipertensión portal. Se realizó una punción, guiada por scanner, de la masa de páncreas con diagnóstico patológico de malignidad y sugestivo de adenocarcinoma, aunque las células aisladas fueron insuficientes para realizar estudios de inmunohistoquímica. Diagnóstico Aunque inicialmente se realizó el diagnóstico de probable adenocarcinoma de páncreas, posteriormente, como veremos tras rebiopsiar el tumor, se confirmó que se trataba de un tumor neuroendocrino de páncreas (TNEp). Tratamiento Con la confirmación histológica de un cáncer de páncreas se decidió, tras consultarlo con el paciente y firmar este consentimiento informado por escrito, iniciar 1ª línea con gemcitabina 1.000 mg/m2/semanal x 3 cada 4 semanas en enero de 2007. A los tres meses, la TC confirmó una progresión del cáncer primario por lo que se inicia, en abril de 2007, 2ª línea con capecitabina 1.000 mg/m2/12 h x 14 días y erlotinib 150 mg/día vía oral. De nuevo, a los 3 meses, en julio de 2007, la nueva TC confirma progresión del tumor primario, por lo que se inicia una tercera línea de quimioterapia con capecitabina 1.000 mg/m2/12 h x 14 días + oxaliplatino 130 mg/m2 cada 3 semanas. El paciente completó 26 ciclos en octubre de 2009 sin progresión clínica ni radiológica, manteniendo un buen estado general sin toxicidad (no presentó neuropatía) y con respuesta clínica, ganancia ponderal y desaparición del dolor y respuesta bioquímica, normalización del calcio y de las pruebas hepáticas. Evolución En diciembre de 2009, debido a la estabilización mantenida más de dos años, poco probable en tercera línea de un cáncer de páncreas, se solicita al servicio de digestivo realizar biopsia pancreática para descartar otra histología. El acceso para la biopsia fue dificultoso por la gran masa en páncreas, la hipertensión portal y el riesgo de sangrado, por lo que finalmente se llevó a cabo una laparoscopia exploradora. Se obtuvo muestra de tejido pancreático con confirmación histológica de un TNEp bien diferenciado con Ki 67 del 1 %, Octreoscan® con gran avidez por el radiotrazador (puntuación Krenning 3), elevación de cromogranina sérica y con índoles en orina normales. En mayo de 2010, a los siete meses de haber detenido la quimioterapia la TC, confirmó enfermedad estable por lo que se pautó tratamiento con análogo de somatostatina, lanreótido autogel 120 mg cada 4 semanas subcutáneo. Tras dos años y medio de tratamiento, en noviembre de 2012, se constata una progresión radiológica a nivel hepático y pancreático. El paciente mantenía buen estado general, ECOG 0 por lo que se decide incluirle en el estudio SAL-SUN-2011-01 del Grupo Español de Tumores Neuroendocrinos (GETNE) con sunitinib que recibió a dosis estándar, 37,5 mg/día vía oral entre diciembre de 2012 y septiembre de 2014, 10 meses, suspendiéndose por progresión. Como toxicidad presentó una neutropenia y trombopenia grado I, decoloración cutánea y del vello e HTA grado I2, 3. En noviembre de 2014, recibió everolimus 10 mg/día vía oral teniendo como toxicidad hiperglucemia, anemia, neutropenia y astenia grado 12. El tratamiento se detuvo en agosto de 2016, a los nueve meses, al constatarse una nueva progresión radiológica y clínica. En ese momento el paciente presenta un ECOG-1, adelgazamiento de unos 6 kg en menos de tres meses, alteración de pruebas hepáticas y reaparición de la hipercalcemia presente al diagnóstico. Ante sospecha de aumento de la agresividad tumoral, se decide rescatar la tercera línea de quimioterapia que se suspendió sin progresión mediante capecitabina y oxaliplatino. El tratamiento se pauta con una reducción de dosis del 20 % comenzando en septiembre de 2016, teniendo que ingresar a los pocos días por deterioro general, encamamiento, empeoramiento de la función renal, hematemesis e hipercalcemia severa. Tras estabilizar al paciente, se decide seguimiento por la Unidad de Cuidados Paliativos a Domicilio falleciendo en noviembre de 2016 a los 10 años del diagnóstico.
[ "Anamnesis", "\n", "Se", "trata", "de", "un", "hombre", "de", "33", "años", ",", "casado", ",", "con", "dos", "hijos", ",", "ingeniero", "de", "profesión", ".", "Tenía", "antecedentes", "familiares", "de", "un", "tío", "materno", "con", "un", "cáncer", "de", "páncreas", "y", "una", "tía", "materna", "con", "cáncer", "de", "ovario", ".", "Como", "antecedentes", "personales", ",", "sobrepeso", "hasta", "un", "año", "antes", "de", "la", "primera", "visita", "en", "Oncología", ",", "fumador", "esporádico", ",", "bebedor", "social", ",", "estaba", "a", "tratamiento", "con", "eprosartán", "600", "mg", "/", "día", "por", "hipertensión", "arterial", "y", "había", "sido", "intervenido", "de", "pie", "varo", "plano", ".", "\n", "En", "enero", "de", "2006", ",", "comenzó", "con", "una", "dieta", "hipocalórica", ",", "con", "una", "pérdida", "ponderal", "de", "hasta", "18", "kg", "incluso", "habiendo", "abandonado", "la", "dieta", ".", "Con", "los", "meses", "se", "asoció", "dolor", "en", "cinturón", "con", "escala", "visual", "analógica", "(", "EVA", ")", "5/10", ",", "diarrea", "e", "intolerancia", "alimenticia", "sin", "esteatorrea", ".", "En", "octubre", "2006", ",", "consultó", "en", "relación", "con", "la", "pérdida", "ponderal", "y", "en", "una", "analítica", "se", "constató", "anemia", ",", "alteración", "de", "pruebas", "hepáticas", "e", "hipercalcemia", "por", "lo", "que", "fue", "derivado", "al", "servicio", "de", "Medicina", "Interna", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", ",", "el", "paciente", "tenía", "un", "buen", "estado", "general", ",", "ECOG-1", "con", "palidez", "cutánea", ",", "no", "se", "palpaban", "adenopatías", "y", "el", "abdomen", "estaba", "doloroso", "al", "tacto", ".", "En", "el", "epigastrio", "se", "palpaba", "una", "dudosa", "masa", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "ampliaron", "estudios", ";", "entre", "ellos", ",", "se", "realizó", "una", "ecografía", "abdominal", "y", "una", "tomografía", "computarizada", "(", "TC", ")", "que", "mostraban", "múltiples", "lesiones", "hepáticas", "y", "una", "gran", "lesión", "en", "páncreas", ".", "Mediante", "resonancia", "magnética", ",", "se", "confirmó", "que", "las", "lesiones", "hepáticas", "eran", "metástasis", "y", "se", "detectó", "la", "presencia", "de", "una", "gran", "masa", "en", "páncreas", "(", ">", "9", "cm", ")", "e", "hipertensión", "portal", ".", "Se", "realizó", "una", "punción", ",", "guiada", "por", "scanner", ",", "de", "la", "masa", "de", "páncreas", "con", "diagnóstico", "patológico", "de", "malignidad", "y", "sugestivo", "de", "adenocarcinoma", ",", "aunque", "las", "células", "aisladas", "fueron", "insuficientes", "para", "realizar", "estudios", "de", "inmunohistoquímica", ".", "\n\n", "Diagnóstico", "\n", "Aunque", "inicialmente", "se", "realizó", "el", "diagnóstico", "de", "probable", "adenocarcinoma", "de", "páncreas", ",", "posteriormente", ",", "como", "veremos", "tras", "rebiopsiar", "el", "tumor", ",", "se", "confirmó", "que", "se", "trataba", "de", "un", "tumor", "neuroendocrino", "de", "páncreas", "(", "TNEp", ")", ".", "\n\n", "Tratamiento", "\n", "Con", "la", "confirmación", "histológica", "de", "un", "cáncer", "de", "páncreas", "se", "decidió", ",", "tras", "consultarlo", "con", "el", "paciente", "y", "firmar", "este", "consentimiento", "informado", "por", "escrito", ",", "iniciar", "1ª", "línea", "con", "gemcitabina", "1.000", "mg", "/", "m2", "/", "semanal", "x", "3", "cada", "4", "semanas", "en", "enero", "de", "2007", ".", "A", "los", "tres", "meses", ",", "la", "TC", "confirmó", "una", "progresión", "del", "cáncer", "primario", "por", "lo", "que", "se", "inicia", ",", "en", "abril", "de", "2007", ",", "2ª", "línea", "con", "capecitabina", "1.000", "mg", "/", "m2/12", "h", "x", "14", "días", "y", "erlotinib", "150", "mg", "/", "día", "vía", "oral", ".", "\n", "De", "nuevo", ",", "a", "los", "3", "meses", ",", "en", "julio", "de", "2007", ",", "la", "nueva", "TC", "confirma", "progresión", "del", "tumor", "primario", ",", "por", "lo", "que", "se", "inicia", "una", "tercera", "línea", "de", "quimioterapia", "con", "capecitabina", "1.000", "mg", "/", "m2/12", "h", "x", "14", "días", "+", "oxaliplatino", "130", "mg", "/", "m2", "cada", "3", "semanas", ".", "El", "paciente", "completó", "26", "ciclos", "en", "octubre", "de", "2009", "sin", "progresión", "clínica", "ni", "radiológica", ",", "manteniendo", "un", "buen", "estado", "general", "sin", "toxicidad", "(", "no", "presentó", "neuropatía", ")", "y", "con", "respuesta", "clínica", ",", "ganancia", "ponderal", "y", "desaparición", "del", "dolor", "y", "respuesta", "bioquímica", ",", "normalización", "del", "calcio", "y", "de", "las", "pruebas", "hepáticas", ".", "\n\n", "Evolución", "\n", "En", "diciembre", "de", "2009", ",", "debido", "a", "la", "estabilización", "mantenida", "más", "de", "dos", "años", ",", "poco", "probable", "en", "tercera", "línea", "de", "un", "cáncer", "de", "páncreas", ",", "se", "solicita", "al", "servicio", "de", "digestivo", "realizar", "biopsia", "pancreática", "para", "descartar", "otra", "histología", ".", "El", "acceso", "para", "la", "biopsia", "fue", "dificultoso", "por", "la", "gran", "masa", "en", "páncreas", ",", "la", "hipertensión", "portal", "y", "el", "riesgo", "de", "sangrado", ",", "por", "lo", "que", "finalmente", "se", "llevó", "a", "cabo", "una", "laparoscopia", "exploradora", ".", "Se", "obtuvo", "muestra", "de", "tejido", "pancreático", "con", "confirmación", "histológica", "de", "un", "TNEp", "bien", "diferenciado", "con", "Ki", "67", "del", "1", "%", ",", "Octreoscan", "®", "con", "gran", "avidez", "por", "el", "radiotrazador", "(", "puntuación", "Krenning", "3", ")", ",", "elevación", "de", "cromogranina", "sérica", "y", "con", "índoles", "en", "orina", "normales", ".", "\n", "En", "mayo", "de", "2010", ",", "a", "los", "siete", "meses", "de", "haber", "detenido", "la", "quimioterapia", "la", "TC", ",", "confirmó", "enfermedad", "estable", "por", "lo", "que", "se", "pautó", "tratamiento", "con", "análogo", "de", "somatostatina", ",", "lanreótido", "autogel", "120", "mg", "cada", "4", "semanas", "subcutáneo", ".", "\n", "Tras", "dos", "años", "y", "medio", "de", "tratamiento", ",", "en", "noviembre", "de", "2012", ",", "se", "constata", "una", "progresión", "radiológica", "a", "nivel", "hepático", "y", "pancreático", ".", "El", "paciente", "mantenía", "buen", "estado", "general", ",", "ECOG", "0", "por", "lo", "que", "se", "decide", "incluirle", "en", "el", "estudio", "SAL", "-", "SUN-2011", "-", "01", "del", "Grupo", "Español", "de", "Tumores", "Neuroendocrinos", "(", "GETNE", ")", "con", "sunitinib", "que", "recibió", "a", "dosis", "estándar", ",", "37,5", "mg", "/", "día", "vía", "oral", "entre", "diciembre", "de", "2012", "y", "septiembre", "de", "2014", ",", "10", "meses", ",", "suspendiéndose", "por", "progresión", ".", "Como", "toxicidad", "presentó", "una", "neutropenia", "y", "trombopenia", "grado", "I", ",", "decoloración", "cutánea", "y", "del", "vello", "e", "HTA", "grado", "I2", ",", "3", ".", "\n", "En", "noviembre", "de", "2014", ",", "recibió", "everolimus", "10", "mg", "/", "día", "vía", "oral", "teniendo", "como", "toxicidad", "hiperglucemia", ",", "anemia", ",", "neutropenia", "y", "astenia", "grado", "12", ".", "El", "tratamiento", "se", "detuvo", "en", "agosto", "de", "2016", ",", "a", "los", "nueve", "meses", ",", "al", "constatarse", "una", "nueva", "progresión", "radiológica", "y", "clínica", ".", "En", "ese", "momento", "el", "paciente", "presenta", "un", "ECOG-1", ",", "adelgazamiento", "de", "unos", "6", "kg", "en", "menos", "de", "tres", "meses", ",", "alteración", "de", "pruebas", "hepáticas", "y", "reaparición", "de", "la", "hipercalcemia", "presente", "al", "diagnóstico", ".", "Ante", "sospecha", "de", "aumento", "de", "la", "agresividad", "tumoral", ",", "se", "decide", "rescatar", "la", "tercera", "línea", "de", "quimioterapia", "que", "se", "suspendió", "sin", "progresión", "mediante", "capecitabina", "y", "oxaliplatino", ".", "El", "tratamiento", "se", "pauta", "con", "una", "reducción", "de", "dosis", "del", "20", "%", "comenzando", "en", "septiembre", "de", "2016", ",", "teniendo", "que", "ingresar", "a", "los", "pocos", "días", "por", "deterioro", "general", ",", "encamamiento", ",", "empeoramiento", "de", "la", "función", "renal", ",", "hematemesis", "e", "hipercalcemia", "severa", ".", "Tras", "estabilizar", "al", "paciente", ",", "se", "decide", "seguimiento", "por", "la", "Unidad", "de", "Cuidados", "Paliativos", "a", "Domicilio", "falleciendo", "en", "noviembre", "de", "2016", "a", "los", "10", "años", "del", "diagnóstico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
glucose is a CHEMICAL, endozepines is a GENE-N
23160530_task0
Sentence: Gliotransmission and brain glucose sensing: critical role of endozepines. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]
Gliotransmission and brain glucose sensing: critical role of endozepines.
[ "Gliotransmission", "and", "brain", "glucose", "sensing", ":", "critical", "role", "of", "endozepines", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
glucose is a CHEMICAL, endozepines is a GENE-N
23160530_task1
Sentence: Gliotransmission and brain glucose sensing: critical role of endozepines. Instructions: please typing these entity words according to sentence: glucose, endozepines Options: GENE-N, CHEMICAL
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]
Gliotransmission and brain glucose sensing: critical role of endozepines.
[ "Gliotransmission", "and", "brain", "glucose", "sensing", ":", "critical", "role", "of", "endozepines", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
glucose, endozepines
23160530_task2
Sentence: Gliotransmission and brain glucose sensing: critical role of endozepines. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]
Gliotransmission and brain glucose sensing: critical role of endozepines.
[ "Gliotransmission", "and", "brain", "glucose", "sensing", ":", "critical", "role", "of", "endozepines", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
villin is a Chemicals & Drugs
7230_task0
Sentence: A novel role for villin in intestinal epithelial cell survival and homeostasis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Chemicals & Drugs
[ "O", "O", "O", "O", "B-Chemicals & Drugs", "O", "O", "O", "O", "O", "O", "O", "O" ]
A novel role for villin in intestinal epithelial cell survival and homeostasis.
[ "A", "novel", "role", "for", "villin", "in", "intestinal", "epithelial", "cell", "survival", "and", "homeostasis", "." ]
[ "Diseases & Disorders", "Chemicals & Drugs", "" ]
villin is a Chemicals & Drugs
7230_task1
Sentence: A novel role for villin in intestinal epithelial cell survival and homeostasis. Instructions: please typing these entity words according to sentence: villin Options: Chemicals & Drugs
[ "O", "O", "O", "O", "B-Chemicals & Drugs", "O", "O", "O", "O", "O", "O", "O", "O" ]
A novel role for villin in intestinal epithelial cell survival and homeostasis.
[ "A", "novel", "role", "for", "villin", "in", "intestinal", "epithelial", "cell", "survival", "and", "homeostasis", "." ]
[ "Diseases & Disorders", "Chemicals & Drugs", "" ]
villin
7230_task2
Sentence: A novel role for villin in intestinal epithelial cell survival and homeostasis. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Chemicals & Drugs", "O", "O", "O", "O", "O", "O", "O", "O" ]
A novel role for villin in intestinal epithelial cell survival and homeostasis.
[ "A", "novel", "role", "for", "villin", "in", "intestinal", "epithelial", "cell", "survival", "and", "homeostasis", "." ]
[ "Diseases & Disorders", "Chemicals & Drugs", "" ]
insulin is a GENE-Y
23471710_task0
Sentence: Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]
Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.
[ "Severe", "hypoglycemia", "from", "helicobacter", "pylori", "triple", "-", "drug", "therapy", "and", "insulin", "detemir", "drug", "interaction", "." ]
[ "CHEMICAL", "GENE-Y" ]
insulin is a GENE-Y
23471710_task1
Sentence: Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction. Instructions: please typing these entity words according to sentence: insulin Options: GENE-Y
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]
Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.
[ "Severe", "hypoglycemia", "from", "helicobacter", "pylori", "triple", "-", "drug", "therapy", "and", "insulin", "detemir", "drug", "interaction", "." ]
[ "CHEMICAL", "GENE-Y" ]
insulin
23471710_task2
Sentence: Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]
Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.
[ "Severe", "hypoglycemia", "from", "helicobacter", "pylori", "triple", "-", "drug", "therapy", "and", "insulin", "detemir", "drug", "interaction", "." ]
[ "CHEMICAL", "GENE-Y" ]
Cognitive is a Intervention_Educational, and is a Outcome_Other, physical rehabilitation is a Intervention_Educational, intensive care unit survivors is a Participant_Condition, survive medical and surgical general intensive care unit care is a Participant_Condition, functional outcomes is a Outcome_Mental, 21 general is a Participant_Sample-size, 8 is a Participant_Sample-size, usual care ( sporadic rehabilitation ) is a Intervention_Educational, in - home cognitive , physical , and functional rehabilitation is a Intervention_Educational, cognitive rehabilitation is a Intervention_Educational, physical / functional rehabilitation is a Intervention_Educational, cognitive functioning is a Outcome_Mental, tolerated is a Outcome_Other, improved is a Outcome_Other, cognitive executive functioning is a Outcome_Mental, planning and strategic thinking is a Outcome_Mental, performance is a Outcome_Mental, Functional Activities Questionnaire is a Outcome_Mental, feasible and possibly effective in improving is a Outcome_Other, cognitive performance is a Outcome_Mental
52755_task0
Sentence: Cognitive and physical rehabilitation of intensive care unit survivors : results of the RETURN randomized controlled pilot investigation . BACKGROUND Millions of patients who survive medical and surgical general intensive care unit care every year experience newly acquired long-term cognitive impairment and profound physical and functional disabilities . To overcome the current reality in which patients receive inadequate rehabilitation , we devised a multifaceted , in-home , telerehabilitation program implemented using social workers and psychology technicians with the goal of improving cognitive and functional outcomes . METHODS This was a single-site , feasibility , pilot , randomized trial of 21 general medical/surgical intensive care unit survivors ( 8 controls and 13 intervention patients ) with either cognitive or functional impairment at hospital discharge . After discharge , study controls received usual care ( sporadic rehabilitation ) , whereas intervention patients received a combination of in-home cognitive , physical , and functional rehabilitation over a 3-month period via a social worker or master 's level psychology technician utilizing telemedicine to allow specialized multidisciplinary treatment . Interventions over 12 wks included six in-person visits for cognitive rehabilitation and six televisits for physical/functional rehabilitation . Outcomes were measured at the completion of the rehabilitation program ( i.e. , at 3 months ) , with cognitive functioning as the primary outcome . Analyses were conducted using linear regression to examine differences in 3-month outcomes between treatment groups while adjusting for baseline scores . RESULTS Patients tolerated the program with only one adverse event reported . At baseline both groups were well-matched . At 3-month follow-up , intervention group patients demonstrated significantly improved cognitive executive functioning on the widely used and well-normed Tower test ( for planning and strategic thinking ) vs. controls ( median [ interquartile range ] , 13.0 [ 11.5-14.0 ] vs. 7.5 [ 4.0-8.5 ] ; adjusted p < .01 ) . Intervention group patients also reported better performance ( i.e. , lower score ) on one of the most frequently used measures of functional status ( Functional Activities Questionnaire at 3 months vs. controls , 1.0 [ 0.0 -3.0 ] vs. 8.0 [ 6.0-11.8 ] , adjusted p = .04 ) . CONCLUSIONS A multicomponent rehabilitation program for intensive care unit survivors combining cognitive , physical , and functional training appears feasible and possibly effective in improving cognitive performance and functional outcomes in just 3 months . Future investigations with a larger sample size should be conducted to build on this pilot feasibility program and to confirm these results , as well as to elucidate the elements of rehabilitation contributing most to improved outcomes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Participant_Sample-size, Outcome_Other, Outcome_Mental
[ "B-Intervention_Educational", "B-Outcome_Other", "B-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cognitive and physical rehabilitation of intensive care unit survivors : results of the RETURN randomized controlled pilot investigation . BACKGROUND Millions of patients who survive medical and surgical general intensive care unit care every year experience newly acquired long-term cognitive impairment and profound physical and functional disabilities . To overcome the current reality in which patients receive inadequate rehabilitation , we devised a multifaceted , in-home , telerehabilitation program implemented using social workers and psychology technicians with the goal of improving cognitive and functional outcomes . METHODS This was a single-site , feasibility , pilot , randomized trial of 21 general medical/surgical intensive care unit survivors ( 8 controls and 13 intervention patients ) with either cognitive or functional impairment at hospital discharge . After discharge , study controls received usual care ( sporadic rehabilitation ) , whereas intervention patients received a combination of in-home cognitive , physical , and functional rehabilitation over a 3-month period via a social worker or master 's level psychology technician utilizing telemedicine to allow specialized multidisciplinary treatment . Interventions over 12 wks included six in-person visits for cognitive rehabilitation and six televisits for physical/functional rehabilitation . Outcomes were measured at the completion of the rehabilitation program ( i.e. , at 3 months ) , with cognitive functioning as the primary outcome . Analyses were conducted using linear regression to examine differences in 3-month outcomes between treatment groups while adjusting for baseline scores . RESULTS Patients tolerated the program with only one adverse event reported . At baseline both groups were well-matched . At 3-month follow-up , intervention group patients demonstrated significantly improved cognitive executive functioning on the widely used and well-normed Tower test ( for planning and strategic thinking ) vs. controls ( median [ interquartile range ] , 13.0 [ 11.5-14.0 ] vs. 7.5 [ 4.0-8.5 ] ; adjusted p < .01 ) . Intervention group patients also reported better performance ( i.e. , lower score ) on one of the most frequently used measures of functional status ( Functional Activities Questionnaire at 3 months vs. controls , 1.0 [ 0.0 -3.0 ] vs. 8.0 [ 6.0-11.8 ] , adjusted p = .04 ) . CONCLUSIONS A multicomponent rehabilitation program for intensive care unit survivors combining cognitive , physical , and functional training appears feasible and possibly effective in improving cognitive performance and functional outcomes in just 3 months . Future investigations with a larger sample size should be conducted to build on this pilot feasibility program and to confirm these results , as well as to elucidate the elements of rehabilitation contributing most to improved outcomes .
[ "Cognitive", "and", "physical", "rehabilitation", "of", "intensive", "care", "unit", "survivors", ":", "results", "of", "the", "RETURN", "randomized", "controlled", "pilot", "investigation", ".", "BACKGROUND", "Millions", "of", "patients", "who", "survive", "medical", "and", "surgical", "general", "intensive", "care", "unit", "care", "every", "year", "experience", "newly", "acquired", "long", "-", "term", "cognitive", "impairment", "and", "profound", "physical", "and", "functional", "disabilities", ".", "To", "overcome", "the", "current", "reality", "in", "which", "patients", "receive", "inadequate", "rehabilitation", ",", "we", "devised", "a", "multifaceted", ",", "in", "-", "home", ",", "telerehabilitation", "program", "implemented", "using", "social", "workers", "and", "psychology", "technicians", "with", "the", "goal", "of", "improving", "cognitive", "and", "functional", "outcomes", ".", "METHODS", "This", "was", "a", "single", "-", "site", ",", "feasibility", ",", "pilot", ",", "randomized", "trial", "of", "21", "general", "medical", "/", "surgical", "intensive", "care", "unit", "survivors", "(", "8", "controls", "and", "13", "intervention", "patients", ")", "with", "either", "cognitive", "or", "functional", "impairment", "at", "hospital", "discharge", ".", "After", "discharge", ",", "study", "controls", "received", "usual", "care", "(", "sporadic", "rehabilitation", ")", ",", "whereas", "intervention", "patients", "received", "a", "combination", "of", "in", "-", "home", "cognitive", ",", "physical", ",", "and", "functional", "rehabilitation", "over", "a", "3-month", "period", "via", "a", "social", "worker", "or", "master", "'", "s", "level", "psychology", "technician", "utilizing", "telemedicine", "to", "allow", "specialized", "multidisciplinary", "treatment", ".", "Interventions", "over", "12", "wks", "included", "six", "in", "-", "person", "visits", "for", "cognitive", "rehabilitation", "and", "six", "televisits", "for", "physical", "/", "functional", "rehabilitation", ".", "Outcomes", "were", "measured", "at", "the", "completion", "of", "the", "rehabilitation", "program", "(", "i.e", ".", ",", "at", "3", "months", ")", ",", "with", "cognitive", "functioning", "as", "the", "primary", "outcome", ".", "Analyses", "were", "conducted", "using", "linear", "regression", "to", "examine", "differences", "in", "3-month", "outcomes", "between", "treatment", "groups", "while", "adjusting", "for", "baseline", "scores", ".", "RESULTS", "Patients", "tolerated", "the", "program", "with", "only", "one", "adverse", "event", "reported", ".", "At", "baseline", "both", "groups", "were", "well", "-", "matched", ".", "At", "3-month", "follow", "-", "up", ",", "intervention", "group", "patients", "demonstrated", "significantly", "improved", "cognitive", "executive", "functioning", "on", "the", "widely", "used", "and", "well", "-", "normed", "Tower", "test", "(", "for", "planning", "and", "strategic", "thinking", ")", "vs", ".", "controls", "(", "median", "[", "interquartile", "range", "]", ",", "13.0", "[", "11.5", "-", "14.0", "]", "vs", ".", "7.5", "[", "4.0", "-", "8.5", "]", ";", "adjusted", "p", "<", ".01", ")", ".", "Intervention", "group", "patients", "also", "reported", "better", "performance", "(", "i.e", ".", ",", "lower", "score", ")", "on", "one", "of", "the", "most", "frequently", "used", "measures", "of", "functional", "status", "(", "Functional", "Activities", "Questionnaire", "at", "3", "months", "vs", ".", "controls", ",", "1.0", "[", "0.0", "-3.0", "]", "vs", ".", "8.0", "[", "6.0", "-", "11.8", "]", ",", "adjusted", "p", "=", ".04", ")", ".", "CONCLUSIONS", "A", "multicomponent", "rehabilitation", "program", "for", "intensive", "care", "unit", "survivors", "combining", "cognitive", ",", "physical", ",", "and", "functional", "training", "appears", "feasible", "and", "possibly", "effective", "in", "improving", "cognitive", "performance", "and", "functional", "outcomes", "in", "just", "3", "months", ".", "Future", "investigations", "with", "a", "larger", "sample", "size", "should", "be", "conducted", "to", "build", "on", "this", "pilot", "feasibility", "program", "and", "to", "confirm", "these", "results", ",", "as", "well", "as", "to", "elucidate", "the", "elements", "of", "rehabilitation", "contributing", "most", "to", "improved", "outcomes", "." ]
[ "Participant_Condition", "Intervention_Educational", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]
Cognitive is a Intervention_Educational, and is a Outcome_Other, physical rehabilitation is a Intervention_Educational, intensive care unit survivors is a Participant_Condition, survive medical and surgical general intensive care unit care is a Participant_Condition, functional outcomes is a Outcome_Mental, 21 general is a Participant_Sample-size, 8 is a Participant_Sample-size, usual care ( sporadic rehabilitation ) is a Intervention_Educational, in - home cognitive , physical , and functional rehabilitation is a Intervention_Educational, cognitive rehabilitation is a Intervention_Educational, physical / functional rehabilitation is a Intervention_Educational, cognitive functioning is a Outcome_Mental, tolerated is a Outcome_Other, improved is a Outcome_Other, cognitive executive functioning is a Outcome_Mental, planning and strategic thinking is a Outcome_Mental, performance is a Outcome_Mental, Functional Activities Questionnaire is a Outcome_Mental, feasible and possibly effective in improving is a Outcome_Other, cognitive performance is a Outcome_Mental
52755_task1
Sentence: Cognitive and physical rehabilitation of intensive care unit survivors : results of the RETURN randomized controlled pilot investigation . BACKGROUND Millions of patients who survive medical and surgical general intensive care unit care every year experience newly acquired long-term cognitive impairment and profound physical and functional disabilities . To overcome the current reality in which patients receive inadequate rehabilitation , we devised a multifaceted , in-home , telerehabilitation program implemented using social workers and psychology technicians with the goal of improving cognitive and functional outcomes . METHODS This was a single-site , feasibility , pilot , randomized trial of 21 general medical/surgical intensive care unit survivors ( 8 controls and 13 intervention patients ) with either cognitive or functional impairment at hospital discharge . After discharge , study controls received usual care ( sporadic rehabilitation ) , whereas intervention patients received a combination of in-home cognitive , physical , and functional rehabilitation over a 3-month period via a social worker or master 's level psychology technician utilizing telemedicine to allow specialized multidisciplinary treatment . Interventions over 12 wks included six in-person visits for cognitive rehabilitation and six televisits for physical/functional rehabilitation . Outcomes were measured at the completion of the rehabilitation program ( i.e. , at 3 months ) , with cognitive functioning as the primary outcome . Analyses were conducted using linear regression to examine differences in 3-month outcomes between treatment groups while adjusting for baseline scores . RESULTS Patients tolerated the program with only one adverse event reported . At baseline both groups were well-matched . At 3-month follow-up , intervention group patients demonstrated significantly improved cognitive executive functioning on the widely used and well-normed Tower test ( for planning and strategic thinking ) vs. controls ( median [ interquartile range ] , 13.0 [ 11.5-14.0 ] vs. 7.5 [ 4.0-8.5 ] ; adjusted p < .01 ) . Intervention group patients also reported better performance ( i.e. , lower score ) on one of the most frequently used measures of functional status ( Functional Activities Questionnaire at 3 months vs. controls , 1.0 [ 0.0 -3.0 ] vs. 8.0 [ 6.0-11.8 ] , adjusted p = .04 ) . CONCLUSIONS A multicomponent rehabilitation program for intensive care unit survivors combining cognitive , physical , and functional training appears feasible and possibly effective in improving cognitive performance and functional outcomes in just 3 months . Future investigations with a larger sample size should be conducted to build on this pilot feasibility program and to confirm these results , as well as to elucidate the elements of rehabilitation contributing most to improved outcomes . Instructions: please typing these entity words according to sentence: Cognitive, and, physical rehabilitation, intensive care unit survivors, survive medical and surgical general intensive care unit care, functional outcomes, 21 general, 8, usual care ( sporadic rehabilitation ), in - home cognitive , physical , and functional rehabilitation, cognitive rehabilitation, physical / functional rehabilitation, cognitive functioning, tolerated, improved, cognitive executive functioning, planning and strategic thinking, performance, Functional Activities Questionnaire, feasible and possibly effective in improving, cognitive performance Options: Participant_Condition, Intervention_Educational, Participant_Sample-size, Outcome_Other, Outcome_Mental
[ "B-Intervention_Educational", "B-Outcome_Other", "B-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cognitive and physical rehabilitation of intensive care unit survivors : results of the RETURN randomized controlled pilot investigation . BACKGROUND Millions of patients who survive medical and surgical general intensive care unit care every year experience newly acquired long-term cognitive impairment and profound physical and functional disabilities . To overcome the current reality in which patients receive inadequate rehabilitation , we devised a multifaceted , in-home , telerehabilitation program implemented using social workers and psychology technicians with the goal of improving cognitive and functional outcomes . METHODS This was a single-site , feasibility , pilot , randomized trial of 21 general medical/surgical intensive care unit survivors ( 8 controls and 13 intervention patients ) with either cognitive or functional impairment at hospital discharge . After discharge , study controls received usual care ( sporadic rehabilitation ) , whereas intervention patients received a combination of in-home cognitive , physical , and functional rehabilitation over a 3-month period via a social worker or master 's level psychology technician utilizing telemedicine to allow specialized multidisciplinary treatment . Interventions over 12 wks included six in-person visits for cognitive rehabilitation and six televisits for physical/functional rehabilitation . Outcomes were measured at the completion of the rehabilitation program ( i.e. , at 3 months ) , with cognitive functioning as the primary outcome . Analyses were conducted using linear regression to examine differences in 3-month outcomes between treatment groups while adjusting for baseline scores . RESULTS Patients tolerated the program with only one adverse event reported . At baseline both groups were well-matched . At 3-month follow-up , intervention group patients demonstrated significantly improved cognitive executive functioning on the widely used and well-normed Tower test ( for planning and strategic thinking ) vs. controls ( median [ interquartile range ] , 13.0 [ 11.5-14.0 ] vs. 7.5 [ 4.0-8.5 ] ; adjusted p < .01 ) . Intervention group patients also reported better performance ( i.e. , lower score ) on one of the most frequently used measures of functional status ( Functional Activities Questionnaire at 3 months vs. controls , 1.0 [ 0.0 -3.0 ] vs. 8.0 [ 6.0-11.8 ] , adjusted p = .04 ) . CONCLUSIONS A multicomponent rehabilitation program for intensive care unit survivors combining cognitive , physical , and functional training appears feasible and possibly effective in improving cognitive performance and functional outcomes in just 3 months . Future investigations with a larger sample size should be conducted to build on this pilot feasibility program and to confirm these results , as well as to elucidate the elements of rehabilitation contributing most to improved outcomes .
[ "Cognitive", "and", "physical", "rehabilitation", "of", "intensive", "care", "unit", "survivors", ":", "results", "of", "the", "RETURN", "randomized", "controlled", "pilot", "investigation", ".", "BACKGROUND", "Millions", "of", "patients", "who", "survive", "medical", "and", "surgical", "general", "intensive", "care", "unit", "care", "every", "year", "experience", "newly", "acquired", "long", "-", "term", "cognitive", "impairment", "and", "profound", "physical", "and", "functional", "disabilities", ".", "To", "overcome", "the", "current", "reality", "in", "which", "patients", "receive", "inadequate", "rehabilitation", ",", "we", "devised", "a", "multifaceted", ",", "in", "-", "home", ",", "telerehabilitation", "program", "implemented", "using", "social", "workers", "and", "psychology", "technicians", "with", "the", "goal", "of", "improving", "cognitive", "and", "functional", "outcomes", ".", "METHODS", "This", "was", "a", "single", "-", "site", ",", "feasibility", ",", "pilot", ",", "randomized", "trial", "of", "21", "general", "medical", "/", "surgical", "intensive", "care", "unit", "survivors", "(", "8", "controls", "and", "13", "intervention", "patients", ")", "with", "either", "cognitive", "or", "functional", "impairment", "at", "hospital", "discharge", ".", "After", "discharge", ",", "study", "controls", "received", "usual", "care", "(", "sporadic", "rehabilitation", ")", ",", "whereas", "intervention", "patients", "received", "a", "combination", "of", "in", "-", "home", "cognitive", ",", "physical", ",", "and", "functional", "rehabilitation", "over", "a", "3-month", "period", "via", "a", "social", "worker", "or", "master", "'", "s", "level", "psychology", "technician", "utilizing", "telemedicine", "to", "allow", "specialized", "multidisciplinary", "treatment", ".", "Interventions", "over", "12", "wks", "included", "six", "in", "-", "person", "visits", "for", "cognitive", "rehabilitation", "and", "six", "televisits", "for", "physical", "/", "functional", "rehabilitation", ".", "Outcomes", "were", "measured", "at", "the", "completion", "of", "the", "rehabilitation", "program", "(", "i.e", ".", ",", "at", "3", "months", ")", ",", "with", "cognitive", "functioning", "as", "the", "primary", "outcome", ".", "Analyses", "were", "conducted", "using", "linear", "regression", "to", "examine", "differences", "in", "3-month", "outcomes", "between", "treatment", "groups", "while", "adjusting", "for", "baseline", "scores", ".", "RESULTS", "Patients", "tolerated", "the", "program", "with", "only", "one", "adverse", "event", "reported", ".", "At", "baseline", "both", "groups", "were", "well", "-", "matched", ".", "At", "3-month", "follow", "-", "up", ",", "intervention", "group", "patients", "demonstrated", "significantly", "improved", "cognitive", "executive", "functioning", "on", "the", "widely", "used", "and", "well", "-", "normed", "Tower", "test", "(", "for", "planning", "and", "strategic", "thinking", ")", "vs", ".", "controls", "(", "median", "[", "interquartile", "range", "]", ",", "13.0", "[", "11.5", "-", "14.0", "]", "vs", ".", "7.5", "[", "4.0", "-", "8.5", "]", ";", "adjusted", "p", "<", ".01", ")", ".", "Intervention", "group", "patients", "also", "reported", "better", "performance", "(", "i.e", ".", ",", "lower", "score", ")", "on", "one", "of", "the", "most", "frequently", "used", "measures", "of", "functional", "status", "(", "Functional", "Activities", "Questionnaire", "at", "3", "months", "vs", ".", "controls", ",", "1.0", "[", "0.0", "-3.0", "]", "vs", ".", "8.0", "[", "6.0", "-", "11.8", "]", ",", "adjusted", "p", "=", ".04", ")", ".", "CONCLUSIONS", "A", "multicomponent", "rehabilitation", "program", "for", "intensive", "care", "unit", "survivors", "combining", "cognitive", ",", "physical", ",", "and", "functional", "training", "appears", "feasible", "and", "possibly", "effective", "in", "improving", "cognitive", "performance", "and", "functional", "outcomes", "in", "just", "3", "months", ".", "Future", "investigations", "with", "a", "larger", "sample", "size", "should", "be", "conducted", "to", "build", "on", "this", "pilot", "feasibility", "program", "and", "to", "confirm", "these", "results", ",", "as", "well", "as", "to", "elucidate", "the", "elements", "of", "rehabilitation", "contributing", "most", "to", "improved", "outcomes", "." ]
[ "Participant_Condition", "Intervention_Educational", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]
Cognitive, and, physical rehabilitation, intensive care unit survivors, survive medical and surgical general intensive care unit care, functional outcomes, 21 general, 8, usual care ( sporadic rehabilitation ), in - home cognitive , physical , and functional rehabilitation, cognitive rehabilitation, physical / functional rehabilitation, cognitive functioning, tolerated, improved, cognitive executive functioning, planning and strategic thinking, performance, Functional Activities Questionnaire, feasible and possibly effective in improving, cognitive performance
52755_task2
Sentence: Cognitive and physical rehabilitation of intensive care unit survivors : results of the RETURN randomized controlled pilot investigation . BACKGROUND Millions of patients who survive medical and surgical general intensive care unit care every year experience newly acquired long-term cognitive impairment and profound physical and functional disabilities . To overcome the current reality in which patients receive inadequate rehabilitation , we devised a multifaceted , in-home , telerehabilitation program implemented using social workers and psychology technicians with the goal of improving cognitive and functional outcomes . METHODS This was a single-site , feasibility , pilot , randomized trial of 21 general medical/surgical intensive care unit survivors ( 8 controls and 13 intervention patients ) with either cognitive or functional impairment at hospital discharge . After discharge , study controls received usual care ( sporadic rehabilitation ) , whereas intervention patients received a combination of in-home cognitive , physical , and functional rehabilitation over a 3-month period via a social worker or master 's level psychology technician utilizing telemedicine to allow specialized multidisciplinary treatment . Interventions over 12 wks included six in-person visits for cognitive rehabilitation and six televisits for physical/functional rehabilitation . Outcomes were measured at the completion of the rehabilitation program ( i.e. , at 3 months ) , with cognitive functioning as the primary outcome . Analyses were conducted using linear regression to examine differences in 3-month outcomes between treatment groups while adjusting for baseline scores . RESULTS Patients tolerated the program with only one adverse event reported . At baseline both groups were well-matched . At 3-month follow-up , intervention group patients demonstrated significantly improved cognitive executive functioning on the widely used and well-normed Tower test ( for planning and strategic thinking ) vs. controls ( median [ interquartile range ] , 13.0 [ 11.5-14.0 ] vs. 7.5 [ 4.0-8.5 ] ; adjusted p < .01 ) . Intervention group patients also reported better performance ( i.e. , lower score ) on one of the most frequently used measures of functional status ( Functional Activities Questionnaire at 3 months vs. controls , 1.0 [ 0.0 -3.0 ] vs. 8.0 [ 6.0-11.8 ] , adjusted p = .04 ) . CONCLUSIONS A multicomponent rehabilitation program for intensive care unit survivors combining cognitive , physical , and functional training appears feasible and possibly effective in improving cognitive performance and functional outcomes in just 3 months . Future investigations with a larger sample size should be conducted to build on this pilot feasibility program and to confirm these results , as well as to elucidate the elements of rehabilitation contributing most to improved outcomes . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Educational", "B-Outcome_Other", "B-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cognitive and physical rehabilitation of intensive care unit survivors : results of the RETURN randomized controlled pilot investigation . BACKGROUND Millions of patients who survive medical and surgical general intensive care unit care every year experience newly acquired long-term cognitive impairment and profound physical and functional disabilities . To overcome the current reality in which patients receive inadequate rehabilitation , we devised a multifaceted , in-home , telerehabilitation program implemented using social workers and psychology technicians with the goal of improving cognitive and functional outcomes . METHODS This was a single-site , feasibility , pilot , randomized trial of 21 general medical/surgical intensive care unit survivors ( 8 controls and 13 intervention patients ) with either cognitive or functional impairment at hospital discharge . After discharge , study controls received usual care ( sporadic rehabilitation ) , whereas intervention patients received a combination of in-home cognitive , physical , and functional rehabilitation over a 3-month period via a social worker or master 's level psychology technician utilizing telemedicine to allow specialized multidisciplinary treatment . Interventions over 12 wks included six in-person visits for cognitive rehabilitation and six televisits for physical/functional rehabilitation . Outcomes were measured at the completion of the rehabilitation program ( i.e. , at 3 months ) , with cognitive functioning as the primary outcome . Analyses were conducted using linear regression to examine differences in 3-month outcomes between treatment groups while adjusting for baseline scores . RESULTS Patients tolerated the program with only one adverse event reported . At baseline both groups were well-matched . At 3-month follow-up , intervention group patients demonstrated significantly improved cognitive executive functioning on the widely used and well-normed Tower test ( for planning and strategic thinking ) vs. controls ( median [ interquartile range ] , 13.0 [ 11.5-14.0 ] vs. 7.5 [ 4.0-8.5 ] ; adjusted p < .01 ) . Intervention group patients also reported better performance ( i.e. , lower score ) on one of the most frequently used measures of functional status ( Functional Activities Questionnaire at 3 months vs. controls , 1.0 [ 0.0 -3.0 ] vs. 8.0 [ 6.0-11.8 ] , adjusted p = .04 ) . CONCLUSIONS A multicomponent rehabilitation program for intensive care unit survivors combining cognitive , physical , and functional training appears feasible and possibly effective in improving cognitive performance and functional outcomes in just 3 months . Future investigations with a larger sample size should be conducted to build on this pilot feasibility program and to confirm these results , as well as to elucidate the elements of rehabilitation contributing most to improved outcomes .
[ "Cognitive", "and", "physical", "rehabilitation", "of", "intensive", "care", "unit", "survivors", ":", "results", "of", "the", "RETURN", "randomized", "controlled", "pilot", "investigation", ".", "BACKGROUND", "Millions", "of", "patients", "who", "survive", "medical", "and", "surgical", "general", "intensive", "care", "unit", "care", "every", "year", "experience", "newly", "acquired", "long", "-", "term", "cognitive", "impairment", "and", "profound", "physical", "and", "functional", "disabilities", ".", "To", "overcome", "the", "current", "reality", "in", "which", "patients", "receive", "inadequate", "rehabilitation", ",", "we", "devised", "a", "multifaceted", ",", "in", "-", "home", ",", "telerehabilitation", "program", "implemented", "using", "social", "workers", "and", "psychology", "technicians", "with", "the", "goal", "of", "improving", "cognitive", "and", "functional", "outcomes", ".", "METHODS", "This", "was", "a", "single", "-", "site", ",", "feasibility", ",", "pilot", ",", "randomized", "trial", "of", "21", "general", "medical", "/", "surgical", "intensive", "care", "unit", "survivors", "(", "8", "controls", "and", "13", "intervention", "patients", ")", "with", "either", "cognitive", "or", "functional", "impairment", "at", "hospital", "discharge", ".", "After", "discharge", ",", "study", "controls", "received", "usual", "care", "(", "sporadic", "rehabilitation", ")", ",", "whereas", "intervention", "patients", "received", "a", "combination", "of", "in", "-", "home", "cognitive", ",", "physical", ",", "and", "functional", "rehabilitation", "over", "a", "3-month", "period", "via", "a", "social", "worker", "or", "master", "'", "s", "level", "psychology", "technician", "utilizing", "telemedicine", "to", "allow", "specialized", "multidisciplinary", "treatment", ".", "Interventions", "over", "12", "wks", "included", "six", "in", "-", "person", "visits", "for", "cognitive", "rehabilitation", "and", "six", "televisits", "for", "physical", "/", "functional", "rehabilitation", ".", "Outcomes", "were", "measured", "at", "the", "completion", "of", "the", "rehabilitation", "program", "(", "i.e", ".", ",", "at", "3", "months", ")", ",", "with", "cognitive", "functioning", "as", "the", "primary", "outcome", ".", "Analyses", "were", "conducted", "using", "linear", "regression", "to", "examine", "differences", "in", "3-month", "outcomes", "between", "treatment", "groups", "while", "adjusting", "for", "baseline", "scores", ".", "RESULTS", "Patients", "tolerated", "the", "program", "with", "only", "one", "adverse", "event", "reported", ".", "At", "baseline", "both", "groups", "were", "well", "-", "matched", ".", "At", "3-month", "follow", "-", "up", ",", "intervention", "group", "patients", "demonstrated", "significantly", "improved", "cognitive", "executive", "functioning", "on", "the", "widely", "used", "and", "well", "-", "normed", "Tower", "test", "(", "for", "planning", "and", "strategic", "thinking", ")", "vs", ".", "controls", "(", "median", "[", "interquartile", "range", "]", ",", "13.0", "[", "11.5", "-", "14.0", "]", "vs", ".", "7.5", "[", "4.0", "-", "8.5", "]", ";", "adjusted", "p", "<", ".01", ")", ".", "Intervention", "group", "patients", "also", "reported", "better", "performance", "(", "i.e", ".", ",", "lower", "score", ")", "on", "one", "of", "the", "most", "frequently", "used", "measures", "of", "functional", "status", "(", "Functional", "Activities", "Questionnaire", "at", "3", "months", "vs", ".", "controls", ",", "1.0", "[", "0.0", "-3.0", "]", "vs", ".", "8.0", "[", "6.0", "-", "11.8", "]", ",", "adjusted", "p", "=", ".04", ")", ".", "CONCLUSIONS", "A", "multicomponent", "rehabilitation", "program", "for", "intensive", "care", "unit", "survivors", "combining", "cognitive", ",", "physical", ",", "and", "functional", "training", "appears", "feasible", "and", "possibly", "effective", "in", "improving", "cognitive", "performance", "and", "functional", "outcomes", "in", "just", "3", "months", ".", "Future", "investigations", "with", "a", "larger", "sample", "size", "should", "be", "conducted", "to", "build", "on", "this", "pilot", "feasibility", "program", "and", "to", "confirm", "these", "results", ",", "as", "well", "as", "to", "elucidate", "the", "elements", "of", "rehabilitation", "contributing", "most", "to", "improved", "outcomes", "." ]
[ "Participant_Condition", "Intervention_Educational", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]
risk scoring algorithm is an outcome
1428_task0
Sentence: Using backward elimination , we derived a risk scoring algorithm ( range 0-63 ) from the final reduced model . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome
[ "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Using backward elimination , we derived a risk scoring algorithm ( range 0-63 ) from the final reduced model .
[ "Using", "backward", "elimination", ",", "we", "derived", "a", "risk", "scoring", "algorithm", "(", "range", "0", "-", "63", ")", "from", "the", "final", "reduced", "model", "." ]
[ "outcome" ]
risk scoring algorithm is an outcome
1428_task1
Sentence: Using backward elimination , we derived a risk scoring algorithm ( range 0-63 ) from the final reduced model . Instructions: please typing these entity words according to sentence: risk scoring algorithm Options: outcome
[ "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Using backward elimination , we derived a risk scoring algorithm ( range 0-63 ) from the final reduced model .
[ "Using", "backward", "elimination", ",", "we", "derived", "a", "risk", "scoring", "algorithm", "(", "range", "0", "-", "63", ")", "from", "the", "final", "reduced", "model", "." ]
[ "outcome" ]
risk scoring algorithm
1428_task2
Sentence: Using backward elimination , we derived a risk scoring algorithm ( range 0-63 ) from the final reduced model . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Using backward elimination , we derived a risk scoring algorithm ( range 0-63 ) from the final reduced model .
[ "Using", "backward", "elimination", ",", "we", "derived", "a", "risk", "scoring", "algorithm", "(", "range", "0", "-", "63", ")", "from", "the", "final", "reduced", "model", "." ]
[ "outcome" ]
Behandlung is an umlsterm, Verletzungen is an umlsterm, Halswirbelsaeule is an umlsterm, Schmerzsituation is an umlsterm, Triggerpunktbehandlungen is an umlsterm, Massagen is an umlsterm, Elektrotherapie is an umlsterm, Schmerzzustaende is an umlsterm, Schmerzhemmung is an umlsterm, Trainingstherapie is an umlsterm, Trainingstherapie is an umlsterm
DerOrthopaede.60250519.ger.abstr_task0
Sentence: Die funktionelle Behandlung der Erkrankungen und Verletzungen der Halswirbelsaeule ( HWS ) richtet sich nach dem klinischen Befund und der aktuellen Schmerzsituation . Mittels passiven Behandlungstechniken wie Triggerpunktbehandlungen , Massagen , Elektrotherapie und anderen Applikationen werden akute und subakute Schmerzzustaende behandelt , so dass die Schmerzhemmung der Muskulatur minimal ist . Erst wenn die Nozireaktion auf ein gewisses Mass reduziert werden konnte , koennen Mobilisations- und Dehngymnastik inklusive Mobilisation mit Impuls durchgefuehrt werden und mittels Trainingstherapie die Rumpf-Schulterguertel-Nackenmuskulatur auftrainiert werden . Bei der Trainingstherapie der Nacken-Schulterguertelmuskulatur sind dreidimensionale Trainingsuebungen sehr wesentlich . Diese sollen durch ein Heimuebungsprogramm ergaenzt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die funktionelle Behandlung der Erkrankungen und Verletzungen der Halswirbelsaeule ( HWS ) richtet sich nach dem klinischen Befund und der aktuellen Schmerzsituation . Mittels passiven Behandlungstechniken wie Triggerpunktbehandlungen , Massagen , Elektrotherapie und anderen Applikationen werden akute und subakute Schmerzzustaende behandelt , so dass die Schmerzhemmung der Muskulatur minimal ist . Erst wenn die Nozireaktion auf ein gewisses Mass reduziert werden konnte , koennen Mobilisations- und Dehngymnastik inklusive Mobilisation mit Impuls durchgefuehrt werden und mittels Trainingstherapie die Rumpf-Schulterguertel-Nackenmuskulatur auftrainiert werden . Bei der Trainingstherapie der Nacken-Schulterguertelmuskulatur sind dreidimensionale Trainingsuebungen sehr wesentlich . Diese sollen durch ein Heimuebungsprogramm ergaenzt werden .
[ "Die", "funktionelle", "Behandlung", "der", "Erkrankungen", "und", "Verletzungen", "der", "Halswirbelsaeule", "(", "HWS", ")", "richtet", "sich", "nach", "dem", "klinischen", "Befund", "und", "der", "aktuellen", "Schmerzsituation", ".", "Mittels", "passiven", "Behandlungstechniken", "wie", "Triggerpunktbehandlungen", ",", "Massagen", ",", "Elektrotherapie", "und", "anderen", "Applikationen", "werden", "akute", "und", "subakute", "Schmerzzustaende", "behandelt", ",", "so", "dass", "die", "Schmerzhemmung", "der", "Muskulatur", "minimal", "ist", ".", "Erst", "wenn", "die", "Nozireaktion", "auf", "ein", "gewisses", "Mass", "reduziert", "werden", "konnte", ",", "koennen", "Mobilisations-", "und", "Dehngymnastik", "inklusive", "Mobilisation", "mit", "Impuls", "durchgefuehrt", "werden", "und", "mittels", "Trainingstherapie", "die", "Rumpf", "-", "Schulterguertel", "-", "Nackenmuskulatur", "auftrainiert", "werden", ".", "Bei", "der", "Trainingstherapie", "der", "Nacken", "-", "Schulterguertelmuskulatur", "sind", "dreidimensionale", "Trainingsuebungen", "sehr", "wesentlich", ".", "Diese", "sollen", "durch", "ein", "Heimuebungsprogramm", "ergaenzt", "werden", "." ]
[ "umlsterm" ]
Behandlung is an umlsterm, Verletzungen is an umlsterm, Halswirbelsaeule is an umlsterm, Schmerzsituation is an umlsterm, Triggerpunktbehandlungen is an umlsterm, Massagen is an umlsterm, Elektrotherapie is an umlsterm, Schmerzzustaende is an umlsterm, Schmerzhemmung is an umlsterm, Trainingstherapie is an umlsterm, Trainingstherapie is an umlsterm
DerOrthopaede.60250519.ger.abstr_task1
Sentence: Die funktionelle Behandlung der Erkrankungen und Verletzungen der Halswirbelsaeule ( HWS ) richtet sich nach dem klinischen Befund und der aktuellen Schmerzsituation . Mittels passiven Behandlungstechniken wie Triggerpunktbehandlungen , Massagen , Elektrotherapie und anderen Applikationen werden akute und subakute Schmerzzustaende behandelt , so dass die Schmerzhemmung der Muskulatur minimal ist . Erst wenn die Nozireaktion auf ein gewisses Mass reduziert werden konnte , koennen Mobilisations- und Dehngymnastik inklusive Mobilisation mit Impuls durchgefuehrt werden und mittels Trainingstherapie die Rumpf-Schulterguertel-Nackenmuskulatur auftrainiert werden . Bei der Trainingstherapie der Nacken-Schulterguertelmuskulatur sind dreidimensionale Trainingsuebungen sehr wesentlich . Diese sollen durch ein Heimuebungsprogramm ergaenzt werden . Instructions: please typing these entity words according to sentence: Behandlung, Verletzungen, Halswirbelsaeule, Schmerzsituation, Triggerpunktbehandlungen, Massagen, Elektrotherapie, Schmerzzustaende, Schmerzhemmung, Trainingstherapie, Trainingstherapie Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die funktionelle Behandlung der Erkrankungen und Verletzungen der Halswirbelsaeule ( HWS ) richtet sich nach dem klinischen Befund und der aktuellen Schmerzsituation . Mittels passiven Behandlungstechniken wie Triggerpunktbehandlungen , Massagen , Elektrotherapie und anderen Applikationen werden akute und subakute Schmerzzustaende behandelt , so dass die Schmerzhemmung der Muskulatur minimal ist . Erst wenn die Nozireaktion auf ein gewisses Mass reduziert werden konnte , koennen Mobilisations- und Dehngymnastik inklusive Mobilisation mit Impuls durchgefuehrt werden und mittels Trainingstherapie die Rumpf-Schulterguertel-Nackenmuskulatur auftrainiert werden . Bei der Trainingstherapie der Nacken-Schulterguertelmuskulatur sind dreidimensionale Trainingsuebungen sehr wesentlich . Diese sollen durch ein Heimuebungsprogramm ergaenzt werden .
[ "Die", "funktionelle", "Behandlung", "der", "Erkrankungen", "und", "Verletzungen", "der", "Halswirbelsaeule", "(", "HWS", ")", "richtet", "sich", "nach", "dem", "klinischen", "Befund", "und", "der", "aktuellen", "Schmerzsituation", ".", "Mittels", "passiven", "Behandlungstechniken", "wie", "Triggerpunktbehandlungen", ",", "Massagen", ",", "Elektrotherapie", "und", "anderen", "Applikationen", "werden", "akute", "und", "subakute", "Schmerzzustaende", "behandelt", ",", "so", "dass", "die", "Schmerzhemmung", "der", "Muskulatur", "minimal", "ist", ".", "Erst", "wenn", "die", "Nozireaktion", "auf", "ein", "gewisses", "Mass", "reduziert", "werden", "konnte", ",", "koennen", "Mobilisations-", "und", "Dehngymnastik", "inklusive", "Mobilisation", "mit", "Impuls", "durchgefuehrt", "werden", "und", "mittels", "Trainingstherapie", "die", "Rumpf", "-", "Schulterguertel", "-", "Nackenmuskulatur", "auftrainiert", "werden", ".", "Bei", "der", "Trainingstherapie", "der", "Nacken", "-", "Schulterguertelmuskulatur", "sind", "dreidimensionale", "Trainingsuebungen", "sehr", "wesentlich", ".", "Diese", "sollen", "durch", "ein", "Heimuebungsprogramm", "ergaenzt", "werden", "." ]
[ "umlsterm" ]
Behandlung, Verletzungen, Halswirbelsaeule, Schmerzsituation, Triggerpunktbehandlungen, Massagen, Elektrotherapie, Schmerzzustaende, Schmerzhemmung, Trainingstherapie, Trainingstherapie
DerOrthopaede.60250519.ger.abstr_task2
Sentence: Die funktionelle Behandlung der Erkrankungen und Verletzungen der Halswirbelsaeule ( HWS ) richtet sich nach dem klinischen Befund und der aktuellen Schmerzsituation . Mittels passiven Behandlungstechniken wie Triggerpunktbehandlungen , Massagen , Elektrotherapie und anderen Applikationen werden akute und subakute Schmerzzustaende behandelt , so dass die Schmerzhemmung der Muskulatur minimal ist . Erst wenn die Nozireaktion auf ein gewisses Mass reduziert werden konnte , koennen Mobilisations- und Dehngymnastik inklusive Mobilisation mit Impuls durchgefuehrt werden und mittels Trainingstherapie die Rumpf-Schulterguertel-Nackenmuskulatur auftrainiert werden . Bei der Trainingstherapie der Nacken-Schulterguertelmuskulatur sind dreidimensionale Trainingsuebungen sehr wesentlich . Diese sollen durch ein Heimuebungsprogramm ergaenzt werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die funktionelle Behandlung der Erkrankungen und Verletzungen der Halswirbelsaeule ( HWS ) richtet sich nach dem klinischen Befund und der aktuellen Schmerzsituation . Mittels passiven Behandlungstechniken wie Triggerpunktbehandlungen , Massagen , Elektrotherapie und anderen Applikationen werden akute und subakute Schmerzzustaende behandelt , so dass die Schmerzhemmung der Muskulatur minimal ist . Erst wenn die Nozireaktion auf ein gewisses Mass reduziert werden konnte , koennen Mobilisations- und Dehngymnastik inklusive Mobilisation mit Impuls durchgefuehrt werden und mittels Trainingstherapie die Rumpf-Schulterguertel-Nackenmuskulatur auftrainiert werden . Bei der Trainingstherapie der Nacken-Schulterguertelmuskulatur sind dreidimensionale Trainingsuebungen sehr wesentlich . Diese sollen durch ein Heimuebungsprogramm ergaenzt werden .
[ "Die", "funktionelle", "Behandlung", "der", "Erkrankungen", "und", "Verletzungen", "der", "Halswirbelsaeule", "(", "HWS", ")", "richtet", "sich", "nach", "dem", "klinischen", "Befund", "und", "der", "aktuellen", "Schmerzsituation", ".", "Mittels", "passiven", "Behandlungstechniken", "wie", "Triggerpunktbehandlungen", ",", "Massagen", ",", "Elektrotherapie", "und", "anderen", "Applikationen", "werden", "akute", "und", "subakute", "Schmerzzustaende", "behandelt", ",", "so", "dass", "die", "Schmerzhemmung", "der", "Muskulatur", "minimal", "ist", ".", "Erst", "wenn", "die", "Nozireaktion", "auf", "ein", "gewisses", "Mass", "reduziert", "werden", "konnte", ",", "koennen", "Mobilisations-", "und", "Dehngymnastik", "inklusive", "Mobilisation", "mit", "Impuls", "durchgefuehrt", "werden", "und", "mittels", "Trainingstherapie", "die", "Rumpf", "-", "Schulterguertel", "-", "Nackenmuskulatur", "auftrainiert", "werden", ".", "Bei", "der", "Trainingstherapie", "der", "Nacken", "-", "Schulterguertelmuskulatur", "sind", "dreidimensionale", "Trainingsuebungen", "sehr", "wesentlich", ".", "Diese", "sollen", "durch", "ein", "Heimuebungsprogramm", "ergaenzt", "werden", "." ]
[ "umlsterm" ]
RAD1 is a Gene/protein/RNA, MSH2 is a Gene/protein/RNA
468_task0
Sentence: In this case, efficient repair does not require RAD1 and MSH2, consistent with our previous observations. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O" ]
In this case, efficient repair does not require RAD1 and MSH2, consistent with our previous observations.
[ "In", "this", "case", ",", "efficient", "repair", "does", "not", "require", "RAD1", "and", "MSH2", ",", "consistent", "with", "our", "previous", "observations", "." ]
[ "Gene/protein/RNA" ]
RAD1 is a Gene/protein/RNA, MSH2 is a Gene/protein/RNA
468_task1
Sentence: In this case, efficient repair does not require RAD1 and MSH2, consistent with our previous observations. Instructions: please typing these entity words according to sentence: RAD1, MSH2 Options: Gene/protein/RNA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O" ]
In this case, efficient repair does not require RAD1 and MSH2, consistent with our previous observations.
[ "In", "this", "case", ",", "efficient", "repair", "does", "not", "require", "RAD1", "and", "MSH2", ",", "consistent", "with", "our", "previous", "observations", "." ]
[ "Gene/protein/RNA" ]
RAD1, MSH2
468_task2
Sentence: In this case, efficient repair does not require RAD1 and MSH2, consistent with our previous observations. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O" ]
In this case, efficient repair does not require RAD1 and MSH2, consistent with our previous observations.
[ "In", "this", "case", ",", "efficient", "repair", "does", "not", "require", "RAD1", "and", "MSH2", ",", "consistent", "with", "our", "previous", "observations", "." ]
[ "Gene/protein/RNA" ]
ABC - Methode is an umlsterm, Routinediagnostik is an umlsterm, antigener is an umlsterm, Techniken is an umlsterm, Beschleunigung is an umlsterm, Erweiterung is an umlsterm, Methoden is an umlsterm, Arbeit is an umlsterm, Zeit- is an umlsterm, Kostenanalyse is an umlsterm, Sensitivitaet und Spezifitaet is an umlsterm, Primaerantikoerper is an umlsterm, IgM is an umlsterm, Antikoerper is an umlsterm, Oestrogen- is an umlsterm, Methoden is an umlsterm, Techniken is an umlsterm, Technik is an umlsterm, Zeitaufwand is an umlsterm, zeitaufwendigste is an umlsterm, Technik is an umlsterm, Zeitaufwand is an umlsterm, ABC - Methode is an umlsterm, Methode is an umlsterm, Zeitaufwandes is an umlsterm, zeitaufwendige is an umlsterm, paraffingaengige is an umlsterm, Standardantikoerper is an umlsterm, Methode is an umlsterm, Verwendung is an umlsterm, Primaerantikoerper is an umlsterm, Standardtechniken is an umlsterm, Antigene is an umlsterm, Hormon - Rezeptor - Antikoerper is an umlsterm, Arbeit is an umlsterm, Techniken is an umlsterm
DerPathologe.90200242.ger.abstr_task0
Sentence: Immunhistochemische Faerbetechniken , wie die APAAP- und ABC-Methode stellen heute in der pathologischen Routinediagnostik ein weit verbreitetes und akzeptiertes Verfahren zur Darstellung definierter antigener Strukturen dar . Neuere Techniken , wie die EnVision- und ImmunoMax-Methode ( Biotinyl-Tyramin-Enhancement ) , stellen Weiterentwicklungen dar , die eine technische Erleichterung , eine Beschleunigung bzw. eine Steigerung der Sensitivitaet des immunhistochemischen Verfahrens ermoeglichen . Die zunehmende Bedeutung und Erweiterung diagnostischer Untersuchungstechniken fuehren zu der Frage , welche Methoden stellen fuer welche Fragestellungen und Anwendungen die geeigneten Verfahren dar ? Das Ziel dieser Arbeit war es , fuer diese unterschiedlichen Verfahren eine vergleichende Zeit- und Kostenanalyse anzustellen und dabei wichtige Parameter wie Sensitivitaet und Spezifitaet zu beruecksichtigen . Zu diesem Zweck wurden relevante und haeufig verwendete Primaerantikoerper wie CD20, CD30, IgM sowie die Antikoerper gegen Oestrogen- und Progesteronrezeptor verwendet . Um eine Vergleichbarkeit der Methoden bezueglich Arbeitsaufwand und -kosten zu ermoeglichen , wurden die Techniken zunaechst in ihrer Empfindlichkeit aufeinander abgestimmt . An ausgewaehlten Faerbebeispielen wurden die sich stark unterscheidenden Kosten fuer jede Technik errechnet und der technische Zeitaufwand fuer jedes Verfahren ermittelt . Die weit verbreitete und etablierte APAAP-Methode stellt die zeitaufwendigste Technik und auch gleichzeitig das mit Abstand kostenintensivste Verfahren dar . Den geringsten Zeitaufwand benoetigt man fuer die EnVision-Detektionsmethode . Die ABC-Methode nimmt eine intermediaere Stellung ein ; sie stellt die kostenguenstigste Methode fuer die meisten Anwendungen dar und bedarf eines mittelhohen Zeitaufwandes . Die ImmunoMax-Methode stellt eine relativ zeitaufwendige und fuer viele paraffingaengige Standardantikoerper nicht notwendige Methode dar ; jedoch fuehrt sie zu dramatischen Kostenersparnissen bei der Verwendung teurer Primaerantikoerper . Darueber hinaus erhaelt man dabei eine bemerkenswerte Sensitivitaessteigerung , was fuer jene Anwendungen bedeutsam sein kann , die mit Standardtechniken zu keinen oder zu unzureichenden Ergebnissen fuehren ( z.B. viele niedrig exprimierte Antigene ) . Dieses wurde hier am Beispiel der kostenintensiven und diagnostisch/therapeutisch bedeutsamen Hormon-Rezeptor-Antikoerper aufgezeigt . Die vorliegende Arbeit verdeutlicht , wie wichtig es ist , neben der Vielzahl verschiedener Untersuchungsverfahren , die entstehenden Kosten einerseits und die potentiellen Moeglichkeiten der Techniken andererseits zu kennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Immunhistochemische Faerbetechniken , wie die APAAP- und ABC-Methode stellen heute in der pathologischen Routinediagnostik ein weit verbreitetes und akzeptiertes Verfahren zur Darstellung definierter antigener Strukturen dar . Neuere Techniken , wie die EnVision- und ImmunoMax-Methode ( Biotinyl-Tyramin-Enhancement ) , stellen Weiterentwicklungen dar , die eine technische Erleichterung , eine Beschleunigung bzw. eine Steigerung der Sensitivitaet des immunhistochemischen Verfahrens ermoeglichen . Die zunehmende Bedeutung und Erweiterung diagnostischer Untersuchungstechniken fuehren zu der Frage , welche Methoden stellen fuer welche Fragestellungen und Anwendungen die geeigneten Verfahren dar ? Das Ziel dieser Arbeit war es , fuer diese unterschiedlichen Verfahren eine vergleichende Zeit- und Kostenanalyse anzustellen und dabei wichtige Parameter wie Sensitivitaet und Spezifitaet zu beruecksichtigen . Zu diesem Zweck wurden relevante und haeufig verwendete Primaerantikoerper wie CD20, CD30, IgM sowie die Antikoerper gegen Oestrogen- und Progesteronrezeptor verwendet . Um eine Vergleichbarkeit der Methoden bezueglich Arbeitsaufwand und -kosten zu ermoeglichen , wurden die Techniken zunaechst in ihrer Empfindlichkeit aufeinander abgestimmt . An ausgewaehlten Faerbebeispielen wurden die sich stark unterscheidenden Kosten fuer jede Technik errechnet und der technische Zeitaufwand fuer jedes Verfahren ermittelt . Die weit verbreitete und etablierte APAAP-Methode stellt die zeitaufwendigste Technik und auch gleichzeitig das mit Abstand kostenintensivste Verfahren dar . Den geringsten Zeitaufwand benoetigt man fuer die EnVision-Detektionsmethode . Die ABC-Methode nimmt eine intermediaere Stellung ein ; sie stellt die kostenguenstigste Methode fuer die meisten Anwendungen dar und bedarf eines mittelhohen Zeitaufwandes . Die ImmunoMax-Methode stellt eine relativ zeitaufwendige und fuer viele paraffingaengige Standardantikoerper nicht notwendige Methode dar ; jedoch fuehrt sie zu dramatischen Kostenersparnissen bei der Verwendung teurer Primaerantikoerper . Darueber hinaus erhaelt man dabei eine bemerkenswerte Sensitivitaessteigerung , was fuer jene Anwendungen bedeutsam sein kann , die mit Standardtechniken zu keinen oder zu unzureichenden Ergebnissen fuehren ( z.B. viele niedrig exprimierte Antigene ) . Dieses wurde hier am Beispiel der kostenintensiven und diagnostisch/therapeutisch bedeutsamen Hormon-Rezeptor-Antikoerper aufgezeigt . Die vorliegende Arbeit verdeutlicht , wie wichtig es ist , neben der Vielzahl verschiedener Untersuchungsverfahren , die entstehenden Kosten einerseits und die potentiellen Moeglichkeiten der Techniken andererseits zu kennen .
[ "Immunhistochemische", "Faerbetechniken", ",", "wie", "die", "APAAP-", "und", "ABC", "-", "Methode", "stellen", "heute", "in", "der", "pathologischen", "Routinediagnostik", "ein", "weit", "verbreitetes", "und", "akzeptiertes", "Verfahren", "zur", "Darstellung", "definierter", "antigener", "Strukturen", "dar", ".", "Neuere", "Techniken", ",", "wie", "die", "EnVision-", "und", "ImmunoMax", "-", "Methode", "(", "Biotinyl", "-", "Tyramin", "-", "Enhancement", ")", ",", "stellen", "Weiterentwicklungen", "dar", ",", "die", "eine", "technische", "Erleichterung", ",", "eine", "Beschleunigung", "bzw", ".", "eine", "Steigerung", "der", "Sensitivitaet", "des", "immunhistochemischen", "Verfahrens", "ermoeglichen", ".", "Die", "zunehmende", "Bedeutung", "und", "Erweiterung", "diagnostischer", "Untersuchungstechniken", "fuehren", "zu", "der", "Frage", ",", "welche", "Methoden", "stellen", "fuer", "welche", "Fragestellungen", "und", "Anwendungen", "die", "geeigneten", "Verfahren", "dar", "?", "Das", "Ziel", "dieser", "Arbeit", "war", "es", ",", "fuer", "diese", "unterschiedlichen", "Verfahren", "eine", "vergleichende", "Zeit-", "und", "Kostenanalyse", "anzustellen", "und", "dabei", "wichtige", "Parameter", "wie", "Sensitivitaet", "und", "Spezifitaet", "zu", "beruecksichtigen", ".", "Zu", "diesem", "Zweck", "wurden", "relevante", "und", "haeufig", "verwendete", "Primaerantikoerper", "wie", "CD20", ",", "CD30", ",", "IgM", "sowie", "die", "Antikoerper", "gegen", "Oestrogen-", "und", "Progesteronrezeptor", "verwendet", ".", "Um", "eine", "Vergleichbarkeit", "der", "Methoden", "bezueglich", "Arbeitsaufwand", "und", "-kosten", "zu", "ermoeglichen", ",", "wurden", "die", "Techniken", "zunaechst", "in", "ihrer", "Empfindlichkeit", "aufeinander", "abgestimmt", ".", "An", "ausgewaehlten", "Faerbebeispielen", "wurden", "die", "sich", "stark", "unterscheidenden", "Kosten", "fuer", "jede", "Technik", "errechnet", "und", "der", "technische", "Zeitaufwand", "fuer", "jedes", "Verfahren", "ermittelt", ".", "Die", "weit", "verbreitete", "und", "etablierte", "APAAP", "-", "Methode", "stellt", "die", "zeitaufwendigste", "Technik", "und", "auch", "gleichzeitig", "das", "mit", "Abstand", "kostenintensivste", "Verfahren", "dar", ".", "Den", "geringsten", "Zeitaufwand", "benoetigt", "man", "fuer", "die", "EnVision", "-", "Detektionsmethode", ".", "Die", "ABC", "-", "Methode", "nimmt", "eine", "intermediaere", "Stellung", "ein", ";", "sie", "stellt", "die", "kostenguenstigste", "Methode", "fuer", "die", "meisten", "Anwendungen", "dar", "und", "bedarf", "eines", "mittelhohen", "Zeitaufwandes", ".", "Die", "ImmunoMax", "-", "Methode", "stellt", "eine", "relativ", "zeitaufwendige", "und", "fuer", "viele", "paraffingaengige", "Standardantikoerper", "nicht", "notwendige", "Methode", "dar", ";", "jedoch", "fuehrt", "sie", "zu", "dramatischen", "Kostenersparnissen", "bei", "der", "Verwendung", "teurer", "Primaerantikoerper", ".", "Darueber", "hinaus", "erhaelt", "man", "dabei", "eine", "bemerkenswerte", "Sensitivitaessteigerung", ",", "was", "fuer", "jene", "Anwendungen", "bedeutsam", "sein", "kann", ",", "die", "mit", "Standardtechniken", "zu", "keinen", "oder", "zu", "unzureichenden", "Ergebnissen", "fuehren", "(", "z.", "B.", "viele", "niedrig", "exprimierte", "Antigene", ")", ".", "Dieses", "wurde", "hier", "am", "Beispiel", "der", "kostenintensiven", "und", "diagnostisch", "/", "therapeutisch", "bedeutsamen", "Hormon", "-", "Rezeptor", "-", "Antikoerper", "aufgezeigt", ".", "Die", "vorliegende", "Arbeit", "verdeutlicht", ",", "wie", "wichtig", "es", "ist", ",", "neben", "der", "Vielzahl", "verschiedener", "Untersuchungsverfahren", ",", "die", "entstehenden", "Kosten", "einerseits", "und", "die", "potentiellen", "Moeglichkeiten", "der", "Techniken", "andererseits", "zu", "kennen", "." ]
[ "umlsterm" ]
ABC - Methode is an umlsterm, Routinediagnostik is an umlsterm, antigener is an umlsterm, Techniken is an umlsterm, Beschleunigung is an umlsterm, Erweiterung is an umlsterm, Methoden is an umlsterm, Arbeit is an umlsterm, Zeit- is an umlsterm, Kostenanalyse is an umlsterm, Sensitivitaet und Spezifitaet is an umlsterm, Primaerantikoerper is an umlsterm, IgM is an umlsterm, Antikoerper is an umlsterm, Oestrogen- is an umlsterm, Methoden is an umlsterm, Techniken is an umlsterm, Technik is an umlsterm, Zeitaufwand is an umlsterm, zeitaufwendigste is an umlsterm, Technik is an umlsterm, Zeitaufwand is an umlsterm, ABC - Methode is an umlsterm, Methode is an umlsterm, Zeitaufwandes is an umlsterm, zeitaufwendige is an umlsterm, paraffingaengige is an umlsterm, Standardantikoerper is an umlsterm, Methode is an umlsterm, Verwendung is an umlsterm, Primaerantikoerper is an umlsterm, Standardtechniken is an umlsterm, Antigene is an umlsterm, Hormon - Rezeptor - Antikoerper is an umlsterm, Arbeit is an umlsterm, Techniken is an umlsterm
DerPathologe.90200242.ger.abstr_task1
Sentence: Immunhistochemische Faerbetechniken , wie die APAAP- und ABC-Methode stellen heute in der pathologischen Routinediagnostik ein weit verbreitetes und akzeptiertes Verfahren zur Darstellung definierter antigener Strukturen dar . Neuere Techniken , wie die EnVision- und ImmunoMax-Methode ( Biotinyl-Tyramin-Enhancement ) , stellen Weiterentwicklungen dar , die eine technische Erleichterung , eine Beschleunigung bzw. eine Steigerung der Sensitivitaet des immunhistochemischen Verfahrens ermoeglichen . Die zunehmende Bedeutung und Erweiterung diagnostischer Untersuchungstechniken fuehren zu der Frage , welche Methoden stellen fuer welche Fragestellungen und Anwendungen die geeigneten Verfahren dar ? Das Ziel dieser Arbeit war es , fuer diese unterschiedlichen Verfahren eine vergleichende Zeit- und Kostenanalyse anzustellen und dabei wichtige Parameter wie Sensitivitaet und Spezifitaet zu beruecksichtigen . Zu diesem Zweck wurden relevante und haeufig verwendete Primaerantikoerper wie CD20, CD30, IgM sowie die Antikoerper gegen Oestrogen- und Progesteronrezeptor verwendet . Um eine Vergleichbarkeit der Methoden bezueglich Arbeitsaufwand und -kosten zu ermoeglichen , wurden die Techniken zunaechst in ihrer Empfindlichkeit aufeinander abgestimmt . An ausgewaehlten Faerbebeispielen wurden die sich stark unterscheidenden Kosten fuer jede Technik errechnet und der technische Zeitaufwand fuer jedes Verfahren ermittelt . Die weit verbreitete und etablierte APAAP-Methode stellt die zeitaufwendigste Technik und auch gleichzeitig das mit Abstand kostenintensivste Verfahren dar . Den geringsten Zeitaufwand benoetigt man fuer die EnVision-Detektionsmethode . Die ABC-Methode nimmt eine intermediaere Stellung ein ; sie stellt die kostenguenstigste Methode fuer die meisten Anwendungen dar und bedarf eines mittelhohen Zeitaufwandes . Die ImmunoMax-Methode stellt eine relativ zeitaufwendige und fuer viele paraffingaengige Standardantikoerper nicht notwendige Methode dar ; jedoch fuehrt sie zu dramatischen Kostenersparnissen bei der Verwendung teurer Primaerantikoerper . Darueber hinaus erhaelt man dabei eine bemerkenswerte Sensitivitaessteigerung , was fuer jene Anwendungen bedeutsam sein kann , die mit Standardtechniken zu keinen oder zu unzureichenden Ergebnissen fuehren ( z.B. viele niedrig exprimierte Antigene ) . Dieses wurde hier am Beispiel der kostenintensiven und diagnostisch/therapeutisch bedeutsamen Hormon-Rezeptor-Antikoerper aufgezeigt . Die vorliegende Arbeit verdeutlicht , wie wichtig es ist , neben der Vielzahl verschiedener Untersuchungsverfahren , die entstehenden Kosten einerseits und die potentiellen Moeglichkeiten der Techniken andererseits zu kennen . Instructions: please typing these entity words according to sentence: ABC - Methode, Routinediagnostik, antigener, Techniken, Beschleunigung, Erweiterung, Methoden, Arbeit, Zeit-, Kostenanalyse, Sensitivitaet und Spezifitaet, Primaerantikoerper, IgM, Antikoerper, Oestrogen-, Methoden, Techniken, Technik, Zeitaufwand, zeitaufwendigste, Technik, Zeitaufwand, ABC - Methode, Methode, Zeitaufwandes, zeitaufwendige, paraffingaengige, Standardantikoerper, Methode, Verwendung, Primaerantikoerper, Standardtechniken, Antigene, Hormon - Rezeptor - Antikoerper, Arbeit, Techniken Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Immunhistochemische Faerbetechniken , wie die APAAP- und ABC-Methode stellen heute in der pathologischen Routinediagnostik ein weit verbreitetes und akzeptiertes Verfahren zur Darstellung definierter antigener Strukturen dar . Neuere Techniken , wie die EnVision- und ImmunoMax-Methode ( Biotinyl-Tyramin-Enhancement ) , stellen Weiterentwicklungen dar , die eine technische Erleichterung , eine Beschleunigung bzw. eine Steigerung der Sensitivitaet des immunhistochemischen Verfahrens ermoeglichen . Die zunehmende Bedeutung und Erweiterung diagnostischer Untersuchungstechniken fuehren zu der Frage , welche Methoden stellen fuer welche Fragestellungen und Anwendungen die geeigneten Verfahren dar ? Das Ziel dieser Arbeit war es , fuer diese unterschiedlichen Verfahren eine vergleichende Zeit- und Kostenanalyse anzustellen und dabei wichtige Parameter wie Sensitivitaet und Spezifitaet zu beruecksichtigen . Zu diesem Zweck wurden relevante und haeufig verwendete Primaerantikoerper wie CD20, CD30, IgM sowie die Antikoerper gegen Oestrogen- und Progesteronrezeptor verwendet . Um eine Vergleichbarkeit der Methoden bezueglich Arbeitsaufwand und -kosten zu ermoeglichen , wurden die Techniken zunaechst in ihrer Empfindlichkeit aufeinander abgestimmt . An ausgewaehlten Faerbebeispielen wurden die sich stark unterscheidenden Kosten fuer jede Technik errechnet und der technische Zeitaufwand fuer jedes Verfahren ermittelt . Die weit verbreitete und etablierte APAAP-Methode stellt die zeitaufwendigste Technik und auch gleichzeitig das mit Abstand kostenintensivste Verfahren dar . Den geringsten Zeitaufwand benoetigt man fuer die EnVision-Detektionsmethode . Die ABC-Methode nimmt eine intermediaere Stellung ein ; sie stellt die kostenguenstigste Methode fuer die meisten Anwendungen dar und bedarf eines mittelhohen Zeitaufwandes . Die ImmunoMax-Methode stellt eine relativ zeitaufwendige und fuer viele paraffingaengige Standardantikoerper nicht notwendige Methode dar ; jedoch fuehrt sie zu dramatischen Kostenersparnissen bei der Verwendung teurer Primaerantikoerper . Darueber hinaus erhaelt man dabei eine bemerkenswerte Sensitivitaessteigerung , was fuer jene Anwendungen bedeutsam sein kann , die mit Standardtechniken zu keinen oder zu unzureichenden Ergebnissen fuehren ( z.B. viele niedrig exprimierte Antigene ) . Dieses wurde hier am Beispiel der kostenintensiven und diagnostisch/therapeutisch bedeutsamen Hormon-Rezeptor-Antikoerper aufgezeigt . Die vorliegende Arbeit verdeutlicht , wie wichtig es ist , neben der Vielzahl verschiedener Untersuchungsverfahren , die entstehenden Kosten einerseits und die potentiellen Moeglichkeiten der Techniken andererseits zu kennen .
[ "Immunhistochemische", "Faerbetechniken", ",", "wie", "die", "APAAP-", "und", "ABC", "-", "Methode", "stellen", "heute", "in", "der", "pathologischen", "Routinediagnostik", "ein", "weit", "verbreitetes", "und", "akzeptiertes", "Verfahren", "zur", "Darstellung", "definierter", "antigener", "Strukturen", "dar", ".", "Neuere", "Techniken", ",", "wie", "die", "EnVision-", "und", "ImmunoMax", "-", "Methode", "(", "Biotinyl", "-", "Tyramin", "-", "Enhancement", ")", ",", "stellen", "Weiterentwicklungen", "dar", ",", "die", "eine", "technische", "Erleichterung", ",", "eine", "Beschleunigung", "bzw", ".", "eine", "Steigerung", "der", "Sensitivitaet", "des", "immunhistochemischen", "Verfahrens", "ermoeglichen", ".", "Die", "zunehmende", "Bedeutung", "und", "Erweiterung", "diagnostischer", "Untersuchungstechniken", "fuehren", "zu", "der", "Frage", ",", "welche", "Methoden", "stellen", "fuer", "welche", "Fragestellungen", "und", "Anwendungen", "die", "geeigneten", "Verfahren", "dar", "?", "Das", "Ziel", "dieser", "Arbeit", "war", "es", ",", "fuer", "diese", "unterschiedlichen", "Verfahren", "eine", "vergleichende", "Zeit-", "und", "Kostenanalyse", "anzustellen", "und", "dabei", "wichtige", "Parameter", "wie", "Sensitivitaet", "und", "Spezifitaet", "zu", "beruecksichtigen", ".", "Zu", "diesem", "Zweck", "wurden", "relevante", "und", "haeufig", "verwendete", "Primaerantikoerper", "wie", "CD20", ",", "CD30", ",", "IgM", "sowie", "die", "Antikoerper", "gegen", "Oestrogen-", "und", "Progesteronrezeptor", "verwendet", ".", "Um", "eine", "Vergleichbarkeit", "der", "Methoden", "bezueglich", "Arbeitsaufwand", "und", "-kosten", "zu", "ermoeglichen", ",", "wurden", "die", "Techniken", "zunaechst", "in", "ihrer", "Empfindlichkeit", "aufeinander", "abgestimmt", ".", "An", "ausgewaehlten", "Faerbebeispielen", "wurden", "die", "sich", "stark", "unterscheidenden", "Kosten", "fuer", "jede", "Technik", "errechnet", "und", "der", "technische", "Zeitaufwand", "fuer", "jedes", "Verfahren", "ermittelt", ".", "Die", "weit", "verbreitete", "und", "etablierte", "APAAP", "-", "Methode", "stellt", "die", "zeitaufwendigste", "Technik", "und", "auch", "gleichzeitig", "das", "mit", "Abstand", "kostenintensivste", "Verfahren", "dar", ".", "Den", "geringsten", "Zeitaufwand", "benoetigt", "man", "fuer", "die", "EnVision", "-", "Detektionsmethode", ".", "Die", "ABC", "-", "Methode", "nimmt", "eine", "intermediaere", "Stellung", "ein", ";", "sie", "stellt", "die", "kostenguenstigste", "Methode", "fuer", "die", "meisten", "Anwendungen", "dar", "und", "bedarf", "eines", "mittelhohen", "Zeitaufwandes", ".", "Die", "ImmunoMax", "-", "Methode", "stellt", "eine", "relativ", "zeitaufwendige", "und", "fuer", "viele", "paraffingaengige", "Standardantikoerper", "nicht", "notwendige", "Methode", "dar", ";", "jedoch", "fuehrt", "sie", "zu", "dramatischen", "Kostenersparnissen", "bei", "der", "Verwendung", "teurer", "Primaerantikoerper", ".", "Darueber", "hinaus", "erhaelt", "man", "dabei", "eine", "bemerkenswerte", "Sensitivitaessteigerung", ",", "was", "fuer", "jene", "Anwendungen", "bedeutsam", "sein", "kann", ",", "die", "mit", "Standardtechniken", "zu", "keinen", "oder", "zu", "unzureichenden", "Ergebnissen", "fuehren", "(", "z.", "B.", "viele", "niedrig", "exprimierte", "Antigene", ")", ".", "Dieses", "wurde", "hier", "am", "Beispiel", "der", "kostenintensiven", "und", "diagnostisch", "/", "therapeutisch", "bedeutsamen", "Hormon", "-", "Rezeptor", "-", "Antikoerper", "aufgezeigt", ".", "Die", "vorliegende", "Arbeit", "verdeutlicht", ",", "wie", "wichtig", "es", "ist", ",", "neben", "der", "Vielzahl", "verschiedener", "Untersuchungsverfahren", ",", "die", "entstehenden", "Kosten", "einerseits", "und", "die", "potentiellen", "Moeglichkeiten", "der", "Techniken", "andererseits", "zu", "kennen", "." ]
[ "umlsterm" ]
ABC - Methode, Routinediagnostik, antigener, Techniken, Beschleunigung, Erweiterung, Methoden, Arbeit, Zeit-, Kostenanalyse, Sensitivitaet und Spezifitaet, Primaerantikoerper, IgM, Antikoerper, Oestrogen-, Methoden, Techniken, Technik, Zeitaufwand, zeitaufwendigste, Technik, Zeitaufwand, ABC - Methode, Methode, Zeitaufwandes, zeitaufwendige, paraffingaengige, Standardantikoerper, Methode, Verwendung, Primaerantikoerper, Standardtechniken, Antigene, Hormon - Rezeptor - Antikoerper, Arbeit, Techniken
DerPathologe.90200242.ger.abstr_task2
Sentence: Immunhistochemische Faerbetechniken , wie die APAAP- und ABC-Methode stellen heute in der pathologischen Routinediagnostik ein weit verbreitetes und akzeptiertes Verfahren zur Darstellung definierter antigener Strukturen dar . Neuere Techniken , wie die EnVision- und ImmunoMax-Methode ( Biotinyl-Tyramin-Enhancement ) , stellen Weiterentwicklungen dar , die eine technische Erleichterung , eine Beschleunigung bzw. eine Steigerung der Sensitivitaet des immunhistochemischen Verfahrens ermoeglichen . Die zunehmende Bedeutung und Erweiterung diagnostischer Untersuchungstechniken fuehren zu der Frage , welche Methoden stellen fuer welche Fragestellungen und Anwendungen die geeigneten Verfahren dar ? Das Ziel dieser Arbeit war es , fuer diese unterschiedlichen Verfahren eine vergleichende Zeit- und Kostenanalyse anzustellen und dabei wichtige Parameter wie Sensitivitaet und Spezifitaet zu beruecksichtigen . Zu diesem Zweck wurden relevante und haeufig verwendete Primaerantikoerper wie CD20, CD30, IgM sowie die Antikoerper gegen Oestrogen- und Progesteronrezeptor verwendet . Um eine Vergleichbarkeit der Methoden bezueglich Arbeitsaufwand und -kosten zu ermoeglichen , wurden die Techniken zunaechst in ihrer Empfindlichkeit aufeinander abgestimmt . An ausgewaehlten Faerbebeispielen wurden die sich stark unterscheidenden Kosten fuer jede Technik errechnet und der technische Zeitaufwand fuer jedes Verfahren ermittelt . Die weit verbreitete und etablierte APAAP-Methode stellt die zeitaufwendigste Technik und auch gleichzeitig das mit Abstand kostenintensivste Verfahren dar . Den geringsten Zeitaufwand benoetigt man fuer die EnVision-Detektionsmethode . Die ABC-Methode nimmt eine intermediaere Stellung ein ; sie stellt die kostenguenstigste Methode fuer die meisten Anwendungen dar und bedarf eines mittelhohen Zeitaufwandes . Die ImmunoMax-Methode stellt eine relativ zeitaufwendige und fuer viele paraffingaengige Standardantikoerper nicht notwendige Methode dar ; jedoch fuehrt sie zu dramatischen Kostenersparnissen bei der Verwendung teurer Primaerantikoerper . Darueber hinaus erhaelt man dabei eine bemerkenswerte Sensitivitaessteigerung , was fuer jene Anwendungen bedeutsam sein kann , die mit Standardtechniken zu keinen oder zu unzureichenden Ergebnissen fuehren ( z.B. viele niedrig exprimierte Antigene ) . Dieses wurde hier am Beispiel der kostenintensiven und diagnostisch/therapeutisch bedeutsamen Hormon-Rezeptor-Antikoerper aufgezeigt . Die vorliegende Arbeit verdeutlicht , wie wichtig es ist , neben der Vielzahl verschiedener Untersuchungsverfahren , die entstehenden Kosten einerseits und die potentiellen Moeglichkeiten der Techniken andererseits zu kennen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Immunhistochemische Faerbetechniken , wie die APAAP- und ABC-Methode stellen heute in der pathologischen Routinediagnostik ein weit verbreitetes und akzeptiertes Verfahren zur Darstellung definierter antigener Strukturen dar . Neuere Techniken , wie die EnVision- und ImmunoMax-Methode ( Biotinyl-Tyramin-Enhancement ) , stellen Weiterentwicklungen dar , die eine technische Erleichterung , eine Beschleunigung bzw. eine Steigerung der Sensitivitaet des immunhistochemischen Verfahrens ermoeglichen . Die zunehmende Bedeutung und Erweiterung diagnostischer Untersuchungstechniken fuehren zu der Frage , welche Methoden stellen fuer welche Fragestellungen und Anwendungen die geeigneten Verfahren dar ? Das Ziel dieser Arbeit war es , fuer diese unterschiedlichen Verfahren eine vergleichende Zeit- und Kostenanalyse anzustellen und dabei wichtige Parameter wie Sensitivitaet und Spezifitaet zu beruecksichtigen . Zu diesem Zweck wurden relevante und haeufig verwendete Primaerantikoerper wie CD20, CD30, IgM sowie die Antikoerper gegen Oestrogen- und Progesteronrezeptor verwendet . Um eine Vergleichbarkeit der Methoden bezueglich Arbeitsaufwand und -kosten zu ermoeglichen , wurden die Techniken zunaechst in ihrer Empfindlichkeit aufeinander abgestimmt . An ausgewaehlten Faerbebeispielen wurden die sich stark unterscheidenden Kosten fuer jede Technik errechnet und der technische Zeitaufwand fuer jedes Verfahren ermittelt . Die weit verbreitete und etablierte APAAP-Methode stellt die zeitaufwendigste Technik und auch gleichzeitig das mit Abstand kostenintensivste Verfahren dar . Den geringsten Zeitaufwand benoetigt man fuer die EnVision-Detektionsmethode . Die ABC-Methode nimmt eine intermediaere Stellung ein ; sie stellt die kostenguenstigste Methode fuer die meisten Anwendungen dar und bedarf eines mittelhohen Zeitaufwandes . Die ImmunoMax-Methode stellt eine relativ zeitaufwendige und fuer viele paraffingaengige Standardantikoerper nicht notwendige Methode dar ; jedoch fuehrt sie zu dramatischen Kostenersparnissen bei der Verwendung teurer Primaerantikoerper . Darueber hinaus erhaelt man dabei eine bemerkenswerte Sensitivitaessteigerung , was fuer jene Anwendungen bedeutsam sein kann , die mit Standardtechniken zu keinen oder zu unzureichenden Ergebnissen fuehren ( z.B. viele niedrig exprimierte Antigene ) . Dieses wurde hier am Beispiel der kostenintensiven und diagnostisch/therapeutisch bedeutsamen Hormon-Rezeptor-Antikoerper aufgezeigt . Die vorliegende Arbeit verdeutlicht , wie wichtig es ist , neben der Vielzahl verschiedener Untersuchungsverfahren , die entstehenden Kosten einerseits und die potentiellen Moeglichkeiten der Techniken andererseits zu kennen .
[ "Immunhistochemische", "Faerbetechniken", ",", "wie", "die", "APAAP-", "und", "ABC", "-", "Methode", "stellen", "heute", "in", "der", "pathologischen", "Routinediagnostik", "ein", "weit", "verbreitetes", "und", "akzeptiertes", "Verfahren", "zur", "Darstellung", "definierter", "antigener", "Strukturen", "dar", ".", "Neuere", "Techniken", ",", "wie", "die", "EnVision-", "und", "ImmunoMax", "-", "Methode", "(", "Biotinyl", "-", "Tyramin", "-", "Enhancement", ")", ",", "stellen", "Weiterentwicklungen", "dar", ",", "die", "eine", "technische", "Erleichterung", ",", "eine", "Beschleunigung", "bzw", ".", "eine", "Steigerung", "der", "Sensitivitaet", "des", "immunhistochemischen", "Verfahrens", "ermoeglichen", ".", "Die", "zunehmende", "Bedeutung", "und", "Erweiterung", "diagnostischer", "Untersuchungstechniken", "fuehren", "zu", "der", "Frage", ",", "welche", "Methoden", "stellen", "fuer", "welche", "Fragestellungen", "und", "Anwendungen", "die", "geeigneten", "Verfahren", "dar", "?", "Das", "Ziel", "dieser", "Arbeit", "war", "es", ",", "fuer", "diese", "unterschiedlichen", "Verfahren", "eine", "vergleichende", "Zeit-", "und", "Kostenanalyse", "anzustellen", "und", "dabei", "wichtige", "Parameter", "wie", "Sensitivitaet", "und", "Spezifitaet", "zu", "beruecksichtigen", ".", "Zu", "diesem", "Zweck", "wurden", "relevante", "und", "haeufig", "verwendete", "Primaerantikoerper", "wie", "CD20", ",", "CD30", ",", "IgM", "sowie", "die", "Antikoerper", "gegen", "Oestrogen-", "und", "Progesteronrezeptor", "verwendet", ".", "Um", "eine", "Vergleichbarkeit", "der", "Methoden", "bezueglich", "Arbeitsaufwand", "und", "-kosten", "zu", "ermoeglichen", ",", "wurden", "die", "Techniken", "zunaechst", "in", "ihrer", "Empfindlichkeit", "aufeinander", "abgestimmt", ".", "An", "ausgewaehlten", "Faerbebeispielen", "wurden", "die", "sich", "stark", "unterscheidenden", "Kosten", "fuer", "jede", "Technik", "errechnet", "und", "der", "technische", "Zeitaufwand", "fuer", "jedes", "Verfahren", "ermittelt", ".", "Die", "weit", "verbreitete", "und", "etablierte", "APAAP", "-", "Methode", "stellt", "die", "zeitaufwendigste", "Technik", "und", "auch", "gleichzeitig", "das", "mit", "Abstand", "kostenintensivste", "Verfahren", "dar", ".", "Den", "geringsten", "Zeitaufwand", "benoetigt", "man", "fuer", "die", "EnVision", "-", "Detektionsmethode", ".", "Die", "ABC", "-", "Methode", "nimmt", "eine", "intermediaere", "Stellung", "ein", ";", "sie", "stellt", "die", "kostenguenstigste", "Methode", "fuer", "die", "meisten", "Anwendungen", "dar", "und", "bedarf", "eines", "mittelhohen", "Zeitaufwandes", ".", "Die", "ImmunoMax", "-", "Methode", "stellt", "eine", "relativ", "zeitaufwendige", "und", "fuer", "viele", "paraffingaengige", "Standardantikoerper", "nicht", "notwendige", "Methode", "dar", ";", "jedoch", "fuehrt", "sie", "zu", "dramatischen", "Kostenersparnissen", "bei", "der", "Verwendung", "teurer", "Primaerantikoerper", ".", "Darueber", "hinaus", "erhaelt", "man", "dabei", "eine", "bemerkenswerte", "Sensitivitaessteigerung", ",", "was", "fuer", "jene", "Anwendungen", "bedeutsam", "sein", "kann", ",", "die", "mit", "Standardtechniken", "zu", "keinen", "oder", "zu", "unzureichenden", "Ergebnissen", "fuehren", "(", "z.", "B.", "viele", "niedrig", "exprimierte", "Antigene", ")", ".", "Dieses", "wurde", "hier", "am", "Beispiel", "der", "kostenintensiven", "und", "diagnostisch", "/", "therapeutisch", "bedeutsamen", "Hormon", "-", "Rezeptor", "-", "Antikoerper", "aufgezeigt", ".", "Die", "vorliegende", "Arbeit", "verdeutlicht", ",", "wie", "wichtig", "es", "ist", ",", "neben", "der", "Vielzahl", "verschiedener", "Untersuchungsverfahren", ",", "die", "entstehenden", "Kosten", "einerseits", "und", "die", "potentiellen", "Moeglichkeiten", "der", "Techniken", "andererseits", "zu", "kennen", "." ]
[ "umlsterm" ]
Stickstoffmonoxid is an umlsterm, Gelenkknorpelzellen is an umlsterm, Methode is an umlsterm, Chondrozyten is an umlsterm, Kaninchengelenken is an umlsterm, Stress is an umlsterm, Stress is an umlsterm, Stress is an umlsterm, Chondrozyten is an umlsterm, Trypsin is an umlsterm, Zentrifugation is an umlsterm, Immunperoxidasefaerbung is an umlsterm, RNA is an umlsterm, RT - PCR is an umlsterm, Stress is an umlsterm, Stress is an umlsterm, Chondrozyten is an umlsterm, Stress is an umlsterm, Gelenkknorpelzellen is an umlsterm, Chondrozyten is an umlsterm, Faehigkeit is an umlsterm, Therapie is an umlsterm
MundKieferGesichtschirurgie.0004s479.ger.abstr_task0
Sentence: Fragestellung : In den letzten Jahren wurde Stickstoffmonoxid ( NO ) zunehmend als bedeutender Mediator entzuendlicher und degenerativer Kiefergelenkerkrankungen erkannt . Ziel dieser Studie war die Evaluierung des Effekts von kontinuierlicher passiver Bewegung auf die Bildung von induzierbarer Stickstoffoxidsynthase ( iNOS ) in Interleukin-1(IL-1)-sensitiven Gelenkknorpelzellen . Material und Methode : Chondrozyten wurden von Kaninchengelenken gewonnen , auf Flexercell-Kulturplatten uebertragen und folgenden 4 Versuchsgruppen zugeordnet : ( 1 ) kein mechanischer Stress ( 10 Hz , 20% Dehnung ) ; ( 2 ) rhIL-1 ( 1 ng/ml ) ; ( 3 mechanischer Stress ; ( ) 4 ) mechanischer Stress und rhIL-1. Nach 24 h wurden die Chondrozyten mittels Trypsin und Zentrifugation auf Objekttraeger aufgebracht . Die Gegenwart von iNOS wurde mittels indirekter Immunperoxidasefaerbung bestimmt und quantifiziert . Zusaetzlich wurde mittels Greiss-Reaktion die NO-Produktion spektrophotometrisch in den Zellueberstaenden gemessen und RNA extrahiert , um mittels Reverser-Transkriptase-Polymerasekettenreaktion ( RT-PCR ) die Expression von mRNA-iNOS festzustellen . Alle Experimente wurden 3-mal wiederholt und die statistische Signifikanz mit dem Student-t-Test ermittelt . Ergebnisse : In der Kontrollgruppe ohne mechanischen Stress ( 1 ) und unter mechanischem Stress allein ( 3 ) konnte iNOS nicht nachgewiesen werden . Unter rh ) ( IL-1-behandelten Chondrozyten ( 2 ) fand sich die intensivste Anfaerbung ( 35% ) , waehrend die zusaetzliche Gegenwart von mechanischem Stress ( 4 ) eine deutlich geringere Anfaerbung zeigte ( 24% ) . Dies korreliert mit statistisch signifikant verschiedenen NO-Messwerten ( p 0,05 ) in den 4 Experimentgruppen und bestaetigt iNOS-mRNA-Resultate . Schlussfolgerung : Unsere Ergebnisse belegen die antientzuendliche Wirkung kontinuierlicher passiver Bewegung auf IL-1-sensitive Gelenkknorpelzellen . Unter anderem liegt aus molekularbiologischer Sicht eine verminderte Menge an induzierbarer Stickstoffoxidsynthase ( iNOS ) in den Chondrozyten zugrunde . Die Faehigkeit von NO , als intrazellulaeres , transzellulaeres und zytotoxisches Molekuel zu agieren , hat fuer die posttraumatische und postoperative Kiefergelenkfunktion sowie den Ablauf und damit die Therapie von Kiefergelenkerkrankungen grundlegende Bedeutung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Fragestellung : In den letzten Jahren wurde Stickstoffmonoxid ( NO ) zunehmend als bedeutender Mediator entzuendlicher und degenerativer Kiefergelenkerkrankungen erkannt . Ziel dieser Studie war die Evaluierung des Effekts von kontinuierlicher passiver Bewegung auf die Bildung von induzierbarer Stickstoffoxidsynthase ( iNOS ) in Interleukin-1(IL-1)-sensitiven Gelenkknorpelzellen . Material und Methode : Chondrozyten wurden von Kaninchengelenken gewonnen , auf Flexercell-Kulturplatten uebertragen und folgenden 4 Versuchsgruppen zugeordnet : ( 1 ) kein mechanischer Stress ( 10 Hz , 20% Dehnung ) ; ( 2 ) rhIL-1 ( 1 ng/ml ) ; ( 3 mechanischer Stress ; ( ) 4 ) mechanischer Stress und rhIL-1. Nach 24 h wurden die Chondrozyten mittels Trypsin und Zentrifugation auf Objekttraeger aufgebracht . Die Gegenwart von iNOS wurde mittels indirekter Immunperoxidasefaerbung bestimmt und quantifiziert . Zusaetzlich wurde mittels Greiss-Reaktion die NO-Produktion spektrophotometrisch in den Zellueberstaenden gemessen und RNA extrahiert , um mittels Reverser-Transkriptase-Polymerasekettenreaktion ( RT-PCR ) die Expression von mRNA-iNOS festzustellen . Alle Experimente wurden 3-mal wiederholt und die statistische Signifikanz mit dem Student-t-Test ermittelt . Ergebnisse : In der Kontrollgruppe ohne mechanischen Stress ( 1 ) und unter mechanischem Stress allein ( 3 ) konnte iNOS nicht nachgewiesen werden . Unter rh ) ( IL-1-behandelten Chondrozyten ( 2 ) fand sich die intensivste Anfaerbung ( 35% ) , waehrend die zusaetzliche Gegenwart von mechanischem Stress ( 4 ) eine deutlich geringere Anfaerbung zeigte ( 24% ) . Dies korreliert mit statistisch signifikant verschiedenen NO-Messwerten ( p 0,05 ) in den 4 Experimentgruppen und bestaetigt iNOS-mRNA-Resultate . Schlussfolgerung : Unsere Ergebnisse belegen die antientzuendliche Wirkung kontinuierlicher passiver Bewegung auf IL-1-sensitive Gelenkknorpelzellen . Unter anderem liegt aus molekularbiologischer Sicht eine verminderte Menge an induzierbarer Stickstoffoxidsynthase ( iNOS ) in den Chondrozyten zugrunde . Die Faehigkeit von NO , als intrazellulaeres , transzellulaeres und zytotoxisches Molekuel zu agieren , hat fuer die posttraumatische und postoperative Kiefergelenkfunktion sowie den Ablauf und damit die Therapie von Kiefergelenkerkrankungen grundlegende Bedeutung .
[ "Fragestellung", ":", "In", "den", "letzten", "Jahren", "wurde", "Stickstoffmonoxid", "(", "NO", ")", "zunehmend", "als", "bedeutender", "Mediator", "entzuendlicher", "und", "degenerativer", "Kiefergelenkerkrankungen", "erkannt", ".", "Ziel", "dieser", "Studie", "war", "die", "Evaluierung", "des", "Effekts", "von", "kontinuierlicher", "passiver", "Bewegung", "auf", "die", "Bildung", "von", "induzierbarer", "Stickstoffoxidsynthase", "(", "iNOS", ")", "in", "Interleukin-1(IL-1)-sensitiven", "Gelenkknorpelzellen", ".", "Material", "und", "Methode", ":", "Chondrozyten", "wurden", "von", "Kaninchengelenken", "gewonnen", ",", "auf", "Flexercell", "-", "Kulturplatten", "uebertragen", "und", "folgenden", "4", "Versuchsgruppen", "zugeordnet", ":", "(", "1", ")", "kein", "mechanischer", "Stress", "(", "10", "Hz", ",", "20", "%", "Dehnung", ")", ";", "(", "2", ")", "rhIL-1", "(", "1", "ng", "/", "ml", ")", ";", "(", "3", "mechanischer", "Stress", ";", "(", ")", "4", ")", "mechanischer", "Stress", "und", "rhIL-1", ".", "Nach", "24", "h", "wurden", "die", "Chondrozyten", "mittels", "Trypsin", "und", "Zentrifugation", "auf", "Objekttraeger", "aufgebracht", ".", "Die", "Gegenwart", "von", "iNOS", "wurde", "mittels", "indirekter", "Immunperoxidasefaerbung", "bestimmt", "und", "quantifiziert", ".", "Zusaetzlich", "wurde", "mittels", "Greiss", "-", "Reaktion", "die", "NO", "-", "Produktion", "spektrophotometrisch", "in", "den", "Zellueberstaenden", "gemessen", "und", "RNA", "extrahiert", ",", "um", "mittels", "Reverser", "-", "Transkriptase", "-", "Polymerasekettenreaktion", "(", "RT", "-", "PCR", ")", "die", "Expression", "von", "mRNA", "-", "iNOS", "festzustellen", ".", "Alle", "Experimente", "wurden", "3-mal", "wiederholt", "und", "die", "statistische", "Signifikanz", "mit", "dem", "Student", "-", "t", "-", "Test", "ermittelt", ".", "Ergebnisse", ":", "In", "der", "Kontrollgruppe", "ohne", "mechanischen", "Stress", "(", "1", ")", "und", "unter", "mechanischem", "Stress", "allein", "(", "3", ")", "konnte", "iNOS", "nicht", "nachgewiesen", "werden", ".", "Unter", "rh", ")", "(", "IL-1-behandelten", "Chondrozyten", "(", "2", ")", "fand", "sich", "die", "intensivste", "Anfaerbung", "(", "35", "%", ")", ",", "waehrend", "die", "zusaetzliche", "Gegenwart", "von", "mechanischem", "Stress", "(", "4", ")", "eine", "deutlich", "geringere", "Anfaerbung", "zeigte", "(", "24", "%", ")", ".", "Dies", "korreliert", "mit", "statistisch", "signifikant", "verschiedenen", "NO", "-", "Messwerten", "(", "p", "0,05", ")", "in", "den", "4", "Experimentgruppen", "und", "bestaetigt", "iNOS", "-", "mRNA", "-", "Resultate", ".", "Schlussfolgerung", ":", "Unsere", "Ergebnisse", "belegen", "die", "antientzuendliche", "Wirkung", "kontinuierlicher", "passiver", "Bewegung", "auf", "IL-1-sensitive", "Gelenkknorpelzellen", ".", "Unter", "anderem", "liegt", "aus", "molekularbiologischer", "Sicht", "eine", "verminderte", "Menge", "an", "induzierbarer", "Stickstoffoxidsynthase", "(", "iNOS", ")", "in", "den", "Chondrozyten", "zugrunde", ".", "Die", "Faehigkeit", "von", "NO", ",", "als", "intrazellulaeres", ",", "transzellulaeres", "und", "zytotoxisches", "Molekuel", "zu", "agieren", ",", "hat", "fuer", "die", "posttraumatische", "und", "postoperative", "Kiefergelenkfunktion", "sowie", "den", "Ablauf", "und", "damit", "die", "Therapie", "von", "Kiefergelenkerkrankungen", "grundlegende", "Bedeutung", "." ]
[ "umlsterm" ]
Stickstoffmonoxid is an umlsterm, Gelenkknorpelzellen is an umlsterm, Methode is an umlsterm, Chondrozyten is an umlsterm, Kaninchengelenken is an umlsterm, Stress is an umlsterm, Stress is an umlsterm, Stress is an umlsterm, Chondrozyten is an umlsterm, Trypsin is an umlsterm, Zentrifugation is an umlsterm, Immunperoxidasefaerbung is an umlsterm, RNA is an umlsterm, RT - PCR is an umlsterm, Stress is an umlsterm, Stress is an umlsterm, Chondrozyten is an umlsterm, Stress is an umlsterm, Gelenkknorpelzellen is an umlsterm, Chondrozyten is an umlsterm, Faehigkeit is an umlsterm, Therapie is an umlsterm
MundKieferGesichtschirurgie.0004s479.ger.abstr_task1
Sentence: Fragestellung : In den letzten Jahren wurde Stickstoffmonoxid ( NO ) zunehmend als bedeutender Mediator entzuendlicher und degenerativer Kiefergelenkerkrankungen erkannt . Ziel dieser Studie war die Evaluierung des Effekts von kontinuierlicher passiver Bewegung auf die Bildung von induzierbarer Stickstoffoxidsynthase ( iNOS ) in Interleukin-1(IL-1)-sensitiven Gelenkknorpelzellen . Material und Methode : Chondrozyten wurden von Kaninchengelenken gewonnen , auf Flexercell-Kulturplatten uebertragen und folgenden 4 Versuchsgruppen zugeordnet : ( 1 ) kein mechanischer Stress ( 10 Hz , 20% Dehnung ) ; ( 2 ) rhIL-1 ( 1 ng/ml ) ; ( 3 mechanischer Stress ; ( ) 4 ) mechanischer Stress und rhIL-1. Nach 24 h wurden die Chondrozyten mittels Trypsin und Zentrifugation auf Objekttraeger aufgebracht . Die Gegenwart von iNOS wurde mittels indirekter Immunperoxidasefaerbung bestimmt und quantifiziert . Zusaetzlich wurde mittels Greiss-Reaktion die NO-Produktion spektrophotometrisch in den Zellueberstaenden gemessen und RNA extrahiert , um mittels Reverser-Transkriptase-Polymerasekettenreaktion ( RT-PCR ) die Expression von mRNA-iNOS festzustellen . Alle Experimente wurden 3-mal wiederholt und die statistische Signifikanz mit dem Student-t-Test ermittelt . Ergebnisse : In der Kontrollgruppe ohne mechanischen Stress ( 1 ) und unter mechanischem Stress allein ( 3 ) konnte iNOS nicht nachgewiesen werden . Unter rh ) ( IL-1-behandelten Chondrozyten ( 2 ) fand sich die intensivste Anfaerbung ( 35% ) , waehrend die zusaetzliche Gegenwart von mechanischem Stress ( 4 ) eine deutlich geringere Anfaerbung zeigte ( 24% ) . Dies korreliert mit statistisch signifikant verschiedenen NO-Messwerten ( p 0,05 ) in den 4 Experimentgruppen und bestaetigt iNOS-mRNA-Resultate . Schlussfolgerung : Unsere Ergebnisse belegen die antientzuendliche Wirkung kontinuierlicher passiver Bewegung auf IL-1-sensitive Gelenkknorpelzellen . Unter anderem liegt aus molekularbiologischer Sicht eine verminderte Menge an induzierbarer Stickstoffoxidsynthase ( iNOS ) in den Chondrozyten zugrunde . Die Faehigkeit von NO , als intrazellulaeres , transzellulaeres und zytotoxisches Molekuel zu agieren , hat fuer die posttraumatische und postoperative Kiefergelenkfunktion sowie den Ablauf und damit die Therapie von Kiefergelenkerkrankungen grundlegende Bedeutung . Instructions: please typing these entity words according to sentence: Stickstoffmonoxid, Gelenkknorpelzellen, Methode, Chondrozyten, Kaninchengelenken, Stress, Stress, Stress, Chondrozyten, Trypsin, Zentrifugation, Immunperoxidasefaerbung, RNA, RT - PCR, Stress, Stress, Chondrozyten, Stress, Gelenkknorpelzellen, Chondrozyten, Faehigkeit, Therapie Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Fragestellung : In den letzten Jahren wurde Stickstoffmonoxid ( NO ) zunehmend als bedeutender Mediator entzuendlicher und degenerativer Kiefergelenkerkrankungen erkannt . Ziel dieser Studie war die Evaluierung des Effekts von kontinuierlicher passiver Bewegung auf die Bildung von induzierbarer Stickstoffoxidsynthase ( iNOS ) in Interleukin-1(IL-1)-sensitiven Gelenkknorpelzellen . Material und Methode : Chondrozyten wurden von Kaninchengelenken gewonnen , auf Flexercell-Kulturplatten uebertragen und folgenden 4 Versuchsgruppen zugeordnet : ( 1 ) kein mechanischer Stress ( 10 Hz , 20% Dehnung ) ; ( 2 ) rhIL-1 ( 1 ng/ml ) ; ( 3 mechanischer Stress ; ( ) 4 ) mechanischer Stress und rhIL-1. Nach 24 h wurden die Chondrozyten mittels Trypsin und Zentrifugation auf Objekttraeger aufgebracht . Die Gegenwart von iNOS wurde mittels indirekter Immunperoxidasefaerbung bestimmt und quantifiziert . Zusaetzlich wurde mittels Greiss-Reaktion die NO-Produktion spektrophotometrisch in den Zellueberstaenden gemessen und RNA extrahiert , um mittels Reverser-Transkriptase-Polymerasekettenreaktion ( RT-PCR ) die Expression von mRNA-iNOS festzustellen . Alle Experimente wurden 3-mal wiederholt und die statistische Signifikanz mit dem Student-t-Test ermittelt . Ergebnisse : In der Kontrollgruppe ohne mechanischen Stress ( 1 ) und unter mechanischem Stress allein ( 3 ) konnte iNOS nicht nachgewiesen werden . Unter rh ) ( IL-1-behandelten Chondrozyten ( 2 ) fand sich die intensivste Anfaerbung ( 35% ) , waehrend die zusaetzliche Gegenwart von mechanischem Stress ( 4 ) eine deutlich geringere Anfaerbung zeigte ( 24% ) . Dies korreliert mit statistisch signifikant verschiedenen NO-Messwerten ( p 0,05 ) in den 4 Experimentgruppen und bestaetigt iNOS-mRNA-Resultate . Schlussfolgerung : Unsere Ergebnisse belegen die antientzuendliche Wirkung kontinuierlicher passiver Bewegung auf IL-1-sensitive Gelenkknorpelzellen . Unter anderem liegt aus molekularbiologischer Sicht eine verminderte Menge an induzierbarer Stickstoffoxidsynthase ( iNOS ) in den Chondrozyten zugrunde . Die Faehigkeit von NO , als intrazellulaeres , transzellulaeres und zytotoxisches Molekuel zu agieren , hat fuer die posttraumatische und postoperative Kiefergelenkfunktion sowie den Ablauf und damit die Therapie von Kiefergelenkerkrankungen grundlegende Bedeutung .
[ "Fragestellung", ":", "In", "den", "letzten", "Jahren", "wurde", "Stickstoffmonoxid", "(", "NO", ")", "zunehmend", "als", "bedeutender", "Mediator", "entzuendlicher", "und", "degenerativer", "Kiefergelenkerkrankungen", "erkannt", ".", "Ziel", "dieser", "Studie", "war", "die", "Evaluierung", "des", "Effekts", "von", "kontinuierlicher", "passiver", "Bewegung", "auf", "die", "Bildung", "von", "induzierbarer", "Stickstoffoxidsynthase", "(", "iNOS", ")", "in", "Interleukin-1(IL-1)-sensitiven", "Gelenkknorpelzellen", ".", "Material", "und", "Methode", ":", "Chondrozyten", "wurden", "von", "Kaninchengelenken", "gewonnen", ",", "auf", "Flexercell", "-", "Kulturplatten", "uebertragen", "und", "folgenden", "4", "Versuchsgruppen", "zugeordnet", ":", "(", "1", ")", "kein", "mechanischer", "Stress", "(", "10", "Hz", ",", "20", "%", "Dehnung", ")", ";", "(", "2", ")", "rhIL-1", "(", "1", "ng", "/", "ml", ")", ";", "(", "3", "mechanischer", "Stress", ";", "(", ")", "4", ")", "mechanischer", "Stress", "und", "rhIL-1", ".", "Nach", "24", "h", "wurden", "die", "Chondrozyten", "mittels", "Trypsin", "und", "Zentrifugation", "auf", "Objekttraeger", "aufgebracht", ".", "Die", "Gegenwart", "von", "iNOS", "wurde", "mittels", "indirekter", "Immunperoxidasefaerbung", "bestimmt", "und", "quantifiziert", ".", "Zusaetzlich", "wurde", "mittels", "Greiss", "-", "Reaktion", "die", "NO", "-", "Produktion", "spektrophotometrisch", "in", "den", "Zellueberstaenden", "gemessen", "und", "RNA", "extrahiert", ",", "um", "mittels", "Reverser", "-", "Transkriptase", "-", "Polymerasekettenreaktion", "(", "RT", "-", "PCR", ")", "die", "Expression", "von", "mRNA", "-", "iNOS", "festzustellen", ".", "Alle", "Experimente", "wurden", "3-mal", "wiederholt", "und", "die", "statistische", "Signifikanz", "mit", "dem", "Student", "-", "t", "-", "Test", "ermittelt", ".", "Ergebnisse", ":", "In", "der", "Kontrollgruppe", "ohne", "mechanischen", "Stress", "(", "1", ")", "und", "unter", "mechanischem", "Stress", "allein", "(", "3", ")", "konnte", "iNOS", "nicht", "nachgewiesen", "werden", ".", "Unter", "rh", ")", "(", "IL-1-behandelten", "Chondrozyten", "(", "2", ")", "fand", "sich", "die", "intensivste", "Anfaerbung", "(", "35", "%", ")", ",", "waehrend", "die", "zusaetzliche", "Gegenwart", "von", "mechanischem", "Stress", "(", "4", ")", "eine", "deutlich", "geringere", "Anfaerbung", "zeigte", "(", "24", "%", ")", ".", "Dies", "korreliert", "mit", "statistisch", "signifikant", "verschiedenen", "NO", "-", "Messwerten", "(", "p", "0,05", ")", "in", "den", "4", "Experimentgruppen", "und", "bestaetigt", "iNOS", "-", "mRNA", "-", "Resultate", ".", "Schlussfolgerung", ":", "Unsere", "Ergebnisse", "belegen", "die", "antientzuendliche", "Wirkung", "kontinuierlicher", "passiver", "Bewegung", "auf", "IL-1-sensitive", "Gelenkknorpelzellen", ".", "Unter", "anderem", "liegt", "aus", "molekularbiologischer", "Sicht", "eine", "verminderte", "Menge", "an", "induzierbarer", "Stickstoffoxidsynthase", "(", "iNOS", ")", "in", "den", "Chondrozyten", "zugrunde", ".", "Die", "Faehigkeit", "von", "NO", ",", "als", "intrazellulaeres", ",", "transzellulaeres", "und", "zytotoxisches", "Molekuel", "zu", "agieren", ",", "hat", "fuer", "die", "posttraumatische", "und", "postoperative", "Kiefergelenkfunktion", "sowie", "den", "Ablauf", "und", "damit", "die", "Therapie", "von", "Kiefergelenkerkrankungen", "grundlegende", "Bedeutung", "." ]
[ "umlsterm" ]
Stickstoffmonoxid, Gelenkknorpelzellen, Methode, Chondrozyten, Kaninchengelenken, Stress, Stress, Stress, Chondrozyten, Trypsin, Zentrifugation, Immunperoxidasefaerbung, RNA, RT - PCR, Stress, Stress, Chondrozyten, Stress, Gelenkknorpelzellen, Chondrozyten, Faehigkeit, Therapie
MundKieferGesichtschirurgie.0004s479.ger.abstr_task2
Sentence: Fragestellung : In den letzten Jahren wurde Stickstoffmonoxid ( NO ) zunehmend als bedeutender Mediator entzuendlicher und degenerativer Kiefergelenkerkrankungen erkannt . Ziel dieser Studie war die Evaluierung des Effekts von kontinuierlicher passiver Bewegung auf die Bildung von induzierbarer Stickstoffoxidsynthase ( iNOS ) in Interleukin-1(IL-1)-sensitiven Gelenkknorpelzellen . Material und Methode : Chondrozyten wurden von Kaninchengelenken gewonnen , auf Flexercell-Kulturplatten uebertragen und folgenden 4 Versuchsgruppen zugeordnet : ( 1 ) kein mechanischer Stress ( 10 Hz , 20% Dehnung ) ; ( 2 ) rhIL-1 ( 1 ng/ml ) ; ( 3 mechanischer Stress ; ( ) 4 ) mechanischer Stress und rhIL-1. Nach 24 h wurden die Chondrozyten mittels Trypsin und Zentrifugation auf Objekttraeger aufgebracht . Die Gegenwart von iNOS wurde mittels indirekter Immunperoxidasefaerbung bestimmt und quantifiziert . Zusaetzlich wurde mittels Greiss-Reaktion die NO-Produktion spektrophotometrisch in den Zellueberstaenden gemessen und RNA extrahiert , um mittels Reverser-Transkriptase-Polymerasekettenreaktion ( RT-PCR ) die Expression von mRNA-iNOS festzustellen . Alle Experimente wurden 3-mal wiederholt und die statistische Signifikanz mit dem Student-t-Test ermittelt . Ergebnisse : In der Kontrollgruppe ohne mechanischen Stress ( 1 ) und unter mechanischem Stress allein ( 3 ) konnte iNOS nicht nachgewiesen werden . Unter rh ) ( IL-1-behandelten Chondrozyten ( 2 ) fand sich die intensivste Anfaerbung ( 35% ) , waehrend die zusaetzliche Gegenwart von mechanischem Stress ( 4 ) eine deutlich geringere Anfaerbung zeigte ( 24% ) . Dies korreliert mit statistisch signifikant verschiedenen NO-Messwerten ( p 0,05 ) in den 4 Experimentgruppen und bestaetigt iNOS-mRNA-Resultate . Schlussfolgerung : Unsere Ergebnisse belegen die antientzuendliche Wirkung kontinuierlicher passiver Bewegung auf IL-1-sensitive Gelenkknorpelzellen . Unter anderem liegt aus molekularbiologischer Sicht eine verminderte Menge an induzierbarer Stickstoffoxidsynthase ( iNOS ) in den Chondrozyten zugrunde . Die Faehigkeit von NO , als intrazellulaeres , transzellulaeres und zytotoxisches Molekuel zu agieren , hat fuer die posttraumatische und postoperative Kiefergelenkfunktion sowie den Ablauf und damit die Therapie von Kiefergelenkerkrankungen grundlegende Bedeutung . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Fragestellung : In den letzten Jahren wurde Stickstoffmonoxid ( NO ) zunehmend als bedeutender Mediator entzuendlicher und degenerativer Kiefergelenkerkrankungen erkannt . Ziel dieser Studie war die Evaluierung des Effekts von kontinuierlicher passiver Bewegung auf die Bildung von induzierbarer Stickstoffoxidsynthase ( iNOS ) in Interleukin-1(IL-1)-sensitiven Gelenkknorpelzellen . Material und Methode : Chondrozyten wurden von Kaninchengelenken gewonnen , auf Flexercell-Kulturplatten uebertragen und folgenden 4 Versuchsgruppen zugeordnet : ( 1 ) kein mechanischer Stress ( 10 Hz , 20% Dehnung ) ; ( 2 ) rhIL-1 ( 1 ng/ml ) ; ( 3 mechanischer Stress ; ( ) 4 ) mechanischer Stress und rhIL-1. Nach 24 h wurden die Chondrozyten mittels Trypsin und Zentrifugation auf Objekttraeger aufgebracht . Die Gegenwart von iNOS wurde mittels indirekter Immunperoxidasefaerbung bestimmt und quantifiziert . Zusaetzlich wurde mittels Greiss-Reaktion die NO-Produktion spektrophotometrisch in den Zellueberstaenden gemessen und RNA extrahiert , um mittels Reverser-Transkriptase-Polymerasekettenreaktion ( RT-PCR ) die Expression von mRNA-iNOS festzustellen . Alle Experimente wurden 3-mal wiederholt und die statistische Signifikanz mit dem Student-t-Test ermittelt . Ergebnisse : In der Kontrollgruppe ohne mechanischen Stress ( 1 ) und unter mechanischem Stress allein ( 3 ) konnte iNOS nicht nachgewiesen werden . Unter rh ) ( IL-1-behandelten Chondrozyten ( 2 ) fand sich die intensivste Anfaerbung ( 35% ) , waehrend die zusaetzliche Gegenwart von mechanischem Stress ( 4 ) eine deutlich geringere Anfaerbung zeigte ( 24% ) . Dies korreliert mit statistisch signifikant verschiedenen NO-Messwerten ( p 0,05 ) in den 4 Experimentgruppen und bestaetigt iNOS-mRNA-Resultate . Schlussfolgerung : Unsere Ergebnisse belegen die antientzuendliche Wirkung kontinuierlicher passiver Bewegung auf IL-1-sensitive Gelenkknorpelzellen . Unter anderem liegt aus molekularbiologischer Sicht eine verminderte Menge an induzierbarer Stickstoffoxidsynthase ( iNOS ) in den Chondrozyten zugrunde . Die Faehigkeit von NO , als intrazellulaeres , transzellulaeres und zytotoxisches Molekuel zu agieren , hat fuer die posttraumatische und postoperative Kiefergelenkfunktion sowie den Ablauf und damit die Therapie von Kiefergelenkerkrankungen grundlegende Bedeutung .
[ "Fragestellung", ":", "In", "den", "letzten", "Jahren", "wurde", "Stickstoffmonoxid", "(", "NO", ")", "zunehmend", "als", "bedeutender", "Mediator", "entzuendlicher", "und", "degenerativer", "Kiefergelenkerkrankungen", "erkannt", ".", "Ziel", "dieser", "Studie", "war", "die", "Evaluierung", "des", "Effekts", "von", "kontinuierlicher", "passiver", "Bewegung", "auf", "die", "Bildung", "von", "induzierbarer", "Stickstoffoxidsynthase", "(", "iNOS", ")", "in", "Interleukin-1(IL-1)-sensitiven", "Gelenkknorpelzellen", ".", "Material", "und", "Methode", ":", "Chondrozyten", "wurden", "von", "Kaninchengelenken", "gewonnen", ",", "auf", "Flexercell", "-", "Kulturplatten", "uebertragen", "und", "folgenden", "4", "Versuchsgruppen", "zugeordnet", ":", "(", "1", ")", "kein", "mechanischer", "Stress", "(", "10", "Hz", ",", "20", "%", "Dehnung", ")", ";", "(", "2", ")", "rhIL-1", "(", "1", "ng", "/", "ml", ")", ";", "(", "3", "mechanischer", "Stress", ";", "(", ")", "4", ")", "mechanischer", "Stress", "und", "rhIL-1", ".", "Nach", "24", "h", "wurden", "die", "Chondrozyten", "mittels", "Trypsin", "und", "Zentrifugation", "auf", "Objekttraeger", "aufgebracht", ".", "Die", "Gegenwart", "von", "iNOS", "wurde", "mittels", "indirekter", "Immunperoxidasefaerbung", "bestimmt", "und", "quantifiziert", ".", "Zusaetzlich", "wurde", "mittels", "Greiss", "-", "Reaktion", "die", "NO", "-", "Produktion", "spektrophotometrisch", "in", "den", "Zellueberstaenden", "gemessen", "und", "RNA", "extrahiert", ",", "um", "mittels", "Reverser", "-", "Transkriptase", "-", "Polymerasekettenreaktion", "(", "RT", "-", "PCR", ")", "die", "Expression", "von", "mRNA", "-", "iNOS", "festzustellen", ".", "Alle", "Experimente", "wurden", "3-mal", "wiederholt", "und", "die", "statistische", "Signifikanz", "mit", "dem", "Student", "-", "t", "-", "Test", "ermittelt", ".", "Ergebnisse", ":", "In", "der", "Kontrollgruppe", "ohne", "mechanischen", "Stress", "(", "1", ")", "und", "unter", "mechanischem", "Stress", "allein", "(", "3", ")", "konnte", "iNOS", "nicht", "nachgewiesen", "werden", ".", "Unter", "rh", ")", "(", "IL-1-behandelten", "Chondrozyten", "(", "2", ")", "fand", "sich", "die", "intensivste", "Anfaerbung", "(", "35", "%", ")", ",", "waehrend", "die", "zusaetzliche", "Gegenwart", "von", "mechanischem", "Stress", "(", "4", ")", "eine", "deutlich", "geringere", "Anfaerbung", "zeigte", "(", "24", "%", ")", ".", "Dies", "korreliert", "mit", "statistisch", "signifikant", "verschiedenen", "NO", "-", "Messwerten", "(", "p", "0,05", ")", "in", "den", "4", "Experimentgruppen", "und", "bestaetigt", "iNOS", "-", "mRNA", "-", "Resultate", ".", "Schlussfolgerung", ":", "Unsere", "Ergebnisse", "belegen", "die", "antientzuendliche", "Wirkung", "kontinuierlicher", "passiver", "Bewegung", "auf", "IL-1-sensitive", "Gelenkknorpelzellen", ".", "Unter", "anderem", "liegt", "aus", "molekularbiologischer", "Sicht", "eine", "verminderte", "Menge", "an", "induzierbarer", "Stickstoffoxidsynthase", "(", "iNOS", ")", "in", "den", "Chondrozyten", "zugrunde", ".", "Die", "Faehigkeit", "von", "NO", ",", "als", "intrazellulaeres", ",", "transzellulaeres", "und", "zytotoxisches", "Molekuel", "zu", "agieren", ",", "hat", "fuer", "die", "posttraumatische", "und", "postoperative", "Kiefergelenkfunktion", "sowie", "den", "Ablauf", "und", "damit", "die", "Therapie", "von", "Kiefergelenkerkrankungen", "grundlegende", "Bedeutung", "." ]
[ "umlsterm" ]
ENBREL is a BRAND, ENBREL is a BRAND, methotrexate is a DRUG, ENBREL is a BRAND, anakinra is a DRUG, ENBREL is a BRAND, ENBREL is a BRAND, anakinra is a DRUG, sulfasalazine is a DRUG, ENBREL is a BRAND, ENBREL is a BRAND, sulfasalazine is a DRUG
Etanercept_ddi_task0
Sentence: Specific drug interaction studies have not been conducted with ENBREL . However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients. In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%). Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L). Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone. The clinical significance of this observation is unknown. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG, BRAND
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Specific drug interaction studies have not been conducted with ENBREL . However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients. In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%). Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L). Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone. The clinical significance of this observation is unknown.
[ "Specific", "drug", "interaction", "studies", "have", "not", "been", "conducted", "with", "ENBREL", ".", "However", ",", "it", "was", "observed", "that", "the", "pharmacokinetics", "of", "ENBREL", " ", "was", "unaltered", "by", "concomitant", "methotrexate", "in", "rheumatoid", "arthritis", "patients", ".", "In", "a", "study", "in", "which", "patients", "with", "active", "RA", "were", "treated", "for", "up", "to", "24", "weeks", "with", "concurrent", "ENBREL", " ", "and", "anakinra", "therapy", ",", "a", "7", "%", "rate", "of", "serious", "infections", "was", "observed", ",", "which", "was", "higher", "than", "that", "observed", "with", "ENBREL", " ", "alone", "(", "0", "%", ")", ".", "Two", "percent", "of", "patients", "treated", "concurrently", "with", "ENBREL", " ", "and", "anakinra", "developed", "neutropenia", "(", "ANC", " ", "1", "x", "109", "/", "L", ")", ".", "Patients", "in", "a", "clinical", "study", "who", "were", "on", "established", "therapy", "with", "sulfasalazine", ",", "to", "which", "ENBREL", "was", "added", ",", "were", "noted", "to", "develop", "a", "mild", "decrease", "in", "mean", "neutrophil", "counts", "in", "comparison", "to", "groups", "treated", "with", "either", "ENBREL", "CI", "or", "sulfasalazine", "alone", ".", "The", "clinical", "significance", "of", "this", "observation", "is", "unknown", "." ]
[ "DRUG", "BRAND" ]
ENBREL is a BRAND, ENBREL is a BRAND, methotrexate is a DRUG, ENBREL is a BRAND, anakinra is a DRUG, ENBREL is a BRAND, ENBREL is a BRAND, anakinra is a DRUG, sulfasalazine is a DRUG, ENBREL is a BRAND, ENBREL is a BRAND, sulfasalazine is a DRUG
Etanercept_ddi_task1
Sentence: Specific drug interaction studies have not been conducted with ENBREL . However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients. In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%). Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L). Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone. The clinical significance of this observation is unknown. Instructions: please typing these entity words according to sentence: ENBREL, ENBREL, methotrexate, ENBREL, anakinra, ENBREL, ENBREL, anakinra, sulfasalazine, ENBREL, ENBREL, sulfasalazine Options: DRUG, BRAND
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Specific drug interaction studies have not been conducted with ENBREL . However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients. In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%). Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L). Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone. The clinical significance of this observation is unknown.
[ "Specific", "drug", "interaction", "studies", "have", "not", "been", "conducted", "with", "ENBREL", ".", "However", ",", "it", "was", "observed", "that", "the", "pharmacokinetics", "of", "ENBREL", " ", "was", "unaltered", "by", "concomitant", "methotrexate", "in", "rheumatoid", "arthritis", "patients", ".", "In", "a", "study", "in", "which", "patients", "with", "active", "RA", "were", "treated", "for", "up", "to", "24", "weeks", "with", "concurrent", "ENBREL", " ", "and", "anakinra", "therapy", ",", "a", "7", "%", "rate", "of", "serious", "infections", "was", "observed", ",", "which", "was", "higher", "than", "that", "observed", "with", "ENBREL", " ", "alone", "(", "0", "%", ")", ".", "Two", "percent", "of", "patients", "treated", "concurrently", "with", "ENBREL", " ", "and", "anakinra", "developed", "neutropenia", "(", "ANC", " ", "1", "x", "109", "/", "L", ")", ".", "Patients", "in", "a", "clinical", "study", "who", "were", "on", "established", "therapy", "with", "sulfasalazine", ",", "to", "which", "ENBREL", "was", "added", ",", "were", "noted", "to", "develop", "a", "mild", "decrease", "in", "mean", "neutrophil", "counts", "in", "comparison", "to", "groups", "treated", "with", "either", "ENBREL", "CI", "or", "sulfasalazine", "alone", ".", "The", "clinical", "significance", "of", "this", "observation", "is", "unknown", "." ]
[ "DRUG", "BRAND" ]